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Abstract 
 
 
Since the 1970s research on how people take, or “adhere” to prophylactic medications, 
has been dominated by individualistic approaches emphasising the role of attitudes in 
explaining adherence, with limited predictive success. Such limitations may be related 
to a restricted conceptualisation of talk about medicine taking as an accurate 
representation of individuals’ attitudes. Using asthma as a case example, this thesis 
explored whether we can more productively view such talk as social action reflecting 
the interactional and social conditions in which it is produced. This enables us to 
examine interactional issues with specific influence on everyday decisions about 
medicine taking. Key amongst these issues are likely to be moral discourses of illness 
management. 
 
Using ideas and tools associated with Discursive Psychology and Linguistic 
Ethnography, the author examined a range of data sources for how moral discourses of 
asthma management structured talk of people with asthma in face-to-face interview and 
focus group settings. Participants could be seen to deploy a range of rhetorical devices 
to justify medicine taking, positioning versions of their asthma management, views and 
themselves within a range of moral discourses that can be seen to circulate different 
social spaces. 
 
Building on Goffman’s term “performance,” these findings indicated that people’s talk 
about medicine taking can be seen as transference of linguistic resources across 
contexts, manifested in different interactions. The “meaning” of performances is 
therefore a result of how different criteria, set up within interactions about illness 
management, match available resources deployed by individuals with chronic illness. 
These findings suggest that rather than seeing lay-professional discussions of medicine 
taking as being about persuading people to adopt particular attitudes, this approach 
allows us to see how mutually-agreed treatment decisions may, instead, require us to 
identify appropriate linguistic resources for facilitating discussion of patients’ everyday 
concerns about illness management, within that interaction. 
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Chapter One 
Background to Research Investigating the Discursive Construction of Talk about 
Prophylactic Medicine Taking 
 
Since the 1970s research on how people have taken prophylactic medications has been 
dominated by individualistic approaches, with limited success for helping predict what 
people will do. Such limitations may be related to a conceptualisation of talk about 
medicine taking as providing an accurate representation of individuals’ attitudes or 
beliefs. Taking asthma as a case example, the study reported here investigated what 
happens if we view that talk in a different way, as a form of social action. What 
different knowledge is produced and how can this knowledge be used to treat people 
with asthma and potentially other people with chronic illness? 
 
This introductory chapter will set the scene for such a study of talk about asthma 
prophylactic medicine taking. This will begin by providing a brief overview of work 
done since the 1970s which has largely attempted to explain and predict the decisions 
that people make about taking prophylactic medications. It will focus on the possibility 
that notions of individual attitudes may be problematic because of assumptions about 
how talk has been understood in generating those attitudes. It will then specify what 
assumptions about talk underlie individualistic approaches, the problems with these 
assumptions and describe research that represents landmarks in how prophylactic 
medicine taking has been understood. 
 
Questions raised about the usefulness of the concept of attitudes in other fields helps us 
to see why attitudinal research may have struggled to predict prophylactic medicine 
taking behaviour. Such questions reflect the view that any constructed relationship 
between behaviour, attitudes and talk, will be an artefact of academic practice rather 
than an accurate representation of human psychology and behaviour. This work will be 
used here to argue that if we want to gain a more robust appreciation of talk about 
medicine taking then we must question the core assumptions underpinning attitudinal 
research on prophylactic medicine taking and then provide alternative assumptions upon 
which to construct our knowledge of this subject. This will be the topic of the following 
section, providing a marker for how the distinctive approach taken in this study differs 
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from approaches commonly adopted until now. It is this new approach, which will 
frame an exploration of how talk about medicine taking can be seen as social action, 
and, through observing the effects of this action, reveal how speakers reproduce and 
create discourses of health, illness and disease in the accounts that they offer to others. 
There is some literature that shows people using talk about health and illness to present 
themselves in particular ways and that, instead of viewing such talk as a neutral account 
of individual’s private beliefs, to better understand the issues that influence medicine 
taking on a daily basis, this talk should be framed as a form of moral practice.  
 
In examining an example from a discursive psychological approach to understand talk 
about chronic fatigue syndrome, this moral practice can be seen to allocate blame and 
accountability for health outcomes, which are situated interactionally and historically 
within moral discourses of health and illness. To understand talk about asthma 
prophylactic medicine taking, examining both the interactional and historical properties 
of this talk may be fruitful by enabling a richer understanding of what happens in these 
interactions and how they might reflect decisions that people with asthma make about 
managing their condition. 
 
In constructing a theoretical argument for how talk about medicine taking might be 
studied differently to earlier approaches, this research is itself situated within an 
historical context. Through conducting this study, I developed an awareness of my own 
construction of the data reported here and this led to some important changes in how the 
research proceeded, which are then summarised within an account of the development 
of this research. The chapter will conclude with a synopsis of thesis chapters. 
 
This research addressed three key questions: 
• How is talk about asthma management and medicine taking constructed with 
people who are not taking prophylactic asthma medications as prescribed? 
• What role do moral discourses play in constructions of medicine taking by 
people with asthma and what does this say about the objectives of asthma 
policies and guidelines? 
• How may discourse-related insights help us understand the limitations and 
achievements of a discursive psychological approach in understanding talk about 
medicine taking? 
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Answering these questions will provide new insights into the production of talk about 
medicine taking for people with asthma but also more generally for people with chronic 
illnesses. The potential problems for understanding decisions about medicine taking 
within an individualistic framework need to be resolved by understanding the process of 
constructing reported attitudes, perceptions and beliefs which shape how people take 
prophylactic medications. Seeing how accounts of medicine taking behaviour are 
influenced by different interactional issues, particularly moral discourses manifested in 
concerns of blame and accountability, may help to identify how different discourses 
constrain or facilitate what people say about their illness management. This will 
contribute importantly to how knowledge about medicine taking behaviour is 
formulated, by suggesting alternative ways to conceptualise and so interpret talk about 
such behaviour and methods. This knowledge can be applied to communication with 
patients in health care settings. If healthcare professionals can be more attuned to the 
discursive construction of talk about medicine taking and the role of morality within 
that talk, then they may come closer to the issues that more intimately influence 
decision-making about medicine taking in the daily lives of people who live with 
chronic illnesses. Recognising the interactional and moral dimensions of talk, may 
enable doctors, nurses and patients to reach more collaborative decisions about 
managing illness. 
 
Overview of Adherence Research since the 1970s 
 
Prophylactic medications are now the first line of treatment in asthma prevention. The 
leading organisation and collaborator with the World Health Organisation promoting 
asthma control worldwide, the Global Initiative for Asthma (GINA) (2009), declares 
that “the goal of asthma treatment, to achieve and maintain clinical control, can be 
achieved in a majority of patients with a pharmacologic intervention strategy developed 
in partnership between the patient/family and the health care professional” (p. 57). 
Achieving and maintaining asthma control is therefore seen as being about finding the 
appropriate medication. This is commonly a prophylaxis, typically a corticosteroid 
inhaler, which requires the person with asthma to take once or twice a day to achieve 
optimum asthma control. Understanding what influences people’s ability or willingness 
to comply or “adhere” to this medical advice, has preoccupied researchers for the last 
thirty five years although the realisation and attempts to understand why patients do not 
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follow medical advice date back as far as Hippocrates (Trostle, 1988, 1300). 
Traditionally, and still common, the term “compliance” denotes people taking and not 
taking prophylactic medication as prescribed. However, more recently, the term 
“adherence” has been used, to avoid the negative connotations associated with 
compliance. Even more recently the term “concordance” has emerged, which although 
not referring to medicine taking per se, symbolises mutual agreement, or “harmony” 
between doctor and patient (Royal Pharmaceutical Society of Great Britain, 1997). The 
term adherence rather than compliance is used in this thesis as the implications of this 
ideological and discursive shift, in understandings of the relationship between doctors 
and patients with asthma, lies at the heart of this study.  
 
Poor adherence to prophylactic medications remains an important issue for the NHS and 
in asthma is described as a “significant burden” accounting for a large proportion of the 
costs of asthma (Barnes, Jonsson, & Klim, 1996). This is despite the investigation of 
nearly 200 potential barriers to adherence (Donovan, 1995; Royal Pharmaceutical 
Society of Great Britain, 1997) and the use of numerous models to predict adherence 
behaviour (Christensen, 2004). Systematic reviews of literature post-1970s research on 
adherence to treatments has found such work to have little success in predicting 
adherence to prophylactic medications (Vermeire, Hearnshaw, Van Royen, & 
Denekens, 2001).  Associated interventions have also proved inconsistent and difficult 
to generalise (Haynes et al., 2005; Peterson, Takiya, & Finley, 2003).  
 
The majority of attempts to achieve the goal set out by GINA have focused on 
identifying the different variables that reduce people’s ability or willingness to take 
medication regularly. Research has focused on components of medications, individual 
patient or doctor characteristics, the doctor-patient relationship, disease features, the 
referral process and factors within consultations. The variables considered to have the 
greatest influence on adherence and shown to correlate with adherence are beliefs about 
medications and medicine in general (Ponieman, Wisnivesky, Leventhal, Musumeci-
Szabo, & Halm, 2009; Roberson, 1992; Royal Pharmaceutical Society of Great Britain, 
1997). Researchers have often drawn on theories from traditional psychology to explain 
the connection between beliefs and adherence to treatments, using and developing 
Social Cognition Models (SCMs). The most well-known of these is the Health Belief 
Model (Becker & Maiman, 1975) which constructed a direct relationship between the 
patient’s belief about their disease and treatment with their adherence behaviour. 
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However, alternative models also exist which either build on the Health Belief Model or 
contend that different aspects of the individual better predict adherence (Christensen, 
2004). Consequently, no one model is regarded as the most predictive of adherence to 
treatments. 
 
Other individual patient characteristics investigated to date as potential indicators of 
adherence have included personality, gender, age, sex, marital status, social class, 
disability and psychosocial factors (Harrison, 2005; Vermeire et al., 2001).  
More recently, greater account has been taken of patient perspectives on health and 
illness which go beyond the specifics of the condition and medications (DiMatteo, 
1994; Donovan, Blake, & Fleming, 1989; Naidoo, Dick, & Cooper, 2009; Stockwell & 
Schulz, 1993) and there have also been other studies that have attempted to understand 
adherence within a cultural context (Sankar, Luborsky, Schuman, & Roberts, 2002). 
This shift has been seen in asthma research on adherence to medications which has 
attempted to move beyond a focus on individual characteristics to understand asthma 
medicine taking in terms of relationships and within the context of people’s everyday 
lives (Adams, Pill, & Jones, 1997; Buston & Wood, 2000; Prout, Hayes, & Gelder, 
1999; Scherman, Dahlgren, & Lowhagen, 2002; Walsh, Hagan, & Gamsu, 2000). These 
studies, using a variety of qualitative methods, have provided alternative ways in which 
people with asthma make sense of their condition, incorporating insights that captured 
the experience of asthma rather than focusing solely on individual attitudes towards 
asthma or medications.  
 
This increasing awareness of the need to understand how people live with asthma and 
other chronic illnesses in everyday life reflects other research seeing the doctor-patient 
relationship and communication as vital in enhancing adherence (DiMatteo, 1994). It is 
now common to place importance on improving communication style to better 
understand patient perspectives, providing appropriate information and educating 
patients about the nature of disease and the functions and effects of medications. 
However, a synthesis of qualitative studies of lay experiences of medicine taking 
(Pound et al., 2005) suggested that a key reason why people do not take medicines as 
prescribed is that people are concerned about the safety of medicines, arguing that 
people “resist” the use of medications. These concerns have been shown to be difficult 
to articulate within consultations (Barry, Bradley, Britten, Stevenson, & Barber, 2000), 
with patient’s views of medications often being unknown to clinicians, demonstrating 
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an absence rather than presence of concordant decision making between clinicians and 
patients (Stevenson, Barry, Britten, Barber, & Bradley, 2000). Pound et al argue that the 
concept resistance indicates a coercive power dynamic between medical care and 
patients but also that patients actively engage with their medications. This argument, 
along with the realisation of the need to capture peoples’ lived experiences of asthma, 
suggests that we may need to account for any such resistance when communicating with 
people about medicine taking, not only in clinical settings, but also in our use of 
research methods. 
 
 
Gaps in Knowledge: Problems with Individualistic Approaches to Understanding 
Talk about Medicine taking 
 
 
The notion that people may resist the use of medicines indicates that people with 
chronic illness, when talking about medicine taking, may wish to present themselves in 
particular ways to enable such resistance. However, the idea of resistance to medicines 
as a function of talk about illness management is typically not reflected in the literature 
to date. In addition there is evidence that many healthcare professionals appear to place 
more importance on clinical perspectives of medicines rather than those expressed by 
families and friends, potentially limiting the opportunity for collaborative decision-
making within consultations (Stevenson, Gerrett, Rivers, & Wallace, 2000). 
Individualistic approaches to medicine taking assume that what people say about 
medicine taking and chronic illness management, in research interviews, questionnaires 
or doctor-patient consultations, accurately represents a specific attitude, perception or 
belief that the person holds about health, their condition or a medication. The “attitude” 
is said to exist in a real sense which can be seen to be distinct from other attitudes or 
beliefs that the person also holds. As this attitude is seen as “owned” by the speaker, it 
is also viewed as relatively stable across a range of social situations. The functions of 
talk are therefore marginalised within this framework as is the role of context in shaping 
those attitudes. Context is commonly viewed as distinct from attitudes, seen as another 
variable that modifies decisions about medicine taking while not affecting the attitude 
itself.  
 
However, there is research on health (Crossley, 2002; Gillies & Willig, 1997) and 
beyond (Gilbert & Mulkay, 1984; Potter & Wetherell, 1987) that provides evidence of 
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attitudes changing even during the same interactions. Crossley, in her study of views of 
health and illness, used focus groups based on a social constructionist methodology to 
explore the co-constructed nature of beliefs between individuals. She highlighted how 
attitudes of responsibility were quickly replaced by attitudes of resistance when she 
circulated health promotion leaflets. A social cognitive interpretation of this 
contradiction would be that “actual” individual attitudes were biased by the context of 
the focus group. In contrast, a social constructionist perspective might argue that 
reported attitudes existed as part of a process of mutual construction between the 
individual members and were constructed with reference to issues of blame and 
accountability within the context of the group’s interactions. Crossley’s individuals 
drew on cultural understandings of health and illness in apportioning blame and 
accountability and in doing so managed their attitudes, beliefs and identities, the key 
issues at stake within the interaction. This suggests that attitudinal approaches to 
adherence exclude important information about the changeability of attitudes within 
interactions which may undermine attempts to categorise those attitudes. Associated 
interventions aimed at changing medicine taking behaviour may therefore be 
inappropriate as they may be based on an attitude that does not accurately represent how 
people view their condition.  
 
If attitudes towards issues of health and illness can be seen to change within interactions 
then we have to ask: what is an attitude? Is it appropriate to use this concept in 
understanding talk about prophylactic medicine taking? If not then what is an alternative 
way to understand this talk and what new sort of knowledge does this provide? The 
following section will address the first two questions by unpicking the assumptions that 
underpin the notion of the individual “attitude”, “belief” or “perception” which have 
been used to generate the epistemology relating to the decisions that people make about 
medicine taking. In addressing the third question, the approach to be taken in this thesis 
to understanding talk about prophylactic medicine taking will be presented. 
 
Core assumptions about talk in attitudinal research on adherence 
 
Four basic assumptions underpin the attitudinal research on adherence: the notion that 
individuals hold a fixed attitude about health and medicine that is stable across different 
contexts; the idea that these attitudes can be elicited through appropriate research 
methods; the idea, that, once elicited, measured attitudes can be used to predict and 
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explain prophylactic medicine taking behaviour; and the view that social, cultural and 
situational issues are separate contextual factors external to our attitudes. These 
assumptions are fundamental to the types of knowledge that are produced or, 
importantly, missed about people and medicine taking. The following research extract 
on asthma medication adherence provides an example of the connection argued for 
between individual utterance, internal cognitive state and behaviour in most adherence 
research undertaken since the 1970s.  
 
In a study of beliefs about asthma and self-management behaviours, Halm, Mora and 
Levanthal (2006) conducted an “interviewer-administered survey” which included the 
primary question “Do you think you have asthma all of the time, or only when you are 
having symptoms?” Respondents were categorised as having either one of these 
attitudes and to seek any association with beliefs about the importance of using 
prophylactic medications. Halm et al found that the “no symptoms, no asthma” belief 
was negatively associated with beliefs about always having asthma, having lung 
inflammation, or the importance of using inhaled corticosteroids, and was positively 
associated with expecting to be cured. The “no symptoms, no asthma” belief, or “acute 
disease belief” was also associated with one-third lower odds of adherence to inhaled 
corticosteroids when the person was asymptomatic.  
 
The title of the article by Halm et al clearly asserts the link between talk, belief and 
behaviour: “No Symptoms, No Asthma: The Acute Episodic Disease Belief Is 
Associated With Poor Self-Management Among Inner-City Adults With Persistent 
Asthma”. It concludes that: “The single question ‘Do you think you have asthma all of 
the time, or only when you are having symptoms?’ can efficiently identify patients who 
do not think about or manage their asthma as a chronic disease” (p. 579). Talk about 
asthma can be clearly seen here as unproblematic in its production and in its access to 
the required belief about asthma. Furthermore, whilst presented as an association, the 
attitude is implicitly presented as a key variable in causing poor self-management of 
asthma as seen from the authors’ perspective.  The objectivity of these findings is 
authenticated through the use of detailed data collection techniques with standardised 
questions, demographic tables detailing the participant’s representativeness of the 
broader population and the use of statistical analyses. However, the simplicity of the 
connection between talk and beliefs and the complete absence of discussion of context 
in how talk is produced is striking. The message in this research is that if we want to 
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find out who has the “wrong” attitude and therefore who we need to educate we just 
need to ask. 
 
Deconstructing the Assumptions of Attitudinal Research on Adherence 
 
The study by Halm et al study builds upon research that also constructed such a 
relationship between individual talk, cognition and behaviour, manifested in the 
modelling of this theoretical relationship. The social cognition models that have been 
produced in the last 35 years represent formal attempts to predict and explain a range of 
health behaviours using the basic tenets that Halm et al propose. It is within these 
models where we can see how the complexity of the individual in a social world is 
managed by a scientific paradigm that places the individual at the heart of its 
epistemology.  
 
The analysis of scientific talk by Gilbert and Mulkay (1984) is a useful tool to help 
deconstruct the assumptions of social cognition models. Their study is one of the key 
influences on the development of discursive psychology, a methodology which is 
foundational for the approach taken in this study. Their analysis is helpful to draw on in 
examining social cognition models, both for its explanatory power and for marking the 
key point of departure from previous adherence research. 
 
Gilbert and Mulkay interviewed 34 scientists working in the field of biochemistry. In 
doing so they were not interested in the “truth” of a scientist’s account but rather how 
the scientists themselves went about building “truth”. They found that the scientists they 
interviewed demonstrated two distinct ways of talking about their own and others work 
in their field, referred to as two distinct “interpretative repertoires”: empiricist and 
contingency repertoires. The interpretative repertoire (Potter & Wetherell, 1987) is a 
concept central to discursive psychology and refers to a higher-order analytical element 
that is repeatedly used by speakers to characterise or evaluate actions, events, or perhaps 
a particular position one might take on a particular topic. It occurs in a particular piece 
of talk to achieve particular functions and is identifiable by patterned styles and 
grammatical forms such as specific phrases, metaphors or figures of speech.  
The empiricist repertoire identified by Gilbert and Mulkay involved statements of fact 
based on “the evidence”, which assert an objective account of “how the world is”. Here 
the researcher is constructed merely as observer of the object of analysis in the true 
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spirit of positivist scientific practice. In contrast, the contingency repertoire involves 
statements which explain “mistaken beliefs” about the same object and these errors 
were attributed to social factors such as failure to understand, personal vendettas, 
commitment to one’s own theories, dislike of the new theory as well as many more 
personal and so non-empirical barriers to objectivity. Gilbert and Mulkay found an 
asymmetry in scientists’ talk whereby the empiricist repertoire was always used in their 
own description of how they obtained their findings and hence their own theory about 
the object of analysis. In contrast the contingency repertoire was deployed to explain 
any alternative theoretical interpretation. Gilbert and Mulkay found this pattern so 
pervasive across scientific talk that every example of theory put forward as empirical 
was found to be explained away by another scientist with the contingency repertoire.  
 
Applying the analysis of Gilbert and Mulkay to social cognition models 
 
Although Gilbert and Mulkay focused specifically on scientists’ talk we can see how the 
same repertoires have been deployed in research papers on adherence to construct 
knowledge of talk about medicine taking. The connection between individual utterance, 
the notions of internal cognitive representation (attitude, belief, perception) and 
behaviour are widely constructed in attitudinal research on adherence as a unidirectional 
causal relationship, an epistemology which is presented on empirical grounds. That a 
theory should be presented as formulated on observable evidence within a scientific 
paradigm is of course not surprising. What is of interest however is how complexity in 
people’s talk and human behaviour is managed in this research, how the coherence of 
this essentially individualistic theory is maintained in light of the range of ways in 
which people talk and behave in relation to their health, illness and medicines. This is 
informative because it demonstrates how context is formulated and managed within 
individualistic approaches and the social cognitive framework. This will provide a key 
point of contrast to the approach taken in this thesis. 
 
In the health belief model by Becker and Maiman (1975) (depicted in Fig. 1), which 
was the earlier model to be applied to asthma medicine taking, we can see how 
perceived susceptibility and seriousness of the disease are constructed as the core 
factors influencing the likelihood of action in the same way constructed by Halm et al 
thirty years later. In this model, individual perceptions are independent entities that are 
stable across all contexts. However, there are a list of demographic and socio-
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psychological factors as well as “cues to action” that may modify a perception and 
action on any one occasion including age, sex, personality, peer group, newspaper 
article or chat with a friend. Importantly though, these variables are seen as outside the 
individual perception, a discrete, independent entity. This version of context constructs 
it as contingency, covering anything beyond the perception itself which can explain any 
utterance or course of action taken but which does not undermine the existence and 
explanatory power of the individual perception. As Becker and Maiman suggest: 
“While it is assumed that diverse demographic, personality, structural, and social factors 
can, in any given instance, affect an individual’s health motivations and perceptions, 
these variables are not seen as directly causal of compliance” (p.13). 
 
In this view, context is seen as a separate variable that accounts for contingent deviation 
from the theoretical expectation. As it covers any action that a person may take 
concerning their health, the key theoretical link between individual perception and 
compliance remains intact. To deal with contradictions in the evidence, Gilbert and 
Mulkay found that scientists could often be seen to use a “truth will out device” 
(TWOD), (Potter & Wetherell, 1987, p.153) in their talk to argue that repeated 
application of a model or theory will triumph over contextual issues in the end. The 
problem for adherence research to date however is that this is yet to be proven. 
 
   
 
 
18
 
 
 
Perceived 
Susceptibility to 
Disease “X” 
Perceived Seriousness 
(Severity) of Disease 
“X” 
Demographic variables (age, sex, 
race, ethnicity, etc.) 
 
Socio-psychological variables 
(personality, social class, peer and 
reference group pressure, etc.) 
Cues to Action 
Mass media campaigns 
Advice from others 
Reminder postcard from physician or 
dentist 
Illness of family member or friend 
Newspaper or magazine article 
Perceived Threat of 
Disease “X” 
Likelihood of taking 
recommended 
preventive health 
action 
Perceived benefits of 
preventive action 
 
Minus 
 
Perceived barriers to 
preventive action 
INDIVIDUAL 
PERCEPTIONS 
MODIFYING FACTORS LIKELIHOOD OF 
ACTION 
Figure 1: The “Health Belief Model” as 
predictor of Health behaviour, Becker & 
Maiman 1975 
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The impact of social cognitive assumptions on research practice 
 
We can see the impact of these methodological assumptions not only in the theoretical 
model used to explain adherence behaviour but also in how this assumption regulates 
the methods routinely used to collect data, the type of data obtained, the results reported 
and any subsequent intervention. An important implicit assumption of social cognitive 
models is that attitudes, perceptions and beliefs reside internally within each individual. 
The way to access attitudes therefore is to focus on the individual and to treat data as 
unique to that individual. For example, the cross-sectional study by Horne and 
Weinman (2002) used questionnaires to explore the role of illness perceptions and 
treatment beliefs for people with asthma. They extended Leventhal’s self-regulatory 
model (Leventhal, Diefenbach, & Leventhal, 1992) of illness perceptions to incorporate 
beliefs about treatment. The questionnaire is ideal in obtaining categorical, 
individualistic statements that can be assigned an “attitude” whilst data, (talk or free text 
comments on questionnaires) that do not specifically answer the questions, are not 
considered as data to be used for the primary analysis. Importantly, by directing the 
respondent to express their experience of asthma in a specific format, in this case by 
using the commonly applied Likert-type scale, the tool’s sensitivity to any variation in 
individual attitudes is restricted. Indeed, any variation would present distinct difficulties 
for categorising a particular attitude and would challenge the assumption of a coherent 
attitude itself. The research of Horne and Weinman produces results reporting 
percentages of participants who express attitudes towards asthma and medications 
within a range of domains, for example how they view causes of their asthma (e.g. 
pollution), its duration “my asthma will last a long time,” consequences “my asthma is a 
serious condition,” the necessity for medication “my health depends on this medicine,” 
side-effects “this inhaler is harmless.” The intervention they go on to propose is 
therefore to modify perceptions and beliefs of asthma and medications through 
appropriate educational techniques. By presupposing that individuals have fixed 
attitudes, the tools used to collect it and the data that is produced will solipsistically 
substantiate the existence of such attitudes. 
 
Applying the “empiricist” and “contingency” repertoires identified by Gilbert and 
Mulkay to social cognitive approaches, enables us to see how the core unit of analysis, 
the attitude, is deployed in research practice to produce an epistemology that provides 
sets of statements about the individual which are predictive of medicine taking 
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behaviour. The methods used to retrieve these data serve to reinforce this unit of 
analysis and the theoretical modelling that is produced forecloses any challenge to these 
fundamental principles by explaining context as contingency.  This form of theoretical 
closure, reducing decisions about medicine taking to a finite set of attitudes and beliefs 
marginalises the importance of social factors such as relationships, family, work, 
constructing them as contingent, random events. In contrast the individual is presented 
as the core source of meaning, presumed to hold a discrete set of rational attitudes, 
perceptions and beliefs which are not random but consistent and largely fixed entities.  
 
Assumptions of Discursive Psychology 
 
Of course, the analysis by Gilbert and Mulkay demonstrated their own aims and 
assumptions and those developed within discursive psychology.  The same assumptions 
form the basis of this thesis and so need to be discussed here in three stages. Firstly, 
instead of trying to establish what the “truth” is in any account, Gilbert and Mulkay 
were more interested in what is achieved in talk; how versions of truth were 
constructed, argued and authenticated in the discourse of scientists, whilst undermining 
alternative versions and disclaiming any vested interest. From this view, talk about 
medicine taking is not about just conveying information that may reside “inside our 
heads” but is about trying to achieve something in that talk. Language therefore can be 
seen as performing an action. In the study of Gilbert and Mulkay study this could be 
seen for scientists attempting to uphold their own theories in their talk while discounting 
alternatives.  
 
Secondly, as talk is seen as oriented towards social action, it will therefore change 
according to the functions and social conditions in which it occurs. Variability in 
people’s accounts is therefore seen as a manifestation of differing social conditions, not 
as a distortion of a cognitive state. Instead of debating the existence of a coherent 
internal representation called an “attitude” or a “belief” or a “perception”, the discursive 
psychologist argues that it is more appropriate to respecify attitudes as language that are 
constructed within and between individuals, groups, institutions and cultures at 
particular points in time. Talk takes place in social spaces and therefore is inevitably 
situated by the time and place in which it occurs. This means that instead of viewing the 
individual with perceptions and context as separate entities we can only understand 
perceptions when seen from within a social historical context.  
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Finally, and as an implicit implication of the first two assumptions, the view expressed 
about the object of thought and the object itself are inseparable. If talk is constructed in 
social spaces and those views can be seen to vary, then so can the definitions and 
descriptions of the objects that are used to convey those views. The issue of account 
variation has been discussed at length by Potter and Wetherell in their critique of 
attitudinal research (1987). They argue, through numerous examples, that a fundamental 
problem for attitudinal research is that evidence of variability in how objects are 
described demonstrates that the object of thought is inextricably linked to the attitude 
being expressed. This raises serious problems for the idea that people, in expressing an 
attitude are always referring to the same thing when expressing that attitude.  
 
Applying discursive psychological assumptions to talk about health and illness 
 
As the assumptions of individualistic approaches have been seen to give rise to 
particular types of knowledge about the person with asthma and prophylactic medicine 
taking, so too can discursive assumptions be seen to produce their own type of 
knowledge. We can see how the discursive assumptions discussed here have been 
applied in other areas of health and illness research.  
The following extract is from Horton-Salway’s thesis (1998) on the discursive 
construction of chronic fatigue syndrome, or ME. Using a discursive psychological 
approach to analyse accounts of the onset and origins of illness, Horton-Salway 
demonstrated that the acceptance and recognition of ME as an organic condition, as 
opposed to “all in the mind” was a hugely contested area. People with ME did not 
merely provide an attitude towards ME in a way that may be considered accurate, 
inaccurate, or distorted in the cognitive sense. Instead, they were describing and 
explaining events in specific styles and with specific pieces of evidence to construct a 
particular version of reality. In this example we can see how Joe chose a particular 
description of events as evidence to support the idea that ME is a real disease. 
 
34. Joe  = I went swimming one week (.) you didn’t feel up to it (.) then the  
35.  following week 
36. Angela = you were alright weren’t you? 
37. Joe  =yeah and this ties in because it’s now known that ME is caused by  
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38.  er  (.) an enterovirus which is a prime place to pick up an enterovirus is 
39.   a swimming baths (.) it’s also the classic(.) used to be the classic place 
40.  to catch polio in the old days (.) hot summers (.) and I think with  
41.  swimming (.) kids being in the bath all through the day (.) at the end of 
42.  the day the water wasn’t getting through the cleansing plant quick  
43.  enough (.) I suspect  if you’d gone first thing in the morning it would  
44.   be absolutely spot clean (.) but er I suppose by the time we got there (.) 
45.  I suppose the enteroviruses were still there (.) yeah (.) just unfortunate 
(Horton-Salway, 1998, p. 174) 
 
Horton-Salway argued that Joe was not just providing a neutral description of events to 
formulate this explanation of what caused Angela’s ME. She showed how Joe blended 
the “classic” script of a polio story with Angela’s personal narrative to add an 
authoritative voice to his argument. The key point being that Joe was showing that 
catching a virus in swimming pools was not an untested idea but was grounded in 
scientific evidence. Angela’s visits to the swimming baths therefore positioned ME 
alongside polio and as recognisable as an organic disease. At the same time, the 
sequence of events constructed by Joe of an everyday mundane activity of going 
swimming positioned Angela as “unfortunate”, Angela was therefore not to be blamed 
for having ME but was at the mercy of fate in the same way as people with polio. 
 
This example illustrates that Horton-Salway’s participants were managing important 
issues at stake around the very nature of a particular condition. Having what Horton-
Salway called “authorship” of this illness could be seen to be critical in managing 
potential accusations of blame and accountability for the particular symptoms that 
people like Angela were experiencing. They were therefore not simply internal 
representations that were being communicated to the listener but were expressions that 
attended to the differing versions of ME that pervaded British society in the 1990s, a 
time when the meaning of this condition was hotly contested. Attitudes towards this 
illness are therefore better seen as a form of social action to manage these issues and 
ME, the object being described, as inextricably linked to that attitude. This type of 
social action is situated not only by the social historical context in which conditions like 
ME were being debated but, as Radley and Billig (1996) emphasised, also within the 
context of the interaction taking place. It is better, they argued, to view beliefs about 
health and illness as accounts given to others in particular situations. As people do so, 
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they deploy ideological themes to naturalise their versions of the world, in ways which 
serve the specific demands of the interaction itself. So, in the case of Joe and Angela, 
Joe used the classic case of polio as a vehicle to employ an interpretative repertoire of 
the “unfortunate” individual coming into contact with an organic virus to naturalise the 
causes of Angela’s symptoms and that of ME. This repertoire is therefore one which 
drew on a cultural explanation of illness which says that suffering from an organic 
condition is acceptable and excusable within British society at this point in time. By 
understanding this moral context we can see that the issue that was salient for Joe and 
Angela in daily life was whether they were responsible for Angela’s condition. This 
could have influenced whether Angela was viewed as a “bad patient” and whether she 
could gain easy access to particular treatments and services. 
 
Horton-Salway’s example demonstrates that the accounts that people provide about 
health and illness can be seen to be influenced by how issues of blame and 
accountability are understood within any particular interaction. This type of moral talk 
has also been identified across a range of conditions and health-related behaviours, 
including smoking (Coxhead & Rhodes, 2006); infant feeding (Lee, 2007); AIDS and 
drug-use (Hassin, 1994); HIV and unprotected sex (Rhodes & Cusick, 2002); back 
(Lee-Treweek, 2001) and chronic pain (Werner, Isaksen, & Malterud, 2004); talking 
positively about cancer (Wilkinson & Kitzinger, 2000) including treatment decisions for 
cancer (Bishop & Yardley, 2004) and talk about medicine taking for older people 
(Lumme-Sandt, Hervonen, & Jylha, 2000; Lumme-Sandt & Virtanen, 2002). The 
accounts provided by people in this literature were historical in that the allocation of 
blame and responsibility within the reported interactions were influenced by how those 
versions came to be evaluated at that point in time and in that particular place. The 
different connections between health, illness and behaviour that were activated by the 
participants within those interactions were key influences on these evaluations. These 
were likely to be drawn from culturally-available explanations (Willig, 1999) of health, 
illness and behaviour that were circulated through discourse (both linguistic as well as 
other forms of discourse for example images of health used in health promotion 
campaigns) between people, groups, social networks, institutions and cultures. These 
discursive connections could be seen to link types of behaviour to particular states of 
health, not purely in terms of the physical consequences but importantly with an 
evaluation of that behaviour as something which was good or bad. They can therefore 
be seen as moral discourses of health-related behav
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blame and accountability will be allocated within interactions according to the moral 
frameworks activated within that interaction. If we can understand the moral context in 
which people talk about prophylactic medicine taking then we will have a firmer 
appreciation of the issues that are salient for people when they talk about the 
management of their condition and how blame and accountability may be distributed 
within healthcare, research and other interactions as a result.  
 
Attending to moral elements of that context may well offer two particular advantages 
over individualistic approaches. First, in viewing talk about medicine taking as 
involving managing moral issues instead of articulating an attitude, we can see how 
these same issues may influence decisions people take about medicine taking and are 
also manifested in talk. Changing behaviour is then not about changing the individual 
attitude through education but instead about recognising the social situations in which 
issues of morality around illness management and medicine taking are relevant and in 
which people make decisions about medicine taking. Second, we can examine the 
potential consequences of particular types of talk for particular treatment decisions and 
follow-up of patients in clinical settings in ways which social cognitive approaches 
cannot do. Reported attitudes towards asthma and medicines and medicine taking 
behaviour are likely to be evaluated differently in different contexts. There are likely to 
be differing implications for how particular types of talk are categorised, in accordance 
with medical notions of appropriate behaviour regarding asthma management. How 
patients are evaluated in asthma consultations may well be influenced by how different 
accounts fit into clinical perspectives. From a medical perspective which maintains 
adherence to prophylactic medications as the ideal asthma management behaviour, 
understanding the role of morality in talk will provide insight into how patients may 
need to “perform” (Goffman, 1959) the correct attitude to gain access to particular 
treatments and how different types of accounts are likely to be categorised.  
 
What has traditionally been conceived of as attitudes can instead be seen as moral 
practice. Discursive psychology shows us how versions of the self and behaviour are 
produced in talk to manage blame and accountability. What is at stake in these accounts 
therefore are competing versions of the self and behaviour which are judged from 
within a particular moral framework. Discursive psychology emphasises the creative 
and productive nature of interactional talk and as Radley has demonstrated the use of 
rhetoric in discussions of health and illness emphasise that cultural explanations are 
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produced through talk as people manage different dilemmas within interactions. 
However, cultural explanations of health and illness are not only a product of particular 
interactions but have their origins in everyday life. Moralities can therefore be seen as 
regulating talk as well as being produced through talk. The production of particular 
cultural explanations, versions of the self and behaviour therefore have a spatio-
temporal component beyond the interaction itself.  
 
Defining talk, discourse and “attitudes” 
 
Having set out how talk was understood differently in the study reported here, to those 
that have previously studied adherence, notably reconceptualising talk as a social, rather 
than individual product, a definition of talk may be usefully introduced that can be 
applied within this alternative discursive framework. It is also important to distinguish 
between the use of “talk” and “discourse” in this study. In addition, having 
problematised the notion of an “attitude” some description of the use of this term in this 
thesis would be beneficial.  
 
Discourse has two meanings in this thesis. The first meaning literally refers to the talk 
of participants. However, using the term “discourse” rather than “talk” is intended to 
firmly position that talk within the linguistic framework of this study. Talk is 
understood in many ways and the attitudinal approaches critiqued in this thesis view 
talk very much as belonging to the individual. Discourse in contrast, places that talk in a 
social space beyond the boundaries of exclusive individual construction. Where the term 
talk is used, it refers to a shared view of what is the raw data for many social scientists 
and which precedes any disciplinary manipulation. However, there are occasions where 
“talk” has been used, where “discourse” could be used instead. In these instances this 
has been done so to avoid confusion with the second use of discourse in this thesis. 
 
The second definition of discourse is much more abstract and refers to the role of 
culture, history and power in the production of meaning. The work of Foucault (1972) is 
particularly illuminating in understanding this definition of discourse and how the 
production of meaning is regulated in society. Foucault argued that it is possible to 
identify sets of statements produced in talk and in text that have their origins in a 
particular way of understanding a part of the social world. These understandings are not 
isolated from society and history but are emergent through particular social conditions 
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and carry with them particular rules and ideologies of knowledge and beliefs. A 
discourse in this sense is a collection of related statements that have been formed by and 
through groups, social networks and institutions and which serve to reproduce this 
understanding. This study, and the topic of Chapter Two, will discuss how collections 
of statements about asthma management can be seen as deploying a “moral discourse of 
asthma management.” It will also discuss the origins of this discourse, how and whether 
it might regulate what people with asthma say about medicine taking and discuss the 
implications of this talk for people with asthma.   
 
In this thesis the term “attitude” is used in two distinct ways: when written without 
quotation marks (attitude), it is used to reflect everyday taken-for-granted meaning, as is 
intended by those adopting this concept in individualistic and social cognitive 
approaches. In contrast, where “attitude” is used, a discursive critique of this term is 
being made which highlights the problems of adopting this term in understanding talk.  
 
Applying discursive psychological assumptions to talk about prophylactic medicine 
taking 
 
Discursive psychological ideas have already been used to understand adherence to 
dietary regimens in diabetes (Peel, Parry, Douglas, & Lawton, 2005); exercise 
(McGannon & Mauws, 2000) and hormone replacement therapy (Hunter, O'Dea, & 
Britten, 1997; Stephens, Budge, & Carryer, 2002). This research has demonstrated how 
people can be seen to construct therapies in a variety of ways to perform particular 
interactional tasks, revealing concerns about treatments and the need for clinicians to 
take greater account of discourses beyond medicine that might influence patients’ 
decisions. Applying discursive psychological assumptions to how people with asthma 
might talk about prophylactic medicine taking enables us to ask: what issues are being 
attended to in talk about prophylactic medicine taking? What is achieved in this talk? 
How is talk about asthma prevention situated by the social historical context in which it 
takes place and what role do discourses (abstract) of health and illness play in the 
accounts of medicine taking that people provide? Providing answers to these questions 
will provide insight into how people with asthma and perhaps chronic illness more 
generally wish to be understood. Their talk produces and reproduces ways of being in 
the social world, that carries with it evaluations of the reported attitude or version of 
events. This implies that if talk about medicine taking is a form of social action, aimed 
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at portraying ourselves in particular ways, then that talk is situated within a moral 
framework. Rather than categorising talk as reflecting an attitude that may need to be 
changed, the issue for researchers and healthcare professionals then becomes what are 
the moral properties that are produced in people’s talk and what implications might this 
have for how people manage their condition? 
 
Summarising differences in approaches to knowledge between individualistic 
approaches and discursive psychology 
 
Both individualistic and discursive approaches to talk about health and illness begin 
with assumptions that have an impact on the type of knowledge that is produced. In 
particular, social cognitive approaches, the predominant paradigm applied to explaining 
adherence, assume that people hold and are able to reliably report attitudes, beliefs or 
perceptions about a particular issue in health. This means that the speaker must 
consistently describe the same object of thought in expressing that attitude. Asthma, 
illness, disease, severity, health, medication etc are objects that are borne out of the 
biomedical paradigm which clearly depends on the objectification of these categories 
for clinical practice to be implemented. However, discursive psychology would argue 
that a difficulty arises when these same assumptions are applied to people’s views of 
asthma and medication. As we saw with the work of Horne et al (2002) the research 
methods employed to access attitudes towards asthma and medications often restrict the 
possibility of picking up any variability in attitude and object description. Discursive 
psychologists, however, assume that variation is an inherent property of accounts and 
ask if and why objects such as asthma, medication and illness, might be described in 
particular ways at certain points but in a different way at other points in an interaction. 
The research methods this approach employs would attempt to facilitate rather than 
restrict variability.  
 
Examining the talk of people with chronic illness has demonstrated that actions and 
what can be seen as attitudes relating to health, are often justified not just reported. This 
rhetorical work in talk suggests that the person’s attitude, identity or version of events is 
at stake within the interaction taking place with the potential threat of competing, less 
desirable alternatives. Seeing talk about health and illness as affected by competing 
versions of the self, identity, knowledge, attitudes, places talk about health and illness 
within a moral framework. If talk about medication use orientates to different 
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moralities, then we cannot be sure that a particular attitude is being accurately 
articulated. This possibility raises doubts about the reliability of categorising talk about 
medications as representing a particular attitude that can then be used as a predictor of 
adherence. Situating talk about prophylactic medicine taking as having a moral agenda 
raises the need to discuss why morality might be a relevant concept to apply here. Why 
might this type of talk be value-laden and what do we mean when we talk about 
morality? This is the focus of Chapter Two but at this point it is now appropriate to 
provide a background, chronology and synopsis of the chapters within this thesis which 
will elaborate the key ideas introduced in this chapter. 
 
Author’s background and chronology to study  
 
The idea for the study reported in this thesis came about through my role as a Research 
Associate in the ELEVATE study, a large randomised controlled trial comparing the 
cost-effectiveness of two prophylactic medications for asthma. These medications 
represented the therapy typically prescribed for the prevention of symptoms, the inhaled 
corticosteroid and a prophylactic tablet called a Leukotriene Receptor Antagonist, or 
LTRA, which although available in the NHS, was rarely prescribed at this point. 
Participants were randomly allocated one of these two treatments and followed up for a 
period of two years using a mixture of questionnaires and breathing measurements. My 
task, whilst largely free for me to design, was initially to compare participants’ 
perceptions of the two treatments and to use these insights to complement the main 
study findings regarding participants’ reported “quality of life”, “asthma control”, 
prescription refill rates and NHS resource use. For example, if prescription refill rates 
for the LTRA tablet were higher than for the inhaled steroid, after patients had spent 
two years in the study, then reported perceptions of the treatment may be able to shed 
some light on the reasons for this difference and these data could therefore also be used 
to triangulate with quality of life and asthma control scores across the two groups. The 
design of this qualitative sub-study was therefore set within this methodological 
framework of measurement and follow-up. Participants taking part in interviews would 
be interviewed when entering the study and then interviewed a second and perhaps even 
a third time at intervals across the two year follow-up period. 
 
However, the sub-study also had the potential to contribute to a broader understanding 
of prophylactic medicine taking. Patients’ ability or willingness to “comply” or 
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“adhere” to regular prophylactic treatment has received much attention since the 1970s 
and is, as yet, largely unresolved. It was therefore appropriate for a study comparing 
perceptions of two different prophylactic medications would be set up within this 
existing literature on adherence to treatments. This was given even greater appeal as it 
presented an opportunity for me to test out two competing approaches to the issue of 
“non-adherence” to medications. The first of these came from the dominant 
methodology used to study patient adherence adopted since the 1970s, the social 
cognitive approach, which aims to elicit patient’s attitudes, beliefs and perceptions 
about their condition and their medications as a way to predict medicine taking 
behaviour. The second of these came from my own background as a psychology 
graduate from the Open University. 
 
The design of the social psychological element of the Open University’s Psychology 
course particularly appealed to me as it raised the possibility that the same object of 
analysis can be understood in completely different ways, having extremely important 
implications for the members of society that these understandings affected. The object 
of analysis could be virtually anything in the social world: notions of intelligence; 
personality; identity; learning; education; relationships; health; racism; and the 
dynamics of group behaviour. The ontology and epistemology of social life was being 
called into question in ways which critiqued traditional individualistic models and 
conceptualisations of these objects, and extended the analytical focus beyond the 
individual to meaning constructed in social spaces.  
 
The input of Wetherell and Potter to these course materials, offering such alternative 
conceptualisations of social life, had the most influence on my approach to this study 
(1987). In developing discursive psychology, Wetherell and Potter critiqued the notion 
of individual attitude and importantly its production in interactional talk. Rather than 
reflecting an individual’s internal cognitive state, Wetherell and Potter showed how talk 
about a social issues such as racism, can be seen to shift according to the demands of 
the interaction, thereby questioning attempts to pin down that talk as a coherent 
articulation of an individual’s attitude. Instead, they argued, we would be better off 
looking at how objects of analysis as “facts” are constructed by speakers themselves and 
examine the implications of those constructions. The re-specification of the meaning of 
interactional talk by Potter and Wetherell therefore offered a way to reconceptualise talk 
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about medicine taking which could then be set against the same assumptions of 
individualistic methodologies. 
 
This study and this PhD thesis was therefore developed from an initial comparison of 
specific medications to become an examination of whether an alternative 
conceptualisation of talk about medicine taking might be fruitful in developing new 
insights about the decisions that people make about medicine taking. However, the 
design of this exploration was not neatly set up at its conception but, as I have 
described, was initially situated within the positivist paradigm of a randomised 
controlled trial comparing participants’ perspectives at different time points. The early 
attempts to identify the interactional issues being managed in participants’ accounts 
were therefore framed in this way and were implemented by attempts to identify the 
different ways individuals justified their medicine taking, their “accounting styles,” 
which could be seen to persist across two different interviews. Data were obtained to 
meet these objectives and it was only through reflecting on these data, that the initial 
aims, assumptions and methods involved in identifying accounting styles were exposed 
as problematic in how they reflected the talk of participants, and moreover as 
methodologically incoherent with a discursive psychological approach. If talk is viewed 
as situated social action, then focusing on the individual and categorising that talk as 
having a particular style is more logical from within an individualistic rather than a 
discursive paradigm. Similarly, seeking persistence of an “accounting style” in two 
different time points represents an attempt at replication more appropriate within a 
positivist rather than discursive framework which embraces difference as evidence 
rather than replication in the phenomena it investigates. 
 
It was following this reflective work that a different strategy was adopted that engaged 
more fully with context in which talk about medicine taking was produced. This was to 
analyse interactional sequences of face-to-face interviews in detail to identify how the 
properties of situated social action set out within the discursive approach of this study 
could be seen to be operating. These properties included evidence of how participants 
could be seen to manage issues of blame and accountability indicating a moral agenda 
in their talk which would therefore address the main issue of enquiry in this study. 
 
However, this analytical work generated its own problems in that it became difficult to 
make claims about talk about medicine taking and the activation of moral discourses in 
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an interaction beyond that of the interviewer-participant dyads that were constructed. In 
addition, there was evidence that some participants did not justify their medicine taking 
at all. This raised the issue of how best to validate the findings from the interview data 
which was both new and methodologically coherent with the approach being taken in 
this study. By taking a broader view of context that went beyond the transcript of the 
interview itself it was possible to specify the social conditions in which participants 
could or could not be seen to be justifying their medicine taking, subject to pre-
interview conditions being constructed through participation in the ELEVATE study. In 
addition, a new data collection strategy was adopted based on a different set of 
interactional conditions to the face-to-face interviews which could be used to examine 
whether moral discourses of medicine taking were activated by participants. This was 
done using a data-sharing focus group (Murdoch, Poland, & Salter, 2010) (published 
article attached as an appendix), presenting participants (of whom, all but one had taken 
part in face-to-face interviews) with anonymous vignettes developed from the data in 
face-to-face interviews. This group task provided different data in which we might see 
moral discourses of medicine taking being activated. In doing this, I was able to make 
stronger claims about the issues faced by people when discussing illness management 
and the role of morality within different interactional contexts which might also 
influence decisions about prophylactic medicine taking. This thesis and the chapters 
outlined here therefore reflect a chronology in the development of the study’s design 
framework: 
  
Synopsis of Chapters 
 
Chapter Two: Morality in Talk about Prophylactic Asthma Medicine taking 
 
This chapter sets up the rationale for investigating the role of morality in participants’ 
accounts, building on the review of literature in Chapter One that identified how 
morality could be seen to be managed within interactions about health and illness. To 
further establish the rationale for a study examining morality, a review of literature was 
undertaken which demonstrated evidence that notions of morality have been linked with 
asthma throughout history and are still pertinent today. This literature review adopted a 
strategy of examining the language used about asthma in sources which appeared to 
represent the dominant conceptualisations of asthma at that point in history, not arguing 
that alternative conceptualisations were not available, but rather that those most widely 
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circulated were those most likely to inform clinical practice and everyday concepts of 
asthma and its management.  
Reporting this evidence is therefore not intended to provide a fixed idea of the moral 
context of medicine taking, but rather to be used as a starting point for investigating the 
circulation of discourse to the talk of people with asthma. It will present possibilities for 
how moral discourses of asthma management have circulated through space and over 
time and which may influence current conceptualisations. These are used to evidence a 
cultural moral context which is likely to influence what people say about asthma 
medicine taking which was evident from a range of sources. This work is situated 
within broader evidence of how health and illness more generally have been informed 
by morality and a review of this evidence is included in Appendix D. It will be argued 
that examining the moral context that was likely to inform how people with asthma 
talked about medicine taking was therefore likely to be productive. 
 
Chapter Three: Methodology and methods for investigating the discursive construction 
and role of morality in talk about prophylactic medicine taking 
 
Building on the rationale that there is a need to understand the interactional issues and 
role of morality in talk about medicine taking, this Chapter explains how this was done 
in this study, first constructing the methodology that was used and secondly the data 
collection methods that followed.  
Three methodological strands were key in analysing interview and focus group data. 
The biggest influence was the discursive psychological (DP) approach of Potter and 
Wetherell already discussed in this chapter. It will be argued that a DP approach 
provided an ideal set of tools in which to examine the discursive construction and role 
of morality in participants’ talk because a moral agenda can be seen as an implicit 
property of talk which is viewed as social action. In addition, the development of DP 
was borne out of a criticism of traditional social psychological concepts such as attitude, 
and so was a logical approach to apply to a similar critique made in this study. Using 
data from relevant literature, the properties of DP are discussed and how they can be 
applied to this study of talk about medicine taking. In doing so the relationship between 
structure and agency in the production of talk is raised and this discussion then leads to 
the second strand forming the methodology which comes from theories on the role and 
function of power. The assumptions about how abstract moral discourses of medicine 
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taking might structure the talk of participants are set out, using data which demonstrates 
a dynamic relationship between individual utterance and systemic discourse. 
This then leads to a discussion of the final strand of this study’s methodology which 
emerged from realising, through the analysis of interview data, that claims about the 
discursive construction of talk about medicine taking and the role of morality within 
that is not a straightforward process whereby the researcher merely observes and lifts 
the relevant meanings from the transcript. Instead, the author will suggest that the 
function and role of power in discussions about medicine taking need to be investigated 
in relation to interactors’ access to linguistic and institutional resources and the 
contextual conditions that may be pertinent to those encounters. Analytical tools and 
ideas from Linguistic Ethnography (LE) (Rampton et al., 2004) will be described which 
enabled such investigation, suggesting ways in which interactor’s resources and the 
contextual conditions of the interview data might be analysed. Details of the participants 
and the methods of data collection will then be set out, arguing how the different forms 
of data collected were appropriate to address the questions raised in this study. 
 
Chapter Four: Analysing Interview Transcripts to Evidence Interactional Issues and 
Moral Discourses in Talk about Prophylactic Medicine taking 
 
This chapter reports the analysis of face-to-face interview data to identify interactional 
issues and the role of morality in participant’s talk about their asthma management. 
Following from the early attempts to identify accounting styles, the properties of talk 
about medicine taking are examined using extracts from the interview data. Based on 
those properties set out by Potter and Wetherell (Potter & Wetherell, 1987, pp. 32-55), 
participants’ talk will be examined, demonstrating how talk about medicine taking may 
be viewed as a process whereby speakers need to manage different dilemmas in their 
accounts which orientate around the allocation of blame and accountability. This 
analysis will assess how identifying such evidence reconfigures our understanding of 
notions of individual attitudes about medicines, asthma and illness by discussing how 
these “attitudes” can be seen as social and moral actions.  
 
Following this analysis of rhetoric and dilemmas in participants’ talk, the same extracts 
are examined for how participant’s management of blame and accountability situates 
their talk within an historical and moral context. These moral discourses are therefore 
discussed for how participants’ versions of events are positioned within different 
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discourses and the connections that can be made to those moral discourses identified in 
the review of asthma literature in Chapter Two. This analysis will indicate the 
relationship between systemic discourse and individual utterance in talk about medicine 
taking. It will then discuss the potential for how individuals’ talk may be seen as a 
manifestation of the moral issues that influence daily decisions about medicine taking. 
 
Chapter Five: Contextualising the Role of Moral Discourses in Talk about Prophylactic 
Medicine taking 
 
The analysis in Chapter Five will highlight specific interactional problems within the 
face-to-face interviews that needed to be overcome in order to make claims about the 
role of morality in talk about medicine taking. The talk identified in a minority of 
interviews could be seen to follow a different pattern to the talk identified in the body of 
the data. These “deviant cases” therefore required some explanation and a solution is 
presented drawing on ideas and techniques associated with Linguistic Ethnography.  
 
This analysis will highlight the importance of understanding how participants’ 
understood, or framed, the interaction taking place for the type of talk that was 
produced. It is argued that these framings are dependent on the interactional conditions 
of the interviews and other techniques from LE are drawn on to help specify the 
conditions of the interviews in this study. This analysis will indicate the circumstances 
under which speakers might have been preoccupied with accounting for their behaviour 
and when the role of morality may be present or absent in talk about medicine taking. 
Emphasising how the talk of participants was potentially restricted to the interactional 
conditions of the face-to-face interviews, raised the need to obtain “new” data that 
might validate the interview data. This was undertaken using a focus group, in which 
data was shared with participants and is the topic of analysis in Chapter Six.  
 
Chapter Six: Analysing Interactional Contexts in a Data-Sharing Focus Group 
 
This chapter discusses an exercise in providing a new piece of data in which moral 
discourses of medicine taking could be seen to be activated in the talk of participants. 
To provide what could be considered to be new data, a different type of interaction from 
the interview data was required which shifted attention away from individual’s asthma 
management. A focus group was used to perform this task but rather than asking 
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participants further questions about their asthma management, data from the face-to-
face interviews was shared with participants. The talk of focus group participants 
therefore provided a dataset which could be triangulated with the data obtained from 
face-to-face interviews and also with the moral discourses of asthma management 
identified in Chapter Two. It also provided a means by which participants could respond 
to findings from the interviews. Extracts from the focus group transcript are therefore 
examined for how moral discourses of medicine taking could be seen to be activated 
within the group’s discussion. This analysis will therefore provide a more substantial 
basis for evaluating the importance of accounting for morality in discussions of 
prophylactic medicine taking. 
 
Chapter Seven: Discussion.  
 
This chapter will review the rationale for this study and discuss what has been learnt 
about talk about medicine taking by using a discursive psychological approach to 
understand it. It will discuss the contribution of the different pieces of evidence about 
asthma medicine taking by considering the insights provided in how such talk is both 
interactionally constructed and also structured by wider moral discourses of illness 
management. Having built on the main analysis of interview data, through an analysis 
of the interactional conditions of the interviews and use of the focus group, the 
examination of properties of talk about medicine taking is extended beyond those 
examined in Chapter Four to incorporate lessons learnt about the production of talk in 
diverse contextual and interactional conditions, the allocation of blame and 
accountability within differing moral discourses and the relationship between structure 
and agency in participants’ talk. Lessons learned from the analysis of data in this study 
will be used to assess how talk about medicine taking may now be better 
conceptualised, by offering an alternative to individualistic notions of attitudes and 
beliefs. This will facilitate insights into how researchers and healthcare professionals 
might be helped to better understand talk about asthma management specifically and 
perhaps chronic illnesses more generally. Suggestions will be made for how they may 
be more attuned to moral issues in talk and how treatment decisions may be made that 
are compatible with those issues. The author will also offer suggestions for further 
research, using the methodological approach taken in this study, within adherence 
research and also in research looking at how people manage chronic illness in everyday 
settings. 
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Chapter Eight: Conclusion 
 
This chapter will summarise what has been learned in this study of talk about 
prophylactic medicine taking for people with asthma and chronic illness generally, 
underlining the contribution of the thesis findings to existing knowledge on adherence 
to medications and the methodologies applied in this field. The chapter will conclude by 
re-emphasising suggestions for future research and also how healthcare professionals 
might more appropriately support people with chronic illnesses manage their conditions.
37 
 
Chapter Two 
Morality in Talk about Prophylactic Asthma Medicine taking 
 
This Chapter is about building the rationale for studying the role of morality in talk 
about asthma management and prophylactic medicine taking. Approaches to medicine 
taking to date have tended to focus on people’s beliefs and attitudes to asthma and 
medicines which have potentially missed important insights about how such talk is 
likely to orientate to cultural notions of appropriate illness management. Such a focus 
raises questions about accepting the meaning of this talk as accurately representing an 
internal cognitive state, such as an attitude. There is therefore a strong case for 
examining how talk about medicine taking is constructed within a discursive and social 
historical context. In Chapter One the interactional components in the production of 
morality in talk were examined. Chapter Two will now examine how asthma and 
morality have been historically situated and therefore the relevance of focusing 
specifically on notions of morality in talk about asthma medicine taking. This will be 
done by concentrating first on historical links between asthma and morality, and 
secondly by examining how morality is linked to the control of asthma symptoms in 
contemporary clinical asthma guidelines. 
 
Initially, historical evidence will be offered that shows how asthma has been discussed 
in moral terms both in conceptualisation of its aetiology and in recommendations for 
prevention and treatment. This account will emphasise how individuals have been seen 
as accountable for the causes and solutions of asthma symptoms in various and shifting 
ways, manifesting in explanatory models focusing on individual psychology, personal 
habits, or individual exposure to environmental triggers. At the heart of these 
explanations lies the concept of control; of one’s emotions, lifestyle or breathing and 
morality is evident in these explanations through the different evaluations that have 
been attached to different displays of control. A key point in the development of modern 
medical understandings of asthma is that although individuals are no longer seen as 
accountable and therefore in control for contracting asthma, morality has potentially 
shifted to how individuals control their symptoms. This shift in the focus of morality 
from cause to the management of asthma is mirrored in parallel shifts in 
conceptualisations of other chronic illnesses over the last hundred years.  
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After investigating the historical linguistic connections between asthma and morality, 
this chapter will go on to examine how morality is linked to asthma in British society 
today. Examining the specific medical conceptualisation of asthma management that 
informs current clinical practice offers insight into the broader moral framework that 
regulates treatment decisions in a clinical setting. Medicine is the dominant institution 
in the management of illness and disease. Whether through the NHS or in privately-
provided services, medicine controls and distributes a vast array of resources to society 
in the management of health and illness. The people who need these resources are 
likely, (but will not necessarily), offer presentations of selves in ways which can enable 
them to gain access to required services and resources. It is therefore likely that in 
talking to other people about their health, they will manage such concerns within which 
control of oneself and one’s asthma symptoms are likely to be a central focus. 
Theorising such regulation of talk by social discourse will then be addressed by re-
interpreting findings from a research study that has reported clinician and patient talk 
about asthma management. This will involve tracing a path from the systemic 
discourses identified in medical discourses to their manifestation in individual 
utterances. However, tracing this path and other evidence will be drawn on to highlight 
how “self-control” is potentially one of many moral discourses that may influence how 
people talk about asthma management and make decisions about related prophylactic 
medicine taking. This will underpin a case to be made for broadening the analysis of 
morality beyond a medical lens to the management of illness in everyday life. Finally, 
having built a case for examining morality in asthma management talk, some 
conclusions will be drawn about what evidence is required for evaluating the 
importance of accounting for morality when interpreting talk about asthma prophylactic 
medicine taking. 
 
Historical Links between Morality and Asthma 
 
For those tracing the history of asthma, the work of Moses Maimonides (1135–1204) 
and his “Treatise on Asthma” is repeatedly cited (Cosman, 1983; Diamant, Boot, & 
Virchow, 2007; Muntner, 1968; Opolski & Wilson, 2005; Rosner, 1981). His work may 
represent the earliest attempt to set out formal guidelines for the prevention and 
management of asthma and we can see how Maimonides constructed asthma self-
management as a moral practice.  
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Maimonides was commissioned by the Sultan Saladin of Egypt to produce a series of 
dietary and behavioural recommendations for the management of the Sultan’s son’s 
acute asthma attacks suffered after having a cold. Maimonides’ book sets out general 
principles of personal conduct relating to asthma, defined as “difficulty of breathing or a 
pain in the chest”, and illness in general. Regulation of individual behaviour, in this case 
controlling one’s diet, emotional state and habits, were seen as fundamental to health 
outcomes. According to Rosner: 
 
Maimonides states that hygienic principles can be grouped into seven categories 
of which the first six are obligatory and the seventh is commendable: clean air, 
correct eating and drinking, regulation of one's emotions, exercise and rest, sleep 
and wakefulness, excretion or retention of wastes, and bathing and massaging. 
To these he adds the regulation of coitus as an important factor in a general 
health regimen. (Rosner, 1981, p. 247) 
 
According to Cosman, Maimonides argued that “mental anguish, fear, excessive 
mourning, and stubborn agitation affect not only gait and appetite but also the 
respiratory organs, causing accumulation of noxious gases and preventing proper 
inhalation”. To overcome psychic phenomena, Maimonides advised diet and medication 
allied with philosophy such as “laughing at death” and keeping the mind occupied with 
useful chores. However, Maimonides also argued that no medication should be 
prescribed for a condition curable by diet alone, “Medications encourage physiological 
dependencies, allowing the body’s natural urges to become ‘lazy’, and ultimately to 
disappear because of lack of use.” With some resonance with both Hippocrates’ 
commitment to the patient and contemporary conceptualisations of patient-centred 
medicine, Maimonides’ philosophy aimed to treat the “whole person” (Muntner, 1968). 
The central message of “The Treatise on Asthma” was that diet can be seen as a life 
pattern. A healthy body was necessary for a healthy soul. Medicine was seen to serve 
not only a physical but an ethical purpose, closely tied to philosophical responsibility - 
“nihil ex nihilo” (“nothing comes from nothing and nothing could be without effect”).  
 
The link between morality and the causes of asthma is less explicitly drawn in the 
Renaissance period from the 14th to 17th centuries, where the main focus on the causes 
of asthma was on environmental triggers (Cserháti, 2005; Ellul-Micalle, 1976). 
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However, Maimonides’ indication that individual psychology played a part in causing 
asthma can still be seen at the heart of explanations of asthma 700 years later (Osler, 
1892; H. H. Salter, 1860). William Osler, considered as a forefather of modern 
medicine, argued that “all writers agree that there is in the majority of cases of bronchial 
asthma a strong neurotic element” (Osler, 1892, p. 628).  
 
In the early 20th Century the link between an individual’s emotional disposition and 
asthma symptoms was increasingly replaced by explanations drawing on insight into the 
influence of the allergen. However, the role of individual psychology was rejuvenated in 
explaining the aetiology of a range of conditions in the 1930s to the 1950s. This largely 
reflected the emergence of the works of Freud and Jung and psychodynamic 
explanations of human psychology and behaviour. Over this period, psychodynamic 
theories were applied to a range of ailments, including asthma, by Alexander and 
colleagues at the Chicago Institute of Psychoanalysis and also by Dunbar based at the 
New York Psychoanalytic Institute. Both Alexander (1952) and Dunbar (1947) cited 
numerous individual patients’ cases as evidence to support the connection between 
emotion and the symptoms of asthma. Clearly drawing on the theories of Freud (1940), 
explanations of asthma were constructed in terms of a relationship between individual 
physiology and unconscious trauma, whereby an emotional state brings about the 
physiological display of asthma symptoms. Early childhood trauma was regularly 
identified as a key to asthma in later life, as frustration of too little or too much 
motherly love, positioning asthma symptoms as a substitute for crying, or as suppressed 
sexual desire. Here the role of deterministic, unconscious, unresolved emotional 
conflicts were foregrounded for the perennial asthma sufferer. The individual’s 
responsibility was not seen as orientated to external habits but to “seek help” to resolve 
internal causes.  
 
In these psychoanalytical accounts of asthma, morality is seen as linked to the existence 
of asthma in two important ways. First, the quality and quantity of motherly love is 
clearly evident, with the mother being wholly responsible for providing the “right” kind 
of love. Second, it is clearly the morality of sexual desire that is central to the causes of 
asthma. Here, the mother is positioned as representing the regulator of social morality 
and is once again responsible for how this morality is communicated to her child. In 
both cases the child and person with asthma was therefore seen as holding unresolved 
frustrations relating to either maternal affection or sexual desire, both carrying 
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associated feelings of guilt and fears about expressing unconscious and shameful 
desires. Dunbar and Alexandar argued that, through some complex process, unresolved 
traumas led to their patient’s asthma, seen as a manifestation of a self-perpetuating 
overdependence on one’s mother, as a strategy for attention-seeking or as a response if 
rejected.  
 
This theoretical link between individual psychology and physiology clearly constructed 
people with asthma as not only holding distasteful, immoral and unresolved desires, but 
also as devious manipulators. Whether these traits are seen as unconscious or not, the 
link between individual morality and asthma are clear and despite the increasing 
evidence that asthma was an organic, allergic condition, receiving a diagnosis of asthma 
would be clearly undesirable in this therapeutic context. In addition, as was typical of 
psychoanalysis, it was the individual’s responsibility, with the analyst as “guide”, to 
“confess" and come to terms with these conflicts (as interpreted by the analyst), in order 
to resolve one’s symptoms. Again, morality can be seen to be elucidated through a 
display of individual control – of motherly love (both control of the child by the mother 
and of the mother by the child); of repressed sexual desire (both by inhibiting it’s 
expression and relinquishing control through psychoanalytic therapy); and through the 
manifestation of asthma symptoms, seen both as a loss of control and as a mechanism 
for gaining control (of a mother’s affection). 
 
Morality and the role of metaphor in apportioning blame for illness 
 
The notion that the individual was responsible for both the causes and solution of one’s 
asthma, theorised through a psychosomatic manifestation of symptoms, is evidenced in 
views of asthma widely-held well into the 20th Century, (Crocket, 1956; Knapp, Carr, 
Mushatt, & Nemetz, 1966). Similar connections have also been identified in numerous 
other conditions, demonstrating how such ideas have pervaded Western cultural 
understanding of illness aetiology and management. Susan Sontag in her passionate 
critique of the metaphorical language of cancer, tuberculosis and AIDS (1991), argues 
that the more an illness has numerous causes and indefinite origins, the more scope 
there is for drawing on metaphor to help frame it in terms of what is socially or morally 
wrong. Sontag argues, citing examples from fiction, poetry, texts from psychoanalysts, 
doctors and personal diaries, that morality has been applied through metaphor to explain 
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illness, and has for centuries, been related to individual psychology, again laying blame 
on the individual both for the causes and the resolution of illness.  
Sontag identifies how in the 19th Century people were thought to get cancer through 
hyperactivity and hyperintensity and, as with asthma in Maimonides’ recommendations, 
were advised to “bear the ills of life with equanimity” and not to “give way” (Sontag, 
1991, p. 54) to grief. In contrast, and resonating with Dunbar and Alexander’s theories 
on the causes of asthma, this connection between inhibited emotional expression and 
cancer has been reversed more recently with the idea that the symptoms of cancer are 
linked to repressed emotion (Sontag, 1991, pp. 23-24). This is also precisely how 
tuberculosis was frequently understood until the identification of the germ “bacillus”. 
As seen with asthma, it is the control (or lack of) and (non)-display of emotions that is 
the cause of the physical symptoms of cancer, (or seen earlier with tuberculosis), and 
which provides the basis for how blame and accountability for one’s illness is 
distributed. Despite the role of the unconscious in many explanations of illness in the 
first half of the 20th century, the effect of linking control of emotions with physical 
health is to equate individual freewill with good or bad health, as Sontag argues, by 
citing the psychoanalyst Groddeck (1977, p. 47) “The sick man creates his disease, he is 
the cause of the disease and we need seek none other”.  
 
Sontag argues that metaphor is used as a device to apportion blame and accountability 
for the existence of illness. The examples discussed here suggest that people with 
chronic illnesses, including people with asthma, may therefore also need to orientate to 
issues of individual control in the metaphors they in turn employ to provide the 
evidence to manage blame and accountability. For example, Sontag cites the journal of 
Katherine Mansfield a year before her death in 1923: 
 
A bad day . . . horrible pains and so on, and weakness. I could do nothing. The 
weakness was not only physical. I must heal my Self before I will be well . . . 
This must be done alone and at once. It is at the root of my not getting better. 
My mind is not controlled. (p. 48) 
 
Identifying how morality has been linked with asthma in ways similar to other illnesses 
emphasises that asthma is one of a range of illnesses which have been interpreted by the 
available cultural understandings in which their physical symptoms are manifested and 
expressed. These understandings are clearly not fixed and, importantly, underline that 
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asthma as a disease and its management can be seen to be as much a social phenomenon 
as an embodied personal experience, carrying important implications for how asthma is 
managed. This highlights difficulties in assuming that people are responding to a fixed 
object (“asthma”) when they talk about medicine taking, and also illustrates that 
decisions about medicine taking may be made in light of culturally available 
understandings of asthma, illness and medicines.  
 
Shifts in individual accountability: From causes to managing asthma 
 
Although it is possible to identify similarities with how the causes of cancer and 
tuberculosis have been conceptualised, asthma has typically not been regarded as 
shameful, morally-laden or as life-threatening as cancer or tuberculosis. Similarly, it is 
easier to identify more recently emerging illnesses which have been more heavily 
associated with moral connotations of causation and management such as AIDS (Sankar 
et al., 2002; Sontag, 1991) or chronic fatigue syndrome, (CFS/ME) (Horton-Salway, 
2001). However, it wasn’t until the 1960s and 1970s that the psychoanalytical links to 
asthma were widely disregarded and asthma was recognised as predominantly physical 
in its causes (although tackling the symptoms of asthma through different forms of 
psychotherapy can still be seen today), (M. Wentworth, personal communication, 2009). 
Whilst, psychology continued to make an important contribution to understanding 
asthma causation, theories linking the mind to the symptoms of asthma placed little 
importance on the dynamics of the unconscious, instead developing theories 
emphasising physiological responses to stress and emotion (Wright, Rodriguez, & 
Cohen, 1998), echoing 19th Century recommendations (as well as Maimonides) that 
asthma symptoms can be reduced by maintaining a calm emotional state.  
 
The continuing connection made between psychology and asthma emphasises that 
whilst asthma is mainly considered to be a physical condition, it is a diagnosis applied 
to an array of symptoms also explained by an array of potential triggers, both physical 
and psychological. However, in contrast to some other non-terminal conditions whose 
aetiology is unclear, such as CFS/ME, (where people may often encounter difficulties in 
having their symptoms recognised and diagnosed as an organic condition), many people 
with asthma are commonly seen as resistant to a diagnosis, (Adams et al., 1997) often 
related to the intermittent nature of the disease (Halm et al., 2006; Horne & Weinman, 
2002). The combination of an historical association of asthma with a fragile individual 
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psychology, explanatory vagueness regarding any one individual’s diagnosis and the 
embodied experience of symptom-free periods help explain this resistance when framed 
within research contexts investigating beliefs about asthma. Importantly however, the 
movement in medical conceptualisations of asthma, from having psychosomatic to 
organic origins, may have shifted the patient’s accountability away from the external 
causes of contracting asthma to personal accountability for the control and display of 
asthma symptoms. With medications being developed, which, for the first time began to 
effectively tackle the inflammatory symptoms of asthma and offer that control, it was 
now the individual’s responsibility to use those medications as instructed. Health 
outcomes therefore, were increasingly seen as a result of conscious decision-making and 
research in the 1970s began to focus more directly on the individual knowledge which 
would ensure that those decisions were the “correct” ones (M. H. Becker, Radius, S.M., 
& Rosenstock, I.M., 1978). 
 
Asthma medications, asthma control and morality 
 
Although asthma medications had been developed since the early 1900s (Crompton, 
2006), it wasn’t until the 1960s that a treatment, salbutamol, which relieved symptoms 
without serious side-effects, was widely available (Diamant et al., 2007) and which is 
still the main form of asthma relief treatment prescribed today. Although forms of 
prophylaxis were in existence, medications largely oriented around the relief of asthma 
symptoms, bringing one’s breathing back under control. A key shift in prescribing came 
about through an increased understanding that airway inflammation is a key feature of 
asthma. Coupled with a greater understanding that regular use of bronchodilator 
treatments potentially masks inflammation meant that, with the introduction of the first 
inhaled steroid prophylactic treatment in 1972, (Brown, Storey, & George, 1972; Clark, 
1972), clinical practice shifted its conceptualisation of asthma care from “symptom 
control” to control by prevention through prophylactic treatments. However, it is only 
since the late 1980s and early 1990s that inhaled steroids have been widely prescribed. 
Explanations for this delay have been seen as public fears about inhalers following the 
UK asthma epidemic in the 1960s, combined with fears about steroids (Crompton, 
2006; Kelloway, Wyatt, & Adlis, 1994; Price, 1994), or as a result of continued 
evidence of asthma as an inflammatory disease and resulting changes in asthma 
guidelines (Diamant et al., 2007; Stafford, Ma, Finkelstein, Haver, & Cockburn, 2003).  
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The delay in the wide dissemination of prophylactic medications indicates that the shift 
in the conceptualisation of asthma pathology and management, to one of inflammation 
that needed to be prevented, is relatively new. This raises the question about how well 
this way of understanding asthma is circulated in society beyond clinical and research 
settings. As Horne, Leventhal et al have found, many people with asthma continue to 
regard asthma as something that is not a continuous disease that needs to be under 
constant control. It is possible that when many people with asthma talk about how they 
view their condition and make decisions about medicine taking, they orientate their talk 
to the older “symptom control” framework of asthma management, in spite of fully 
understanding the need for prophylactic medications. This may be because a symptom 
control discourse is normalised within a wider range of social spaces and which may be 
more compatible with the everyday lives of people with asthma. Having looked at 
examples of how asthma has been linked with morality, realising that new forms of 
discourse may operate concurrently with older discourses raises questions about how 
discourses of illness management interact and transfer across discursive contexts to 
influence treatment decisions. In the following section more recent examples of text and 
talk are investigated to understand contemporary moral discourses of asthma 
management. This examination looks for evidence that the medical discourse of 
preventive asthma management carries notions of morality regarding asthma 
management that will be communicated through the use of clinical documents and will 
function to structure the talk and decision-making of clinicians and patients.  
 
The Role of Morality in Contemporary Asthma Management 
 
The biggest influence on the practice of clinical asthma management today is the body 
of asthma guidelines. Asthma guidelines are based on what is considered to be the best 
available evidence and provide the main source of guidance for clinicians treating 
people with asthma in primary care in Britain. This evidence, largely generated through 
randomised controlled trials, seen as the gold-standard evidence informing guidelines, 
promotes the idea that the way to manage asthma is through the use of self-management 
plans and appropriate pharmacological treatment. Self-management plans (SMPs) 
incorporate advice about prophylactic medicine taking and adherence to both the plan 
and the medication is a key requirement for the plan to be effective. The review 
undertaken here will present key elements of policies that set out strategy and guidelines 
for managing asthma. It will then focus on asthma SMPs to build an argument for how 
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notions of morality can be seen to transfer from asthma management policies to clinical 
decisions and hence medicine taking. SMPs can be seen as “fixed texts” (Blommaert, 
2005), potentially a powerful tool which may be transferred across contexts. In this 
instance the text of the SMP is “guided” by the recommendations within asthma 
guidelines within a clinical context which is then transferred to people’s everyday lives. 
To follow this process, the findings from a piece of qualitative research by Jones, Pill 
and Adams (2000) will be re-interpreted. Jones et al explored nurse, doctor and patient 
views of SMPs and reported general resistance to SMPs amongst these different 
participants. In addition, they reported a gulf between professionals’ concept of the 
“responsible asthma patient” and patients’ views. Instead of viewing the talk of 
participants reported in their findings as accurately representing individual attitudes, we 
can view this talk as a form of social action, enabling insight into how the clinicians and 
patients orientated to issues of blame, autonomy and accountability. This type of talk 
can be seen as an activation of an institutional moral discourse of asthma management 
apparent in asthma policy documents and which positions clinicians and patients as 
simultaneously empowered and accountable for their decisions. This will highlight how 
the individualistic ideology of patient-centred medicine creates a decision-making 
paradox for clinicians and patients when set against the evidence informing asthma 
guidelines.  
 
Asthma Management Policies and Guidelines 
 
Two different sources were examined to identify evidence of a moral discourse of 
asthma management being constructed within current asthma policy. Although 
numerous guidelines have been developed over the last 30 years, the two most 
influential governing bodies influencing asthma management in clinical settings in the 
UK are the Global Initiative for Asthma (GINA) (2009) and the British Thoracic 
Society (BTS), (2008 revised June 2009). GINA, launched in 1993, is comprised of a 
network of asthma care experts, organisations and public health officials that collaborate 
to disseminate a global strategy for asthma management and prevention. GINA receives 
unrestricted educational grants from numerous pharmaceutical companies and works 
closely with the National Heart, Lung and Blood Institute and the World Health 
Organisation in the development of its strategy. The British Thoracic Society has 
worked in collaboration with the Scottish Intercollegiate Guidelines Network (SIGN) 
and who have jointly developed asthma guidelines since 1999. This decision to 
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collaborate was based on an agreed view that a new guideline was needed using 
“explicitly evidence-based methodology.” It was developed by a multidisciplinary 
group of practising clinicians who review the evidence using a standard methodology 
based on a systematic review of the evidence.  
 
The language of the GINA report and BTS guidelines was examined for its discursive 
positioning of the roles and responsibilities of clinicians and patients. By choosing to 
review these documents, it is being proposed that one way in which medical 
representations and moralities of health behaviour are communicated through 
institutions is through the discursive power of bureaucracy and governance. This is not 
to exclude the possibility that moralities within medicine might come about and be 
disseminated in other ways but to argue that the institutional power of formal 
documentation is an important means for this. The focus here is therefore the study of 
the power of language in communicating the meaning of illness and how language and 
treatment decisions about illness are regulated, reproduced and produced through talk. 
These documents will be examined by drawing on the principles of language seen as 
social action discussed in Chapter One. On a literal level, this is self-evident in that 
asthma reports and guidelines are intended to “guide” clinical practice. However, 
guidelines may also be viewed as a form of rhetoric which construct doctors and 
patients in particular ways and links these constructions to specific types of behaviour. 
In particular, asthma guidelines work to “recommend” certain types of behaviour and 
not others, thereby indicating a moral value to these respective behaviours. The extracts 
selected here represent the rhetorical acts that the guidelines appear to perform. We can 
then examine these forms of rhetoric for the sort of moral discourse that appears to be 
constructed and subsequently whether we can see this discourse activated in talk about 
taking prophylactic medications. 
 
GINA 
 
In 2004, a key objective of the GINA guidelines was redefined. This was to develop a 
strategy for asthma management that was based on clinical asthma control rather than 
classification of the patient by asthma severity. The role of the health care professional 
was to: “establish each patient’s current level of treatment and control, then adjust 
treatment to gain and maintain control.” Asthma control is then defined as: 
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• No (twice or less/week) daytime symptoms 
• No limitations of daily activities, including exercise 
• No nocturnal symptoms or awakening because of asthma 
• No (twice or less/week) need for reliever treatment 
• Normal or near-normal lung function results 
• No exacerbations 
(Global Initiative for Asthma (GINA), 2009, p. xii) 
 
GINA emphasises that any fall from this optimum state should result in re-assessment 
of asthma treatment, a warning of deteriorating asthma being an increased use of 
reliever medication. To achieve this control GINA sets out the appropriate medications 
that should be prescribed, “stepping up” and down asthma treatments as the required 
level of control is achieved. Stepping up may involve the introduction or increase in the 
use of prophylactic therapies, typically inhaled corticosteroids, but may also include 
leukotriene receptor antagonists, (an alternative tablet therapy) or long-acting beta-
agonist treatments, which are usually prescribed in addition to inhaled corticosteroids.  
 
The challenge to medicine is to ensure that control is achieved to help reduce “the 
burden of asthma.” This is viewed “not only in terms of health care cost but also of lost 
productivity and reduced participation in family life.” Preventive or prophylactic 
medications therefore have a critical role to play within GINA’s strategy and to succeed 
in their objectives it is essential that people with asthma take prophylactic medications 
as prescribed. GINA proposes that there are five interrelated components to their asthma 
management and prevention program: 
 
1. Develop Patient/Doctor Partnership 
2. Identify and Reduce Exposure to Risk Factors 
3. Assess, Treat and Monitor Asthma 
4. Manage Asthma Exacerbations 
5. Special Considerations 
(p. 50) 
 
Component 1 has been a recent addition to the prevention programme and the 
doctor/patient partnership is seen as a process of relationship-building: 
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The partnership is formed and strengthened as patients and their health care 
professionals discuss and agree on the goals of treatment, develop a 
personalized, written self-management action plan including self-monitoring, 
and periodically review the patient’s treatment and level of asthma control. 
Education remains a key element of all doctor-patient interactions. (p. xii) 
   
It is also argued that clear communication between the health care professional and 
patient is the key to enhancing compliance. Key factors to facilitate communication are 
reported as: 
 
• A congenial demeanour (friendliness, humor, and attentiveness) 
• Engaging in interactive dialogue 
• Giving encouragement and praise 
• Empathy, reassurance, and prompt handling of any concerns 
• Giving of appropriate (personalized) information 
• Eliciting shared goals 
• Feedback and review 
(p. 51) 
 
These factors are presented within a section which emphasises the importance of 
delivering effective education, seen as an integral part of consultations. In this section, 
the report also discusses barriers to adherence to prophylactic medications. Non-
adherence is defined: “in a non-judgemental way as the failure of treatment to be taken 
as agreed upon by the patient and health care professional” (pp. 52-53). The following 
drug and non-drug factors are identified as related to non-adherence: 
 
Drug factors 
• Difficulties with inhaler devices 
• Awkward regimes (e.g., four times daily or multiple drugs) 
• Side effects 
• Cost of medication 
• Dislike of medication 
• Distant pharmacies 
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Non-drug factors 
• Misunderstanding or lack of instruction 
• Fears about side-effects  
• Dissatisfaction with health care professionals 
• Unexpressed/undiscussed fears or concerns 
• Inappropriate expectations 
• Poor supervision, training, or follow-up 
• Anger about condition or its treatment 
• Underestimation of severity 
• Cultural issues 
• Stigmatization 
• Forgetfulness or complacency 
• Attitudes towards ill health 
• Religious issues 
(p. 53) 
 
The extracts presented here from the GINA report illustrate how the subjective 
experience of the patient is interwoven with the objective components required in 
achieving asthma control. We can see how these twin concerns manifest themselves 
within the context of patient education. Individual patient experience, feelings, beliefs 
and attitudes are recognised, but within the context of factors that may influence 
patient’s adherence. The role of the clinician is to ascertain the level of asthma control 
and prescribe accordingly (the objective component), but also to act as educator to the 
patient, working to align patient attitudes and understanding with those required to 
adhere to the relevant medication. This is constructed as working in “partnership” which 
is “strengthened”, principles which adhere closely to the concept of concordance held 
within patient-centred medicine initiatives (Pollock, 2005; Royal Pharmaceutical 
Society of Great Britain, 1997). However, with patient education positioned as central 
to the consultation, medical knowledge is upheld as the gold standard by which to 
measure the accuracy of beliefs and perceptions about health and illness. This tension 
between the knowledge of the patient and the knowledge of medicine is even more 
pronounced when specific guidelines and recommendations are set out for clinicians to 
follow within asthma consultations. 
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BTS Guidelines 
 
At the outset, the BTS guidelines state that the guidelines are not intended to be 
construed or to serve as a standard of care and stress the important role played by the 
individual clinician and patient in making decisions about asthma management. 
However, as with GINA, the BTS state that the aim of asthma management is the 
control of the disease and sets out its definition of asthma control which closely matches 
the GINA definition. However, the BTS also state that “In clinical practice patients may 
have different goals and may wish to balance the aims of asthma management against 
the potential side effects or inconvenience of taking medication necessary to achieve 
perfect control” (p. 33). The BTS emphasise a “stepwise approach” for determining the 
most appropriate treatment to start with, stepping up or down the quantity and types of 
medication as is necessary according to the level of asthma control indicated by the 
patient’s symptoms. A key part of this assessment states that “Before initiating a new 
drug therapy practitioners should check compliance with existing therapies, inhaler 
technique and eliminate trigger factors” (p. 33). 
 
The guideline consists of recommendations which are graded according to the amount 
and quality of the evidence available. Evidence is graded from 1++ being the highest 
quality down to 4. Randomised controlled trials (RCTs) or systematic reviews of RCTs 
are considered the gold standard evidence within this grading system. This is then 
followed by case control and cohort studies. At the bottom end of the grading are “non-
analytic studies, e.g. case reports, case series’ and expert opinion”. The “Grades of 
Recommendation” A, B, C and D are assigned based on the levels of evidence that are 
available for each area of asthma management. A tick box is also used to indicate 
“recommended best practice based on the clinical experience of the guideline 
development group.” We can see this grading method played out in the stepwise 
recommendations where each of the 5 asthma steps, from mild asthma at step 1 to 
severe asthma at step 4 and 5, recommend a medication and state clearly the grading 
which that recommendation is based upon. The recommendation for the use of regular 
preventive therapy has an “A” grade, meaning it has a range of high-quality evidence 
available to support that recommendation (p. 36). This recommendation provides clear 
guidance for the practising health care professional which can be broadly applied to all 
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asthma patients. BTS also set out the asthma-related features which indicate that a 
patient is likely to benefit from an inhaled steroid. 
 
• Exacerbations of asthma in the last two years 
• Using inhaled β2 agonists three times a week or more 
• Symptomatic three times a week or more 
• Waking one night a week 
(p. 36) 
 
The asthma review and self-management plans/action plans:  
 
According to the BTS guidelines, finding the optimum treatment for the patient’s level 
of asthma severity involves regular review to enable “stepping down” of treatments. 
 
Regular review of patients as treatment is stepped down is important. When 
deciding which drug to step down first and at what rate, the severity of asthma, 
the side effects of the treatment, time on current dose, the beneficial effect 
achieved, and the patient’s preference should all be taken into account.  (p. 46) 
 
A key proposal within the guidelines is that a central part of any asthma review is for 
the use of self-management (SMPs, also known as action plans) (see pages 107-108 of 
BTS guidelines for example plan). It also recommends that the number of patients 
receiving SMPs should be audited. It also suggests that audits that feed back the 
guidelines’ recommendations to clinicians, regarding the management of individual 
patients, may improve outcomes.  
 
Proactive clinical review of people with asthma improves clinical outcomes. 
Evidence for benefit is strongest when reviews include discussion and use of a 
written action plan. (p. 80) 
 
The ideal content of an asthma review consultation is uncertain. Discussion and 
provision of a written action plan leads to improved outcomes. Other activities 
likely to be important are reviewing understanding of medication role and use, 
checking inhaler technique, recording lung function. Structured review systems 
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such as… improve the recording of relevant data and may prompt a search for 
causes of suboptimal asthma control, such as under-treatment, poor adherence or 
poor inhaler technique. However, such tools can lead to a more physician-
centred or template-directed consultation. Reviewing patients using a patient-
centred style of consultation can lead to improved outcomes. (p. 81) 
 
This emphasis on a “patient-centred style of consultation” is evident throughout the 
BTS guidelines. There are lots of reference to the perspective of the patient and 
emphasis of the individual and personalised nature of asthma management, 
“personalised action plans”, “patient-centred style of consultation”, “ownership”, 
“patients may have different goals”, “patient preference”. In addition the “ultimate 
judgement” of the clinician is essential.  
 
As was seen in the GINA report, the role of education, offered by the clinician, is 
nevertheless fundamental in this approach as we can see in the extracts below. 
 
Successful [self-management] programmes vary considerably, but encompass: 
Structured education, reinforced with written personal action plans, though the 
duration, intensity and format for delivery may vary. 
Recommendation: Introduce personalised action plans as part of a structured 
educational discussion. (p. 85) 
 
Checklist 1. Suggested content for an educational programme/discussion. 
This checklist is intended as an example, which health professionals should adapt to 
meet the needs of individual patients and/or carers. The purpose of education is to 
empower patients and/or carers to undertake self management more 
appropriately and effectively (my emphasis). Information given should be tailored 
to individual patient’s social, emotional and disease status, and age. Different 
approaches are needed for different ages. (p. 86) 
 
Here, (and also within the GINA report), we can see how the provision of information 
and an SMP is equated with the individual patient as empowered decision-maker. This 
positioning of the clinician and patient as informed decision-makers means that 
responsibility for treatment decisions is considered to lie with the doctor, nurse and 
patient. However, the graded “evidence” means that if clinicians do decide to reject the 
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recommended treatment option they are going against the “best practice” set out within 
the guidelines. This position is reinforced at different points within the document and 
the advice is clear that patient and clinician choice needs to take place within the 
structure of the guidelines. 
 
Self management programmes will only achieve better health outcomes if the 
prescribed asthma treatment is appropriate and within guideline 
recommendations. There is some evidence that ownership of a self management 
plan may attract better treatment (i.e. increased steroid provision from attending 
physicians). (p. 86) 
 
Recommendation: Initiatives which encourage regular, structured review 
explicitly incorporating self-management education should be used to increase 
ownership of personalised action plans. (p. 88) 
 
The BTS guidelines offer little insight into how to overcome situations where the goals 
of patients do not easily match the advice in the guidelines, other than to ask open 
questions, as set out in a section titled “Compliance and Concordance” (p. 86). It is 
arguable that the space for treatment options is therefore limited within the structure of 
the asthma guidelines. This potentially creates a situation whereby patients, doctors and 
nurses are held accountable for problems arising in the management of a patient’s 
asthma as we can see in the below extract taken from the opening paragraphs of the 
BTS guidelines. 
 
The ultimate judgement must be made by the appropriate healthcare 
professional(s) responsible for clinical decisions regarding a particular clinical 
procedure or treatment plan. This judgement should only be arrived at following 
discussion of the options with the patient, covering the diagnostic and treatment 
choices available. It is advised, however, that significant departures from the 
national guideline or any local guidelines derived from it should be fully 
documented in the patient’s case notes at the time the relevant decision is taken. 
(p. 1)  
 
This discursive framework of the doctor-patient relationship as “concordant”, 
“proactive” and “empowered”, set against the need to document “significant departures” 
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from the guidelines arguably creates a decision-making paradox whereby patients, 
doctors and nurses are simultaneously responsible or “empowered”, yet restricted by the 
treatments available and regulated in their decisions. As a result, poor health outcomes, 
or the “burden” of asthma, is potentially positioned a result of treatment decisions being 
outside of “best practice”, lacking “concordance” with patient’s perspectives, or 
clinicians not being “proactive” enough.  
 
The Manifestation of Accountability in Talk about Asthma Management 
 
The positioning of clinicians and patients, within asthma guidelines, as both accountable 
and empowered can be seen to be manifested in interviews with clinicians and patients 
regarding SMPs. In a qualitative study using focus groups, Jones, Pill and Adams 
(2000) explored the views of health professionals and patients with mild to moderate 
asthma on the role of guided SMPs for asthma. Jones et al found that in the majority of 
cases, SMPs were received unenthusiastically and neither patients nor clinicians 
considered them to be either useful or effective in managing asthma. This resistance to 
SMPs may indicate the underlying tensions manifest within asthma guidelines between 
the evidence-based recommendations and the notion that doctors, nurses and patients 
have autonomy and are responsible for the decisions that are made about treatment. We 
can briefly re-examine some of the extracts that Jones et al provide to theorise that this 
tension might be transmitted from the proposal to use SMPs stated within asthma 
guidelines to the talk of doctors, nurses and patients in their discussion about the role of 
SMPs in asthma management. This might then be used to theorise more generally 
regarding the provision of asthma interventions and the everyday lives of people with 
asthma. 
 
In primary care, specialist respiratory nurses are commonly responsible for managing 
patients’ on-going asthma through asthma reviews, whilst the GP tends to see asthma 
patients for emergencies. The review of the work of Jones et al reported here, therefore 
focuses on the views of nurses rather than GPs as this is likely to most effectively 
demonstrate a case where the prevalence of accountability in talk about SMPs can be 
seen. Their study offered vignettes of patients talking about SMPs to elicit participant’s 
views in focus group discussions. The following extract was provided by Adams et al as 
representing the main issues to emerge from focus group discussions with nurses. 
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Nurse W: They do have a place but you have to give them to motivated 
patients—with instructions there to make sure they will seek medical advice if 
the condition is deteriorating . . . And not give it to people who would take it too 
far and leave it too long before seeking help.  
Nurse X: Well they say, “The nurse has given me this so I should be able to 
manage myself.” Your concern is then whether they will try to manage too long 
before coming back, and then they reach a crisis. 
Nurse Y: You can't cover every eventuality on a plan either—you can't account 
for every symptom so some of them would say, “Well, I haven't got that or the 
peak flow hasn't quite got to that stage so I'd better wait until it gets there.” 
Moderator: You're making them sound quite dangerous. 
Nurse X: They can be, especially for very intelligent people—they are the worst. 
(Jones et al., 2000, p. 1508) 
 
These researchers report that some nurses considered patients as “overconfident” or 
“cocky” and that their own guided SMPs could lead to “bad habits” which could 
militate against optimal health and treatment. Nurses (and GPs) also reported that the 
clinician-patient perspective was regarded as fundamental in ensuring effective asthma 
management and were concerned about patients “blind obedience” to standardised 
plans, particularly with patients who lacked “intelligence”, “commonsense” or didn’t 
understand the SMP. The clinician is therefore the key in educating patients, who, along 
with SMPs, are accountable for asthma management problems.  
 
In the examples provided by Jones et al, patients were seen as “not the best judges of 
their own health” and were constructed into diverse groups: motivated-unmotivated; 
intelligent-unintelligent; cocky and overconfident; self-doubting and lacking 
confidence. Different asthma management behaviours are associated alongside these 
identities. “Motivated” patients follow instructions and seek help when needed, 
unmotivated “leave it too long”. “Intelligent” patients think about their asthma and the 
SMP too much and make incorrect decisions about their asthma and again avoid seeking 
medical advice. “Cocky and overconfident” patients are also associated with a 
reluctance to seek medical advice when needed. These statements serve the purpose of 
managing any potential accusations that the nurse is incompetent or has not effectively 
communicated the correct piece of education about their patient’s asthma. Whether this 
is true is not the issue here. Instead, the focus is that nurses can be seen to be managing 
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their accountability for their patients’ asthma, and their expertise as nurses in 
discussions about SMPs. By constructing SMPs as potentially rigid and patients as 
having difficult personalities, they achieved two things. First, crises in patients’ asthma 
are blamed on SMPs and patients, and not nurses. Second, the role of the nurse is the 
most important in achieving positive outcomes positing that if patients attended the 
surgery when they needed to then there would be fewer problems. They are therefore 
managing the potential threat to their expertise as nurses, that SMPs potentially 
undermine the need to have a nurse at all. The moderator neatly summarises what has 
been achieved in the talk about SMPs in this focus group when they say “You're making 
them sound quite dangerous.” 
 
The management of accountability and expertise in the nurses’ talk highlights a moral 
dimension for their clinical practice and hints at tension between the dictates of 
medicine within asthma guidelines and clinical opinion. By dealing with potential issues 
of blame for patients’ poor asthma management, the talk of these clinicians can be seen 
as versions of the moral discourse of asthma management evident in the asthma 
guidelines. In the guidelines, it is the clinician who is simultaneously autonomous and 
independent, (in concordance with the patient) and accountable for treatment decisions. 
From the limited data available in the reported views, the nurses appeared to be 
reproducing a version of this discourse, produced interactionally within the focus group 
of the study reported by Jones et al. This is evidenced in how nurses appeared to be 
managing an interactional tension between professional autonomy and accountability, 
argued as creating a “decision-making paradox” for clinicians. They did this by 
constructing a contingent relationship between the level of the patient’s asthma control 
and the clinician’s accountability. The nurses’ constructions of SMPs as potentially 
standardising patient’s asthma management, patients as “not the best judges of their 
own health” using various categories of patient, alongside a concept of time (“leave it 
too long”), are critical rhetorical devices in building this relationship. The moral 
discourse of asthma management can be seen to structure the nurses’ talk but at the 
same time a newer, more complex version of this discourse is created within the focus 
group interaction. Understanding how SMPs, patients and time are constructed and 
deployed as devices within this talk, links the individual utterances of the nurses to the 
systemic discourse of asthma management suggesting that such a discourse is 
transferred across contexts through the fixed text of the guidelines.  
 
   
 
 
58
We can now briefly examine the patient views in the paper by Jones et al for evidence 
that issues of accountability and autonomy were also managed in their discussions of 
asthma management.  
Jones et al reported that:  
 
“All but one of the patients agreed that self-management plans might be of use 
to other patients but, for differing reasons, were not relevant for them.” 
“Non-compliant patients felt plans could be useful for people with “more 
serious” or “proper” asthma, whereas compliant patients felt they were 
“pointless for them personally” or “they already had a full understanding of the 
issues.” (Jones et al., 2000, p. 1509) 
 
Although there is limited data to interpret the talk of patients reported in the study by 
Adams et al, there is a strong indication that the patients within the focus group 
“minimised” and “normalised” their asthma. This was evident in how participants 
positioned their own asthma with those with “proper” or “more serious” asthma. This 
sort of talk which minimises illness has been identified across a range of conditions and 
levels of severity (Bury, 2001; Coxhead & Rhodes, 2006; Protudjer, Kozyrskyj, Becker, 
& Marchessault, 2009; Prout et al., 1999). It has been argued that this type of rhetoric is 
common because people with chronic illness need to present themselves as fit to 
participate in society (Frank, 1995; Williams, 1993), to restore former selves (Charmaz, 
1990; Yoshida, 1993) or as someone with a “health problem that is not an illness” 
(Cornwell, 1984). Despite the limited available data, it can be argued that the idea of 
using SMPs, for patients in the study by Jones et al, potentially placed them and their 
asthma outside of these categorisations and may have been seen as threatening the 
discursive positions that they constructed in their talk. “Why do I want something 
written down? You know . . . your chest tells you” (p. 1509). The version of asthma that 
the person constructed was therefore critical in undermining the potential view that they 
needed to be taking their asthma more seriously; that they should have been using an 
SMP in their everyday life; and should be held accountable for adhering to the 
instructions set out in the SMP.  
  
As with the nurse’s views, we can see how patients attempted to provide an autonomous 
and authoritative version of their asthma which functioned to resist the use of SMPs, as 
well as indicating how they were responsibly managing their condition, “we are self 
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managing to a certain extent, where they give us the medication to take—so we are self 
managing ourselves, aren't we” (p.1509). However, the patients’ discursive positions 
regarding SMPs and their own asthma hinted at worlds where minimising their illness 
might be appropriate. For these people, with mild to moderate asthma, managing their 
condition potentially needed to be done in a way which did not place the person beyond 
the realms of what is considered normal for the activities that they engage in everyday 
life. This indicates a moral agenda in the patient’s everyday lives about what constituted 
normal and acceptable behaviour within the different social networks that they 
participated in. It may be argued that these concerns were hinted at in their talk because 
of the need to resist the challenge to these notions of normality that meanings of asthma 
and SMPs represented. Their minimisation of asthma can be seen as an attempt to resist 
alternative perspectives that view their asthma as “more serious” or a “proper” disease 
that needs close monitoring. It would be likely that people, considered to have mild to 
moderate asthma, in dealing with healthcare professionals and researchers, may 
construct a version of their asthma that orientates to these everyday concerns when 
discussing their use of prophylactic medications. These may be managed in conjunction 
with ideas about responsible illness management as seen from a medical perspective.  
 
There is therefore a conceptual need to engage with these alternative moral perspectives 
of everyday life and how they do or do not interact with medical perspectives on illness 
management. More fully appreciating how different moralities may operate in asthma 
management talk may help understand the limitations of the current clinical discursive 
context that positions clinicians and patients as responsible within a restricted range of 
choices. We might also be able to understand how cultural explanations of illness 
management influence the decisions that people make about medicine taking and illness 
prevention in everyday life.   
 
The Role of Lifeworld Discourses of Illness Management and Medicine Taking 
 
The moral discourses of illness management which may have most influence on 
everyday decisions about medicine taking are those discourses which circulate social 
settings, such as work, home, school, where the individuals concerned have an interest 
at stake. The importance of locating the accounts that people provide within a cultural 
framework has already been illustrated in studies of talk of people with other chronic 
illnesses (Bury, 2001; Lawton, Ahmad, Peel, & Hallowell, 2007; Williams, 1993) and 
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in studies of health and illness perspectives more generally (Backett, 1992; Cornwell, 
1984; Crawford, 1984). In asthma, “minimisation talk” such as that identified in the 
research of Jones et al research, potentially provides one example of the value of 
engaging in the symbolic space of people with asthma outside of medicine’s illness 
management discourse. This symbolic space of everyday life can be referred to as the 
“lifeworld”. Originally a concept coined by Schutz (1962) as “natural attitude”, it is 
used in this research to refer to the “symbolic space in which our personality and culture 
are experienced” (C. I. Salter, 2005).  
 
In this study, the objective was to identify evidence that moral discourses, from medical 
and lifeworld origins, were activated in talk about prophylactic medicine taking which 
then indicated some of the grounds upon which decisions about medicine taking were 
made. Lifeworld discourses were therefore theorised as alternatives to institutional 
medical discourses of asthma and illness management that have been discussed in the 
analysis of asthma guidelines. For example, Adams, Pill and Jones (1997), in a study of 
different asthma identities, highlighted how participants varied in the people and 
contexts in which asthma was revealed. Respondents’ talk was interpreted as “identity 
work” drawing direct links between respondents’ “attitudes to medication” and “beliefs 
about their condition.” Whilst this study adopted an alternative perspective in how such 
talk is conceptualised, the realisation that illness talk, illness identity and illness 
management differs across social contexts reveals the differing moral dimensions that 
circulate these social networks and lifeworld contexts. 
 
Self-control and other lifeworld discourses 
 
Individual culpability, for the causes and display of asthma and other chronic illnesses, 
has been shown in this chapter as linked, circulated and shifted in a variety of linguistic 
contexts through history. Sontag’s (1991) analysis of illness metaphors highlighted how 
the need for self-control has been evident in culturally common, or “lay” 
conceptualisations, as well as authoritative theories of illness aetiology and symptom 
prevention. Gareth Williams also identifies lifeworld concerns with self-control, in his 
analysis of the role of morality in interview transcripts with people living with 
rheumatoid arthritis (Williams, 1993). His analysis demonstrated that the moral life of 
the lifeworld has a powerful influence on decisions made about health and illness, to 
which medicine taking is only part. He discusses how (p. 102) society values “self-
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control” and the tension this has with living with a chronic illness because it involves a 
loss of control through interference on daily activities. Williams’ analysis reconstitutes 
behaviour surrounding chronic illness management as less about denial or acceptance 
within a rehabilitation framework but, rather, what he calls “moral practices”, that are a 
continued expression of the self in a moral context through mundane activities.  
 
Williams also argues that terms such as “adaptation”, “adjustment”, “coping”, when 
applied to how people live with chronic illness, are based on a world of contingency. 
These are categorisations of actions according to potential adverse outcomes, and in the 
case of asthma, this is an asthma attack, (this type of talk was evident in the nurse 
vignettes discussed in the research by Jones et al). Williams argues that these 
categorisations fail to account for peoples’ talk about their illness not orientating to 
these contingencies. People with chronic illness, he argues, are not trying to display an 
optimum management strategy but how they wish to be understood according to the 
differing moral dimensions that inform their lives.  
 
Self-control has been made even more explicit in asthma management literature where 
control of one’s breathing has been regarded as a display of emotional or symptom 
control. Self-control in asthma management is therefore set within an institutional and 
lifeworld context and is potentially an important discourse which circulates these 
different cultural spaces. A moral life set within a lifeworld context where self-control is 
paramount, may mean a life where medications have limited functions and are hence 
used selectively. Interpreting people’s talk about chronic illness and medicine taking as 
“attitudes”, lacking a consideration of moral and interactional context, runs the risk of 
inappropriately judging that person outside of that moral context and according to a 
different set of criteria. Such “attitudes” are often subsequently used as evidence that the 
attitude needs to be changed if the health-related behaviour is to change. Seen in this 
light, educational strategies are only likely to work if they can be accommodated into 
this moral framework.  
 
However, talk about health and illness may not be restricted to notions of self-control 
and the embodied display of symptoms, but may also orientate to other lifeworld 
discourses that impact upon discussions of health and illness (Cornwell, 1984; Pajari, 
Jallinoja, & Absetz, 2006). For example, Cornwell’s study of East Londoner’s accounts 
of health and illness demonstrated a range of lifeworld concepts and discourses that 
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speakers connected between work and health including: good and bad people, 
malingerers, hypochondriacs, stoics, hard-working, lazy, moaners and cheerful people. 
These insights showed that in discussing one’s health it may not be sufficient to only 
present oneself as fit for work but it is also necessary to display a set of personality 
characteristics that go along with “being healthy.” This point emphasises that health-
related discourses do not have clear boundaries that speakers orientate to independently. 
Cornwell’s data highlighted how lifeworld concepts, that circulate lifeworld settings 
regarding work, interact with one another but also with medical discourses. In 
discussing health and illness management therefore, speakers can be seen to manage 
multiple concerns simultaneously. Decisions about medicine taking may be informed by 
the moralities of differing social networks in which people live their lives and 
competing moralities may create difficulties for the rhetorical work the participants 
undertake.  
 
Insights of talk within lifeworld contexts offer a distinctly different understanding of 
medicine taking talk, than that offered by social cognitive conceptualisations. Rather 
than viewing statements about medicine taking as orienting to one object of thought, 
such as asthma or medicine taking, a lifeworld view raises the possibility that multiple 
concerns are attended to simultaneously. Some of these concerns are likely to be based 
on the circulation of moral discourses of illness management and others regarding 
acceptable personality characteristics and behaviour in the social settings which 
speakers have a stake in. In addition, understanding talk about health and illness as 
about speakers attending to multiple perspectives within differing social spaces and 
social networks, positions medicine taking as an activity that needs to be compatible 
with participation in everyday life and extends the experience of asthma from a physical 
to social experience. 
 
Evidence Required to Investigate the Discursive Construction and Role of 
Morality in Talk about Prophylactic Medicine Taking 
 
Chapters One and Two have thus far presented a rationale for exploring how people 
construct prophylactic medicine taking within interactions and link these constructions 
with notions of morality. This argued that our understanding of talk about asthma 
management and medicine taking needs to be reconstructed and re-specified, to move 
from a view of talk as representing individual attitudes to one which sees talk as 
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language constructed within social spaces. This re-specification emphasised that it is 
only when we view such talk from within a discursive framework that we can fully 
understand speaker’s orientations to moral issues in their talk. It is now important at this 
stage to establish what is meant by morality in this study and the evidence that is 
required to investigate this definition of morality in talk about prophylactic medicine 
taking.  
 
Definition of morality 
 
By situating the role of morality within an historical and interactional context the author 
of this study constructed a version of morality itself. This is a concept that is not fixed 
or real but one that varies both between and within interactions about illness 
management and medicine taking. Members of interactions may mutually construct 
these versions drawing on culturally-available and shared understandings about 
appropriate illness management and behaviour. In this chapter a “moral discourse of 
asthma management” was discussed within asthma prevention initiatives and clinical 
practice that carries with it notions of good and bad patients, correct or incorrect beliefs 
and therefore a code of conduct about appropriate behaviour regarding asthma 
prevention and management. However, people may also orientate their talk to social 
aspects of life in any number of ways, such as a code of conduct within the workplace 
or a morality of motherhood. Moral discourses of illness management are therefore 
likely to be used in flexible ways by different people in different circumstances at 
different times and used functionally to position the person within those particular 
moral frameworks. The connections that speakers make between morality and illness 
are therefore related to the social networks which reproduce those moralities. The 
“communicative ecology” (Gumperz, 1999, pp. 453-471) of our lifeworlds determines 
the sorts of moralities that are reproduced and produced in our interaction with other 
people. They are therefore likely to be multiple, can be seen to be managed 
simultaneously (Radley & Billig, 1996) and conceivable that moralities may be 
contradictory.  
 
Identifying evidence in a discursive analysis of talk 
 
The aim of this study is to evaluate the importance of understanding how medicine 
taking is discursively constructed within interactions and how moral discourses of 
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medicine taking can be seen to structure this talk. We therefore have to ask what counts 
as adequate evidence that interactional issues and discourses of morality will influence 
such talk in a variety of social contexts. The answer to this question will vary depending 
on the assumptions that the analyst brings to the data: how talk is understood (its 
ontological assumptions); and the knowledge that it produces (its epistemological 
assumptions). One way to clarify the differences between the view of evidence taken in 
this study from the previous work examining talk about medicine taking is to apply 
some different ontologies and epistemologies to a single sequence of interaction, as it is 
how different paradigms of knowledge treat these cases which reveal their differences 
most effectively. The study by Adams, Pill and Jones (1997) on medication, asthma and 
identity argued that people, in living with chronic illness, actively constructed their 
identity in one of three ways: as accepters, deniers or as pragmatists. They adopted 
Mead’s symbolic interactionism (1934) to emphasise a dialectical relationship in 
respondents’ “asthma identity work” between personal identity, the “I”, and social 
identity, the “Me”. The following extract is taken from a respondent categorised in their 
study as an “accepter.” 
 
I know that some people have funny ideas about asthma. Think you’re 
weak...disabled almost. Mind, I never have that sort of attitude from people. I 
think it depends on what sort of person you are. I don’t act ill or weak or 
anything so people don’t think of me that way. I work all hours and keep the 
house going. 
(Woman, aged 32, shop worker, Adams, Pill & Jones, 1997) 
 
From a symbolic interactionist perspective it may be argued this particular person drew 
on an “organised set of attitudes of others” (Mead, 1934, p.26) regarding “asthma as a 
disability”, to construct her own self-image as someone who “don’t act ill or weak”. 
When viewed from within this framework, identity, attitudes and beliefs are viewed as 
an aggregation of interactions and in this sense are seen as a series of discrete 
encounters. The extract by Adams et al extract is therefore treated as unique to that 
interaction as are the set of beliefs, attitudes and identities the person holds. When 
viewing this extract from within a positivist framework, which has been the dominant 
paradigm in explanations of medicine taking and adherence, this person’s talk is also 
likely to be seen as unique to this individual and is certainly not sufficient to 
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demonstrate that people with asthma more generally, or even just those who can be 
classified as “non-adherent”, engage with a moral agenda in their talk.  
 
Rather than viewing the talk within this extract as unique to the individual or as a 
relationship between the generalised attitudes and identity, this study was interested in 
how notions such as “asthma as a disability” are circulated through society and drawn 
on by individuals within interactions to address particular moral agendas that were 
activated within those interactions. From this view the speaker in the extract by Adams 
et al was not just reporting her self-image, she was doing so in a cultural framework 
which assigns a positive moral connection between illness and work. Viewed in this 
way, her talk can be seen to be a product of discourses which are commonly shared but 
manifested in novel ways to meet particular interactional demands. The anthropologist 
Birdwhistell (Varenne & McDermott, 1998) provided a particularly illuminating 
analogy to describe such connectivity in language. Individuals in a social context can be 
viewed as threads on a rope which, on their own, are discrete, discontinuous objects but 
when made into a rope become impossible to delimit within the twisted continuity of 
the rope. Within an individual sequence of talk, the analyst is not just looking at an 
individual account or thread that is discrete and separate from other individuals. Rather, 
the language that is produced at different points is seen as inseparable from the language 
produced by other individuals (threads) in other interactions because both are a product 
of and productive of wider historical discourses—the rope—in which talk about health, 
illness, and medicine taking can be seen. This is not the same as saying that all threads 
or individuals are the same, but rather to say that the language in one account is 
connected with the language used in another through social contexts that are shared and 
that can be seen to be manifested in talk. When seen within this view, assigning 
individuals into different categories is a choice of our level of analysis and an artefact of 
traditional social scientific practice.  
 
From the discursive perspective taken in this study, it made no logical sense to 
demarcate the analysis as related to separated individuals; instead the author looked for 
sequences of interaction which were the different threads through which to trace a path 
from a broader discourse of morality on asthma medicine taking to the individual. The 
methodology required (and set out in the next chapter) would therefore provide the tools 
to identify some of these different threads. By doing so, we can see some of the ways in 
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which different social discourses of morality, as different parts of the rope, may be 
momentarily manifested within interactions. 
 
Types of evidence required for a study of interactional issues and moral discourses 
 
Having established what was counted as evidence within this study of talk about 
medicine taking, the different types of evidence that were required can now be set out. 
This chapter has reviewed literature that identified evidence that discourses of asthma 
causation and management have historically been intimately connected with notions of 
the virtuous or irresponsible patient. The discursive concept of  “control” (asthma and 
emotional) could be seen to lie at the heart of these discourses and which allocate 
responsibility and accountability for the causes and more recently the management of 
asthma and chronic illness management more generally. There was also evidence that 
suggests that notions of self-control as well as alternative notions of appropriate illness 
management circulate the lifeworlds in which people live with conditions on a daily 
basis. The evidence that is required in this study is to make these connections with the 
talk of the participants and there are three types of evidence that are presented here as 
necessary to make these links. 
 
First, there was a need to identify evidence of talk about medicine taking that could be 
seen to have a moral agenda. That is, talk that could be seen not simply as accurately 
articulating an internal cognitive state such as an attitude or a belief but evidence that 
demonstrated the speaker’s talk as serving a particular function to which the speaker 
could be seen to be orienting towards. This goes beyond simply reporting one’s views 
but identifying evidence that shows the speaker working to present themselves, their 
behaviour and versions of events in particular ways, whilst at the same time 
undermining any potential threats to this construction of “facts.” It is the specification 
of this evidence that is necessary here which will allow us to shift our conceptualisation 
of this talk to one which views it as language constructed within a social space and 
which will illustrate that the interactional context is vital for understanding this type of 
talk.  
 
The second type of data that was used and which is intimately connected to the first is 
evidence that moral, culturally-available explanations of asthma, illness management 
and medicine taking were activated within interactions and structured the talk within 
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those interactions. Identifying evidence of participants engaging with moral discourses 
is evidence that they are not simply reporting attitudes but that their talk is structured by 
culturally-shared understandings of illness management. This enables us to make 
assertions about the circulation of different moral discourses to different social spaces 
which play a role in what is said about illness management and medicine taking. 
Instances of interactional sequences in which participant’s talk can be traced to the 
discursive connections between morality and medicine taking identified in published 
literature such as the asthma guidelines, situates that talk within a social structure. This 
is achieved by identifying talk that orientates to issues of blame and accountability that 
positions the speaker within these explanations of illness management. It also allows the 
possibility for insight into alternative moral discourses of illness management and 
medicine taking. These may be discourses that may be circulated in the social networks, 
the lifeworld of participants and which may be particularly pertinent to the decisions 
that the participant makes about taking medications.  
 
Third, it was necessary to identify evidence that allowed the author to make some 
generalising statements about the interactional circumstances in which moral discursive 
constructions of prophylactic medicine taking are likely to be reproduced. This is an 
exercise in identifying links from talk identified in one interactional space to a different 
interactional space. The need for this evidence was emergent in this study through a 
realisation that some participants did not justify their medicine taking. It was therefore 
necessary to contextualise the talk of study participants to identify boundaries to moral 
talk of medicine taking and to provide evidence that enabled the author to assess the 
limits of extending these interpretations of talk beyond that of this study’s participants. 
This was achieved in two ways: firstly by comparing and contrasting sequences of 
interaction where participants could and could not be seen to be justifying their 
medicine taking and secondly by identifying moral discourses of medicine taking in the 
talk of participants in a different interactional space. The analysis of deviant cases in 
Chapter Five will demonstrate that obtaining this sort of evidence required the view of 
context to be broadened outside of linguistic manifestations of discourse to incorporate 
more ethnographic, non-textual forms of context that might have influenced what 
participants said within interactions. This is because what people say about medicine 
taking may be dependent on having access to resources that are not overtly apparent in a 
purely textual analysis.  
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The knowledge developed from this work will then be applied in Chapter Six in a data-
sharing focus group. These data, in this research setting, were constructed with both 
linguistic and ethnographic features of context in mind. The choice and implementation 
of this method was based on the rationale that if participants could be seen to be 
justifying their asthma management and medicine taking in a different interactional 
context then this provides a new piece of evidence in which the influence of moral 
discourses of illness management and medicine taking can be seen.  
 
Summary  
 
The solution to asthma management problems as offered through the GINA initiatives 
and the BTS guidelines is to educate the patient so they are “empowered” to manage 
their asthma more effectively. This implicitly assumes that medical interventions 
become more acceptable through the acquisition of knowledge and Jones et al showed 
this relationship as also constructed within the clinician’s accounts. It has been argued 
here that the result of this simple relationship between individual knowledge and 
individual choice is the construction of notions of responsibility within talk about 
chronic illness management (Crawford, 1984; Lupton, 1995) which focus at an 
individual level. This involves a discourse about who is responsible for treatment 
decisions, what a “responsible patient” means, what actions are “responsible actions” to 
control asthma by patients and clinicians, and who is responsible for the experiences 
that patients have with their asthma, whether as well-controlled or in the event of an 
asthma crisis.  
 
The review of asthma in this chapter was developed by selectively identifying literature 
to formulate a theoretical link between how asthma has been conceptualised and notions 
of morality. It presented the case that it may be fruitful to investigate how moral 
discourses of asthma management influence talk and decisions about medicine taking. 
However, it is important to be cautious about being over-deterministic in extrapolating 
to what happens when people with asthma talk about medicine taking across a range of 
social situations. People live with chronic illness and asthma in a variety of social 
contexts and interactions.  The notion that people with asthma need to display different 
forms of embodied control has its origins in an analysis of the institutions which have 
had the greatest influence on the production of the knowledge about asthma and its 
management. It may be that only in certain types of clinical encounters that these types 
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of concerns are activated in talk. Although clinical encounters play a vital role in 
decisions about appropriate treatment and follow-up with patients, they are only part of 
a social world in which people live with asthma. There may be many other notions of 
morality that have been linked with illness and asthma management that have not been 
documented or have been of interest to researchers. This point is highlighted by Frank 
in drawing on Tim Brookes’ reflections on his life with asthma: as becoming someone 
who is “successfully ill”. This moral success is not confined to how he is perceived 
within clinical encounters but is about being “more than compliant: his ‘healing’ means 
learning to live with asthma creatively and meaningfully and he knows he can only 
learn this not as a patient but by going outside the clinic” (Frank, 1997, p. 136).  
 
Identifying the interactional and moral in talk about medicine taking entails active 
discovery and investigating such talk will help make visible how notions of morality 
operate so as to structure and be constructed within dynamic interactional spaces.  It is 
argued that such an investigation can provide a richer understanding of this talk than 
that provided by individualistic notions of attitude or belief. It is this understanding that 
may then provide clues to a fuller appreciation of the medicine taking decisions made 
by people with asthma, and other chronic illnesses in everyday life. 
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Chapter Three 
Methodology and methods for investigating the discursive construction and role of 
morality in talk about prophylactic medicine taking 
 
In Chapters One and Two it was argued that attitudinal approaches to adherence risk 
overlooking important insights about how attitudes to health and illness, beliefs about 
medications are situated within institutional, historical and interactional contexts. 
Examples of talk about health and illness were shown to be situated within these 
contexts, manifesting in notions of morality being oriented to by speakers. The research 
approach being developed here identifies problems for traditional attitudinal approaches 
to adherence, as it suggests that talk about medicine taking for people with chronic 
illnesses is also likely to be set within a moral framework and therefore will not simply 
represent some internal state. Chapter Two concluded by setting out the types of 
evidence required to adequately examine the discursive construction and role of 
morality in talk about medicine taking. This chapter will now detail the methodological 
framework required to plan the collection of these data, focusing on the properties of 
talk within interactions around prophylactic medicine taking and how wider social 
systemic influences might structure that talk.  
 
The view of talk within a social space taken within this study also means having to 
define the boundaries of that social space, as different definitions of these spaces will 
differently define the context in which talk is produced, with important implications for 
what counts as data and what insights are enabled. For example, an analysis of talk 
within interactions from a conversation analytical (CA) perspective (Atkinson & 
Heritage, 1984), typically adopts a view that the only context pertinent to the analysis is 
that to which participants orientate their talk within interactions. It is this context which 
the analyst will also access, although some attempts have been made to combine CA 
with macro processes in health research, such as Silverman’s studies of the discourses 
of counselling (1997). Conversely, an analysis of structural discourse, such as in Critical 
Discourse Analysis (CDA) (Fairclough, 1995), typically views context as linguistic, 
macro-discourses that regulate the meanings made available within any particular 
discursive framework, including interactional talk. Whilst these perspectives have very 
different analytical foci and assumptions, both view context as largely restricted to 
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identifiable linguistic forms. The present study’s methodology, informed by both CA 
and CDA approaches to discourse, builds on this linguistic focus to enable a view of 
context unavailable to a solely linguistic analysis, by also incorporating ethnographic 
features in the production of talk. Such features may be crucial in shaping participant’s 
talk.  
 
This chapter begins by explicating the methodology used in this study and the analytical 
tools applied to understanding the discursive construction and role of morality in 
participants’ talk. The related details of the participants and methods used for data 
collection are then discussed as well as the ethical considerations in conducting these 
methods.  
 
Methodological Tools – Discursive Psychology and Linguistic Ethnography  
 
Three different methodological threads have influenced the design of the methodology 
in this study. First, and central to this methodology is the discursive psychological 
approach of Potter, Edwards and Wetherell (Edwards & Potter, 1992; Potter & 
Wetherell, 1987) to the study of fact construction in interactional talk. Applying 
discursive psychology (DP) enables us to examine interactional talk about health and 
illness and to reveal the moral agenda implicit in constructions of medicine taking. 
Second, understanding how the talk of participants has come about requires some 
evaluation of the uses of discursive psychological tools for understanding how moral 
discourses of medicine taking may be activated and how they structure the talk within 
interactions. This involves setting out the view taken in this study, of the relationship 
between systemic discourses and individual utterances, specifically the role of power in 
regulating meaning to examine how far the tools developed in the DP approach may 
meet these ends. Third, this discussion of power raises questions not only about how 
power regulates meaning but also in what circumstances power is manifested.  
Approaches such as CDA have sometimes been accused of being over-prescriptive in 
interpreting the role of institutional discourse (Blommaert, 2005), potentially missing 
important ethnographic contextual features that offer very different interpretations into 
the production of talk in institutional settings not amenable to a linguistic analysis alone 
(Collins, 2009; Collins, Drew, Watt, & Entwistle, 2005; Mehan, 1996; Sudnow, 1967). 
The recent development of linguistic ethnography (LE) (Rampton et al., 2004) in the 
UK now offers a range of potentially useful methods, some of which have contributed 
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to the present study methodology. As will be seen in Chapter Five, LE can be used to 
specify the conditions of power and morality within research settings and to help 
explain the deviant cases discussed in Chapter Five.  
 
Applying Discursive Psychology to Interactional Talk about Asthma Management 
and Medicine Taking  
 
Discursive psychology (DP), emerging in the 1980s, is one of many forms of discourse 
analysis reflecting theories of language developed between the 1950s and 1970s. The 
review by Edwards and Potter of DP (Edwards & Potter, 1992, p. 27) traces the 
theoretical origins of discursive psychology to the linguistic philosophical reworkings 
of language and knowledge (Austin, 1962; Wittgenstein, 1953), cultural and literary 
theory which studied texts as constructed and active (Barthes, 1974; Derrida, 1976; 
Shapiro, 1988) and the functional approaches of language use seen in speech act 
theories (Grice, 1975; Searle, 1969) and ethnomethodology (Garfinkel, 1967; Heritage, 
1984). These traditions themselves constituted part-responses to criticisms of Noam 
Chomsky’s theory of the rules of generative grammar developed in the 1950s. A key 
principle of generative grammar was that a limited set of rules are responsible for 
generating grammatical sentences. Whilst hugely influential in our understanding of 
language learning, Chomsky’s theory was criticised for not adequately accounting for 
naturally occurring talk with all its ungrammatical complexity as used in particular 
contexts (Lyons, 1967).  
 
Viewing talk as social action 
 
The disciplinary approaches to studying discourse which emerged from these criticisms 
developed distinctive views and definitions of discourse analysis while sharing 
assumptions about the role of language; that text and talk are constructed within social 
spaces, within and between people, social groups, institutions and cultures; that text and 
talk does not merely convey information but serves specific functions; and hence text 
and talk constructs reality through language. These ideas greatly influenced the 
sociology of scientific knowledge (Ashmore, 1989; Gilbert & Mulkay, 1984; Potter & 
Mulkay, 1985) and applications to social psychology (Potter, 1984; Potter & Wetherell, 
1987; Potter & Wetherell, 1988). 
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The application of DP in this study has origins in the theoretical critique of social 
psychological notions of attitude by Wetherell and Potter (1987). This critique was 
based on Austin’s philosophy of language and his notion of the “speech act”, which 
fundamentally changed notions of descriptive talk or text as straightforwardly and 
accurately reflecting an objective reality. Austin (1962) rejected logical positivist 
arguments, linked (although perhaps incorrectly) from Wittgenstein’s “Tractatus 
Logico-Philosophicus” (Wittgenstein & Ogden, 2003) that statements which could not 
be evaluated as either true or false are meaningless and therefore that truth and falsity 
are critical in an understanding of language. Instead, Austin argued that language does 
not just describe something but it also does something. This was therefore a radical shift 
from the conceptualisation of language as something which was logical and which 
could be assigned a reality. Wittgenstein’s later work “Philosophical Investigations” 
(Wittgenstein & Anscombe, 2001) critiqued both the basic assumptions of logical 
positivism and also Tractatus, by viewing language-use in everyday contexts, using the 
term “language games” to emphasise the contextual functions of language use in public 
space. In a similar way, Austin’s philosophy of language reframed language as a human 
activity within a social context. Rather than viewing individual talk as a way to uncover 
the internal reality of individual attitudes, he asks us to understand what social actions 
language performs. 
 
This alternative view of everyday language as a form of social action formed the basis 
for DP. Potter has argued (2008, July) that DP can be understood as re-specifying many 
traditional social psychological concepts, namely: memory, attribution, script, attitude, 
categories. Such re-specification happens when the language used to articulate these 
concepts comes to be seen as a form of social action. As discussed in Chapters One and 
Two, much evidence shows how peoples’ discussions of health and illness do not just 
report their memories and attitudes but can also be seen to orientate towards a specific 
interactional moral agenda. As Radley (1993) argues, in his analysis of the role of 
metaphor in people’s narratives of adjustment to chronic illness, the illness experience 
is not just about the person meeting the physical requirements to participate in society 
but is also about arranging the detail of their lives to avoid stigmatization. Their health-
related actions therefore need to be legitimated in dealing with other people, to avoid 
moral condemnation (Bredmar & Linell, 1999; Hassin, 1994; Lawton et al., 2007; Lee, 
2007), and to achieve a status that does not separate them from “normal” health status.  
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Talk as sequentially and rhetorically situated  
 
The key conceptual notion of attitude critiqued in this study, is therefore re-specified 
not as an articulation of internal cognitive state but as situated linguistic action. As such 
actions take place within interactions, the “attitudes” that people adopt should therefore 
be seen as constructed sequentially as participant’s talk unfolds. This view of the 
sequential construction of talk within discursive psychology relates closely to the 
central assumption of conversation analysis (Sacks, Shegloff, & Jefferson, 1974; 
Schegloff, 1968). In this view, health narratives, or accounts are therefore analysed as 
part of a conversational sequence rather than as a representation of broader variables. In 
addition, CA analysts also view accounts as a hallmark of “dispreferred seconds”, in 
other words a response to a question which does not meet the preferred or expected 
response. When an expected response is not provided in an interaction, there is a 
conversational requirement to explain and justify the alternative provided. Accounting 
for one’s health, illness and related attitudes can therefore be seen as situated not only 
sequentially but also rhetorically. In Chapter One an example of this could be seen in 
Horton-Salway’s extract from the account of Angela and Joe discussing the causes of 
ME. The discursive work that they undertook in relating their account could be seen as 
a sequential and mutual process between Angela and Joe to construct and validate 
Angela’s ME as an organic condition. People, in “expressing an attitude” towards a 
health issue can therefore be seen to justify the position they take towards this issue. 
Billig (1987) argues that we can only view attitudes in a context of debate and conflict, 
arguing that an “attitude” is an expression of “for” something and “against” something 
else. This view of “attitudes” seen in a context of debate and conflict shifts the 
researcher’s analytical attention from what individual attitudes may be to what 
expressing attitudes does: the interactional functions those expressions serve; the 
interactional conditions in which those attitudes are manifested (i.e. why this attitude 
and not another); and how those attitudes are constructed and legitimated.  
 
Variation in talk 
 
Viewing talk about medicine taking as both sequential and rhetorical suggests that an 
articulated view about illness or medicines, rather than being seen as a consistent and 
accurate representation of the individual’s attitude, may instead be seen as distinct to 
specific interactional demands. This raises the possibility that talk about illness 
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management might vary according to different interactional contexts. Such discursive 
variation in talk about health and illness has already been highlighted in a range of 
research (Crossley, 2002; Gillies & Willig, 1997; Radley & Billig, 1996) and these 
insights may be applied to how talk about asthma is commonly reported. People with 
asthma are frequently seen to “minimise” and “normalise” the impact of asthma in their 
daily lives (Adams et al., 1997; Protudjer et al., 2009; Prout et al., 1999). However, 
within examples of this “minimising” talk participants can be seen to display both 
dependence and independence in managing their asthma and using medications. 
Researchers aiming to identify some internal reality of participant’s attitudes and 
understanding have to reconcile such contradictions if they are to succeed in upholding 
any decontextualised “attitude” or “understanding”. By contrast, a discursive 
psychological study will recognize and attend to these contradictions as situated and 
diversely co-existing social and moral actions. People with asthma can be seen in 
articulating such normalisation talk to orientate to more widely circulated moral 
discourses which demand that speakers be simultaneously understood as both 
responsibly managing their condition and also as people who are demonstrably fit to 
participate in society. Realising these twin aims can therefore lead to observed shifts in 
descriptions of asthma medication-use (Protudjer et al., 2009) and to pose potential 
interactional dilemmas when these different moral agendas appear incompatible. 
 
Analytical Tools to Examine the Construction of Talk about Medicine Taking 
 
People can be seen to deploy a range of devices in justifying their attitudes and 
behaviour (Potter, 1996). The analytic focus in this study aimed to uncover some of 
these devices in participants’ talk about medicine taking. Using DP to examine how 
people justify attitudes and behaviour, allows us to specify some analytical tools which 
might be useful in interpreting the devices participants’ deploy in constructing versions 
of events and themselves. We are then able to examine how these devices are deployed 
in the analysis of participants’ talk. The main analytical tools which were considered 
useful in this study to analyse the role of morality in participant’s talk were discursive 
objects and interpretative repertoires and the rationale and definition of these tools are 
now discussed. 
 
 
 
   
 
 
76
Discursive objects 
 
A key critique that Potter and Wetherell made of attitudinal research relates to how 
people construct “objects of thought” (1987, pp. 43-55) in their accounts and the term 
“discursive objects” used in this study, was based on such a critique. “Objects of 
thought” is a term that has been used in social psychological theories of attitudes to 
refer to established categories with often taken-for-granted meanings, and attitudes as a 
manifestation of individuals locating these objects on “dimensions of judgement” 
(McGuire, 1985). However, Potter and Wetherell demonstrated how people’s 
construction of such objects can vary even for one person within one interaction. In this 
study, diagnosis of asthma may well be seen as a commonly-used object of thought in 
justifying medicine taking. Research on the perspectives of people with asthma has 
repeatedly highlighted how asthma is viewed in a range of ways including: “not proper 
asthma;” the sort of asthma not warranting close management; (Jones et al., 2000); a 
chronic condition; “not an illness” (Adams et al., 1997); an acute episodic condition 
(Halm et al., 2006). These versions of asthma are typically treated as distorted 
perceptions of an objectively fixed category of “asthma” founded in scientific, 
biomedical evidence. However, there is plenty of evidence that demonstrates how 
people can be seen to actively construct illness and health (Bury, 2001; Charmaz, 1990; 
Frank, 1995; Yoshida, 1993) to enable their participation in everyday life, suggesting 
that these non-medically-based versions may be more socially acceptable within 
important everyday settings such as work. This insight therefore repositions different 
individual’s versions of asthma as constructions that are critical to dealing with 
everyday interactions and gaining access to activities within lifeworld contexts, rather 
than to be viewed merely as distorted perceptions.  
 
Consider the following extract, taken from a qualitative study on asthma which found 
that families construct a sense of “ordinariness” in managing their child’s asthma, with 
prophylactic inhalers seen as enabling rather than inhibiting ordinariness: “It’s a firm 
twice a day commitment that she [my daughter] is supposed to fulfil…]” (Prout et al., 
1999, p. 150). The findings of Prout et al clearly resonate with theories that emphasise 
the active construction of illness within lifeworld settings. However, we can build on 
this insight of the individual as active agent if we examine this extract from a rhetorical 
perspective. The parent’s use of “firm” positioned them as taking responsibility for 
implementing what is “supposed” to be done. This can be seen as a response to a moral 
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discourse having been deployed, that parents are not “good parents” unless they actively 
ensure that the advice of doctors and nurses is followed. They need to affirm that their 
daughter has to “fulfil” this “commitment;” and that they have entered into an 
agreement with their parents in the same way that they might enter into any other 
parental child arrangement where a task has to be performed. Within the context of 
being interviewed by a health researcher on how families manage a chronic illness, 
inevitably a number of issues will be invoked which centre around both the appropriate 
behaviour of the child and of the parents. This relates to whether their child’s condition 
may be considered to be physiologically under control and also that the family is a 
healthy environment for a child with asthma to live in. Their actions are laid open to 
public criticism and appraisal and so they are unlikely to be willing to depict their 
child’s asthma as anything other than ordinary and normal and their child’s medication-
use as anything other than compliant and responsible. By analysing the lexical and 
grammatical features used in constructing this statement, the parents’ talk can be seen as 
enacting the medical directive on asthma management which upholds adherence to 
prophylactic medications as morally responsible. In addition, their talk could also be 
seen as positioned within broader cultural and moral discourses of responsible 
parenthood and child protection.  
 
The same objects of thought are potentially constructed in a range of ways by 
individuals to perform different functions and with reference to different consequences 
of blame and accountability. Different lexical and grammatical features may be 
deployed by speakers to construct these different versions of the “same” object. Within 
talk about how individuals manage their condition, the construction of asthma, does not 
reflect an internal reality which may be viewed as distorted, but can also be seen as a 
flexible device which a person can use to enable them to be understood in particular 
ways. In this sense we can view these objects of thought as discursive constructions, 
which speakers act to situate within different moral and culturally-available discourses 
of illness management. By deploying discursive objects as an analytical tool we may 
therefore gain insight into the moral discourses that structure talk about medicine 
taking. 
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Interpretative Repertoires 
 
Another tool which may help in understanding the role of morality in participants’ talk 
is the “interpretative repertoire”. This has been described by Potter (1996, pp. 115-116) 
as “systematically related sets of terms, often used with stylistic and grammatical 
coherence, and often organised around one or more central metaphors”. In Chapter One, 
the concept of interpretative repertoire as set out in Gilbert and Mulkay (1984) was 
introduced to help set out specific differences between social cognitive and discursive 
conceptualisations of talk. Gilbert and Mulkay noted an asymmetry in scientists’ 
explanations of their own and others research findings (the empiricist and contingency 
repertoires respectively). This discursive variation indicated not only the rhetorical 
nature of these scientists’ talk but also the use by the same person and in the same 
interaction, of very different explanations when discussing the same topic. In the 
present study, “interpretative repertoire” is used to refer to the sorts of explanations that 
participants provided regarding their medicine taking and in so doing to emphasise how 
this talk can be seen as social action rather than as reflecting internal attitudes.  
However, interpretative repertoires, like discursive objects, were viewed in this study 
not only as products of interactions but also as regulated constructs set within wider 
structural discourses of chronic illness management and medicine taking. The reason 
why explanations that people provide in their accounts may often be seen as rhetorically 
convincing is that the devices they use tap into commonly understood explanations. 
Consider the following three examples from the study of older people and discussions 
of medication-use by Lumme-sandt, Hervonen and Jylha (2000). Lumme-Sandt et al 
identified three interpretative repertoires in the talk of their participants: moral; patient; 
and self-help repertoires. We can examine examples of each these repertoires for how 
the speakers enacted versions of moral, culturally-available discourses of illness 
management to account for their medicine taking. 
 
The following first example was reported as belonging to the moral repertoire: “All I 
have on prescription are these children's aspirins and even they are for dizziness” (2000, 
p. 1846). Lumme-Sandt et al argued that there is a strong moral dimension in this type 
of talk which orientates around the speaker’s need to minimise and to offer justification 
for their use of medications. Presenting medication-use in this way serves to present the 
speaker as morally responsible in the management of their illness, deploying the same 
kind of minimisation talk seen earlier in talk about asthma medications. However, we 
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can also see a moral dimension in both the patient and self-help repertoires reported in 
the study by Lumme-Sandt et al: 
 
Patient repertoire: “I only have these doctor's prescriptions. Six different ones 
in the morning and three in the afternoon” (2000, p. 1847) 
Self-help repertoire: “I have used onions all my life and I now use flaxseeds and 
parsley as medication and they are good. These are my drugs”. (2000, p. 1847) 
 
As Lumme-Sandt et al report, the talk identified within the patient repertoire is set 
within the role of the compliant and satisfied patient. We can therefore see a moral 
incentive to position oneself as a “good patient” within what might be called a discourse 
of Parson’s “sick role” (Parsons, 1951). In contrast, we can see a very different moral 
discourse being orientated to in the self-help repertoire. Here the speaker can be seen to 
be positioning themselves as actively engaged, not dependent on medications and 
therefore a fully engaged, responsible manager of their health. This is not necessarily a 
responsibility set within a medical perspective but instead sitting comfortably within an 
alternative lifeworld perspective about what it means to be responsibly engaged with 
life, health and oneself. The object “drugs” can also be seen to be discursively subverted 
in a way which also alludes to these alternative therapies, thereby positioning the 
speaker as compliant within such an alternative discursive paradigm of healthy lifestyle 
choices and illness prevention. 
 
“Interpretative repertoires” then can be viewed as orientating to versions of discourses 
that circulate shared social spaces and which will be appropriated by speakers to 
perform specific functions within interactions. In the present study, such functions are 
viewed as moral actions and both interpretative repertoires and discursive objects are 
seen as linking the detail of rhetorical talk to wider moral discourses of chronic illness 
management and medicine taking. The DP approach adopted in this study enabled these 
links to be made by focusing on the lexical items and grammatical styles that people use 
to construct discursive objects and interpretative repertoires that position their attitudes 
and versions of behaviour within wider moral discourses.  
 
By asking people with asthma questions about medicine taking, in particular, people 
who have not taken prophylactic medications as prescribed, the researcher places 
demands on the responder to orientate in some way to the medical directive to follow 
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the instructions of those medications. Even if the “responder” says nothing, their “non-
response” tells us something about how, within the conditions of the research interview, 
that person does or does not engage with the medical agenda that preventive therapies 
need to be taken regularly if asthma control is to be achieved. This interactional 
dynamic therefore locates this interaction, institutionally within a research and health 
context and, historically, within a contemporary context of reducing risky lifestyles, 
preventing chronic illness and prophylactic medicine taking. This talk is highlighted as 
sequential, rhetorical and interactionally-constructed and regulated by wider moral 
discourses. This tension between the constructed and constructive nature of talk reveals 
important issues of power in talk relating to medicine taking. We may now briefly draw 
on some theories about the exercise of power in talk in order to theorise how moral 
discourses of medicine taking may circulate to different social spaces and to the talk of 
the participants in this study. 
 
Issues of Power and Structuring Talk about Medicine taking 
 
In Chapter Two the language presented in asthma guidelines was linked to talk 
produced within interactions. An argument for a moral discourse of asthma 
management could therefore be constructed, regulating what clinicians and patients are 
able or willing to say about taking prophylactic medications. This argument reflects 
Foucault’s use of the term “abstract discourse” in the “Archaeology of Knowledge”, a 
term typically used when referring to sets of related statements that are identifiable as 
regulated and produced through the practices of specific institutional frameworks 
(Foucault, 1972, p. 121).  
 
In the asthma guidelines such discursive statements may be grouped together as 
“recommendations” or “best practice” which offer a limited range of options, typically a 
regular pharmacological treatment, and which decisions about patient’s asthma 
management have to conform to. It may be argued that the implications of this asthma 
management discourse for clinical practice is that talk of treatment options within 
clinical consultations is limited to statements that refer closely to these guidelines.  
The relationship between systemic discursive structures and the regulation of meaning 
has preoccupied generations of scholars and can be understood within theories on the 
function of “soft power”, set out by Gramsci (1891-1937) in Prison Notebooks 
(Gramsci, Hoare, & Nowell-Smith, 1971). In contrast to the coercive and violent notion 
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of “hard power”, “soft power” refers to winning “hearts and minds” (J. Blommaert, 
personal communication, November, 2007), the acceptance and popular support of 
rulers by the ruled. To gain such popular acceptance the language of propaganda is 
exercised, and an essential component to this propaganda in gaining societal control is 
Gramsci’s concept of “hegemony”. This refers to the “intellectual or moral leadership”, 
the creation of an ethics or morality by state institutions, an “ethical state”, backed up 
and enforced by the capacity to use coercive, or “hard power”.  
 
Fairclough’s (1995) approach to CDA draws links between hegemony and discourse 
that are of key relevance in addressing the impact of institutional morality in the talk of 
people with chronic illnesses. He argues that discourse conventions (as within a doctor-
patient consultation, or a job interview and even a research interview) naturalise 
particular ideologies of the participants and relationships within that setting, (doctor-
patient, researcher-participant), particular types of knowledge and beliefs and attitudes 
and so, appropriate or inappropriate behaviour, within and outside that environment. In 
the case of people with chronic illness, the naturalisation of discourse surrounding the 
doctor-patient relationship and discourses of illness management will involve following 
medical advice, typically through the use of prophylactic medications. Naturalising 
these discourse conventions, Fairclough argues, enables the ideological dimensions of 
existing hegemonies to be reproduced.  
 
This naturalisation of discourse within institutional settings has clear links with 
Bourdieu’s notion of “habitus”. Bourdieu (1984, pp. 169-225) argued that individuals 
incorporate social structures in every “habitual act” including speaking and writing. The 
notion that certain types of talk are naturalised and habitual in institutional settings 
implies that certain other types of talk will be considered inacceptable, irrational or even 
radical. In the context of talk about medicine taking and in view of the 
recommendations set out in guidelines for the treatment of asthma, choosing 
prophylactic medications are presented as natural and habitual whilst other “alternative” 
forms of therapy/decisions may be considered irrational, radical or simply incorrect. As 
seen in the analysis of these guidelines in Chapter Two, such alternative decisions are 
not easy to take and are monitored: “significant departures from the national guideline 
or any local guidelines derived from it should be fully documented in the patient’s case 
notes at the time the relevant decision is taken.” (British Thoracic Society & Scottish 
Intercollegiate Guidelines Network, 2008 revised June 2009, p. iv1)  
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Whilst this research draws on theories of power, it also queries how we can identify the 
evidence for this. The risk of taking a pre-determined view on power is that this will fix 
the role of structural discourse and presume that participants within a particular 
institutional setting will always orientate to institutional notions of moral behaviour 
constructed as a hegemonic and discursive practice. Conversation analysis of 
interactional data in institutional settings has revealed how the exercise of power should 
not be taken for granted (Silverman, 1987; Thornborrow, 2002) and there may also be 
“asymmetries” (ten Have, 1991) in the amount of talk and the style of turn-taking 
available for roles within institutional settings and activities. These do not necessarily 
entail a power imbalance, they may just be inevitable aspects of “expert-provider” and 
“layman-listener” roles. Power dynamics therefore have to be identified rather than 
assumed within a micro-analysis of data. The present study adopts an approach which 
attempts to avoid being prescriptive about how discourse is manifested and what 
function it serves. Power may be accepted or resisted and may have its origins in 
multiple locations. An example may be taken from the analysis of accounts of health 
and illness by Radley and Billig (1996): 
 
Wife: ‘He didn’t rest as much as he should have done. There’s no doubt about 
that. That used to bother me. He used to go out pottering about in the shed and 
doing things that I didn’t think he should do. I can’t remember anything in 
particular.’ 
Husband: ‘Like chopping sticks one afternoon – all afternoon, while she was at 
work.’ 
Wife: ‘There’s no holding him when he’s alright!’ 
Husband: ‘Another time I was splitting logs for an hour.’ 
Wife: ‘That was naughty too!’ 
Husband: ‘Some people would say it was too much, but I thought it was getting 
me better quicker....And I felt that the more exercise I did the quicker I got 
better.’ (Radley & Billig, 1996, p. 227) 
 
The analysis by Radley and Billig of this extract emphasised the potential for seeing the 
production of the story of the husband’s behaviour as a joint activity in reproducing 
their shared memory. Radley and Billig also discussed how the account provided by the 
husband and wife was situated within a discursive framework of gender relations and 
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moral order with the husband emerging as the “victorious hero” and the wife the 
“worrying female”. Radley and Billig argued that this sequence is typical of how 
people, who are considered ill, draw on versions of health in their accounts to negotiate 
themselves out of weak positions of ill health which, if we view from with a Parsonian 
“sick role” discourse, evades their social responsibilities and their place in the social 
order. The husband, in his activities, not only provided evidence of how he was 
responsibly overcoming illness, but with the help of his wife, also asserted his place 
within a traditional discourse of gendered roles. The activation of the sick role discourse 
in this account was not pre-determined or fixed, with the husband being designated an 
inevitable place within medical notions of good and bad patients. Instead, the husband 
and wife’s version of the sick role worked simultaneously in conjunction with a cultural 
discourse on gendered roles, and positions were negotiated as their story developed. 
These positions can be seen to be in turn: “naughty”; irresponsible activity for a person 
with this illness; a sensible risk-taker; a person doing manly activities like chopping 
wood; heroic. Again talk about health and illness can often be seen to involve 
orientating to and undermining contesting alternative interpretations of behaviour “some 
people would say it was too much, but I thought it was getting me better”. (Radley & 
Billig, 1996, p. 227)  
 
This complexity in referential meaning relates to the contextualised function and 
orientation of interpretative repertoires analysed in this study in talk about medicine 
taking; that there are no rules about who uses different repertoires and when, and they 
will be used flexibly to perform particular functions within specific interactional 
demands. The same speaker can assume different voices or “footings” (Goffman, 1981) 
and thus, it can never be assumed that the same type of talk refers to exactly the same 
meaning. Interpretative repertoires and discursive objects are concepts used in this study 
to capture this relationship between structural, abstract discourses such as the sick role 
discourse, and the constructive properties of interactional talk.  
 
If a proposition, a sentence, a group of signs can be called “a statement”, it is not 
therefore because, one day, someone happened to speak them or put them into 
some concrete form of writing; it is because the position of the subject can be 
assigned. (Foucault, 1972, p. 107) 
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The approach taken in this study treats what people say about chronic illness as not 
necessarily submitting to the dominant morality of medical notions of appropriate 
illness management, but, rather, to suggest that participants may manage several 
moralities simultaneously. These moralities may originate and circulate through a range 
of social spaces and as explored in Chapter Two, may be particularly pertinent in 
participants’ everyday lives, their lifeworlds (C. I. Salter, 2005; Schutz, 1962) to play a 
key role in their decisions about medicine taking. The DP approach and associated 
analytical tools discussed in this chapter will be applied to the data in Chapter Four to 
gain insight into these moral manifestations in participant’s talk. 
 
The Distribution of Interactional Resources in the Construction of Moral Talk 
about Medicine Taking 
 
So far, the need to demonstrate rather than assume the role of moral discourses in talk, 
has informed a methodological framework facilitating insight into participants’ 
orientating towards multiple moralities in their talk about medicine taking. However, 
while these analytical tools may enable a path to be traced from systemic, cultural 
discourses to individual utterances, they have limited ability to specify the 
circumstances in which such talk might occur and their moral implications, as will be 
seen in Chapter Four which describes the analysis of interview data. Chapter Five, will 
go on to examine the absence of moral discourses in participant’s talk in relation to the 
presence or absence of resources that members of interactions may have had available 
to them. Misunderstandings within interactions have been found to highlight 
inequalities in access to resources which may importantly affect how that interaction 
proceeds. Consider the following example from a study of misunderstandings within 
primary care consultations (Roberts, Moss, Wass, Sarangi, & Jones, 2005).  
 
Here, a Bangladeshi patient has come to ask his GP to sign his passport form. 
1 D black pen and this is for you M isn’t it 
2 P yeah M B’s my name 
3 D how long have I known you B 
4  (1.5) 
5 P my name 
6  (..) 
7 D How long (0.5) how long do I know you for how many years 
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8 P oh:um (..) e::h 9 years (..) come to the re- I come to this country  
9  in er (.) 1990(.) but [then I am] 
10 D           [I saw you] in ninety: six 
11 P 96 
12 D (0.5) ((counts on fingers of left hand)) 5 years I’ve known you 
13  (.) 
14 P really 
 
Roberts et al highlight in relation to this extract, how the text in bold represents a crucial 
misunderstanding in the interaction between the doctor and patient with important 
implications for how the consultation continues. The causes of the misunderstanding are 
evident on a number of levels: phonetically, (“known” and “name”); grammatically, 
(have known vs. do know); metaphorically (how long..?); bureaucratically (the use of 
the expression “how long have I known you” within this bureaucratic context); and 
institutionally, (the patient may not appreciate that to sign the passport the GP must 
have known the patient for a minimum length of time). The consequence for 
misunderstanding within this sequence is that the doctor has to reformulate the spatial 
metaphor “how long have I known” from the present perfect to the present tense which 
then elicits the required response.  
 
Whilst the focus of the research by Roberts et al was to identify some specific reasons 
for misunderstandings between GPs and patients from diverse language and cultural 
backgrounds, important insights can also be drawn from their analytical findings which 
may be applied to any instance of interactional talk within institutional settings. Such 
talk has the potential to involve misunderstandings within interactions when there are 
mismatches in how members of those interactions understand that talk, even if members 
might be regarded as speaking the same first language or from similar cultural 
backgrounds. These misunderstandings are likely to occur for a variety of reasons, but 
as seen in the extract from the data of Roberts et al, may be located in inequalities in 
members’ access to key linguistic, bureaucratic and institutional resources. Members’ 
understandings of the meaning of an interaction and the talk within it therefore has 
consequences for how those interactions proceed, with important implications for 
analysing the role of moral discourses in talk about medicine taking.  
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The production of naturalised institutional talk referred to by Fairclough, which in the 
present study involved examining the production of medical notions of appropriate 
illness management in talk about medicine taking, may depend on how the members of 
that interaction understand what that interaction is about. The activation and sequential 
development of moral discourses of medicine taking within such talk may be reliant on 
members having access to and interpreting the interaction as pertinent to that discourse. 
If interacting members do not share understandings of the talk taking place within that 
moral discursive framework then the interaction is likely to proceed very differently to 
other interactions where that discourse is considered relevant and available to both or all 
participants. Chapter Five will examine whether differences in understanding about the 
meaning of interactions may be linked to the distribution of resources related to 
participants’ involvement in the study and discuss the implications of potential 
differences for the production of moral discourses of illness management and medicine 
taking.  
 
However, the analysis of Roberts et al indicates that while misunderstandings may be 
manifested within interactions, insight into the distribution of resources within 
interactional talk is enhanced by moving beyond the evidence solely available to a 
linguistic analysis. This may mean looking beyond specific interactions to other 
contextual features that may influence that interaction. To understand these contexts, 
ideas and techniques were drawn from linguistic ethnographic approaches to 
communication and language. 
 
Linguistic Ethnography  
 
Linguistic ethnography, which has emerged in the UK in the last 10 years, has been 
described as a site of encounter for different disciplines and perspectives, rather than a 
conceptually-unified school of thought (Rampton et al., 2004). Whilst those associated 
with LE conduct their work from a wide range of disciplines, these scholars have come 
together in order to help resolve some common difficulties identified in the analysis of 
text and talk, particularly with regards to communication. A central area of difficulty 
lies in definitions of context, how context is investigated and what implications these 
issues have for how power can be seen to operate in text and talk. LE forums in which 
the analysis of communication have been explored, have generally agreed that important 
contextual influences on communication can be seen as both ethnographic and linguistic 
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and that context should be investigated and not assumed. Ethnographic and linguistic 
approaches to communication have often been seen to work as separate disciplines and 
as a consequence have potentially missed opportunities to draw on respective strengths 
in answering similar research questions regarding communication. LE has drawn on a 
range of theories, methodologies and analytical techniques to apply to studies of 
communication and to help generate new insights about the production of talk and how 
we might better go about analysing communication.  
 
Rampton describes LE as an attempt to “tie down” ethnography and “open up” 
linguistics. Such opening up of linguistics has particular relevance to the methodology 
constructed in this thesis at this point. Incorporating ethnographic analytical techniques 
into an otherwise linguistic approach offered the potential to provide important insights 
into important contextual features that might otherwise go unnoticed, offering 
techniques to move beyond research interview transcripts to examine those processes 
and steps that influenced the research setting, vital in an evaluation of the discursive 
work taking place.  
 
As indicated by the data of Roberts et al, sequences of interaction follow from those 
resources available to members of interactions. To follow a particular interactional 
pattern, the appropriate linguistic resources need to be activated. When the appropriate 
resources are not easily accessible for member(s) of interactions misunderstandings may 
occur, indicated by a different interactional pattern. Similarly, the prevalence of 
individual justification and morality in talk about medicine taking may depend on 
participants having access to and deploying particular moral discourses in their talk. 
Moral talk about prophylactic medicine taking was therefore examined while taking 
account of participants’ available resources, working towards an understanding of when 
moral discourses of medicine taking may be likely to be activated.  
 
Understanding resources available to participants within the present study meant 
looking at how participant’s understandings could be seen to be manifested in the 
specifics of language produced, i.e. the rhetoric of the talk, moments of tension in turn-
taking sequences and interactional patterns which suggested different resources and 
mismatches in interactional framings. However, to seek insight of how these 
understandings came to be manifested also required the author to examine the 
conditions that led to the research setting – the process of selection, eligibility and 
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recruitment, any documents used, the research setting itself, the roles that were 
constructed as well as how the data were captured, recorded, transcribed and 
interpreted.  
 
The analysis of data in Chapters Four and Five will therefore move from an analysis of 
rhetoric and moral discourses in researcher-participant interactions, to an examination 
of researcher and participant presuppositions, activity types within the research 
interaction, multi-modal constraints within the interaction and an examination of how 
participant’s identities were constructed and transferred across contexts prior to 
interview. This aims to enable specific insight into the interactional conditions in which 
participants deployed linguistic resources that orientated to moral discourses of 
medicine taking.  
 
Methods, Data Collection and Participants 
 
The study was carried out as a qualitative sub study linked to a large, quantitative 
asthma study (ELEVATE). The ELEVATE study consisted of two randomised 
controlled trials (Step 2 and Step 3 trials) with almost 700 participants. The qualitative 
sub study was linked to the Step 2 trial and each participant, upon entering the study, 
was allocated either an inhaled corticosteroid inhaler or a leukotriene receptor 
antagonist tablet. These participants were considered to have mild to moderate asthma 
upon entering the Step 2 trial. 
 
Details of recruitment to the qualitative and quantitative studies 
 
The steps involved in identifying and recruiting participants are now described. This 
includes documenting the steps to recruitment for the quantitative study set out in the 
final report for this study (Price et al., in press), extracts of which are included in 
Appendix C. The summary account given here has edited the full report of these steps to 
provide only those details needed to contextualise the study of the present thesis, 
omitting some of the technicalities relating to medication type and asthma severity. Full 
documentation of these is available in the full report of the ELEVATE study.  
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Recruitment Stage 1: The Asthma Control and Quality of Life Questionnaire 
 
People who might be eligible to participate in the ELEVATE study were identified by 
searching the electronic databases of General Practice medical records. These were 
patients aged 12 to 80 years attending 53 participating GP practices in Norfolk, Suffolk, 
Essex, Cambridgeshire, Bedfordshire, Hampshire and Dorset. Patients were asked to 
complete and return to their GP practice, two questionnaires (both disease-specific 
validated tools): the Asthma Control Questionnaire (ACQ) used to evaluate asthma 
control (Juniper, O'Byrne, Guyatt, Ferrie, & King, 1999); and the Mini Asthma Quality 
of Life Questionnaire (MiniAQLQ), (Juniper, Guyatt, Cox, Ferrie, & King, 1999), used 
to evaluate the impact of asthma on quality of life. Patients who met the entry criteria 
(see Appendix C) were invited for a screening visit (Visit 1).  
 
Recruitment Stages 2 and 3 - The ELEVATE study Visits 1 and 2: Assessing eligibility 
and entry into the randomised controlled trial.  
 
At Visit 1, participants (and parent or guardian if appropriate) gave written informed 
consent and were allocated a unique study number. Participants were given the option 
of consenting to interviews and some brief details were provided in addition to the main 
information and consent forms, (see Appendix C).  
 
The nurse reviewing the patient’s asthma made a clinical judgement about the potential 
benefit that the patient might receive from taking an additional medication based on a 
combination of objective measurements commonly used in the assessment of asthma 
control and quality of life. This nurse assessment was conducted at Visit 1 and Visit 2, 
which took place 2 weeks after Visit 1. All patients later entered into ELEVATE were 
therefore considered likely to benefit from additional treatment to control their asthma 
and improve their quality of life. Eligible patients were randomised according to their 
asthma severity and current medication-use. The patients recruited for qualitative 
interviews would have been allocated one of the two prophylactic treatments for their 
asthma being comparatively tested in the Step 2 quantitative trial: a corticosteroid 
(brown) inhaler or a leukotriene receptor antagonist tablet. 
 
Recruitment Stage 4 - Analysis of prescription records for evidence of history of non-
adherence 
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The qualitative study, focused on the insights offered by those people who had been 
entered into ELEVATE as likely to benefit from taking a prophylactic medication 
regularly but who had not previously taken this medication as prescribed. By 
implication, by not following the instructions of that treatment these people could be 
considered as “non-adherent”. 
 
Patients were identified from prescription records, who had been prescribed the standard 
prophylactic therapy, inhaled corticosteroids prescribed in the previous year, but who, 
according to the standard dosage and frequency of use given by the British Thoracic 
Society guidelines (2008 revised June 2009, p. 36), did not appear to be taking it 
regularly. 
 
Recruitment Stage 5 - Telephone call to check non-adherence to inhaled steroids and 
invitation to participate in interviews. 
 
Each participant potentially eligible for the qualitative study was telephoned to discuss 
the details of the research interview, to invite them to take part and to gain further 
information on how they did or did not use their brown inhaler prior to entry into the 
ELEVATE study. Prescription refills and adherence self-reports as indicators of 
adherence have generally shown to be unreliable in research studies (Christensen, 2004) 
which have also found a general trend of patients overestimating rather than 
underestimating their adherence to medications. Any admission by the person of non-
adherence was therefore considered as a potentially eligible participant for the 
qualitative study. An interview was set up if participants appeared to have a history of 
non-adherence and agreed to take part.  
 
A confirmation letter was then sent to participants with details of what the interview 
was about as well as another questionnaire that has been used to assess patient 
adherence – the Medication Adherence Report Scale – MARS (Horne & Weinman, 
2002), (see Appendix C). However, in the qualitative study, this was to be used to 
provide a starting point for discussion in the research interview rather than as any 
intended measurement aid of adherence.  
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Participants - demographic information and relevance to analysis 
 
Twenty-four people were identified as potentially “non-adherent” to prophylactic 
medications and therefore eligible to participate in qualitative interviews. Two further 
people were identified who had not taken prophylactic medications before entering the 
study. These people were invited to participate as their talk could potentially provide 
useful contrasts with the other participants’ discursive strategies. All 26 people had 
consented to take part in the ELEVATE study and qualitative interviews at visit 1. All 
participants were white British, lived in Norfolk, Suffolk and Cambridgeshire and spoke 
English as a first language. Participants were aged between 17 and 80 years. Thirteen 
were women and 13 were men. Five participants had received a diagnosis of asthma less 
than three years prior to interview. The participants reported having one of the 
following occupations: farmer, farm manager, school pupil, retired general practitioner, 
social services employee, telephone engineer, caterer, housewife, car showroom 
manager, retired, trainee school teacher, and pub landlord. 
 
Data Collection Methods 
 
Face-to-face interviews and a focus group were the two main methods used to collect 
data. However, the discursive approach taken in this thesis meant that any instance of 
language in text or talk could also be treated as data and hence other data sources were 
also examined in this study which played a fundamental role in understanding the 
participants’ talk in the interviews and focus group. The Chapter Two review of 
literature examined text from a variety of additional sources. The moral discourse of 
asthma management identified in the analysis of asthma guidelines, texts on asthma 
causation and management as well as sources which did not concern asthma were used 
in this study to examine how cultural discourses of illness and asthma management 
might structure the talk of participants in the interviews and focus groups. Similarly, the 
process by which participants were recruited has also been examined and can be viewed 
as providing data. The recruitment process set out for the quantitative study offered 
details of the conditions which preceded the interview and focus group data, and which 
may have importantly shaped the content and interactional process within these core 
data. Participant recruitment is therefore analysed in more detail in Chapter Five to 
address a particular concern about the circumstances in which participants could be seen 
to justify their medicine taking. These non-interview-based sources of data are crucial in 
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providing further evidence of what might structure the talk of participants and to situate 
such talk within a social historical context. However, the selection of these additional 
materials was not to assert these sources as the only relevant influences likely to 
structure participants’ talk. The production of talk within research interviews would 
likely have been affected by a multitude of influences. Rather, the choice of these 
additional materials was based on those which were accessible for analysis, but also 
those that could be seen as likely to play an important role in the production of talk 
about medicine taking within the context of participants taking part in an asthma study 
comparing prophylactic medications. 
 
Face-to-Face Interviews 
 
Face-to-face, semi-structured interviews were conducted with all 26 participants who 
agreed to take part in the qualitative component of the ELEVATE study. Interviews 
were chosen because this study was interested in how people with asthma constructed 
an account of their asthma management and so interviews provided a means to directly 
obtain these perspectives. As discussed in Chapter One, seven of these were also 
interviewed a second time to explore persistence in how they talked about medicine 
taking at two time points. The second interview took place a year after their initial 
prescription of the randomised prophylactic treatment and participation in the main 
asthma trial. For the first interviews, Mason’s (2002, pp. 68-74) guide to structuring 
qualitative interviews was used to construct a flexible interview schedule and a series of 
“topic cards” to guide the discussion, including: “biography of asthma”, “treatments”, 
“relationships and asthma” and “risk and severity” (see Appendix A). Topic cards were 
used to help the interviewer elicit a mixture of narratives and “attitudes” from 
interviewees. This talk could then be analysed to examine ways in which medicine 
taking behaviour and views were situated by participants within a social historical 
context. An additional interview guide was developed for participants who were 
interviewed a second time. Topics covered included the participant’s story of their 
asthma since the first interview; views on their asthma and risk; medication-use; 
life/asthma goals; views of health and illness; experiences of encounters with 
doctors/nurses; issues of trust in illness management; and the future and their asthma. 
These changes were implemented following an understanding that the participants’ 
lifeworlds may be fundamental in how they managed their condition. In addition the 
author was exploring the notion of risk as a relevant issue for asthma and medicine 
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taking and considered asking participants direct questions about risk a useful way to 
understand this issue.  
 
Despite the imposition of a structure on participants’ talk by the interviewer’s use of 
topic cards, interviews were conducted with the aim of allowing participants to say 
whatever they felt relevant, following typical guidance on effective qualitative 
interviewing techniques, which suggests the use of open questions, avoiding imposing 
the researcher’s own opinions and use of prompts to elaborate or clarify (Lincoln & 
Guba, 1985). Interviews therefore did not rigidly follow a standardised interview 
structure and in several cases some of the planned topics were not explicitly discussed. 
Interviews typically lasted approximately one hour, with the shortest interview lasting 
thirty minutes and the longest about one hour and forty five minutes. Issues typically 
covered included: the history of the person’s breathing condition, events around 
receiving a diagnosis of asthma, history and habits of using medications and details of 
communication between themselves and doctors and nurses. However, using topic cards 
required the researcher to enact some assumptions about the issues that were pertinent 
to discuss, structuring the talk of participants and hence impacting on the data that were 
produced. These same issues were also likely to be selected in conducting the analysis 
as most pertinent to justifying asthma management and medicine taking. The 
implications of this structure for participants’ talk and the data produced are examined 
in Chapter Five.  
 
Data-Sharing Focus Group 
 
A single focus group was undertaken with participants from the face-to-face interviews. 
Within the focus group, data, in the form of anonymous vignettes, was shared with 
participants. These vignettes were not taken from any single interview but were 
constructed from the accounting styles that were identified in the initial phase of the 
analysis of interview data. The rationale for collecting the focus group data emerged as 
a response to questions raised after the analysis of the interview data about the role the 
author played in helping to construct the talk of interviewees. The focus group offered a 
means of addressing these difficulties by obtaining data that was based on a different set 
of interactional conditions to the face-to-face interviews. The methodological rationale 
for the development and design of the focus group will therefore be reported in detail in 
Chapter Six after the analysis of interview data. 
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Ethical Considerations 
 
Participants were invited to take part in the qualitative sub-study at the same time as 
being invited to participate in the larger quantitative asthma study. If willing, they 
provided their consent to participate in interviews at Visit 1 of the ELEVATE study. On 
contacting the participants to invite them to be interviewed, and at the interview itself, 
the researcher informed them that the aim of the interviews was to understand their 
views about their asthma and the medication they had been prescribed in the study. 
They were also given information to clarify that the research sought to investigate issues 
that influenced people’s decisions to take medications commonly used to prevent 
asthma symptoms and that this may involve discussing how the patient viewed health 
and illness in general, lifestyle choices and the person’s attitudes to life in general. 
Participants were also informed that: 
• They could withdraw their participation at any time and without giving a reason. 
• The interviews were part of a student project and were in addition to the main 
study.  
• The interviewer had not received any medical training and was not able to offer 
any advice regarding their asthma. As necessary participants were advised to 
contact their local surgery if they had any questions regarding their asthma. 
• The interviews would be recorded, a transcript generated and that the results of 
the study would be published in academic journals. All steps would be taken to 
protect the individual identity of participants in the use of these materials. 
 
After conducting several first interviews the author considered that participants should 
be verbally re-consented regarding the aims of the interviews. This was because the 
focus of the PhD study had shifted beyond a specific focus on asthma and medications 
to the meanings of asthma within a lifeworld context. Re-consenting participants to 
these study aims was not only to ensure participants understood the researcher’s aims 
but also to facilitate discussions that went beyond a specific focus on asthma. Details of 
the rationale and steps taken to re-consent participants are provided in Appendix D.  
 
All but one focus group participant had provided informed consent to take part in the 
quantitative and qualitative studies and had already taken part in the qualitative 
interviews which preceded the focus group. Before the focus group discussion, 
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participants were reminded both in writing and on the telephone that the aim of the 
qualitative part of the study was to obtain their perspectives regarding their asthma and 
medicine taking. They were also informed that the aim of the focus group was to share 
some of the interview findings and to obtain their views of those findings.  
 
The participant who had not previously consented to take part in the ELEVATE 
quantitative study, nor had taken part in any other part of the qualitative study, had 
attended the focus group with his father and was invited to take part. Despite being 
recruited in a very different way to the other participants, this person could count as an 
appropriate member of the group discussion when viewing talk about asthma 
management from a discursive perspective. This is because his talk, like the other 
participants, could also be viewed as situated within a social historical context in which 
moral discourses of illness management are circulated to different social spaces. His 
inclusion therefore offered an opportunity to examine how issues of morality might be 
manifested differently to the other participants. On inviting this individual to participate, 
the focus group moderator, and author of this thesis, gave him verbal information 
regarding the details of the study and purpose of the focus group; his right to withdraw 
at any time; and that if he took part then his name would not be used in the transcript. 
The other participants were asked if they minded this individual taking part in the focus 
group. After the focus group he was provided with further details of the study and was 
offered, but declined, the opportunity to withdraw his contribution. All participants 
were also informed that their own views would not be presented in the data, reminded 
of their right to withdraw their participation and asked not to share personal comments 
arising in the discussion with anyone outside of the focus group. 
 
Summary of Methodological Approach 
 
Understanding how culturally-available discourses help to structure interactional talk 
provides a “loose coupling” (Goffman, 1983, p.11) for examining talk about medicine 
taking. This allows us to consider and discuss the circumstances in which participants 
within interactions about prophylactic medicine taking may reproduce moral discourses 
of illness management and which may also influence decisions about medicine taking. 
To understand how interactional data comes to be structured, the specific approach set 
out here builds on DP by examining the language used in a range of documents which 
detail cultural conceptualisations of the causes and management of illness. The language 
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identified within the review of the asthma and other health and illness literature in 
Chapter Two provided a range of discursive elements used to construct a moral 
discursive framework about asthma prophylactic medicine taking that can be seen to be 
activated in talk and text across time and space. A key source used was the body of 
contemporary clinical asthma guidelines for asthma management, commonly used by 
clinicians in asthma consultations. Asthma guidelines are used to regulate and control 
the allocation of treatments for asthma, so offering the potential to regulate not only 
clinical and patient decisions about medicine taking but also, by implication, to regulate 
the talk which governs those decisions. By deploying this methodological tactic, a 
specific discourse can be seen to circulate the treatment and management of asthma. 
This discourse of asthma management focuses on the need for asthma control by: 
drawing on a limited range of therapeutic options; patients monitoring their own 
symptoms; and adherence to self-management plans which orientate to adherence to 
prophylactic medications. These parameters of asthma management constructed within 
this discourse therefore carry important codes of conduct regarding the behaviour and 
decisions of clinicians and patients which are also likely to regulate the talk related to 
those actions.  
 
The discourse identified within asthma guidelines can therefore be seen as a moral 
discourse of asthma management and the core task identified for the analysis of 
interview and focus group data in this study is therefore to trace a path from this moral 
discourse to the talk of participants. The discursive psychological tools are useful here 
because they enable examination of the moral components of talk through an analysis of 
rhetorical devices that participants deploy. Notions of morality can be seen to be 
implicit to the rhetorical construction of accounts of behaviour, versions of events and 
versions of the self. In the present study, accounts of medicine taking are examined in 
terms of their deployment of a range of rhetorical devices which orientate to the 
particular discursive issues that are activated within the interactions taking place. 
Rhetorical devices work not only to present a particular version but also to undermine 
alternative versions and it is this then-observable discursive work that will indicate the 
particular notions of morality that speakers are attending to. Two rhetorical devices that 
have been identified here as likely to be used by speakers in managing competing 
alternatives are “interpretative repertoires” and “discursive objects”. Reasons why 
speakers are likely to use such devices and why they may be relevant for the analytical 
approach taken in the present study are that these devices appropriate culturally 
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available discourses and objects respectively, are likely to be shared between members 
of the interaction and can be seen as critical in how blame and accountability are 
allocated. Moral discourses can therefore be usefully viewed as both constructing and 
constructive in speaker’s accounts with repertoires and objects being used flexibly by 
speakers to perform specific and sometimes multiple contextualised tasks. However, the 
nature of this relationship between systemic moral discourses and utterances is not fixed 
and the analysis of rhetoric in the interview data will examine the limitations of these 
data for interpreting the role of morality in the talk of participants beyond those 
interviews. The conditions in which participants are likely to engage with notions of 
morality in their talk needs to be investigated rather than assumed and it is for this 
reason that this study has also drawn on techniques associated with linguistic 
ethnography. These techniques, which originate from a range of disciplines, are used to 
identify contextual influences on the production of participants’ talk, which may not be 
directly accessible to a more narrowly linguistic analysis. Conducting this task will then 
provide the rationale to provide data generated on a different set of interactional 
conditions to the face-to-face interviews. Moving to this developed analytical position 
provides a basis for evaluating the interactional issues and role of morality in talk about 
prophylactic medicine taking. 
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Chapter Four 
Analysing Interview Transcripts to Evidence Interactional Issues and Moral 
Discourses in Talk about Prophylactic Medicine taking 
 
I’m not one of these people who get up in the morning and think “right, inhaler, 
take it (.) before I go to bed, take it”  
(501441, Interview 1, page 3, lines 6 to 9) 
 
This chapter will present the analysis of face-to-face interview data, undertaken to 
identify evidence of moral discourses influencing participant’s talk about medicine 
taking. Participants may need to justify their asthma management and medicine taking 
in face-to-face interviews to manage the potential allocation of blame and accountability 
for their reported views, medicine taking decisions and other actions regarding the 
management of their asthma. One type of justification participants might attempt, 
deploying a range of rhetorical devices, is to demonstrate that they are in control of their 
asthma, potentially deploying historical discourses of asthma causation and 
management. It is conceivable that some of these discourses might be activated by 
participants in their interviews with a health researcher in justifying any “non-
adherence” to prophylactic medication. 
 
The purpose of the analysis reported here was to identify evidence of blame and 
accountability in participant’s talk and how this may have been linked to moral 
discourses of medicine taking and asthma management. This will be used to assess the 
merits of this approach for understanding talk and decisions about prophylactic 
medicine taking. Analysis of the face-to-face interviews was therefore aimed at 
identifying interactional rhetorical devices that showed the participant orienting to 
issues of blame and accountability and how the management of different discursive 
positions activated in this process linked to culturally-available moral discursive 
frameworks such as those identified in the analysis of asthma guidelines and other 
sources in Chapter Two. 
 
The analytical strategy which was adopted to analyse interactional talk began with an 
attempt to identify patterns in how decisions about taking prophylactic medications 
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were justified across all face-to-face interviews. This was to provide evidence that a 
moral agenda in the talk of participants was pervasive in the dataset whilst at the same 
time also allowing deviant cases to be identified. As will be seen this early analytical 
approach raised particular problems relating to an attempt to individualise participant’s 
accounts as having a particular style, their “accounting style”. A solution to these 
analytical problems is therefore set out and which prepares the ground for the second 
area of analysis which examined the properties of talk about prophylactic medicine 
taking if viewed from a discursive psychological perspective. This highlights the 
dilemmas that many participants could be seen to be managing in their talk which were 
intimately connected to notions of blame and accountability. This takes us to the final 
area of analysis in this chapter which examined the links between participant’s 
management of blame and accountability with wider discourses of illness management. 
 
The analysis of interview data therefore focused on four areas: 
• A description of the different ways, referred to as “accounting styles”, in 
which talk about prophylactic medicine taking and asthma management were 
discussed in face-to-face interviews. 
• A demonstration of the properties of this talk, as seen from within a 
discursive psychological framework and the interactional dilemmas that can 
be seen to be activated within the interactions for participants. 
• An illustration of how these dilemmas are managed by participants and 
thereby how issues of blame and accountability are managed. 
• An examination of the culturally-available moral discursive frameworks that 
are activated within interactions and which allocate blame and 
accountability. 
 
Although the majority of participants could be seen in their interviews to be legitimising 
their medicine taking there were three participants who did not appear to attend to 
justifying their medicine taking. The limitations of the findings reported in this chapter 
will therefore be discussed, thus preparing the ground for a further examination of these 
“deviant” cases in Chapter Five.  
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Analysis of Face-to-Face Interviews to Identify Accounting Styles 
 
In Chapter One, the primary objective of these early analytical steps was shown to 
emerge from the need to develop a sample to follow up for a second round of 
interviews, intended to be used to validate findings from a first round of face-to-face 
interviews. An analysis of patterns in accounting styles across participants was 
undertaken to examine how these styles and thence moral discourses of medicine taking 
deployed by individuals in their first interview may have persisted in their talk in their 
corresponding second interviews. This sample was to be selected to reflect preliminary 
categorisations of a limited set of analytically distinct ways which it was intended 
should cover all participants’ accounting for and justification of how they took 
medicines. However, only 18 interviews from the 26 first interviews were characterised 
in this way because, in performing this task, significant problems were identified.  
These were found to relate to the level of analysis being undertaken, to developing 
understanding of discursive variation within the interactions and the attempt to validate 
findings using a second interview. 
 
The process for identifying each participant’s accounting style is described in Appendix 
D. To help organise the identification of accounting styles, NVivo software was used. 
NVivo is commonly used within qualitative research to organise and facilitate the 
coding of transcribed data. It is designed to support the use of coded data as labels to 
apply to data subsequently analysed such as in thematic or grounded theoretical 
approaches (Glaser & Strauss, 1967). In the present study, words, phrases and sections 
of text were coded by the specific effect the speaker achieved in a particular piece of 
talk. Annotations were used to detail those devices used to achieve this effect. Such 
coded effects were then collated to represent different interpretative repertoires they 
appeared to build within the interview.  
 
Preliminary Characterisation of First Interviews  
 
Accounting styles 
 
Within the data from the 18 interviews analysed, five preliminary accounting styles 
were identified:  
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• Compliance as passive: The participant positioned her(him)self as engaged with 
their asthma, emphasising themselves as responsible and in control. There was a 
frequent use of the self-regulatory repertoire to position her(him)self against those 
who uncritically comply with medication instructions. This was an active rejection 
of compliance as an ideal. For example, the following participant constructed 
compliance to prophylactic medications as an act of uncritical and habitual 
dependence, positioning himself against “one of these people” who “rely” on 
medications and take it without question: 
 
I’m not one of these people who get up in the morning and think “right, inhaler, 
take it (.) before I go to bed, take it”. I don’t want to rely on it like you know. 
Cos some people obviously will rely on their inhalers and they’ll take it just 
because (1) it’s their medication and I don’t want to do that  
(501441, interview 1, page 3, lines 6-13). 
 
• Minimisation repertoire using several rhetorical devices to justify medicine taking: 
Participants with this accounting style either claimed that they did not have asthma, 
or that their condition was too mild to warrant adherence to prophylactic 
medication. Their own version of their condition was pivotal in justifying non-
adherence to prophylactic medications, but did not blame healthcare for any mis-
diagnosis. In this following example, laziness operated as an acceptable device to 
justify non-adherence because it works to authenticate the speaker’s (S) version of 
her asthma as something too mild be taken seriously: 
 
S: well always, ever since I’ve had the inhalers, I’ve never done it properly. 
JM: why was that at the beginning then? 
S: lazy [laughs] I suppose because I don’t have it badly enough. I would do it, 
lets put it this way, if I really suffered from asthma, and it affected my life, I 
would make sure I did it.  
(530181, interview 1, page 3, lines 19-27) 
 
• Tension between lifeworld and medicine. Adherence potential threat to lifeworld: 
Participants positioned prophylactic medicine taking as incompatible with activities 
in their everyday life. However, individuals with this style appeared to resist 
challenging the medical directive on adherence. In the following example, this 
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participant hinted at a tension between challenging clinical “experts” and his own 
preferred view: 
 
If its proved to be effective (.) and it is the considered opinion of the 
experts...was proved that this you know the preventative was instrumental in in 
you know (.) in in doing that or helping (.) helping relieve those symptoms then 
so be it if that’s what it takes that’s what it takes. 
 (670287, interview 1, page 20, line 36 to page 21, line 5). 
 
• Blame of healthcare breaches sick role contract: Participants blamed healthcare for 
not identifying the “real” cause of symptoms or for not communicating with them 
effectively regarding their condition and health generally. Taking prophylactic 
medications was therefore positioned as potentially treating the wrong condition. In 
the following extract, a key device in justifying non-adherence lay in this 
participant’s concept of the “root cause” of her breathing problems, which medicine 
was failing to address: 
 
What … I am being sold at the moment is um something to keep me ticking over 
so that (3) I suppose so that I can breathe when I need to I I don’t know how to 
put it really. It’s not examining what the root cause…  
(351823, page 10, lines 39-43). 
 
• Minimisation repertoire using few rhetorical devices to justify medicine taking: 
Participants with this accounting style did not enter into much of a dialogue about 
their asthma, appearing to have either nothing to justify, unwilling or unable to 
articulate an explanation for their medicine taking. Asthma was considered not to be 
a big issue in their life. These participants appeared to represent deviant cases 
because of the lack of a narrative about asthma and justification of medicine taking 
behaviour. The following example demonstrates a typical interactional sequence 
with the participant providing only short responses to questions regarding asthma 
management and medicine-use. 
 
JM: Yeah. How would you compare the tablets with the inhalers 
 (3) 
J: Al. Alri↑ght  
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JM: Do you think there’s any differences? 
J: Er (2) they don’t seem to have no side effects or something (2) so long as 
I remember you know try to keep remembering to take one you have to to 
take one at night don’t you  
 (650405, interview 1, page 10, line 13-25) 
 
Two participants were harder to categorise in these accounting styles. One participant 
constructed a pathological cause of their asthma management behaviour, positioning 
himself as passive and out of control. Problems experienced with asthma were blamed 
entirely on himself, “I had asthma all my life and (.) still don’t have it under control (1) 
which is down to me, you know really” (660345, interview 1, page 2, lines 21-24). 
Another participant, unlike the rest of the sample adopted a compliant position with 
prophylactic medications. Previous non-adherence was explained on being prescribed a 
prophylaxis with too low a dose, but in contrast to those who blamed healthcare, this 
participant praised doctors and nurses for the care he had received, “Yeah that 
((increased dose)) and the nurse yeah yeah it made one hell of a difference well I’m not 
blaming the doctor.” (261284, interview 1, page 3, lines 36-38). 
 
Interpretative Repertoires 
 
The interpretative repertoires that were identified within these accounting styles were 
designated as: 
• Self-regulatory: Participants deploying this repertoire constructed themselves as 
active and engaged with their condition. The use of prophylactic medications 
was recognised as important but people who took them regularly were described 
as passive compliers. 
• Self-monitoring: Participants using this repertoire could be seen to minimise the 
importance of asthma in their life and were reluctant to take prophylactic 
medications, preferring to respond to symptoms as necessary. 
• Self-blame: This type of explanation involved acknowledging the importance of 
adherence to prophylactic medications and the role played by clinicians, then 
blaming oneself for not following medical advice.  
• Sick role: Participants using this repertoire constructed a contractual relationship 
between themselves and clinicians. These explanations could be seen as versions 
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of Parson’s sick role (1951), where patients should follow advice from a 
competent physician. 
• Root cause: This type of explanation could be seen to be used by participants in 
conjunction with a sick role repertoire to argue that clinicians’ failure to identify 
the real or “root cause” of their breathing problems represented a failure to fulfil 
the role of a competent physician.  
• Minimisation: By minimising the importance of asthma in everyday life, this 
repertoire enabled participants to justify non-adherence to prophylactic 
medications. This could be seen either as constructing asthma as not real asthma 
or too mild to warrant regular preventive therapy. 
• Compliance: This type of explanation could be seen as reproducing medical 
advice. This repertoire could be seen to be used within different interactional 
tasks, for example in conjunction with self-blame repertoire or as an indication 
of current medicine taking. 
 
To illustrate the process of developing repertoires, extracts detailing effects and devices 
that constitute the self-regulatory repertoire can be seen in Appendix D. 
 
Methodological problems in the analytical construction of accounting styles 
 
Through attempting to identify the different ways participants accounted for their 
medicine taking, their “accounting style”, a number of methodological problems were 
identified for interpreting the analysis of that data. These problems were related to the 
appropriate level of analysis required to examine interactional talk about medicine 
taking, the implications of this analysis for the ability to identify discursive variation in 
participant’s talk and the appropriate method by which to validate findings from a 
discursive analysis of participant’s talk.  
 
Level of analysis: Setting an objective of identifying individual’s accounting styles 
presupposed that the “individual” was the appropriate unit at which to conduct the 
analysis. The discursive psychological approach applied in this study viewed talk as 
language produced in a social space, situated in time and space. Viewing talk about 
medicine taking as connected to social historical contexts, entails adopting an analytical 
framework which can enable insight into those contexts which are activated in that talk. 
Viewing such talk only through the analytical lens of the individual however, limited 
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scope for a discursive analysis. This is because an individualistic focus has the potential 
to isolate that talk from these social conditions, so reducing interpretations to individual 
characteristics rather than reflecting the circulation and activation of different discourses 
in that talk. 
 
Discursive variation: Adopting an individualistic focus also had implications for the 
types of insights that could be derived from such an analytical approach. These can be 
seen in the process of attempting to identify separate categorical accounting styles in the 
analysis. This process aimed to list “effects” and “interpretative repertoires” in 
participants’ talk with potential to generate thematic categories within the same 
interview or later, when interpreting further talk between participants. However, 
attempting this could also be seen to gloss over complexity and variation in the talk of 
participants. This can be seen in how interactional talk was de-contextualised so as to 
transfer it to the discrete categories of “effects” and “interpretative repertoires”, which 
were then to be used to develop the “accounting style.” In compartmentalising and 
abstracting individual utterances as accounting styles in this way, talk could be seen to 
be treated in a similar way to those individualistic approaches attempting to identify 
individual attitudes, potentially missing important variations in the functions of talk 
assigned to a particular accounting style. 
 
Validating analytical interpretations from first interviews: Further problems were posed 
by attempting to provide an analytically sound basis for conducting a second interview 
with each participant. Second interviews were undertaken to validate interpretations of 
talk in the first interviews, and to identify persistence in moral discourses. Such a step 
did not fit logically with a discursive approach that treated talk as situated in 
interactional conditions.  
 
It may be considered that by recreating the same interactional conditions in a second 
interview, participants could be seen to produce the same kind of talk on both 
occasions. Such similarity might be allowable when viewed from within a positivist 
paradigm, with similarities between the two occasions being seen as evidence that 
participant’s talk had persisted across two time points thereby strengthening claims that 
the same kind of talk might be found in a range of interactions. However, taking a 
discursive psychological perspective means that this talk must be examined in terms of 
its specificity to this interactional setting and not in the expectation that these data will 
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tell us anything new about how participants will talk in other interactions about their 
asthma. From a discursive perspective, identifying persistence therefore becomes 
problematic if data from two different circumstances are treated as representing talk 
from a broader range of interactions about illness management. Allowing for persistence 
within the same type of interaction does not fit with a discursive approach which, 
instead, will focus on how participants link medicine taking with morality under 
different interactional conditions, potentially enabling different discourses to be 
activated.  
 
Resolving problems highlighted in analysing accounting styles 
 
The next phase of the analysis sought to resolve these methodological difficulties by 
adopting an entirely different analytical strategy to identify the role of moral discourses 
of asthma management and medicine taking in participants’ talk. Rather than attempting 
to identify accounting styles through analytical review of those interviews, this 
alternative strategy, was to analyse full transcripts from face-to-face interviews so as to 
evidence morality in participants’ talk. This reduced the extent of decontextualisation of 
talk from the context of research interviews. Whilst the production of “data”, captured 
from an audio recording, can be seen as one form of decontextualisation (Burman, 
2004) of talk, analysing transcribed talk nonetheless offered some opportunity to 
overcome the analytical problems of discursive variation identified. It also allowed an 
analysis of the process of production of meaning as something constructed between 
participants rather than derived from an individual, so resolving the problem of the 
individualistic focus apparent in the analysis of accounting styles. Finally, it enabled 
insight into what sorts of data would be required, to strengthen, or validate the author’s 
interpretations about the role of morality that were made through the analytical process.  
 
Adopting this alternative analytical strategy required decisions then to be made about 
how to treat the second interviews that had already been conducted with seven 
participants (reported in Chapter Three), and how to place the analytical concepts 
“accounting style” and “interpretative repertoire”. The analytical focus had now shifted 
away from examining persistence in accounting styles across time points. From the 
discursive perspective now adopted, similar interactional conditions were being created 
in the second interview as in the first. It was therefore decided that the seven interviews 
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with participants who had previously been interviewed would be treated in the same 
way as first interviews and included as part of the main body of interview data.  
 
The process of identifying “accounting styles” had shown to be useful for identifying a 
range of ways in which participant’s justified their asthma management and medicine 
taking and for substantiating the concept “interpretative repertoire”. However, because 
of the problems posed by individualising participants’ talk, the concept of “accounting 
style” was not deployed further as an analytical tool. However, the concept 
“interpretative repertoire” continued to be used to illustrate the variety of ways in which 
decisions about medicine taking could be seen to be explained by participants. 
Interpretative repertoires are produced interactionally to perform particular tasks. Unlike 
accounting styles, groups of people do not use some interpretative repertoires and not 
others. The same repertoires may be used by different people to perform very different 
functions. The “interpretative repertoire” was therefore a useful tool in helping to 
emphasise discursive variation in interactional talk, and so supporting a shift away from 
an individualistic focus on individual attitudes to talk about prophylactic medicine 
taking in multiple and dynamic moral discursive contexts.  
 
Analysing Properties and Dilemmas in Talk about Prophylactic Medicine taking 
 
In this section, extracts from face-to-face interviews are examined, providing examples 
of some of the different ways in which moral discourses influenced the talk of 
participants. This is not to provide an exhaustive account of the many different ways in 
which people with asthma talk about asthma management. It will, however, 
demonstrate, through case examples, what can happen in talk about asthma management 
and medicine taking when public morality converged with personal experience in this 
research context. The presentation of this analysis will begin by showing how the 
properties of the discursive psychological approach adopted in this study could be seen 
as displayed in participants’ talk. These properties were seen in how: participants’ talk 
could be seen as situated social action; versions of events were authenticated and 
alternatives undermined using rhetorical devices which indicated a moral agenda for 
participants; talk was both constructed and constructive; and different types of talk may 
have operated simultaneously. These properties demonstrated the discursive dilemmas 
that participants faced within research interactions which were related to the allocation 
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of blame and accountability for participant’s views and behaviour regarding medicine 
taking.  
 
This analysis of how participants resolved interactional dilemmas revealed different 
moral positions that were activated through the ongoing discussion within face-to-face 
interviews. The analysis of talk about asthma management was therefore extended to 
engage with culturally-available moral discursive frameworks that could be seen to be 
activated within interactions. These discursive frameworks referred to moral discourses 
of illness management and medicine taking but also to other “lifeworld” (C. I. Salter, 
2005; Schutz, 1962) discourses that may have interplayed with those specifically 
relating to the management of asthma. Talk was analysed to seek evidence of a 
discourse of accountability in participants’ accounts which may have reflected the 
abstract discourses identified in asthma guidelines and other sources discussed in 
Chapter Two as well as other discourses that may have originated in different social 
spaces to the institutionalised medical discourses. Before examining the transcripts 
however, the process of transcription and analysis undertaken in this part of the analysis 
must be explained. 
 
Process for Analysing Face-to-Face Interviews 
 
Transcription: The face-to-face interviews were captured on audiotape and then 
transcribed, based on a system developed set out in Atkinson and Drew’s “Order in 
Court” (1979) which was based on Gail Jefferson’s conversation analytic transcription 
conventions. Although many nuances of talk are lost in transcriptions, these conventions 
offered the best technique to facilitate an analysis of rhetorical devices as they enable as 
much of the detail of participant’s talk as possible to be captured in written form, (see 
Appendix B for full details of conventions).  
 
A first pass of the tape was taken to construct a loose transcription of the content of the 
interview. The tape was then listened to a second time to check choices in the transcript 
and to make further edits. This was originally done to incorporate as much of the detail 
of a sequence as the researcher could interpret as relevant. This included pauses below 1 
second, changes in pitch and intonation, speech volume and the tempo of an utterance. 
This approach can be seen in interviews 670287 and 670289. However, having 
completed these transcripts, it became clear that the author selected sequences within 
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the transcript which related most closely to participant’s asthma management. It was 
therefore decided that this level of transcription detail would only be undertaken when 
the researcher could identify relevance in a particular sequence for the participant’s 
explanation of medicine taking. Details of transcription such as tempo and pitch were 
only included where the researcher noted them as helping interpret the turn-taking 
sequence between the researcher and participant or to interpret the rhetorical devices 
being deployed. For example, several participants told stories to justify their asthma 
management. In these cases it was considered that much of the detail of the story was 
the main focus of the analysis and key rhetorical device rather than how the speaker told 
the story. In contrast, where a participant seemed to be foregrounding a particular part 
of an explanation as critical in justifying their asthma management, then this was given 
emphasis in the transcript.  
 
The transcript was then read through slowly, interesting phrases underlined and broken 
into sections if it seemed appropriate. When medicine taking, asthma management, or 
other health behaviour was discussed, an analysis of the rhetorical devices being used 
was undertaken. Other sequences which were also used as starting points were 
discussions of the participant’s GP surgery and the NHS generally or views of health 
and illness.  
 
Analysis: Appendix B sets out some key questions that were considered in analysing 
transcripts. Chapter Three proposed that the construction of objects of thought, 
otherwise referred to as “discursive objects”, and interpretative repertoires are likely to 
be useful tools in analysing the accounts that participants provide, focusing on lexical 
features and grammatical styles used by speakers. In applying these tools a key 
requirement in providing a plausible interpretation of the data was to demonstrate 
“participant’s orientation” (Potter & Wetherell, 1987, p. 170) to interactional issues. 
Speakers, in constructing rhetorical accounts, do not only deploy devices that will build 
a specific version of events but may also be seen to deploy devices that undermine 
alternative versions that pose a potential threat to how that person wants to be 
understood. Identifying participant’s orientation to discursive issues meant pinpointing 
devices that address these threats to versions of the self, behaviour or “attitudes” 
towards a particular issue. This enabled participants’ talk to be viewed from a moral 
framework where blame and accountability could be managed and allocated within 
interactions.  
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After analysing key sections in the transcript, the next step was to look for links and 
contrasts between analysed sections to examine whether similar positions were being 
constructed. This involved identifying important similarities or differences in the 
content and construction of talk. In addition sections not explicitly discussing asthma 
management were examined for any further insight into the interpretations formed thus 
far by the analyst. This then led to formulating the kinds of explanations that speakers 
appeared to be constructing at different points through the rhetorical devices they 
deployed. This part of the analysis developed the higher-order concept of the 
interpretative repertoire, as set out in Chapter Three (Potter & Wetherell, 1987).  
 
The next stage involved specifying when the interviewee used a particular repertoire 
and not another which was used elsewhere. Repertoires may be used at different points 
for different reasons, may be multiple and contradictory. A key aspect of this part of the 
analysis involved looking for whether different repertoires created new problems for the 
speaker. Wetherell has suggested that a key way to validate the identification of 
repertoires is to examine if a particular combination of repertoires creates “trouble” for 
the speaker, (M. Wetherell, personal communication, February 2, 2006). We saw in 
Chapter Two how the nurses in the research of Jones et al (2000) on asthma self-
management plans appeared to manage such a tension between notions of autonomy 
and accountability, by constructing a contingent version of the nurses’ role in their 
patient’s asthma. Their orientation and management of these tensions provided evidence 
that they were drawing on a moral discourse of asthma management also identified 
within asthma guidelines. The analysis by Gilbert and Mulkay (1984) of scientific talk 
provides another example as seen in Chapter One. They identified a “truth will out 
device” (Potter & Wetherell, 1987, p.153) was being used in scientist’s talk to manage 
potential accusations of bias that seemed to emerge as an issue in their talk, when 
discussing the differences between their own work as “empirical” and other scientist’s 
work as “contingent.” Identifying these devices therefore provides a form of validation 
for the analysis and enhances the trustworthiness of an analytical interpretation (Potter 
& Wetherell, 1987). However, such devices may be difficult to identify and caution is 
needed when interpreting tensions and contradictions in a participant’s talk. What may 
appear as a contradiction may have some supportive causal link which made sense in 
the context of the interview. In analysing discursive tension the issue was to examine 
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whether the sequences of talk were closely linked in the interview and whether the 
person could be seen to actively manage any such contradiction. 
 
Finally, having provided evidence that interviewees were engaged in a moral agenda to 
justify their asthma management and medicine taking, the data were analysed to see 
whether links could be made to different moral discourses that circulate society 
regarding asthma and illness management. These could be the moral discourses 
discussed in Chapter Two around appropriate illness management as seen from the 
asthma guidelines, older discourses of asthma and emotional control, contemporary 
notions of illness prevention or those relating to symptom control as seen in the latter 
half of the twentieth century. Alternatively other discourses may have been activated 
which may have contributed something new to those already identified. To make these 
links, the interpretative repertoires that participants deployed were re-examined for 
evidence that these repertoires could be interpreted as versions of moral discourses of 
illness management or of other discourses that may influence an evaluation of the 
speaker’s asthma-related behaviour. As illustrated in the analysis of data provided in the 
study by Jones et al, the technique for doing this lies in how rhetorical devices, such as 
discursive objects, function to construct repertoires that appear as versions of culturally-
shared moral discourses.  
  
The analysis presented in this chapter will therefore set out and identify key sections of 
face-to-face interviews which appear to show participant’s orienting to competing 
versions of their medicine taking behaviour. These examples will be used to make links 
with the moral discourses of asthma and illness management and medicine taking 
described in Chapter Two so as to provide a basis for a discussion of the implications of 
morality in talk about prophylactic medicine taking in Chapter Seven. 
 
Analysis of Interview Transcripts 
 
To demonstrate the discursive properties within participants’ talk, extracts from four 
face-to-face interviews are presented here as case examples and then analysed in depth. 
They were chosen as they display very different ways in which participants could be 
seen to justify their medicine taking, and were each deliberately selected from different 
accounting styles identified in the early analysis. Despite being assigned very different 
accounting styles, these participants can be seen to have distinct similarities in the 
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interpretative repertoires that they deployed and the moral discourses of medicine taking 
that were activated within those interactions. By identifying what is different and what 
is shared in these interactional sequences we will be able to demonstrate the analytical 
problems in identifying accounting styles, how these have been resolved in a detailed 
analysis of transcripts, examine the relationship between discourses of morality and 
individual utterances and highlight what can be gained by taking a discursive 
psychological approach to this problem. The face-to-face interview dataset collected in 
this study therefore represents a range of ways in which talk about medicine taking may 
be manifested within a particular type of interaction. By drawing links to wider cultural 
discourses, it aims to illustrate the circulation and activation of morality within this 
interactional context which might indicate the importance of considering the influence 
of morality in talk about medicine taking more generally.  
 
Excerpts from transcripts from the four interviews reported in this chapter can be found 
in Appendix B. Each excerpt includes at least one of the extracts reported in this chapter 
and enable the author’s choice of extracts to be examined and facilitate further insight of 
how participant’s versions were sequentially constructed within the interactions taking 
place. In addition, full transcripts of all interviews cited within the main text of this 
thesis have been provided in a CD as an appendix. Pseudonyms have been used in all 
extracts presented here. The line numbers quoted in the title of each extract correspond 
to the line numbers of the excerpt included in the appendices. However, the line 
numbers used in presenting this analysis correspond to the numbers used in the extracts. 
 
Constructing “Non-Adherence” using Scientific and Psychological Repertoires 
 
Extract One is taken from a second interview with Dave. Dave was aged 39, had asthma 
all his life and lived in a detached house in a rural location. He stated that he was a 
manager of a car showroom or company, a Chelsea football supporter, golfer, keen 
gardener, visited his local pub regularly where he met with friends and had talked about 
asthma. He also stated that he was financially well-off, went on holiday three times a 
year and had left a large sum of money to asthma research in his will. 
 “I have my solicitor raising his eyebrows when he saw how much money I left asthma 
research in my will” (page 30, line 51 to page 31, line 1). Dave was prescribed an 
asthma prophylactic tablet which was supposed to be taken once a day to be effective. 
This treatment replaced the brown inhaler which he was prescribed prior to participation 
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in the ELEVATE study. In the analysis of first interviews, Dave was categorised as 
having accounting style 1 - Compliance as passive. In Extract One, we can see an 
example of how Dave justified not taking the prophylactic brown inhaler by deploying 
two repertoires. Early on in this extract we can see a scientific, rational repertoire. This 
has similarities with the “empiricist” repertoire identified by Gilbert and Mulkay, 
reviewed in Chapter One. Then we can see a psychological repertoire. 
 
Extract One: Participant 500367 (Dave). Interview 2, page 5, line 1 to page 6, line 51  
 
1.  JM: (1) So what, what are the differences do you think, or the relative  
2.   difference between (1) eh, tablets and the brown inhaler? 
3.  D: (3) I think it’s, I think there’s an element of psychology comes into it.  
4.   (1) And I think there’s a degree of psychology comes into everything 
5.   (1) in as much as (.) partly because I think those tablets are doing some 
6.   good (.) it’s certainly got to help the job a lot (1) help the fact that they 
7.   are. 
8.  JM: Yeah. 
9.  D: (2) Em, (1) the brown one I’m absolutely, I’ve managed to convince  
10.  myself beyond a reasonable doubt, it doesn’t work or its effects are (.)  
11.  minimum, minimum effectiveness. (2) I know, I, I’ve had (1) asthma 
12.  (1) all my life. I’ve you know, I started with the little pink tablet but 
13.  through to the Ventolin, then went on to the big white ones which were 
14.  foul, before that we had spin halers and all these thing we used to have 
15.  to put out fucking cups in and things and cracking and things. I’ve 
16.  been through the full nine yards with this. (1) As soon as Ventolin 
17.  appeared (1) instantly you have something which is a cure (1) (??). 
18.  You went from having (1) asthma (1) to using it (.) to being perfectly 
19.  normal again (1), like that. (1) It was (2) a big, big difference. (5) The 
20.  brown, I mean with, I’ve had two or three or four different doses of the 
21.  brown one and I’ve played about with it for (1) a week, for (.) nine 
22.  months sort of thing, and I’m adamant that it’s not made any 
23.  difference. (3) It really hasn’t. (1) Yeah and I did forget to take it and I 
24.  did forget to, it was just (.) h, how (4) and the, this thing about using 
25.  the two in conjunction. (1) Well, (2) it just, I just never (1) really 
26.  accepted it. 
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27. JM: (1) So is it, is it just the eh (3) the drug itself or is it the device that,  
28.  that’s in it as well [is there anything else about] 
29. D: [Oh no, I don’t think] there’s anything (??). No. 
30. JM: It’s not like I 
31. D: (3) I, (2) it’s, it’s, I, I have experimented with it and, and you know a  
32.  week playing with it and then a week without it and then a week with it 
33.  and I really can’t tell you that there, that there was a great deal of 
34.  difference among any. 
35. JM: Right 
36. D: There really was none (?) (2). I’ve been better with these tablets in as  
37.  much as I know for a fact that I have ordered less Ventolin (.) since I’ve 
38.  been using those than I was before. 
39. JM: (1) Do you think you’ve eh, (1) taken (.) the tablet more regularly? 
40. D: I’ve taken the tablet, yeah. 
41. JM: Right. 
42. D: Oh definitely, definitely (2). 
43. JM: What would you say about the (2) given what you’ve said about  
44.  psychology (2) what you know about it and the fact that you definitely 
45.  taken them (??) more regularly (1) what do you think the possible 
46.  differences in treatments? 
47. D:  Going back to what I said at the beginning (1) I think there’s an  
48.  element of psychology in as much as (.) because I’m (1) pretty 
49.  adamant I’ve been told that this will (1) help effectively but, (.) I’ve 
50.  been taking it, I’ve been going along with it, I’ve certainly as I said, 
51.  used less Ventolin at the same time (2). No, no problem at all. (1) 
52.  Brown one was very hit and miss in as much as I would forget to take 
53.  it didn’t matter where I put the thing. (2) I had them scattered, I had 
54.  one in the car, one in the, beside my bed, one in my office and I’d still 
55.  forget to take it. (1) I don’t know why but I just did.  
56. JM: (3) That’s interesting. 
57. D: (2) I think it was, I think it was (1) the fact that (1) it, it’s so similar to  
58.  the original (.) the blue one, the Ventolin (.). That (1) you use when 
59.  you’ve got asthma, when you’re having an asthma attack or (??), you 
60.  use the (??) (1) and it’s (1) that’s a cure, you pick it up, you reach for it 
61.  at that point (2) to (1) go to the action of using exactly the same sort of 
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62.  (1) when there’s nothing wrong with you, is not a natural (2), and I 
63.  think there is an element of that feeling. 
 
A key way in which Dave explained his use of prophylactic medications and which is 
evident in this sequence is through his use of a scientific repertoire. He constructed his 
argument using legal and scientific terminology “beyond a reasonable doubt” (line 10), 
“minimum effectiveness” (line 11), combined with an empirical approach to test out the 
brown inhaler (lines 31 to 34). This active construction juxtaposes with a sense of 
passivity with the types of medication provided, a dependency with what has been 
available at different times, emphasised with a sense of frustration in lines 15 to 16. 
This mixture of articulating objectivity alongside subjective, long-term experience, “I 
know, I’ve had asthma all my life” (lines 11 to 12), displayed a powerful piece of 
rhetoric for demonstrating that his account of the effectiveness of the brown inhaler 
medication was the authoritative one. The effect was to construct his asthma 
management and himself as well-intentioned, rational and reasonable, but thwarted by 
inadequate treatments. Not only this, but he was not someone who just accepted the 
advice he was given, but someone who made his own mind up, “I’ve managed to 
convince myself beyond any reasonable doubt” (lines 9 to 10). This is a direct rejection 
of the notion that patients should passively comply with instructions to take medications 
as prescribed, instead asserting active monitoring of the medication’s effects. His “non-
adherence”, within this repertoire that Dave constructed is perfectly plausible in the 
context of recounting the work he had done himself to test out the effectiveness of 
brown inhalers.  
 
However, Extract One also demonstrates Dave using a psychological repertoire to 
account for his non-adherence to the brown inhaler. Dave discussed different elements 
of psychology including forgetting, visual association with blue inhalers (lines 57 to 
63), notions of psychological acceptance, “I just never really accepted it” (lines 25 to 
26), the placebo effect (lines 4 to 7) and the psychological impact that the introduction 
of Ventolin as a new treatment had in the management of asthma. The detail provided in 
his endeavour to overcome his poor memory and take the brown inhaler regularly, in 
lines 52 to 55, suggests Dave was attempting to discredit any notion that he did not try 
hard enough with the brown inhaler. As already identified by Cornwell (1984) and more 
recently Radley and Billig (1996), notions of being in work, or a hard worker, are often 
linked to undermining potential accusations of being a malingerer. Dave, using a 
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metaphorical “scattering” of inhalers in key locations, constructed a version of himself 
as someone who is in many places on a daily basis, of which his office is one. 
Forgetting to look after his health is set within this context and the “scattering” strategy 
is therefore represented as a proactive attempt to overcome the limitations of his own 
psychology brought about by this busy lifestyle. Dave’s non-adherence was set within a 
broader cultural discourse of the busy working individual and importantly not within a 
context where remembering things might be seen as not a problem. This rhetorical work 
therefore undermined potential criticism that Dave was lazy in his attempts to adhere to 
the medication. As well as using the scientific repertoire in this extract, Dave also 
undermined any suggestion that he had an irrational and incorrect perception of his 
medications. This was achieved by constructing himself as committed to seeking out the 
truth through endeavour, objective empiricism and experience, three attributes that can 
be widely seen as core values in a working context. 
 
An important device Dave used when deploying the psychological repertoire was the 
construction of the brown inhaler as something that wasn’t “natural” to use “when 
there’s nothing wrong with you” (line 62). From a social cognitive perspective, this type 
of statement has been repeatedly identified and categorised as an individual attitude 
where the individual does not view their asthma as a long-term condition (Halm et al., 
2006; Horne & Weinman, 2002). However, Dave clearly demonstrated in this extract 
that asthma was something he had lived with all his life, repeatedly confronted and, 
with his regular taking of the tablet prophylaxis, that he fully understood the function of 
prophylactic medications in that his adherence to the tablet had resulted in Ventolin 
being required on fewer occasions. By viewing Dave’s talk from a discursive 
perspective, his statement about the brown inhaler was contextualised in a version of 
Dave as the informed scientist and not someone who has incorrect beliefs. 
 
Blame, accountability and moral discourses in Extract One:  
 
By deploying a scientific and psychological repertoire, Dave could be seen to have been 
simultaneously active and passive in accounting for his medicine taking behaviour and 
both repertoires could be seen to have worked in tandem to manage potential 
accusations that he was not managing his asthma appropriately. This was achieved by 
demonstrating the steps he had actively taken to take control of his asthma whilst also 
demonstrating the limits to his own agency in asthma management. This was shown 
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initially in expressing his frustration at having to follow strange and ever-changing 
regimens that had not, until the advent of Ventolin, provided the level of control he had 
sought; and then with unconscious aspects of individual psychology limiting his ability 
to remember to adhere (set within a context of being a busy working individual) and to 
“naturalise” and “accept” the brown inhaler as a creditable treatment for his asthma. 
Seen in this way, Dave’s symptoms were as a result of understandable and acceptable 
limiting circumstances, and not due to personal laziness or any "irrational” rejection of 
the value of medications, or denial of his condition.  
 
This analysis indicates that a moral discourse of asthma management was activated in 
these interactional sequences which can be seen to orientate around Dave constructing a 
version of the virtuous ill person. This was someone who made an active attempt to 
control their condition in difficult circumstances, not merely accepting the advice they 
were given. This is not a traditional medical idea of the ideal patient but is a 
reconstruction of more contemporary notions of the “asthma expert” seen within recent 
patient-centred initiatives, (Department of Health, 2001; Taylor & Bury, 2007) but also 
within wider ideologies of twenty first century working life and of the “reflexive 
consumer.” By positioning himself on the positive end of this moral dimension of 
illness behaviour, Dave provides plausible explanations for his medicine taking 
behaviour, problems with asthma control and control of his asthma management and 
health more generally. Importantly, rather than viewing statements about his individual 
psychology in isolation, as a social cognitive perspective might do, the interpretative 
repertoires that Dave uses in this sequence are interdependent and lead to a different 
interpretation when seen together. 
 
Deploying a Sick Role Repertoire to Blame Healthcare 
 
In contrast to Dave’s stance, Extract Two is taken from a second interview with Irene, 
who can be seen to have taken up a more passive and fatalistic stance towards the 
healthcare she received. Irene was classified in her first interview as having accounting 
style 4 - Blame of healthcare breaches sick role contract. Irene was 63 years old but 
was 48 years old when she had been diagnosed with asthma. In this extract, Irene was 
explaining why she didn’t like taking tablets. She was prescribed an asthma 
prophylactic tablet as part of the main asthma trial and argued here that she stopped, as 
she thought they made little difference to her asthma. 
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Extract Two: 121221 (Irene). Interview 2, page 3, line 11 to page 4, line 2 
 
1.  JM: yeah, so you, when you entered the study and you were prescribed the  
2.   tablet. 
3.  I: Mmmm. 
4.  JM: You said you stopped taking it two or three months ago, were you  
5.   taking it every day or? 
6.  I: I took it every night. I had it up beside my bed, but what actually  
7.   happened I lapsed (1) eh, over Christmas time (.) I didn’t get one in 
8.   because I didn’t order it in time (1) and then I went without and then I 
9.   just sort of (1) left it you know? 
10. JM: (2) You said you didn’t notice any difference? 
11. I: I haven’t noticed any difference because (1) I still had the attacks (1)  
12.  you know, (1) but em, (2) as I said I’ve also got another one I take for  
13.  (2) eh, (??). (2) Arthritis (1) now I don’t like that tablet at all (1) I, and 
14.  I don’t even think that works either (1) [and actually] 
15. JM: [What don’t] you like about them? 
16. I: Pardon? 
17. JM: What don’t you like about the tablets? 
18. I: (1) I think you keep filling your body up with all these tablets and (1)  
19.  you know (3), I don’t know I just feel that, is that causing my problem 
20.  (2), you see with my problem (1) my stomach problem (1) I just, I (??) 
21.  with my stomach. (2) em, (1) I feel everything I eat (1) I get pain in 
22.  here I ain’t been to the doctors with it yet (1). Sort of there like, I don’t 
23.  know if I got an ulcer or what (.) and I, I think tablets (2) you know, 
24.  (1) I don’t know it might be me, I ain’t really a (1) big fan of tablets. 
25.  (1) You see but I have been taking them for years (1) coproximol and 
26.  I’m saying years, no they’re now telling you (1) that they’re bad. (1) 
27.  They going to take them off the shelf, don’t know if you saw the 
28.  article? 
 
Irene, like Dave, reported that she did not notice any difference in her symptoms after 
taking a prophylactic treatment regularly, although with Irene this was the tablet form 
rather than the brown inhaler. Like Dave, this perceived failure to change her symptoms 
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formed the main basis of the argument for not continuing with the treatment on a daily 
basis. Irene also reported forgetting to take prophylactic medications used for the 
prevention of symptoms, “I lapsed” (line 7). However, we can see that Irene’s statement 
of forgetting had a very different effect within the interaction than that of Dave. Dave 
reported forgetting but only in the context of also demonstrating how active he was in 
managing his asthma, how many steps he took to prevent himself forgetting and that his 
good intentions were thwarted by unconscious psychological forces. Here, Irene showed 
how she managed to take the treatment regularly by keeping the tablets at her bedside, 
but this only preceded a simple statement that she “didn’t order it in time (1) and then I 
went without and then I just sort of (1) left it you know?” (line 9). In contrast to Dave, 
there was little rhetorical work done by Irene to justify this forgetting and in this 
sequence, non-adherence to the asthma medication did not appear to be a major 
concern. Instead of forgetting being set within a context of active engagement with 
asthma, the effect of Irene’s talk is open for interpretation, one of which could be that 
she had “given up” or “misunderstood” the function of the medication and her asthma. 
  
Following the interaction further however, we can see that Irene provided a broader 
concern about tablets which served to contextualise the decisions about the asthma 
tablet. “I think you keep filling your body up with all these tablets” (line 18). Irene used 
a powerful metaphor to directly challenge the value of taking an aggregated category 
“tablets.” The idea of the body as a container which can be filled up stressed the 
argument that adherence meant her body can’t keep anymore tablets in, spilling over 
with medication. She blended mitigating phrases “I don’t know I just feel that” and “I 
don’t know it might be me” with a personal narrative of her long experience with tablets 
and current stomach problems to present her criticism of tablets. The sense of 
apprehension, emphasised with a lack of cohesion in the sentence “(1) I just, I (??) with 
my stomach. (2) em, (1) I feel everything I eat (1) I get pain…” (lines 20-21) suggested 
an uncertainty in presenting this position, yet her arguments were supported and 
therefore normalised with reference to a press article as evidence “they’re now telling 
you (1) that they’re bad” (line 26). By using the collective term “they” to refer to 
scientists and medicine, Irene might have been justifying not using the tablet therapy for 
the prevention of asthma by associating it with and undermining the solidity of medical 
knowledge regarding another tablet. Her behaviour could then be accepted as reasonable 
because if the medical knowledge about medications changes then it cannot be trusted, 
raising questions for taking them. Her earlier statement that she “just sort of left it” (line 
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9), could then be understood as acceptable and freeing her from blame for not taking the 
asthma prophylaxis as prescribed. 
 
As this sequence in the interaction continued, Irene’s position on medications was set 
further within dissatisfaction with healthcare more generally. Again we can see similar 
rhetorical devices were being used by Irene to account for her (lack of) attendance at her 
local surgery. 
 
Extract Three: 121221 (Irene). Interview 2, page 6, line 38 to page 7, line 7 
 
1.  JM: So you’ve been (1), how many times have you been back in to the  
2.   surgery in the last year? [for your asthma?]  
3.  I: [I’m a], you see this is the thing (1)  
4.   I should see an asthma nurse but thing is (.) the only time my asthma’s 
5.   ever mentioned (1) down that surgery (1) is if I had, like when I had 
6.   bronchitis (1), “ooh, you got asthma (1) eh, take (1) more (1) inhaler”  
7.   you know, “do more(.) inhaler” (1) but apart from that there’s no (1) 
8.   em, (1) request to see the asthma nurse or anything like that, (1) and as 
9.   far as “I’ll be honest with you (1) I do find in today’s world (1), and  
10.  I’m not alone (1) we got one of the best surgeries I think down there, I 
11.  really do (1) but, (.) they still like say you went down with a complaint 
12.  (2) and you got two or three other things on your mind (1), they don’t  
13.  want to hear, you got to make another appointment all the time. (1) For 
14.  the specialised thing, whatever you want (1) and invariably I think they 
15.  don’t really (2) you know, want to know really to be honest.” 
 
In this extract, the interviewer’s (JM) question appeared to represent a face-threatening 
act which Irene could be seen to orientate towards. The issue appeared to be the possible 
criticism that she was not taking responsibility for her asthma because she had not 
attended the surgery as often as she should. This concern is first evidenced with the use 
of the modal verb “should” (line 4). However, this was merely a preface to direct 
criticism of the quality of care that she had received, namely that the surgery did not 
take enough of an interest in her asthma, “the only time my asthma’s ever mentioned (1) 
down that surgery” (lines 4-5) and that “they don’t really (2) you know, want to know 
really to be honest.” (lines 14-15). Irene constructed a very clear picture of herself on 
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the one hand - as a patient with concerns she wanted to discuss, and “that surgery” on 
the other - as dismissive of these concerns and lacking interest in her individual 
circumstances. These versions were not merely described however, but were 
authenticated using a range of rhetorical devices. First of all, she provided a specific 
example to script a typical response to her expressions of concerns about her asthma, 
adopting the voice of doctors and nurses in an ironic tone “ooh, you got asthma (1) eh, 
take (1) more (1) inhaler” you know, “do more(.) inhaler” (lines 6-7). This was followed 
by a normalisation device, positioning her uncaring surgery as pervasive of the NHS 
more generally and representative of an uncaring world. Moreover she used the 
evidence of allies in her viewpoint “I do find in today’s world (1), and I’m not alone” 
(lines 9-10). This served to rationalise her argument by erasing any notion that this view 
was radical or an irrational judgement of her local surgery.  She also added further 
weight to her argument by twice revealing that she was confiding in the interviewer – 
“I’ll be honest with you…to be honest.” This is a truth claim, something which has been 
thought through already and to which she has amassed evidence to support. Irene, also 
set these criticisms within a mitigating phrase which served to position her criticisms as 
reasonable, “we got one of the best surgeries I think down there, I really do” (lines 10-
11). 
 
Blame, accountability and moral discourses in Extracts Two and Three:  
 
Like Dave, Irene could be seen to manage issues of blame and accountability for her 
decisions and views about medications and healthcare generally. In doing so, a moral 
discourse of illness management and health behaviour appeared to be activated within 
the interaction which Irene deployed in allocating who was to blame for her symptoms 
and decisions about medicine taking. In both extracts taken from the transcript of 
Irene’s interview, we are left in no doubt that Irene made a particular connection 
between the provision of health and a particular moral expectation. In Extract Two, the 
expectation was that the treatments provided should meet their intended purpose, that 
those who prescribe it do so with a commitment to making the patient better, and 
therefore not with detrimental side-effects. In Extract Three, Irene set up a moral 
connection between those who provide healthcare, how that care should be delivered 
and the motivations and characteristics of those doing the caring.  
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It may be interpreted that Irene was deploying a “sick-role repertoire”, drawing on a 
Parsonian sick role discourse (Parsons, 1951) commonly understood in British society. 
The principles of Parson’s sick role that have traditionally been associated with the 
doctor-patient relationship are that illness is a form of social deviance in which an 
individual adopts a certain role. The sick person is exempted from normal social 
responsibilities, is not blamed for being sick, is expected to seek competent help in the 
form of a doctor and is expected to comply with the regimen prescribed by a competent 
physician. The interpretative repertoire that Irene deployed was not an exact replica of 
Parson’s concept but instead drew on this traditional model of the doctor-patient 
relationship, which is circulated through British society, to construct a version which 
tackled the particular issues at stake within the interaction. These issues appeared to 
orientate around whether Irene was or was not appropriately managing her asthma, 
whether she was justified in not attending her surgery more frequently and whether her 
decision to not take prophylactic asthma medication was an acceptable one. Irene’s 
version of the sick-role included criteria for a competent physician - somebody who 
attends to each patient’s individual circumstances, “the specialised thing” (line 14), and 
one which should be proactive in the management of patient’s asthma (lines 7-8). Her 
sick role repertoire also included images of medications and the people who take them. 
In deploying a visual metaphor of the individual passively filling up and spilling over 
with tablets (Extract Two, line 18), she activated a culturally-available conceptualisation 
of the sick individual with a range of unspecified symptoms and vague causes of which 
the tablets were producing rather than solving. By constructing the sick-role in this way 
Irene was able to justify not only her non-attendance but also her decision to not take 
the prophylactic asthma tablet, which was positioned as virtuous and preventive rather 
than causative of illness. 
 
Irene’s approximation of the widely understood sick-role discourse enabled herself, 
medications, doctors and nurses, to be positioned within that discourse, according to her 
personal experiences and circumstances, and assigned a moral value to the different 
participants set up within that discourse. Irene’s justification of her decisions about her 
asthma and medicine taking rested on the argument that doctors, nurses and the 
institution of medicine had not met the conditions of competent physician and reliable 
treatment regimen. Irene’s criteria of the (de)-personalised doctor-patient relationship 
and visual imagery of the passive patient spilling over with medication detailed the 
evidence of how this condition had not been met. In
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medicine can be said to have violated the sick-role contract that Irene had set up within 
this interaction.  
 
Deploying a Sick Role Repertoire for Self Blame 
 
In the case of Irene we saw how her explanation for asthma symptoms and other health 
problems were managed by directing blame towards the dangers of medications, the 
lack of certainty in the knowledge of the medical profession as well as directly 
questioning the motivations of clinicians themselves. This strategy was identified in 
several participant’s accounts (e.g. see full transcripts on CD for 261906; 141693; 
351823). In contrast, Stephen was the only participant who repeatedly blamed himself 
for his problems with asthma.  
 
In the lead up to Extract Four, near the end of this interview, Stephen had been asked 
how he saw the future in terms of his asthma management and also to reflect on his 
experiences with doctors and nurses. Here we can see how Stephen directly positioned 
himself as a bad patient within a moral framework of a sick role discourse. 
 
Extract Four: 660345 (Stephen). Interview 1, page 23, lines 41-45 
 
1.  S: I don’t have any complaints (2) over (1) my treatment of doctors or  
2.   asthma nurses over the last few years. I think basically they’ve been  
3.   banging their head against a brick wall with me over the years (1). 
 
Here, Stephen used a common metaphor of banging one’s head against a brick wall to 
describe GPs’ and nurses’ roles in helping him. This positioned clinicians as persistent 
and well-intentioned and importantly active in doing the “banging.” In contrast, Stephen 
was constructed as the wall - a fixed, immovable object. Having “no complaints” 
therefore set this metaphor within a moral discourse of roles and responsibilities which 
clinicians were fulfilling. Again, like Irene, Stephen was deploying a sick role repertoire 
which set up a contract between him and the doctors and nurses. The issue then was 
how Stephen positioned himself within this discursive moral contract and in Extract 
Five, Stephen seems to be summarising how he wished to be understood within this 
moral context. In contrast to Irene, it was Stephen who was violating the sick role 
contract.  
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Extract Five: 660345 (Stephen). Interview 1, page 27, lines 33-41 
 
1.  JM:  Is there anything you feel you haven’t said? (1) Or anything you want  
2.   to ask me?  
3.  S:  I’m just sort of glad to be part of this study and (2) in a way feel  
4.   guilty (1) on my part over (2) the years of not (1) being very helpful or  
5.   (1) cooperative or whatever hhh and I just think well if I’ve got a  
6.   chance… 
 
However, Stephen did not only admit guilt but he also displayed remorse for his 
behaviour and then offered a commitment to become a better person given a chance. We 
can view these notions of guilt, cooperation and having chances as reproducing a 
rehabilitation discourse which is not only set within a dominant medical discourse of 
remission (Frank, 1995) but can also be seen in wider society in reference to the 
probationary discourse of criminals (Proeve, Smith, & Niblo, 1999). Stephen’s 
justification of non-adherence, which these examples demonstrate, orientated around 
constructing himself at a crossroads in his life. Within the sick role discourse that was 
activated in this interaction, Stephen could be seen morally to be taking the right road at 
this crossroads. Whilst his previous behaviour was positioned as uncooperative and as a 
violation of a sick role contract, the commitment to change, functioned interactively to 
present himself as on a different road, as a purposeful and rehabilitated patient.  
However, this talk of self-blame and rehabilitation was also set within a psychological 
repertoire which resonated with Dave’s account. Like Dave, Stephen constructed 
notions of an unconscious psychology influencing the management of his asthma, seen 
in Extracts Six to Eight.  
 
Extract Six: 660345 (Stephen). Interview 1, page 18, lines 19-26 
 
1.  S: It’s sort of been a pattern of (.) not having many symptoms and not  
2.   having any preventative or reliever (1) or very little reliever (1) and then  
3.   (1) when the times come when I’m not well or seasonally in summer (1)  
4.   I have (3) still no preventative medicine. Go and get prescribed it (.)  
5.   from the doctor (.) knowing full well that I’m not going to take it (1). I  
6.   don’t know why. 
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Extract Seven: 660345 (Stephen). Interview 1, page 23, line 52, to page 24, line 8 
 
1.  S: it’s been myself that’s been (2), not unwilling I wouldn’t say but just (2),  
2.   °“ah it’s alright”°  you know just (.) carry on (1) really (2), °just carry on  
3.   with it° (1) You know? “I haven’t, I’m not wheezy so, (2) you know I’m  
4.   alright.” (1) And it’s sort of that sort of mentality really (1). Sort of  
5.   accepted that I’ve got asthma and eh (3) at times “I’m not wheezy (2)  
6.   °I’m fine” (1) you know?° 
 
Extract Eight: 660345 (Stephen). Interview 1, page 11, lines 12-22 
 
1.  S: Em, (1) if you haven’t got the Ventolin at hand (1) then you can sort of  
2.   get panicky, do you know what I mean? 
3.  JM: Yeah. 
4.  S: If for example, it’s getting low or (1) you’ve left it somewhere else,  
5.   you know you’re out and you haven’t got it (1) or, you know, if it’s not  
6.   at hand basically (1) it’s (2) there’s a sort of (1) panic, as such. 
 
Blame, accountability and moral discourses in Extracts Four to Eight:  
 
In contrast to Dave, but similarly to Irene, Stephen drew on traditional ideas of the 
doctor-patient relationship and constructed versions of himself, doctors and nurses in 
explaining his non-adherence to medications. However, unlike Irene, Stephen undertook 
little rhetorical work to discredit potential alternative interpretations of his actions. This 
was most likely because he blamed himself for his non-adherence and positioned his 
explanation within broader discourses of remission, rehabilitation and remorse. Blaming 
oneself and not doctors offers a submissive and compliant position within traditional 
doctor-patient conceptualisations. This discursive action does not challenge a powerful 
institutionalised set of roles and relationships but instead reproduces a widely 
understood discursive object, the “bad patient” within this common discourse. In 
addition, in British society an explanation of self-blame and remorse is typically viewed 
as “honest” when activated within a rehabilitation discourse. There was therefore little 
need for Stephen to provide supporting evidence for the version being constructed. A 
slightly different interpretation to this might be that we can view Stephen’s admission of 
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guilt as his attempt to save “face” within the interaction taking place. Criticising himself 
arguably enabled Stephen to “own” any judgement of his behaviour, rather than 
potentially having it directed at him through the ongoing discussion. Stephen’s 
“owning” of the criticism may therefore have limited the need for Stephen to justify his 
asthma management any further. 
 
This contrast between Stephen and Irene’s accounts, in how the sick role discourse was 
deployed, provided an important point of triangulation between the two forms of 
justification. This was that the construction of the “bad patient” within Stephen’s sick 
role discourse, (requiring little rhetorical work and supporting evidence), and the “bad 
doctor” within Irene’s account, (requiring a lot of rhetorical work and supporting 
evidence), highlighted the moral value attributed to being a compliant patient within a 
medical discourse regarding clinical advice and prescription instructions. As Chomsky 
argued, when discussing structural constraints within mainstream media on the 
production of unconventional thought: “The beauty of concision…is that you can only 
repeat conventional thoughts.” (Achbar & Wintonick, 2009). This point of contrast 
between the interviews of Irene and Stephen therefore provided further evidence that a 
moral discourse of illness management was activated within participants’ talk which 
included traditional notions of compliance to doctors’ instructions. 
 
In contrast to Dave’s use of a psychological repertoire which functioned to justify non-
adherence within a busy lifestyle, Stephen constructed a version of his psychology 
which appeared to reinforce his discussion elsewhere that he was to blame, (set within a 
sick role repertoire), for his poor asthma management. In Extract Six, Stephen 
constructed himself as at the mercy of unconscious forces and pathologised his 
behaviour “Go and get prescribed it (.) from the doctor (.) knowing full well that I’m 
not going to take it (1). I don’t know why.” (Extract Six, lines 4-5). In Extract Seven by 
contrast, it was a symptom control “mentality” that was normalised, which prevented 
him from taking prophylactic medications. Finally, in Extract Eight, his relationship 
with asthma relief medication was constructed as psychologically dependent, leading to 
panic if the inhaler was “not at hand.”  
 
The psychological repertoire that Stephen deployed resonates with the discourses of 
control identified in Chapter Two. The notion that Stephen’s medicine taking behaviour 
was driven by something he was unaware of reflects 1950s psychoanalytical 
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connections between unconscious, repressed emotions and the manifestation of asthma 
symptoms and asthma-related behaviour (Alexander, 1952; Dunbar, 1947); while the 
links he made between panic, relief medication and asthma attacks echoed theories 
constructing the converse relationship between emotional control and the symptoms of 
asthma (Wright et al., 1998). These connections were identified elsewhere in the sample 
(participant 261906, pages 4-5; 670217, page 2). However, there was little evidence in 
the analysis that these participants were directly orientating to or had access to these 
specific discourses and the connections made here are the interpretations of the 
researcher. As discussed in Chapter Two, notions of self-control (Williams, 1993, pp. 
92-108) have circulated British society in a range of contexts and talk such as Stephen’s 
may have origins within broader moral discourses of embodied control in lifeworld 
settings. In contrast, there was stronger evidence that a “symptom control” discourse 
was activated within Stephen’s psychological repertoire, which could also be seen to be 
used by Dave as well as other participants in the study. Non-adherence to prophylactic 
medications was frequently explained in the context of forgetting, a “mentality”, or in 
terms of responding to symptoms, despite these participants displaying a clear 
understanding of the function and need to take prophylactic medication regularly. We 
saw earlier how Dave situated his forgetting within a busy working context. A key 
device in presenting forgetting as a justification for non-adherence, which participants 
such as Dave and Stephen shared, was to present this explanation in the context of a 
willingness and intention to comply. In Stephen’s case this was clearly stated: “not 
unwilling I wouldn’t say but just (2), °‘ah it’s alright.’°” This indicated that a “symptom 
control” discourse was perhaps widely circulated at the time of interviewing participants 
and that this form of explanation was considered acceptable and more compatible with 
participant’s everyday lives than a discourse of asthma prevention.  
 
However, it is possible to see how Dave’s and Stephen’s use of symptom control 
explanations have the potential to be judged differently, depending on how their 
different justifications are positioned within different moral frameworks that were 
activated within interactions. Dave’s “scattering” of relief medication in a variety of 
locations, (line 53) was functionally plausible when set within a discursive framework 
of active engagement and management of one’s health. Actively taking control of one’s 
body is potentially a powerful explanation within medical and lifeworld moral 
discourses of illness management and also broader discourses of individual 
responsibility. Dave also positioned himself as someone who donated money to asthma 
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charities and as someone well-informed about asthma and experienced in the different 
treatments that had been available. Responding to symptoms, rather than preventing 
them was therefore constructed by Dave as responsible and morally acceptable when 
positioning himself within a discourse of the active manager and contributor of society. 
Contrast this explanation with Stephen’s account of a similar kind of behaviour. 
Stephen positioned his behaviour within a sick-role discourse where the advice had 
been to take his prophylactic medication regularly. Managing asthma through symptom 
control rather than prevention was therefore constructed as irresponsible and it was 
Stephen who was to blame for poor asthma outcomes. 
 
Both Dave and Stephen’s explanations “made sense” within these discourses, at the 
time the interaction took place, yet despite similar behaviours, blame and accountability 
were distributed differently.  Blame and accountability are therefore apportioned 
according to the individual’s constructed position within the moral discourses that are 
activated within interactions. However, different moral discourses may function more 
effectively than others at different points in time and within different interactions. From 
a clinical perspective it is conceivable that explanations such as Dave’s could be seen as 
inadequate and irresponsible within a moral discourse of asthma management that puts 
prophylactic medications at the heart of that discourse. We saw in the work of Jones et 
al that talk such as Dave’s could be seen as “cocky” or “overconfident” rather than 
someone who is actively managing their condition.  
 
Minimising Asthma and Symptom Control in a Lifeworld Context 
 
The idea that, for many participants, a symptom control discourse was more compatible 
than an asthma prevention discourse, within lifeworld contexts, appeared to have strong 
links with Cornwell’s concept of a “health problem that is not an illness” (Cornwell, 
1984, pp. 130-131). In the final extract from the analysis to be presented in this chapter, 
we can see further evidence for this interpretation but also some of the potential 
implications of adopting this position within lifeworld settings such as the workplace. 
Extract Nine presents another type of justification identified in the data. This was a 
common rhetorical strategy for not taking medications as prescribed, which involved 
minimising the severity and impact of asthma on everyday life. In the lead up to this 
extract Martin was asked about the history of his asthma and what doctors and nurses 
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communicated to him about asthma and medications. Martin’s interview was 
categorised as having accounting style 3 - Tension between lifeworld and medicine. 
Adherence potential threat to lifeworld. The extract is of particular interest because of 
the strong stylistic assertion in the opening line. 
 
Extract Nine: 670287 (Martin). Interview 1, page 11, line 35 to page 12, line 7 
 
1.  M:   =So I have it has been. But I stress it is not a debili(.)tating (.) problem 
2.   insofar as my (.) y’know ˚my work is concerned or my you know my  
3.   life is concerned. (.) Um (.) I don’t play (.) football I do (.)  
4.   occasionally bouts of strenuous work (1) um but its managed˚ and I’m 
5.   very fortunate in that (.) you know I can choose (in the middle?) ((of 
6.   something?)) what what I do (.) a- at work rather than (.) um (.) you 
7.   know being in a managerial position I mean I don’t wanna (1) y’know 
8.   er (2) brag but you do have a little bit of flex(h)ib(h)ility  um and if  
9.   there’s you know y’know there’s somebody else available who will 
10.  move the grain lorry up and you know I would do his job while he did  
11.  while he did that (.) and if its unavoidable well I (.) I’ll do you know  
12.  put a mask on and move the lorry myself which is its not an issue as far  
13.  as I’m concerned (1) you know the guy um (.) you know I can 
14.  certainly ask somebody else can you just move down (.) while I take 
15.  over from you= =Everybody knows that the reason I’m doing it I’m  
16.  not frightened of work but they just (.) I can manage it in that way (.)  
17.  um (.) so (.) I suppose you could say well actually you are changing  
18.  your lifestyle but not to that degree. 
  
An analysis of the rhetorical work in the extract demonstrates how Martin deployed 
several devices to provide evidence to support his claim that his asthma was not 
debilitating and therefore that he was responsibly managing his condition. He illustrated 
how he was in control of his asthma by detailing a common scenario at work; a flexible 
situation that was agreed and understood by his colleagues and that was afforded by his 
managerial position. Combined with a list of other activities where his asthma was 
represented as being “managed”, this provided a catalogue of evidence to support the 
case that “it is not a debilitating problem” (line 1). However, as a consequence of 
scripting a typical work scenario to demonstrate that his asthma was managed, Martin 
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can be seen to negotiate a number of positions or “footings”, (Goffman, 1981, pp. 124-
159) activated by using this scripting device and which threaten an alternative 
interpretation of his behaviour. This is evidenced in interactional repair work that 
Martin displays. First, he can be seen to have orientated to a potential interpretation that 
the adaptive strategies he used at work show someone struggling to cope with everyday 
work activities, “its not an issue as far as I’m concerned” (lines 12-13), then, that he is 
exploiting his employees, “= =Everybody knows that the reason I’m doing it” (line 15), 
and that he is lazy or workshy, “I’m not frightened of work but they just” (lines 15-16). 
We can see that, in a discussion of asthma management, Martin was simultaneously 
attempting to construct different versions of his self which included “responsible person 
with asthma”, “person with health problem that is not an illness”, “conscientious 
worker”, and “good manager.” Finally, Martin’s assertion that his lifestyle had not 
changed “to that degree” offered further evidence of a key issue at stake in this 
discussion of asthma prevention. Whether his lifestyle had changed was not a question 
put to him. So it seems fair to infer that here he was responding to the framing of this 
interactional sequence within competing moral discourses of appropriate and 
responsible illness management, while also responding to different moral discourses 
from his everyday life, defining what it means to be a good manager and a hard worker. 
 
Blame, accountability and moral discourses in Extract Nine:   
 
The analysis of Extract Nine demonstrated Martin engaged in justifying his asthma 
management and also that he had some access to a moral discourse of asthma 
management which places emphasis on patients to responsibly manage their condition. 
This was primarily evident in Martin’s account of a typical work scenario, 
demonstrating a moral agenda to be understood as in control of his condition and to 
undermine any suggestion he was irresponsibly managing his asthma. This 
preoccupation dominated key sections of his interview and he could frequently be seen 
to argue that he monitored and managed his symptoms as necessary, either through a 
regulation of behaviour, (as seen in Extract Nine), or with the use of prophylactic or 
relief medication. This strategy therefore has close links with the symptom control 
discourse identified in Stephen’s account but unlike Stephen, Martin constructed 
himself as someone proactively managing, or “self-regulating” his condition, rather than 
reactively responding to symptoms.  
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This self-regulating repertoire has similarities with the active construction of asthma 
management that Dave deployed, showing someone engaged and actively managing 
their condition. Like Dave, Martin could be seen to contextualise his justification of 
asthma management in a work, and specifically, management setting. Martin’s version 
of his asthma management may therefore be seen as plausible within an institutional 
discourse of organisational management where he is someone who possesses 
management skills. However, we can see here that he also has to manage other 
moralities of his lifeworld. In Extract Nine these different moralities do not appear to fit 
neatly with a self-regulatory repertoire being deployed where Martin’s explanation runs 
the risk of positioning himself as a manager who exploits members of his workforce for 
his own ends. This is potentially a rhetorical cul de sac for Martin, relying on the 
listener to provide any discursive space for this tension to pass without confrontation. 
Martin demonstrated how these competing versions of himself, from medical and 
lifeworld perspectives, operated simultaneously within the interaction, creating an 
interactional tension that needed to be managed. There was evidence that Martin 
orientated to and managed these alternatives thereby validating the importance of these 
different moral frameworks within the interaction taking place. This insight into the 
moral dimensions of Martin’s talk shows that an approach which would reduce Martin’s 
talk to an attitudinal statement that Martin viewed his asthma as “not debilitating”, 
would miss important insights that have a significant bearing on his use of medications. 
These are that Martin’s decisions about medicine taking may be influenced as much, if 
not more by a preoccupation in being seen as a good manager; a good worker; and as 
someone who does not have an illness; rather than just a view of his asthma as not 
serious enough to warrant regular prophylactic treatment. From a discursive 
psychological perspective, the “attitude” that Martin’s asthma is debilitating is 
inseparable from these other concerns that he is faced with on a daily basis. 
 
Summary of Findings from Face-to-Face Interviews  
 
The analysis of interview data in this chapter has demonstrated that participants who 
had a diverse range of explanations for their medicine taking were engaged with a moral 
agenda when discussing their asthma management. By viewing participants’ talk from a 
discursive psychological perspective, it was possible to readily identify properties in 
this talk that are not accessible when viewed from an individualistic perspective. 
Participants could be seen not merely to be describing their asthma management and 
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medicine taking but also to be engaged in a range of discursive actions, with the 
objective of presenting themselves, their behaviour and their attitudes in particular 
ways, whilst undermining competing alternatives. This was evident in the range of 
rhetorical devices that participants deployed. Key amongst these were the different 
discursive objects that participants’ constructed regarding themselves, their asthma and 
doctors and nurses. This was achieved by drawing on a range of culturally-available 
representations of health and illness such as “virtuous ill person”, “expert patient”, 
“responsible person with asthma”, as well as traditional and well-established 
conceptualisations of the doctor-patient relationship. In performing these constructions, 
participants could also be seen to work to undermine potential alternative versions of 
themselves such as someone having “incorrect beliefs”, “disengaged with his/her 
condition”, or “non-compliant.” These versions could be seen to interact with other 
constructions that had origins in lifeworld contexts, such as “someone full up with 
medications”, “hard-working manager”, “wealthy benefactor”, “rational scientist.” 
These different discursive objects, along with other rhetorical devices, (such as 
normalising or generalising devices or the identification of external evidence to 
authenticate an argument), were deployed by participants to construct particular types of 
explanation, referred to as interpretative repertoires, for their asthma management and 
medicine taking. This discursive action that participants undertook emphasised the 
dilemmas that needed to be managed regarding how speakers would potentially be 
categorised, thereby indicating a moral agenda in their talk about medicine taking.  
 
By highlighting the properties of participants’ talk, a more dynamic understanding of 
talk about medicine taking was possible, moving the analytical focus away from 
attempts to categorise individuals. In doing so, the problems highlighted in the attempt 
to identify individual accounting styles could also begin to be addressed. These related 
to the level of analysis being conducted, being able to identify discursive variation, and 
how to validate analytical interpretations. The analysis of transcripts reported in this 
chapter demonstrated how the talk of participants could be seen to be connected despite 
each account offering very different explanations for their asthma management. This 
connectivity was seen through the shared moral discourses that were activated within 
interactions and deployed by participants as interpretative repertoires. These repertoires 
could also be seen to be multiple and to interact with one another, highlighting both the 
variation in the sorts of explanations that participants provided and also how different 
moral discourses were managed simultaneously by participants. Participants’ orientation 
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to competing discourses also provided some validity for analytical interpretations that 
those discourses were activated within interactions and were pertinent to participants in 
justifying their asthma management.  
 
A process of analysis which isolates talk into sets of de-contextualised statements, risks 
categorising that talk in ways which mask the function of that talk within the interaction 
of its production, and also its function in daily decisions about medicine taking. This 
type of approach has been seen with individualistic and social cognitive approaches to 
studying medicine taking, which have been the predominant method to date in 
explaining non-adherence to prophylactic medications. Viewing talk about medicine 
taking instead as a form of situated social action, we can see that reported “attitudes” 
work interdependently in constructing versions of self and behaviour and may reflect 
attention to multiple concerns about asthma management both from medical 
perspectives as well as viewpoints circulated within participant’s family, work and other 
social networks.  
 
Moral discourses and the structuring of talk 
 
The connectivity in participants’ talk emphasised how different moral discourses of 
illness management and medicine taking circulate over time and in a range of social 
spaces. The discursive objects participants deployed and the interpretative repertoires 
they constructed could be seen to have some explicit links with historical and 
contemporary discourses of asthma management, in particular a discourse of symptom 
control. A range of participants could be seen to deploy this discourse in explaining 
non-adherence to prophylactic medications and it could be seen to function alongside 
other concerns within participant’s lifeworlds. This indicated that a symptom control 
discourse may be more compatible with other moral discourses of illness management 
in participants’ lifeworlds whilst a prevention discourse could pose a threat to 
participant’s roles and activities in everyday life.  
 
Deploying a symptom control discourse could be seen in conjunction with speakers 
constructing the authoritative version of their asthma, functioning as a key rhetorical 
device, for several participants, in managing blame and accountability regarding their 
medicine taking. Constructing the authoritative version of asthma to indicate speakers 
responsibly managing their condition, provided evidence of a moral discourse of asthma 
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management, reflecting tensions identified in asthma guidelines which positions 
clinicians and patients as simultaneously empowered and responsible. There was also 
some evidence that participants reproduced notions of the educated patient evident 
within asthma guidelines whilst notions of shared decision-making, or concordance 
between doctor and patient were less evident. As was discussed in Chapter Two, the 
language used in asthma guidelines represents a bureaucratic manifestation of 
institutional tensions between evidence-based and patient-centred medicine. However, 
whilst these twin concerns may be particularly acute for clinicians in making decisions, 
the evidence in the interview data suggested that participants’ talk had more coherent 
links with other recognisable, culturally-available, moral discursive frameworks of 
patient and doctor roles, rules and rights as well as other discourses of illness 
management that circulate lifeworld contexts. In the data analysed in this chapter these 
discourses included: versions of a Parsonian sick-role; the expert patient; consumerist 
and management discourse; a cultural discourse on what it means to be sick; a work-
ethic discourse; and a rehabilitation discourse. The purpose of the analysis was not, in a 
Foucauldian sense, to detail the range of discursive objects, concepts and statements, 
which are associated with these different discourses. Rather the aim was to indicate 
different moral discourses which appeared to be activated within interactions, could be 
seen to be managed by participants, who attempted to position themselves and their 
behaviour within those discourses.  
 
Being accountable for one’s health, whilst a notion clearly evident in asthma guidelines, 
is a moral concern reflected within a variety of discourses of health and illness and it is 
these different moral discourses towards which participants appeared to orientate their 
talk. However, the analysis also showed that the discourses which participants drew on 
were not exact replicas of these discourses but were constructed to meet particular 
interactional demands on them to justify their medicine taking. The identification of 
interpretative repertoires was used in the analysis to emphasise this “loose coupling” 
(Goffman, 1983, p.11) between systemic structure and individual utterance. Doing this 
indicated how notions of morality, illness management and medicine taking may 
circulate a wide range of social spaces which structure talk in interactions about 
medicine taking but which may be creatively used to meet a range of interactional 
concerns. In addition the different repertoires that participants constructed appeared to 
have multiple origins and functioned interdependently in talk about illness management. 
This manifestation of the different moral dimensions in such talk may indicate that the 
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issues that influence medicine taking decisions may be as likely to originate in everyday 
life as in individuals’ understandings of asthma and associated medications. 
 
Limitations of interpreting the interactional issues and role of morality in 
participant’s discourse from interview data  
 
The extracts from the face-to-face interviews provided examples of how participants in 
the study could be seen to deploy rhetorical devices to position themselves within 
culturally-available discourses of appropriate health-related behaviour. However while 
the extracts reported so far clearly provided evidence that these participants were 
preoccupied with justifying their behaviour, not all participants simply reproduced the 
type of rhetorical defence of their medicine taking being sought in this study. The 
analysis also yielded three interviews where there were few rhetorical devices being 
deployed by participants and which did not follow the pattern identified in the body of 
the data. We also need to know what can be learnt from interviews where participants 
do not appear to be justifying their medicine taking and whether this can inform the 
patterns so far reported which highlight a moral agenda in participants’ talk. 
 
In Chapter Five, sequences of interaction are discussed which show examples of 
participants deploying few rhetorical devices to account for their asthma management. 
These extracts will be seen as difficult to analyse using the discursive psychological 
framework set out thus far in this thesis. The reasons for this difficulty will be explored 
enabling the role of moral discourses in the talk of participants to be contextualised. 
Developing a richer understanding of the circumstances under which participants’ 
justified their asthma management suggested that, in order to generalise about the 
interactional issues faced by people when talking and making decisions about medicine 
taking, we might need to obtain data based on a different set of interactional conditions 
to the interview data. This will be the topic of Chapter Six which will analyse data 
collected from a focus group in which data was shared with participants. These 
additional data will then enable a discussion in Chapter Seven of the importance of 
considering interactional issues and morality to better understand talk and decisions 
about medicine taking. 
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Chapter Five 
Contextualising the Role of Moral Discourses in Talk about Prophylactic Medicine 
taking 
 
D: SORRY I’M NOT VERY HE(h)LPFUL 
JM: NO YOU ARE NO NO WHAT I WANT TO DO is understand your 
 point of view. 
 (670289, Interview 1, page 23, lines 38 to 40) 
 
In the previous chapter, data were presented which demonstrated evidence of the 
interactional issues and role of morality in talk about medicine taking. Participants’ talk 
could be seen to be structured by a moral discourse of illness management as well as 
other lifeworld discourses. However, Chapter Four concluded by introducing some of 
the limitations in interpreting the role of morality to how people with asthma and other 
chronic illnesses talk about prophylactic medicine taking in interactions outside of the 
interview setting reported in this study. These concerns were related to how the face-to-
face interviews came about and were set up. This chapter will attempt to address some 
of these concerns, beginning by analysing extracts from interviews where participants 
did not appear to be justifying their medicine taking behaviour. Key features of these 
interviews, which led to this interpretation, were that they lacked a “qualitative” 
narrative; involved a lot more turn-taking and input from the researcher; and were 
shorter interviews than those interviews where participants provided long narratives and 
extensive explanations for their medicine taking. 
 
This analysis of “deviant cases” led to the interpretation that one reason that 
participants, within interviews, might justify their medicine taking would be if they had 
access to the particular framing of the interview that the interviewer was attempting to 
activate. The following section describes how this interpretation was investigated by 
examining evidence of interactional misunderstandings in the deviant cases. It will then 
demonstrate how an analysis of the conditions of the interviews may enable insight into 
potential misunderstandings and the circumstances under which participants were likely 
to justify themselves. This discussion will then be used to provide the rationale for the 
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additional data that was collected in this study in which interview data was shared with 
participants in a focus group. This will be the topic for Chapter Six. 
 
Talk about medicine taking deploying few rhetorical devices  
 
In this section two extracts are analysed to provide insight into why some participants 
did not appear to justify their medicine taking as expected. These extracts were chosen 
because they provided two very different types of interaction which appeared to result 
from a mismatch in resources between researcher and participant. Each extract can be 
found as part of a longer excerpt in Appendix B and the full transcript for the interviews 
included in this chapter are available on a CD as an appendix. As with the earlier 
extracts discussed in Chapter Four, the excerpts enable the choice of interactional 
sequences to be examined and facilitate further insight of how participant’s versions 
were sequentially constructed within the interactions taking place. 
 
In Extract 10, Dawn was responding to a request from the interviewer to clarify her 
views and that of her doctor regarding the use of the brown prophylactic inhaler. In 
contrast to the extracts presented in Chapter Four, there was much less evidence of the 
use of rhetorical devices that might suggest a moral discourse of asthma management 
was dominating Dawn’s account. Throughout the interview, Dawn seemed to minimise 
the importance of asthma for her. However, whereas Martin (for example, in Extract 9 
of Chapter Four), constructed a typical work scenario to manage potential accusations 
of irresponsibility in not taking his prophylactic medication, Dawn can be seen to offer 
a much more straightforward explanation. As with other interviews, the researcher 
sought to uncover any tensions between the participant’s presentation of how they 
managed their asthma and any clinical guidance they had received regarding their 
asthma management. Extract 10 presents an attempt by JM to go over earlier comments 
to pursue these points further because little such material had been previously obtained, 
despite there being a strong indication and assumption by JM that a tension existed 
between Dawn’s perspective and the medical perspective and that Dawn would 
orientate to this. 
 
Extract 10: 670289 (Dawn). Interview 1, page 18, line 51 to page 19, line 36 
 
1. JM: And and (.) the (.) um do you talk to him about how you use (.) the  
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2.  brown inhaler we talked about that briefly before um (.) and he said  
3.  that you should take that (.) to did he say that you should take that  
4.  every day or (.) a long period or did he how did he say you should use  
5.  it over a long period of time (.) cos you sort of mentioned did you  
6.  mention to him that you stopped using it  
7. D: Yes yeah (1) ahhh well he sort of (.) hhh ((sounding slightly  
8.  exasperated)) I mean his advice is really that I should use it (.) all the  
9.  while and its totally down to me that I don’t because his advice to me  
10. is (.) to use it (.) y’know most of the time but I mean I feel fine without  
11. it I don’t really know why I need to use it because without using it (.)  
12. I’m alright I don’t get breathless or get any asthma symptoms 
13. JM: And do do you actually share that view with him or  
14. D: Yes he know I stopped using it yes yeah (.) spose he just you know he  
15.  just (.) said you know if I you know its up to you really (??) SO I I  
16.  MEAN IF I’M IF I’M do have a bad attack alright I will start using it  
17. (1) for any reason um (.) have a bad attack but (.) normal run of the day  
18. things I don’t (.) I don’t want to use it (.) hh every day 
19. JM: I’m just trying to understand why exactly heh heh ((slightly nervous  
20. laughter))  
21. D: WELL I I DON’T KNOW I THINK ITS JUST AS I SAY ITS JUST  
22. THE THOUGHT OF TAKING IT EVERYDAY WHEN I DON’T  
23. REALLY FEEL I NEED IT  
24. JM: ˚Okay that’s fine˚… 
 
If we analyse this extract using the analytical tools developed and used in Chapters 
Three and Four to look for evidence of Dawn justifying her medicine taking, limited 
evidence emerges that Dawn was deploying a range of rhetorical devices and 
interpretative repertoires to account for her medicine taking. We can see that Dawn does 
display an awareness of a potential tension between her view and medicine with use of 
the modal “should,” perhaps triggered by JM’s own use of should. However, in contrast 
to extracts in Chapter Four, Dawn didn’t seem to manage these potential tensions any 
further other than to say that her doctor said she could do what she liked. Dawn seemed 
to avoid being too confrontational with phrases which hedged her position - “sort of”, 
“yes he know…” and switched from a position that perhaps blamed herself for not 
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following her doctor’s instruction “down to me” to one which was more empowering 
“up to me”. There was little evidence that Dawn was preoccupied with managing 
different moral positions in her talk about her asthma management, despite being aware 
of potential tensions between her view and medicine’s, instead simply asserting her 
view in a very clear voice, (lines 21-23).  
 
This extract can exemplify two interpretations of Dawn’s account of her asthma 
management. The first of these was that Dawn’s ability to justify her medicine taking 
was constrained when she had to reproduce the voice of medicine, spoken through the 
voice of her doctor. This resonates with the extracts within Stephen’s interview, where 
he could also be seen to orientate to the perspectives of doctors and nurses. Stephen 
explained his non-adherence to prophylactic medications by blaming himself for his 
decisions and positioned clinicians as “banging their head against a brick wall”, (Extract 
Four). This explanation was set within a lengthy discussion of his problems in 
managing his asthma and complying with prophylactic medication. In the case of Dawn 
however, the voice of medicine was possibly constraining her ability to provide an 
intelligible narrative. In both Stephen’s and Dawn’s accounts there was a lack of 
rhetorical work evident in explaining how they managed their condition. In contrast to 
Stephen, where his self-criticism appeared to require little defence within a moral 
discourse of remorse and rehabilitation, Dawn’s lack of rhetoric was perhaps more to do 
with alternative lifeworld discourses being restricted by the voice of medicine that acted 
out the clinical discourse of asthma management. These types of distinctions were 
identified in a number of extracts within and between interviews and formed part of a 
separate analysis on the concept of “discursive space” between structure and agency. 
This work has not been reported in depth in this thesis but some analytical notes have 
been included in Appendix D. 
 
The second interpretation of Dawn’s account, which can perhaps be seen in conjunction 
with the first, is that Dawn did not frame the discussion as a “qualitative interview” 
where participants are often expected to talk at length about their experiences and 
viewpoints. To obtain evidence to support this interpretation required an alternative 
analytical technique to the discursive psychological tools available up to that point. This 
was because the analytical focus was to seek mismatches between the interviewer’s and 
Dawn’s understanding of the encounter rather than to identify rhetoric. Such an 
alternative interpretation was enabled by drawing on the concept of contextualisation 
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cues from interactional sociolinguistics (Gumperz, 1999). Contextualisation cues are 
signals (verbal and otherwise) to indicate what context is being referred to within an 
interaction and which are relied upon in everyday interactions to interpret the intention 
of the speaker. In Extract 10, JM asked Dawn to resolve the apparent tension between 
her own decision to stop taking the brown inhaler and the doctor’s advice that she 
“should” be taking it. The presentation of this potentially difficult issue for Dawn, the 
specific context being referred to, was set within a long wordy opening question, which 
suggested a problem, rather than directly point out the issue that needed addressing. 
Phrases were deployed by JM to highlight the specific context, using the modal verb 
“should” to activate the medical voice and “did you mention” to position Dawn’s own 
previously iterated position. However, Dawn seemed exasperated by JM’s continued 
questioning on this point, perhaps either because she felt she had already provided an 
answer and had nothing to add, or did not appreciate the point that JM was trying to get 
at. This appeared to be an insufficient response for JM who then made another attempt 
to get the response required with a further contextualisation cue – “do you actually share 
that view with him” (line 13). However, Dawn still didn’t address the issue, of her and 
the doctor having different views, in a way that appeared satisfactory for JM. As a 
result, another bid for the information was made in line 19, with the nervous laughter 
suggesting the interactional tension was increasing. Dawn then stated very loudly her 
position but only after saying ‘I DON’T KNOW’ (line 21), which again suggested she 
didn’t see the point being sought. This appeared to demonstrate increasing pressure for 
Dawn to say something assertive about her view, which then led to a rapid retreat by 
JM, “˚Okay that’s fine˚” (line 24). This signalled a different contextualisation cue, that 
JM would stop asking this question and that they were now moving to another topic. 
Although Dawn provided a clear reason for not wanting to take the brown inhaler, 
spoken in a louder tone, her lack of elaboration on this point was not what JM as the 
interviewer was expecting or hoping for. Her inability to meet this framing suggested 
that she was not able to access or utilise the particular discursive framework of asthma 
management that JM was constructing within the interaction, summed up towards the 
end of the interview in Extract 11: 
  
Extract 11: 670289 (Dawn). Interview 1, page 23, line 38 to 41 
 
1.  D: SORRY I’M NOT VERY HE(h)LPFUL 
2.  JM: NO YOU ARE NO NO WHAT I WANT TO DO is understand your 
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3.   point of view. 
 
The next extract demonstrates another example of an interview where the talk of the 
participant suggested that the interviewer’s (JM) understanding of the interview, (how it 
should have proceeded and what it was about), was not shared by the participant. As a 
consequence, the interview appeared to lack the sort of narrative and rhetorical devices 
identified in other face-to-face interviews, perhaps indicating that there was little 
justification of asthma management. In contrast to most of the face-to-face interviews 
the interview with Janet (J) took place at her local surgery. In Extract 12 we can see 
evidence that this different location appeared to set up a particular expectation of how 
the interaction would proceed.  
 
Extract 12: 650405 (Janet). Interview 1, page 8, line 14 to page 10, line 51, local 
surgery 
 
1. JM: Your inhaler um again I’m not here to sort of say 
2. J: No 
3. JM: why aren’t you using it but why did you decide not to or why did you  
4.  decide  
5. J: Well I think I probably I did forget to take it first thing in the morning  
6.  sort of thing I think that was half of it and you know if you felt alright  
7.  you sort of didn’t think to take it it weren’t not very often 
8.  (3) 
9. JM: Ok. Um and have you been did you go back to the doctors after?  
10. J: I think I probably had to go back to check that everything you know  
11.  was alright I’m sure I did. He wanted to check you know to make sure  
12.  it was alright (1) yeah 
13. JM: And what did he say do you remember 
14. J: He said that was y’know sort of carry on with your inhalers and  
15.  y’know take them how you should sort of thing 
16. JM: You say you’ve been doing that for about 30 years?= 
17. J: =°Yeah° 
18. JM: (??) um okay and the first time you changed was when you entered this  
19.  study 
20. J: Yeah 
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21. JM: What made you um decide to take part in the study was there 
22. J: Well I I think I don’t know if I had a letter or they rung me up 
23. JM: Yeah 
24. J: And I said providing that worked round me sort of thing I could do it 
25. JM: And you were happy to try something different 
26. J: Yeah 
27. JM: And um so you’ve been taking the tablet for  
28. J: A couple of weeks I think (1) I think I’m on the (1) cos there’s four  
29.  strips I think in the packets I think I must be now on the third strip 
30. JM: Right 
31. J: something like that 
32. JM: And how’s that going 
33. J: Alri↑ght yeah 
34. JM: You’re sort of 
35. J: I think I’ve got to go and see her again oh I forget I’ve got it in my  
36.  diary 
37. JM: It’s a few weeks wasn’t it 
38. J: Yeah. 
39.  ((searches in bag for diary)) 
40. JM: That’s alright don’t worry it’s a few weeks isn’t it 
41. J: Yeah that is the 20th it’s when I’m starting a new job I think  
42. JM: Yeah 
43. J: I’d better tell them I might be a bit late well I aint gonna be long here  
44.  about half an hour 
45. JM: Yeah 
46. J: I’ve only got to go a little way up there so it aint far away 
47. JM: That’s handy 
48. J: Yeah 
49. JM: Um but you manage to remember to take it every [day or] 
50. J: [Yeah] (1) well I try to heh heh heh 
51. JM: Yeah. How would you compare the tablets with the inhalers 
52.  (3) 
53. J: Al. Alri↑ght  
54. JM: Do you think there’s any differences? 
55. J: Er (2) they don’t seem to have no side effects or something (2) so long  
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56.  as I remember you know try to keep remembering to take one you have  
57.  to to take one at night don’t you  
58. JM: Yeah 
59. J: Yeah 
60. JM: And how do you think they work do you feel that they work 
61. J: Ye↑ah. (2) Yeah 
62. JM: How have you noticed just how long it takes sort of thing 
63. J: Um. .hhhh hhhhhhh um no I took them I take them alright and they I  
64.  seemed alright y’know after I took them and that so 
65. JM: But, you said you mentioned the brown inhaler took about a week two  
66.  weeks 
67. J: Yeah I think that was when I first had it I suppose to get use you know  
68. JM: Get used to it 
69. J: Yeah get used to them 
 
Extract 12 is typical of how quickly turns were taken in this interview, with Janet’s 
responses amounting to a few sentences at most and leading to a higher number of turns 
and the talk being approximately evenly shared between interviewer and participant. 
This is a notable contrast to other interviews where participants did most of the talking 
in long responses to questions. In the lead up to this extract, Janet verbally completed 
the Medication Adherence Report Scale (MARS), was asked about the circumstances 
surrounding her diagnosis of asthma and was then asked to explain when she was first 
prescribed the brown inhaler and her experiences of using it. As with the extract 
presented here, Janet provided short explanations and descriptions of the events. This 
extract was interesting for the analysis as JM attempted to directly address the issue of 
non-adherence in line 1. However, the context for this question was specified “again 
I’m not here to sort of say why aren’t you using it”. This contextualisation cue provided 
a reframing of JM’s role “I’m not here to” and the normative expectations of what Janet 
could and could not say about her medications within this interaction. Providing a 
reframing suggested that Janet had not done what was expected up to this point in her 
talk about asthma. In other words, she hadn’t provided a long account of her asthma and 
decisions about medications and didn’t seem to be justifying any of her behaviour. 
Despite this reframing by JM, Janet provided a straightforward response with few 
rhetorical devices being deployed. Her forgetting is set within an historical context of 
having had asthma for 30 years, potentially distancing her current asthma management 
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from any decision that she made. However, Janet also offered little explanation of her 
motivations for taking part in the current asthma study (line 22), or of how she had 
experienced the new tablet treatment (lines 51-69). In each of these three responses 
Janet presented a simple description of events. What is notable in these simple 
descriptions as with her talk elsewhere in the interview is that her responses stuck 
closely to the question and once that had been addressed she ceased her response. This 
was in contrast to other interviews where a question was often followed by an elaborate 
response, often bringing in different aspects of the person’s lifeworld and views of 
issues outside of asthma. Here, Janet consistently stuck to the specific question with 
virtually no elaboration.  
 
If we view Janet’s talk as accurately reflecting how she engaged with her asthma, then 
one interpretation of this interaction could be that asthma does not play a big part in 
Janet’s life. From a medical perspective with an objective to get patients to adhere to her 
medications, she appeared to be happy to follow whatever instructions she was given 
and perhaps just needed a little reminder of the need to adhere to her prophylactic 
medication more regularly. However if we view this interaction as a product of the 
social, historical and interactional context then we can see evidence that Janet was 
responding to the dialogical expectations of a particular type of interaction. The short 
responses and frequent turn-taking appeared much more like an asthma review 
consultation than a qualitative research interaction. Asthma review consultations 
typically check patient’s symptoms and how they are using their medications. Janet 
checked how often she needed to be taking the tablet (line 56-57), started to check her 
diary for study visit dates (which function as asthma reviews) for the main asthma study 
(line 39), detailed how many “strips” there were on her prescription (lines 28-29) and 
provided responses that did enough to affirm that the medications were ok and working 
(lines 33, 53, 61). We can see how this framing of the interaction was jointly 
constructed by JM and Janet, as JM filled the spaces between Janet’s talk with further 
questions or clarification, functioning to reinforce that this was a “checking” type of 
interaction. There was also evidence of a moment of tension as JM attempted to move 
on from this “checking talk” by providing answers for Janet (line 40). Unfortunately, 
this only served to reinforce the dialogical expectation being mutually constructed (lines 
35-48).  
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However, when viewing this extract from within the social space in which it took place, 
a new and very different interpretation of this interaction is possible. The interview not 
only took place within Janet’s local surgery but was conducted in a doctor’s consulting 
room which Janet had previously attended for an asthma consultation with a nurse. The 
interviewer, sat in the clinician’s chair next to a computer, asked direct questions about 
Janet’s asthma as she sat in the “patient’s chair”. This ethnographic context appeared to 
set up a communicative expectation within the interview which was closer to that found 
within an asthma review than a qualitative interview. When viewing Janet’s talk as a 
qualitative interview, her lack of narrative appeared to indicate a lack of justification for 
her asthma management. However, if we now view the interaction as an asthma review 
then we can see that Janet was indeed engaged in demonstrating that she was 
appropriately managing her asthma. This was evidenced by the checking talk that took 
place, including Janet counting medication strips, repeating the prescription’s 
instructions and indicating she had recorded appointments by searching for her diary. 
 
One interpretation of the uncomfortable moments in the two extracts presented here is 
that there were mismatches in expectations between the interviewer and interviewee 
about the meaning of the interaction. One purpose of the face-to-face interviews was to 
elicit a narrative from participants to enable understanding of how and whether 
“lifeworld” discourses might conflict with medical discourses of asthma management 
and adherence. The moments of tension in the two extracts suggested that neither 
participant was engaged with this presupposition and was therefore not doing what was 
expected within their respective research interviews. This was evident in Dawn’s and 
Janet’s responses to contextualisation cues provided by JM, suggesting that one way to 
gain insight into when participants do or do not justify their medicine taking would be 
to examine how both researcher and participants perhaps understood what the 
interviews were about and how the research interview as a method regulated what 
participants were able to say. 
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Analysing Interactional Conditions in which Participants Justified Medicine 
taking within Face-to-Face Interviews 
 
A technique which was used to gain insight into mismatches in how researchers and 
participants “framed” interview interactions was to analyse some of the interactional 
conditions of the face-to-face interviews. Ideas from linguistic ethnography (Rampton et 
al., 2004) were drawn on in conducting this part of the analysis. This is because 
approaches that have been associated with linguistic ethnography (LE) have shown a 
way to unite a range of linguistic and ethnographic disciplines when studying 
communication. A scholar, whose ideas have been used to critique research interviews 
from an LE perspective, has been Charles Briggs. Briggs, who has worked to combine 
linguistic and medical anthropology with social anthropology in a range of fields, 
provided a sociolinguistic appraisal of research interviews in “Learning how to ask” 
(1986). Here Briggs highlighted a number of areas that can be investigated to 
understand these conditions in research interviews. Using data from his own interviews 
Briggs demonstrated how “communicative blunders” (pp. 39-60) over contextual or 
indexical meanings are a frequent occurrence in interviews, revealing a divergence in 
and lack of access to each member’s presuppositions, goals and framings of the purpose 
and meaning of the research interview and it’s communicative procedures. This is set 
alongside a transformative process whereby participants are asked questions which 
force them to artificially summarise and provide abstract meaning from everyday 
experiences, a process which bears little relation to the experience itself. Briggs argued 
that researchers frequently fail to recognise these processes and as a consequence 
interpret participant’s talk in ways which typically fit their own conceptualisation of the 
interview and which mask indexical meaning by asserting its content as “real.”  
 
To analyse some of the conditions of research interviews that Briggs sets out required a 
different analytical approach to the one set up so far. The reason for this is that the 
discursive psychological methodology taken to analyse rhetoric in talk has a particular 
conceptualisation of context which was limited for the purposes of analysing the 
interactional conditions of interviews. The discursive psychological view is that while 
wider discourses may shape interactions, context is produced by participants through 
the interaction and is made pertinent to the analysis by participant’s own orientation to 
particular discursive issues. We saw this in the analytical path that was traced between 
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the identification of moral discourses in asthma management in Chapter Two and the 
rhetorical talk about medicine taking of the participants in this study. This analysis of 
moral discourses was based on a theoretical link between discourses that circulate 
cultural and institutional spaces to the activation and regulation of interactional talk. 
This was therefore a view of context that limited its analytical lens to a linguistic 
analysis, which although providing much that is rich about what happens when people 
talk about potentially contentious issues, was limited in its ability to specify the roles, 
presuppositions and communicative expectations that had preceded and been set up 
within the interview. Instead, a view of context was needed that allowed an examination 
of features that were not apparent in a purely textual analysis of interview data, but 
required going beyond the transcript itself. This meant attending to more ethnographic 
features of the research interview that may have played a key part in what was said 
within face-to-face interviews.  
 
One useful way to conceptualise these features of context can be found in the work of 
Jan Blommaert. He argued that a purely textual analysis fails to account for “forgotten 
contexts” (2005, pp. 56-57). These contexts are not features of single texts but are of 
“larger economies of communication and textualisation” and offer additional evidence 
that bridges the gap between social structure and its manifestation in talk and text. It is 
the analysis of these forgotten contexts that are now discussed to enable an 
understanding of how researcher and participant’s presuppositions, goals and framings 
of the research interviews may have been divergent. This analysis of what participants 
brought to these interactions enabled the interactional conditions in which participants 
were likely to justify their asthma management and medicine taking to be specified. 
 
Interactional Conditions of the Face-to-Face Interviews 
 
Attending to several interactional conditions here helped suggest that misunderstandings 
were likely to occur between researcher and participant. Revealing these 
misunderstandings indicated that justifying medicine taking was dependent on 
participants having access to and utilising linguistic resources regarding their 
involvement in the study that were not directly referred to within the interaction but 
which were implicit within the larger economies of communication and textualisation to 
which Blommaert refers. 
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Pre-textual identities 
 
The first interactional condition to attend to relates to the process of recruitment for the 
interviews described in Chapter Three as set within the context of a large, randomised 
controlled trial (the ELEVATE study). To be interviewed, participants needed to be 
categorised in all of the following ways, determined by a mixture of objective breathing 
tests and questionnaires: 
• A person with asthma 
• A person with inadequate quality of life 
• A person with inadequate asthma control 
• A person who is non-adherent to medications 
 
These “pre-textual” identities were not explicitly made reference to within interviews, 
or at any point in the participant’s involvement with the ELEVATE study, but were 
implicit in the process of recruitment and eligibility described in Chapter Three. 
 
The talk within Dawn’s extract suggested that JM attempted to activate the pre-textual 
identities that had been constructed through Dawn’s participation in the main asthma 
trial. These were indicated by JM’s asking Dawn about her reluctance to take the brown 
inhaler and how this fitted with her doctor’s viewpoint. However Dawn was not able to 
respond to JM’s contextualisation cues and her lack of access to or use of these 
contextual resources resulted in a very different type of interaction. If we contrast this 
with the extracts in Chapter Four, we find much stronger evidence that these pre-textual 
identities were activated in the interviews with Martin, Irene, Stephen and Dave, and 
that they responded accordingly. In contrast to Dawn’s talk, Janet demonstrated clearer 
evidence of a moral agenda in her talk. However, unlike the interviewees discussed in 
Chapter Four, Janet’s talk was not orientated to justifying previous actions but instead 
involved her presenting herself as compliant with her current asthma therapy. The pre-
textual identities that JM attempted to activate were therefore re-framed within a context 
of an asthma review consultation leading to another type of interaction taking place. 
This indicated that pre-textual identities were activated within interactions and engaged 
with by participants in a number of ways, appearing to play a key role in influencing 
whether participants justified their medicine taking. 
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Researcher and participant presuppositions 
 
The second interactional condition of the interviews, which may have influenced how 
participants talked, was related to the different presuppositions held by the researcher 
and participant about the resources and goals that each member brought to the interview 
setting as well as their understanding about what happens within research interviews. 
The goal of the interviewer was to elicit data on the discursive construction of 
medications and views of health and illness. The goal of the interviewee, by contrast, 
might have been to have a chat, help out, get something off their chest, to finish the 
interview as quickly as possible, or to get some evaluation of their own opinions or 
position. The interview questions set out in the interview schedule (Appendix A) 
constructed normative expectations about how participants engaged with their asthma, 
their goal for participation in the interview and what they were able to say about their 
asthma. Even the loosest questions aimed at eliciting narratives “tell me about your 
views on illness” suggested that the participant should be able and willing to discuss a 
view on illness. This potentially constrained participants’ narratives to a format that 
they may or may not have been able or happy to participate in. This could be seen in 
how the interview schedule focused on asking questions about what was told to 
participants by doctors and nurses, how well it was done and how they felt about having 
an asthma diagnosis and prescription of medication. There was a presupposition that 
because they did not take their medication as prescribed, participants should have had a 
grievance about their health treatment and that the interview offered an opportunity for 
participants to express those grievances.  
 
Both researcher and participant had potentially very different understandings about what 
a “research interview” was about, which were therefore likely to lead to 
misunderstandings. Using the term “interview” with participants to describe the 
conversations taking place, imposed a set of conventions on that situation, not only 
about who should ask the questions but what sort of questions were to be asked, i.e. 
open-ended questions aimed at eliciting narratives. Participants may have or may not 
have been familiar with this particular genre (Duranti, 2001) and whether they had such 
familiarity may have influenced how they participated within it. In addition, there were 
different activities within the interviews which set up different interactional 
expectations. Generically, this was a research interview and specifically a qualitative 
interview. However, participants were also asked to complete the Medication 
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Adherence Report Scale – MARS (Horne & Weinman, 2002). This was sent by post but 
was reviewed at the beginning of the interview. In contrast to the qualitative interview it 
required short responses. There was therefore a mix of activity types that required 
different types of responses, or “production formats” (Goffman, 1981) potentially 
leading to misunderstandings about which production format was appropriate and when. 
Janet’s interview began with her verbally completing the MARS questionnaire, as she 
had not already completed it by hand. This may have set up a particular expectation 
about the type of response required which, along with a possible lack of familiarity of 
qualitative research interviews, may have contributed to her framing that interaction as 
something akin to a clinical consultation. 
 
In addition to problems being raised in switching production formats across activities, 
participants’ talk could also be seen to be controlled within activities, regulating the 
type of talk that was produced. The standard interview format of question and answer 
sets up a particular interactional sequence which regulates what interviewees are able to 
talk about and how they deliver it. Qualitative interviews typically involve a series of 
sub-sequences which follow a particular pattern. Frequently the interviewer begins with 
an opening question from the interview schedule, provided with a contextualising 
preface. This is often followed by a narrative from the participant with the interviewer 
providing listening confirmation cues. Possible clarification questions interrupting the 
narrative sometimes occur and then the interviewer may use follow-up questions to pick 
up again on something said earlier in the narrative. 
 
We can see this type of pattern in the transcripts of the face-to-face interviews 
(Appendix B and CD). The interviewer was seen to control the rhythm of the interview 
and also to select what the issues “are” in participant’s talk which, although open to 
cues from the interviewee, decided what needed to be followed up and focused on. This 
was evident in the researcher’s preoccupation with participant’s reasons for not taking 
their medication. The choice of questions in the interview schedule that met this 
purpose therefore controlled the boundaries of relevance in what and how topics, set out 
on topic cards, were discussed and later, what was analysed and “seen” in the data. This 
structuring of talk therefore regulated the production and interpretation of the role of 
moral discourses in talk, further influenced by how talk was captured within the 
interview, documented as “data”, subsequently analysed and produced for a particular 
audience. Face-to-face interviews were recorded on tape, taken away to be transcribed 
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with a limited set of transcription conventions and analysed at a later date for the 
purposes of a PhD thesis. Much of the richness and nuances within the original verbal 
interaction were lost as a result of this process. Data were therefore “made” rather than 
provided and ran the risk of decontextualising how moral discourses were produced 
within interactions, minimising the possibility of alternative interpretations of that data.   
 
As a researcher on the ELEVATE study, participants potentially viewed the author’s 
(JM) role as an expert on asthma. This framing of the researcher’s role combined with 
an interview format of direct questions potentially reproduced the individualising 
discourse being critiqued in this study, demanding that participants justified their 
medicine taking behaviour. The use of the MARS questionnaire may have reinforced 
this by activating an “adherence discourse”.  Similarly the act of setting up a one-to-one 
interaction which was about “your asthma”, may also have called for participants to 
provide morally acceptable explanations for the decisions that they had made. As 
Radley and Billig (1996) point out, being interviewed by a presumably healthy and 
employed “health researcher” about one’s health-related behaviour will create a 
particular type of interactional dynamic whereby interviewees are faced with a dilemma 
of presenting themselves as fit for work yet presenting with authentic symptoms and not 
a “malingerer.” Consider the following extract taken from the interview with Martin 
discussed in Chapter Four. The sequence shown in Extract 13 followed shortly after 
Extract 9 in Chapter Four which demonstrated Martin orientating to a variety of 
concerns with his health and his work. 
 
Extract 13: Participant 670287, (Martin). Interview 1, page 12, line 11 to line 47 
 
1. JM: Um (.) Um when you entered the study (.) and you were randomised to  
2.  the (.) brown inhaler= 
3. M: =↑Mmhm 
4.  (1) 
5. JM: did the nurse talk about how she would like use it= 
6. M: =Yes 
7. JM: ˚What did she say˚ 
8. M: She said morning and night 
9.  (.) 
10. JM: ˚What did you say˚ 
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11. M: I said fine. if its part of the study, of course I’ll do it 
12. JM: And and [have] 
13. M:     [And ] I have been doing it 
14. JM: ˚And how long’s that been, how long have you been on it˚ 
15.  (1) 
16. M: With the study you should have the de↑tails of that= 
17. JM: =I have but its in my car= 
18. M: =Right [okay]  
 
The latched responses and softly spoken, yet direct questioning, resemble what might be 
found with a witness taking a stand in a courtroom. What is important here is that the 
participant, Martin, didn’t seem to pick up the framing of this questioning as asking 
about the nurse’s behaviour and not his. Rather, the defensive work suggested that he 
considered it an interrogation of his behaviour, potentially seen as continued from the 
earlier discussion. This was indicated at lines 16-17, where Martin appears to regain 
some authority within the interaction by initiating a reverse in the turn-taking sequence 
followed by JM’s own rather weak latched response.  
 
The author’s role as both researcher on the main asthma trial and qualitative research 
student had the potential to seed a mixture of cues within interactions. Participants may 
have seen the interview as either an interrogation of their asthma management, an 
opportunity to air grievances or as something else entirely. The direct questioning about 
a failure to take prophylactic medications had the potential to exacerbate any tensions 
whilst providing a barrier to different contrasting framings of the influences on 
participants’ asthma management that the interviewer attempted to construct. 
Participants were therefore likely to differ in how they understood the dialogical 
expectation set up within the interview and would differ in how the linguistic resources 
available to them were utilised in a discussion of their asthma management. This would 
make for lack of clarity in what was required from interviewees and there was a range 
of evidence that there was gap between the researcher’s expectations and how the 
participants framed the interactions, evidenced with statements such as “that’s why I felt 
that perhaps I was wasting everyone’s time, you know, by doing this survey” (530181, 
page 1, line 50 to page 2, line 2), “SORRY I’M NOT VERY HE(h)LPFUL” (670289, 
page 23, line 38). It is therefore possible that lack of access to the interviewer’s agenda 
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(and vice versa) and to the linguistic tools of adherence may have created some of the 
interactional tensions and misunderstandings apparent within the data. 
 
Summary 
 
Being asked to provide a long narrative about one’s asthma was likely to be an unusual 
occurrence for many participants in this study. The research interviews, while well-
defined from an academic perspective, may well have had vague boundaries and 
definitions for participants. Whilst participants may have had some similar discussions 
with relatives and friends about their asthma they would have been unlikely to have 
participated in a discussion where their asthma management was the sole focus of 
attention. Although individuals’ asthma management is the focus of discussion in 
asthma consultations, this research encounter with a relative stranger was, unlike 
clinical consultations, one which they had not initiated. The topics of discussion, 
agendas of the researcher and participant, backgrounds, experience and roles were 
potentially unclear and the style of questioning could be seen to be interpreted in a 
number of ways including as an interrogation of the participant’s asthma management. 
 
Without the presence of well-defined parameters and criteria for discussion that were 
easily accessible to participants, it is conceivable that those who justified their medicine 
taking may have been responding to a particular set of interactional conditions that were 
activated within those interviews. These conditions were an individualising discourse 
within a research context which had recruited participants based on their asthma being 
categorised as inadequately controlled and one which could have positioned participants 
as blameworthy for that inadequate control. For many participants, being interviewed by 
someone, working on that study, about their medicine taking decisions was therefore 
likely to activate issues of blame and accountability about those decisions. In contrast, 
participants who did not appear to deploy many rhetorical devices, either blamed 
themselves (in the case of Stephen); framed the interaction as a clinical review (and 
therefore adopted a different style of rhetoric); or appeared uncertain as to the purpose 
of the discussion and unable to utilise the necessary resources to justify their medicine 
taking.  
 
The “researcher” and “participant” in this study were institutionalised roles formed 
through medicine and scientific research that were implemented through research 
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interviews. The purpose of the interview, the roles, rules, rights, communicative 
expectations and responsibilities of the participants were therefore external 
constructions that were partially and unevenly activated within the interview 
interactions. In addition, both researcher and interviewee brought their own differing 
theories, presuppositions and expectations about what the interactions were about. 
These constructs therefore moved across time and space and had an influence across 
contexts. The resources available to interviewer and participant were likely to differ and 
yet it is the interviewer who set the normative expectations of what was expected from 
“a person with asthma who is discussing health, illness and medications.” The 
justification of medicine taking within interviews was therefore intimately connected to 
participants’ ability and willingness to access the resources that the interviewer 
possessed and attempted to activate within the interaction. These attempts were not 
explicit statements but could be seen through the interviewer’s use of “contextualisation 
cues.” Similarly, participant’s framings were constructed in the dialogue. These 
framings were also not made obvious because of their lack of explicit discussion within 
the interaction taking place. These insights therefore raised uncertainties for the author 
in the ability to extend claims about the role of morality in participant’s talk beyond the 
face-to-face interviews to other types of interaction about prophylactic medicine taking. 
Such uncertainties posed an analytic requirement to identify data that could be 
considered “new” which could be used as further evidence that participants and people 
with asthma engage with notions of morality when discussing prophylactic medicine 
taking. Chapter Six reports findings from a focus group where data from the face-to-
face interviews was shared with participants. The focus group could be considered as 
providing new data because a different interactional dynamic was constructed from the 
interviews, building on the lessons learnt from the analysis reported in this chapter. 
These new data were then analysed to identify evidence of whether moral discourses of 
medicine taking might also be activated and which would therefore enhance the 
plausibility of interpretations generated from the face-to-face interviews. 
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Chapter Six 
Analysing Interactional Contexts in a Data-Sharing Focus Group 
 
Viewing talk as a product of interactions between people raised challenges for 
indicating how the participants in this study might have talked in a different type of 
interaction than interviews. Taking into account the conditions under which the research 
interviews took place entailed interpreting the role of morality in that talk as unique to 
that particular form of interaction. Deriving more general statements about the role of 
moral discourses in a range of everyday interactions about illness management was not 
possible without some comparison of talk in another kind of interactional space offering 
a different type of data that could also be seen to find moral discourses in talk. This is a 
distinct departure from positivist notions that a specific sample size is needed to 
generalize to a wider population. Here, talk was viewed as implicitly linked to systemic 
discourses that circulate through society within different interactions, social networks, 
and institutional and cultural settings, and which structure that talk. Talk about health 
and illness can be seen to be a product of discourses which are commonly shared but 
manifested in novel ways to meet particular interactional demands.  
 
The different data required in this study to generalize about the role of morality in talk 
about medicine taking therefore had to represent an “extended case” (Burawoy, 2003) in 
which to trace threads in the production of morality. To be considered different, it had 
to be based on a different set of interactional conditions to those constructed in the face-
to-face interviews already undertaken. A focus group could be used to set up such a 
different type of interactional dynamic.  
 
Apart from the obvious difference that using a group discussion has in contrast to a one-
to-one interaction, a key strategy in setting up this alternative interactional dynamic was 
to share findings from the face-to-face interviews with the focus group participants. 
Sharing results with research participants is widely recognized as an important way to 
acknowledge their contributions to research projects, an essential component of 
knowledge transfer (Crosswaite & Curtice, 1994) as well as a powerful qualitative 
research tool to enhance the interpretation and validity of research findings (Lincoln & 
Guba, 1985, p. 373). However, such sharing is sometimes found to present difficulties 
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for researchers and participants (Scheper-Hughes, 2000) because the content of findings 
might be challenging and it might be difficult to find accessible means of 
communicating results to participants. The specific use of a focus group to consider 
findings raised dilemmas for participants in identifying with those findings, creating a 
different type of activity in which moral discourses of asthma management and 
medicine taking might be activated.  
 
Focus Group Recruitment and Design 
 
The five ways of accounting for non-adherence, reported in Chapter Four, were: 
• Compliance as passive. Participants with this accounting style reported 
monitoring their asthma and responding accordingly; 
• Minimisation repertoire using several rhetorical devices to justify medicine 
taking. Participants with this style minimised the impact of asthma on 
everyday life;  
• Tension between lifeworld and medicine. Adherence potential threat to 
lifeworld. Participants with this style constructed asthma as both interfering 
and as having minimal impact on everyday life; 
• Blame of healthcare breaches sick role contract. Participants with this style 
blamed health care for incorrect diagnosis or treatment; 
• Minimisation repertoire using few rhetorical devices to justify medicine 
taking. Participants with this style provided little or no explanation for non-
adherence.  
 
The author drew on these findings from the analysis of face-to-face interviews in 
designing the focus group activity. Key characteristics of four of the accounting 
styles found in the face-to-face interviews were used to construct four brief 
vignettes, each presenting statements made in the first person voice. Vignettes were 
deliberately constructed from the early analysis of interview data to represent each 
accounting style and not as specific views of individual participants. Presenting each 
vignette provided a basis for participants to position themselves in relation to the 
person represented in each vignette. All vignettes are set out in full as follows: 
 
Vignette 1. Medications are necessary to control my asthma but I don’t rely on 
them. I decide for myself whether I need to take a particular medication. Some 
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people use medication for the sake of it and are dependent on it. I assess how I 
feel and then take the necessary action. 
Vignette 2. I do not have proper asthma. I have very few breathing problems and 
the brown inhaler doesn’t make any difference to the way I feel. I don’t have any 
concerns about taking medication but I often forget to do so. 
Vignette 3. Asthma is a nuisance, an inconvenience, but it doesn’t interfere with 
my life. I use my blue inhaler to stay in control of my asthma and I avoid 
situations that affect my breathing. I should take the brown inhaler every day 
and it is my fault that I haven’t, but I don’t want to be hooked on too many 
medications. 
Vignette 4. I don’t think I have asthma. I think doctors and nurses do not 
understand my symptoms and I don’t feel that they listen when I go to see them 
or talk about the causes of asthma properly. I am concerned about the side 
effects of medications. The experts say that some medications are now unsafe, 
so I don’t want to take a medication every day that I don’t think works very 
well. 
 
At least one person linked to each accounting style identified in the face-to-face 
interviews was invited to attend the focus group. Within the wider sample available, the 
first author made an active attempt to invite a balance of men and women, and people 
with a range of ages and social backgrounds. Ten people agreed to take part, four of 
whom later stated they were unable to attend and one further participant did not attend 
on the day. One other person who had not taken part in the study attended because he 
was accompanying his father, and he was then invited to participate. The inclusion of 
this participant created a particular interactional dynamic in that he was the only focus 
group participant who could contribute to the discussion without having the issue of 
potentially being represented in the vignette descriptions. The discursive methodology 
adopted in this study meant that this participant’s talk could be analysed using the same 
assumption that was applied to the talk of other participants. This was that moral 
discourses of illness management are likely to be manifested and circulated to text and 
talk in a variety of social spaces involving a range of different people. This participant 
could therefore be included in the focus group discussion because his talk would offer 
an opportunity for the author to analyse a potentially different orientation to moral 
issues of illness management than that provided by the other focus group members. 
Analysing the contributions of an individual whose medical background was not known 
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to the author and who also had no direct connection with the vignettes presented, would 
be potentially fruitful if any discursive variation or tension between himself and the 
other participants was identified within the focus group discussion. All participants 
were White British, lived in Norfolk, England, and spoke English as a first language. 
Participants were aged between 40 and 80 years old. Five of the six participants were 
men. 
 
Methodological Assumptions  
 
Using a focus group for triangulation to contextualise the production of talk on 
medicine taking called for this form of data collection to be managed using assumptions 
different from those often adopted. Although there is an increasing engagement with the 
variability of talk in focus groups (Clavering & McLaughlin, 2007; Puchta & Potter, 
2004), researchers frequently see individual contributions and group dynamics as 
reflecting participants’ underlying attitudes and values (Kitzinger, 1994; Redmond & 
Parrish, 2008). The discursive psychological approach used in this study meant that 
contributions in the focus group were viewed as open to change and therefore not as 
contributions that could be easily categorized in terms of underlying attitudes.  
 
The task of validating findings through data sharing in this study was therefore viewed 
differently than research approaches that treat talk as reflecting individuals’ inner 
realities. Individual member checking is a commonly used technique, for instance in 
phenomenological or grounded theory approaches, to validate research findings from 
face-to-face interviews by checking the researcher’s interpretations individually with 
participants (Bloor, 1997, p. 41; Lincoln & Guba, 1985, pp. 373-378; Seale, 1999, pp. 
63-72). Participants are typically asked to directly report on whether they agree or 
disagree with the researcher’s interpretation of their interview. Any disagreements 
identified in this way might then lead to a reinterpretation of that data. However, using 
such an approach to validate individual interviews in the present study would raise 
rather than answer questions about any agreement between the two sources of data. 
Karnieli-Miller, Strier, and Pessach (2009) argued that the participant–researcher 
relationship activates important power relations, which poses difficulties for validating 
findings with participants. In this study, the act of member checking might also have 
been set within a moral discursive context in which the participants could be seen to 
justify themselves. Consider the following example taken from a face-to-face interview.  
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Extract 14:  261284, (Frank). Interview 1, page 7, lines 16-25 
 
1.  F: Well no, because I just thought well you know everybody’s got asthma  
2.   and it seems such a common thing and um, quite frankly you don’t feel 
3.   ill you know that’s the thing you don’t feel ill, ill as such, just the fact  
4.   you can’t breathe. Do you see what I mean? You don’t, its not like  
5.   you’ve got a cold or you’ve got the flu, anything like that. You haven’t, 
6.   you, you’re perfectly okay apart from the fact you can’t, you, you’re  
7.   gasping for breath so sometimes I’ll feel a bit of a fraud for, for . . .  
 
A key interpretation of this extract was that Frank was constructing the discursive object 
“asthma” as something that was not really an illness. This version of his asthma was 
crucial in justifying his lack of attendance at his local doctor’s surgery. However, asking 
Frank whether the researcher was correct in interpreting Frank’s view of his asthma as 
“not a proper illness” might have raised the issue not only of the accuracy of Frank’s 
understanding of asthma but also his rights to access services to treat his asthma. This 
would potentially create a discursive cul-de-sac for Frank who, depending on his 
response, could be seen as in denial, as having distorted beliefs, as not requiring 
treatment or, rather, as a malingerer. 
 
In the alternative discursive framework, sharing data for the purposes of triangulation is 
not just an activity in which the content of findings are confirmed or challenged by 
participants. It is also generating data. This process forces the researcher to consider the 
method by which findings are communicated and responded to by participants. In this 
study, it was necessary to confront the problem of how to share findings with 
participants in a way that did not reproduce the interactional dynamics of the face-to-
face interviews. 
 
Interactional conditions of the interviews and focus group 
 
Instead of the analytical lens being focused on each individual’s behaviour in 
interviews, using a focus group offered the chance to analyse a collective management 
of data that was not attributed to any single individual. As well as offering participants 
an opportunity to set out their own perspective on those findings presented, a focus 
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group was therefore used to provide a new set of data against which to analyse the 
prevalence of morality in talk about medicine taking. These data could then be 
triangulated with the analysis of face-to-face interviews. However, the reason for use of 
this form of triangulation in the study was not to seek confirmation in the focus group 
data of the accuracy of interpretations of the content of the accounting styles identified 
in the interview data. Instead, triangulation involved examining how the different 
interactional conditions produced different kinds of talk influenced by moral discourses. 
As with the interview data, within a discursive psychological framework, validation was 
achieved by examining “participants’ orientation” (Potter & Wetherell, 1987) to 
different moral discourses. The focus group data could therefore be treated as 
analytically additional because members were participating in an activity that was not 
only different, but was based on interactional conditions differing from the face-to-face 
interviews, requiring a different kind of participant orientation to the talk taking place. 
Instead of being confined within the demands of individual face-to-face engagement as 
with an interview, focus group participants had more freedom to stay silent and also to 
respond to participants other than the moderator; no set of questions was to be directed 
at any one person, and the author, who also acted as the focus group moderator, was 
primarily to act as observer rather than interviewer. 
 
Issues in using a focus group to share findings 
 
A series of extracts selected from the transcript of the data-sharing focus group are used 
here to explicate specific considerations that had to be attended to when analysing this 
type of focus group from a DP perspective. The transcription conventions that were 
applied to the interview data were also used here, adapted from conversation analytic 
conventions to enable close scrutiny of talk in interaction. The extracts illustrate the 
different ways in which participants responded to and discussed the vignettes, 
medications, and medicine taking, underlining both the variation in participants’ 
responses and the different discursive strategies they adopted as a group. These 
examples illustrate the range of ways participants orientated to issues of morality and 
medicine taking within this research setting and emphasise the issues that had to be 
considered in analysing the data. The first consideration was what strategies the focus 
group moderator could adopt to construct a different interactional dynamic from the 
face-to-face interviews and what evidence in the data might indicate that this had been 
achieved. The second arose from examining what types of issues participants could be 
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seen to manage within this different research setting and with this task. Answers to 
these questions were needed to show ways in which this was a new dataset and so could 
support a broader examination of the role of moral discourses in talk about medicine 
taking. 
 
Constructing an Interactional Dynamic in the Focus Group 
 
A key issue for constructing an interactional dynamic that differed from that generated 
in face-to-face interviews was linked to the moderator’s role in the focus group 
discussion. In British media representations, researchers are commonly conceptualized 
either as people with clipboards on high streets asking a series of questions or as people 
who work in laboratories. The use of face-to-face interviews that preceded the focus 
group potentially reinforced the former conceptualization. In the context of the focus 
group, therefore, a key task was to redefine any such notions of what researchers do. 
This was done by the moderator informing participants on arrival that  
 
What we will be doing in today’s group will be to have a good discussion and to 
get your reactions, as a group of people who may well have some differing 
views, to some of the findings from the first interviews. The materials I will be 
showing you are sets of opinions that different people may make. They have no 
names attached and are not taken from any one interview. They have been put 
together from my own interpretations after I closely examined the different ways 
that people in interviews talked about their asthma. This is a chance to talk about 
what you think. (Murdoch et al., 2010) 
 
Before they discussed any vignettes, the moderator asked participants to jot down on 
paper their ideas of a healthy person and an ill person. They then shared their notes with 
the person sitting next to them and then with the whole group. This was done to help 
prepare participants both to discuss the vignettes between themselves rather than 
directing comments to the moderator and also for the reflexive task of comparing their 
own positions with those presented in each vignette. Copies of Vignette 1 were 
distributed to each member of the focus group to read for themselves, and the moderator 
also read out each vignette to clarify the content. The moderator asked the participants, 
“What do you think?” when presenting the vignettes and then tried to minimise his own 
talk from that point onward, to avoid guiding the discussion of the vignettes in any 
   
 
 
162
particular way. This approach contrasts with research that also used vignettes in focus 
groups but where the moderator took a much more active role in facilitating the 
discussion (Brondani, MacEntee, Bryant, & O'Neill, 2008). The moderator minimised 
his talk by avoiding answering specific questions and allowing silences to be managed 
by participants. When the group’s discussion of Vignette 1 appeared to have reached a 
“natural halt,” the moderator then passed around and read out Vignette 2, and repeated 
this process until the group had discussed all four vignettes. Extract 15 demonstrates the 
consequences of this strategy for the interaction that followed and how participants 
managed the moderator’s silence. The talk in this extract immediately followed the 
presentation of Vignette 1. In these extracts, each participant has been assigned a 
number. Participant 4 was the only member who did not participate in the main asthma 
study and qualitative interviews; he did not state whether or not he had asthma. 
 
Extract 15: Data-sharing focus group, page 5, line 19 to page 6, line 45 
 
1. Participant (P) 2: Yes that’s it. 
2. P6:  ºYep [( . . . )]º 
3. P2:      [Yeah     ] I I yes. I suppose some people do use medication just for the  
4.  sake of it but um where where you know ( . . . ) are are virtually   
5.  dependent on it. 
6. P4:  Yeah but also a lot of the medications you take you have to keep a   
7.  regular taking of it otherwise how do you know whether you you need  
8.  it or do you don’t it's like taking a tablet it don’t work immediately you  
9.  take it well it is something you got to keep taking to keep ya whatever  
10. it is under control so in one respect that's ((the vignette)) wrong and in  
11. another way it is right. 
12. (4) 
13. P6:  Particularly with the preventative. 
14. P4:  Yeah. 
15. P6:  Cos you don’t know whether 
16. P4:  No exactly. 
17. P6:  if that’s the whether you are feeling better because you changed  
18. something 
19. P4:  Yeah. 
20. P6:  rather than actually keeping the  
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21. P4:  Yeah. 
22. P6:  keeping the medication it might be that you’ve you know you've taken  
23. the carpets out 
24. P4:  Yeah. 
25. P6:  or wha(h)te(h)ver 
26. P4:  Yeah. 
27. P6:  whatever it is or changed your job or 
28. P4:  Yeah. 
29. P6:  whatever but this was summed summed me up I think. 
30. P4:  I mean that would be right with the inhalers I agree you you don’t   
31. squirt an inhaler if you don't need it but with the tablets you've got to  
32. keep 
33. P5:  Provided there’s no after effects of taking the tablet after a long period  
34. of time if you are taking the tablet and you are not using the inhaler  
35. afterwards um that's quite a good solution. 
36. (4) 
37. P4:  So to sum it up that’s right and that’s wrong ((referring to the  
38. vignette))  
39. heh heh. 
40. ?  Mm. 
41. P5:  Yeah. 
42. (7) 
43. P6:  So your first sentence “Medications are necessary to control my   
44. asthma but I don’t rely on them” well you do in a way. 
45. P4:  You do don’t ya because if you didn't, 
46. P6:  If they are necessary are you relying on them? 
 
After Participant (P) 5 had put forward his view, P4 attempted to close off the 
discussion of the vignette by summarizing the views of the few members who had 
contributed so far, a summary apparently accepted by 2 other participants. This agreed-
on position was potentially a cue for the group to stay silent and await direction on how 
to move the discussion forward, perhaps with the moderator presenting Vignette 2. The 
moderator offered no response, however, and a 7-second silence followed. This silence 
was eventually broken by P6, who attempted again to move the discussion on. This type 
of interactional sequence, where a series of turns is followed by a comparatively long 
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silence, was repeatedly made evident throughout the discussion. As the moderator 
continued to refrain from filling these interactional spaces, participants were obliged to 
continue the discussion. This contrasts significantly with face-to-face semi-structured 
interviews in which it is commonly the researcher who resolves long silences with a 
new question. 
 
This evidence for a different interactional dynamic, poses questions about which 
discourses of medicine taking can be seen as being activated within this sequence and 
what might this talk of participants tell us about contextualising the production of talk 
about medicine taking. The position taken by P4 seems to embody the medical directive 
that prophylactic medications should be taken regularly. Throughout the whole 
discussion it was only P4 who continued to return to the task of reviewing the vignettes. 
The use of phrases such as “you got to keep taking” (line 9) focuses medicine taking on 
the individual behaviour rather than the medication itself. In addition, P4 positioned the 
person in the vignette as both “right” and “wrong” according to notions of necessity and 
reliance on medication. Such positioning can be seen to set up an evaluation of the 
knowledge and associated actions of the speaker in this vignette, framed within a 
medical discourse of right and wrong attitudes and actions in asthma self-management. 
This discursive positioning of right and wrong behaviour and attitudes provided 
evidence that a moral discourse of medicine taking was being activated in the discussion 
and was evident in a different type of interaction from the face-to-face interviews. This 
new data provided in the focus group supported evidence identified previously in the 
face-to-face interviews that the participants in this study engaged with moral notions of 
illness management in their talk.  
 
A further question arises, however, about why the other participants who, from a 
medical perspective, could be considered not to have taken prophylactic medications as 
prescribed, did not overtly resist the medical directive constructed by P4. Rather, 
participants appear to have worked together to collectively uphold the dominant medical 
position without voicing questions about its assumptions. One interpretation could be 
that this reflected the attitudes that participants actually held. From a DP perspective, 
recognizing that a moral discourse was being activated between participants entails then 
looking at the sequences of the interaction to identify issues seen to be at stake for 
speakers, and therefore to identify reasons why speakers did not resist the medical 
position constructed by P4. 
   
 
 
165
 
Interactional Dilemmas 
 
Extract 16 demonstrates how using a focus group to triangulate with the analysis of 
face-to-face interviews created particular issues of interpretation for the analysis of that 
data. The focus of triangulation here did not concern whether participants could confirm 
the accuracy of the vignettes. Instead, the focus was placed on the different ways 
participants oriented to the vignettes and medicine taking, which emphasised how and 
whether moral discourses of medicine taking were active within the interaction. The 
task of the analyst in this case was therefore to identify phrases, syntax, metaphors, as 
well as other devices that demonstrated this orientation. As can be seen in Extract 16, 
presenting findings in this research setting raised particular types of dilemmas for 
participants which they were seen to have to manage in their discussion.  
 
Extract 16: Data-sharing focus group, page 27, line 19 to page 28, line 26   
 
1. Moderator (JM): Ok this one says “I don’t think I have asthma. I think doctors  
2.  and nurses do not understand my symptoms and I don’t feel that they  
3.  listen when I go to see them or talk about the causes of asthma   
4.  properly. I am concerned about the side effects of medications. The  
5.  experts say that some medications are now unsafe so I don’t want to  
6.  take a medication every day that I don’t think works very well.” 
7.  (11) 
8. P6:  Well I feel sorry for em they 
9.  (7) 
10. P1:  Well I was lucky when I went to see the nurse she actually suffered  
11.  from asthma which was great because she knew exactly what I was 
12.  talking about and what I should do and shouldn’t do and I seem to   
13. remember she said there were no side effects from the brown one but  
14. the blue one be careful with the blue one seem to remember her saying. 
15. (2) 
16. P6:  Oh I didn’t know tha:t. 
17. P5:  What is the compound difference then between the brown and the blue  
18. one? 
19. P1:  The bro[wn one coats] 
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20. P6:    [used to be] ventolin but it’s sort of salbutamol int it. 
21. P1:  Mm the brown one coats the lung don’t it though and stop irritation  
22. and the blue one opens the opens the bronchial tubes up. 
23. (2) 
24. P6:  Mm but the I don’t know whether I was (2) completely awake at the  
25. time but I thought when they when they hook you on to a nebul a   
26. nebulizer I don’t know if that has happened to any of you but you’re  
27. getting 10 times the dose of the blue one so it really is a really is a kick  
28. in the system. 
29. P1:  Mm. 
30. P5:  Mm. 
31. P6:  Um but that I may have got that wrong but you get the blue one you do  
32. have a puff on the blue one but actually when hooked on to a nebulizer  
33. you’re actually going to get 10 times the dose um the blue one in   
34. theory can’t be that harmful can it not your blue puffer if that’s the  
35. case. 
 
Vignette 4 depicted an openly critical position on medications and medical expertise. 
After the vignette was read out there was an 11 second pause, followed by a partial 
sentence from P6 to distance himself from the speaker and which conveyed pity -“Well 
I feel sorry for em they” - but which stopped short of continuing with the evaluation of 
the person. This was followed by another 7-second pause. These silences and a 
truncated response from P6 offered a contrast to responses to the other vignettes, which 
were less critical, and suggested that participants were more reluctant to articulate a 
view that might be seen as closely aligned with the view expressed by the person 
represented in the vignette. There was additional evidence for this interpretation as the 
sequence continued. P1 broke the silence but did not offer a direct reaction to the 
vignette. Instead, he referred to his own experience with the use of a story about what 
the nurse told him about specific drugs and their side effects. 
 
There is plenty of evidence elsewhere of how stories serve different functions in talk 
about health and illness (Cornwell, 1984; Frank, 1995; Lumme-Sandt et al., 2000; 
Lumme-Sandt & Virtanen, 2002; Wong & Ussher, 2008). One function described by 
Lumme-Sandt and Virtanen (2002) in their analysis of focus group discussions of 
medication among older people is that stories can act as a vehicle for controversial 
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opinions without those opinions being attributed to the speaker. Stories can be presented 
as a “fact” which the speaker is “just relating” to listeners, the effect being that the 
message within them is upheld as “truth.” They therefore present conflict in indirect 
terms, transmitting arguments about a particular issue without making explicit reference 
claims and so are difficult to argue against. Here, the opinion was that of the nurse, and 
so it was presented as being distanced from P1 and projected as “fact” because it came 
from someone with medical expertise. It could be seen as even more authentic because 
the nurse had asthma herself, “which was great” (line 11).  
 
This information seemed to create a problem for how P6 understood this medication: 
“Oh I didn’t know tha:t” (line 16). However, the story of the nurse not only allowed P1 
to express his own view indirectly, but it also served as a device for the rest of the group 
to test out their own knowledge without being held accountable for anything that might 
be considered inaccurate. The elongated vowel in “that,” which P6 used in response, 
emphasises how this was not just fresh knowledge: it was knowledge that made a 
significant difference to how he had been managing his asthma. In contrast to his earlier 
statement, which he cut short, this provided an open admission of ignorance about the 
dangers of the different medications. He then appeared to test out his own 
understanding by referencing a story of when he was “blue lighted,” how he received 
“ten times the dose” and so effect of the blue inhaler was minimal and should not be 
worried about. This alternative point of view was presented as “what happened,” 
thereby removing claims to truth on his own part but as a truth presented through the 
actions of medical experts. In addition, he refrained from making a strong assertion and 
challenge to the argument of P1, made with his opening line, “I don’t know whether I 
was completely awake at the time” (line 24) and “I may have got that wrong”(line 31). 
This set an alternative argument against the one presented by P1, again in an indirect 
way.  
 
This evidence suggests that the speakers were managing a number of different issues 
between themselves in their contributions to this discussion. First, there seemed to be 
reluctance to openly criticise medications and health care professionals in the same way 
as the speaker in Vignette 4, initially emphasised by the long silences. Second, the use 
of stories and deference to medical expertise allowed different opinions to be aired 
without direct ownership. This not only avoided directly aligning speakers with the 
person in the vignette (and thereby implicitly criticizing the medical profession), but the 
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stories also acted as a vehicle for the individuals to test out their own knowledge. This 
hints at participants’ uncertainties about the effects of medications which they were 
maybe not willing to express too overtly.  
 
This example shows that using a focus group to share findings in a study investigating 
the role of moral discourses in talk about medicine taking can create specific 
interactional dilemmas for participants. P2 had an accounting style in his individual 
interview that closely matched the doubts about medications and health care expressed 
in Vignette 4, but he was silent in this sequence. Moreover, the other participants 
avoided direct evaluation of the vignette by discussing their own experiences and 
testing out their own understandings of medications. 
 
Participants might or might not have identified with the accounting style of the person 
in the vignette they were asked to consider. This required additional decisions by them 
about whether they had anything to share with the other participants. If they did identify 
with the accounting style, they would position themselves both in relation to the 
fictitious person associated with the accounting style and also to the other research 
participants. Despite the moderator informing participants that the vignette was not 
taken from any single interview, they might have speculated about whether it was they 
who were being represented. These issues created a potential dilemma for any 
participant about how and whether to share their view of the vignette with the wider 
focus group. This is because such sharing would have raised the risk of their then 
finding they were standing alone in their view, of their knowledge and beliefs being 
challenged or judged, or of presenting themselves as contradictory and inconsistent 
from the views they had expressed in the earlier face-to-face interview.  
 
The issues participants faced in sharing their views are likely to be seen as limiting or 
confounding factors when viewing member checking as a task where findings are 
confirmed or challenged. In this study, however, issues of personal identification (or 
not, in the case of P4) with data offered opportunities rather than constraints to examine 
how these issues were managed by participants. The analysis of Extract 16 revealed 
how participants could be seen to be negotiating personal accountability as the 
discussion proceeded. The talk of P4 was also analytically fruitful, as the absence of 
personal identification could be seen to function as a contrast to the other participants’ 
discursive strategies. Evincing such negotiations offered insight into a range of ways in 
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which moral discourses of medicine taking were activated within this interactional 
setting, and how participants positioned themselves in relation to those discourses. The 
content of the discussion also revealed how this type of focus group presented an 
opportunity for participants to share their experiences of asthma in a way not available 
to them previously. The group’s shift in topics to personal experience indicated ways in 
which participants both shared concerns and tested out their understanding.  
 
In Extract 17, another device can be observed through which participants managed these 
dilemmas, by collectively aligning themselves to a mutually held view. Here, the 
moderator attempted to get Participants 2 and 3, who had so far not spoken, to voice 
their opinion on Vignette 4, because in their face-to-face interviews they had indicated 
some concerns about steroids in medications.  
 
Extract 17: Data-sharing focus group, page 29, line 50 to page 30, line 40 
 
1.  JM:  ((To P2 and P3, could not get eye contact)) What do other people think  
2.  about the statement on the “I am concerned about the side effects of  
3.  medications”? 
4.  P1:  You mean in general or just asthma? 
5.  JM:  Yeah I’m just interested in what other people think about um. 
6.  P2:  I’m just worried heh. I don’t think you well you may think about it but 
7.  I mean if something is doing good you don’t worry much about that do  
8.  you what is the er if you start worrying about whatever you take you     
9.  [wouldn’t take it would you.] 
10. P4: [It’s the same with everything] they tell you not to eat this not to  
11. [drink that so] 
12. P3:  [That’s right ] 
13. [that’s the same.  ] 
14. P2:  [I don’t think that] really.  
15.  Some people you know I suppose do who would think would worry 
16.  about it but basically I don’t think um the majority of people are too 
17.  concerned  
18. P1:  Yeah but with one tablet might not but several different types of tablet  
19. I mean an accumulation of tablets [( . . . )   ] 
20. P2:     [Oh well yeah] 
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21. (1) 
22. P4:  Yet referring to this guy or person I mean that they don’t know they  
23. don’t think they got asthma I mean well what have they got then you  
24. know um it if you go to the doctor's with the symptoms they can   
25. usually tell you what what you've got and what you haven’t you know  
26. to say um they don’t listen to me and another. 
 
In this extract, it is possible to see how speakers worked together to achieve an agreed-
on position on the person presented in Vignette 4. P2 provided a normalizing 
abstraction: “if something is doing you good you don’t worry much about that do you” 
(lines 7-8). This “normal” position on medications was then equated with all things 
related to health and illness by P4 with an overlapping statement: “it’s the same with 
everything” (line 10). P3 continued to establish this truth with her own overlapped 
repetition: “that’s right” and “that’s the same.” P2 then switched back to the first 
person. “I don’t think that really” (line 14), and restated his own position, which linked 
back to his opening comment on line 6, and again made an explicit claim that this was a 
normal position: “I don’t think um the majority of people are too concerned” (lines 16-
17). By adopting such a collective position in relation to the person represented in 
Vignette 4, concerns about medicines were attributed to only a small group of people 
and medicines were upheld as trustworthy. P1, who did not follow this position, seemed 
to represent this minority group in this extract, and his statement “yeah but with one 
tablet might not but several different types of tablet I mean an accumulation of tablets” 
(lines 18-19) posed a threat to this consensus by hinting that taking medications for a 
long period of time might be dangerous. However, because a consensus had already 
been reached between Participants 2, 4 and 3, this potential threat was largely ignored 
rather than directly challenged. 
 
Despite the repeated pattern of the group predominantly upholding the medical directive 
on the efficacy and safety of medicines, Extract 18 depicts an abrupt shift to the 
disclosure of a very different perspective on asthma and medicines that the whole group 
then worked together to share.  
 
Extract 18: Data-sharing focus group, page 30, line 42 to page 31, line 36 
 
1.  P6:  Is there a stigma attached to [that] 
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2.  P4: [Yeah] 
3.  P6:  name asthma do you think (4) >are you trying to say< admitting  
4.  weakness  
5.  if you went for a [job  ] 
6.  P4:      [Yeah.] 
7.  P6:  interview 
8.  P4:  Yeah. 
9.  P6:  for instance 
10. P4:  Yeah. 
11. P6:  “Oh by the way I’ve got asthma” do you think that would actually do 
12. you any harm 
13. P2:  Yeah. 
14. P6:  in your job interview. 
15. P4:  Yes, it’s going to go against you isn’t it. 
16. P6 & P2: Yeah. 
17. P4:  In the majority 
18. P6:  Do you say “I I have a bit of shortness of breath sometimes but I can  
19. cope with it.” 
20. P4:  Yeah. 
21. P2:  Mm. 
22. P6:  You know that doesn’t sound quite so bad. 
23. P4:  No. 
24. P6:  You say “Oh I suffer from asthma" people think 
25. ALL: ((Inaudible, at least 3 people responding to P6, including P3, who I  
26. think said “That happened to me the other week, yeah, that’s right  
27. yeah,” all making noises of agreement.)) 
 
Lines 25-27 in this sequence are striking for the level of contribution that this topic 
elicited from several members of the group. The discussion was then dominated by P2’s 
expressing how he was continually referred to hospital with no real coherent sense of 
what his condition might have been, and dismay at how he had been treated. In Extract 
19, these issues were pursued further in the discussion and the views of P2 were then 
supported by other participants. The articulation of this topic was then followed by 
other participants expressing their doubts about the safety of some medications. 
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Extract 19: Data-sharing focus group, page 33, line 10 to page 34, line 28 
 
1. P2:  Go through all the tests and then it’s up to them the doctor will say  
2.  “Right at the moment it’s not too bad but it will get worse” this is what  
3.  they said to me some years ago “It will get worse as you get older” but  
4.  medication will sort of keep it in check and and this is that’s how it’s  
5.  been so  
6. P6:  The worry is too that it might be masking some underlying problem. 
7. P2:  This is yes absolutely. 
8. P6:  So that you may well have more serious complaints but because you 
9.  think it is all wrapped up in the asthma think 
10. P2: That’s right. 
11. P6: they aren’t taking no notice of ya. 
12. P2:  No no. 
13. P1:  Mm. 
14. P6:  Whereas somebody who’s healthier and suddenly had  
15. P2:  Yeah. 
16. P6:  you know lung problems 
17. P2:  Yeah. 
18. P6:  might well 
19. P2:  Yeah. 
20. P6:  be thinking about other other causes. 
21. P2:  Yeah. 
22. P1:  When you go to some hospitals they vary terrifically in the type of  
23. treatment you get as well 
24. ?:  ((noise)) 
25. P1:  Sometimes you’re in there two seconds “Oh yeah” blah blah blah  
26.  another one you go there and they really go to town on you. 
27. (2) 
28. P6:  (To P1) But you’ve been having, well I’m I’m picking up that you’re  
29. actually having, you've had quite a good discussion about that blue 
30. P1:  Yeah. 
31. P6:  um remedial inhaler there’s warnings about on that that I didn't realize  
32. about don’t know if anybody else did but 
33. P1:  They are steroids aren’t they or a type of steroid aren’t they 
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34. P6:  Mm. 
35. P1:  which um they always tell you 
36. P6:  I think next time I will go I would just like to know a bit more about  
37.  the ((P6 stopped speaking)) 
  
When compared with other extracts from the focus group, this sequence demonstrates a 
very different orientation to the issue of medicine taking and medicine safety. In 
contrast to when the group collectively upheld the “medical” position in earlier extracts 
and marginalized challenges to that position, discussion here articulated a series of 
concerns about asthma, medications, and how health care is delivered. Instead of this 
discussion following the presentation of a vignette however, it followed the shared 
expression of opinion that a stigma is attached to the diagnosis of asthma. This informed 
a related shared discourse to argue that accepting a diagnosis is far from a simple 
matter: that health care can be experienced as a patient being passively handed around 
different specialists without the patient really knowing what is going on; that no one 
was very certain about what counts as safe limits to medicine taking or what is in them; 
that they might mask other more serious conditions; and that the standard of care 
seemingly differs hugely depending on luck.  
 
The variation in how participants oriented to the vignettes and to discussion of medicine 
taking highlighted in these extracts provide different types of evidence of the ways in 
which participants engaged with moral discourses in their talk. At some points in the 
talk generated in the focus group, the dilemmas encountered by participants discussing 
the vignettes could be seen to be resolved using diverse strategies. This was done by 
avoiding direct reference to the vignettes and by collectively aligning perspectives with 
the medical directive on medicine taking and its implications for appropriate behaviour. 
However, the participants could also be seen to reveal concerns about medications and 
to test their understanding of medications through stories. These concerns appeared to 
be revealed more openly the further the discussion moved away from the vignettes 
themselves, to display a type of orientation to medicine taking that was grounded in 
moral discourses from participant’s everyday lives. This shift in participants’ articulated 
position on the safety of medications undermines an interpretation that participants 
necessarily “hold” a consistent medical view on medicine taking indicated in earlier 
extracts. Instead, it suggests that talk about medicine taking is contextualised in the 
demands of the ongoing interaction taking place. 
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Summary 
 
The analysis presented in this chapter has underlined how moral discourses of medicine 
taking were also activated within the differently-structured focus group interaction, thus 
lending support to the main analytical contention that moral discourses influence how 
people with asthma talk about medicine taking. Deploying a focus group to share 
findings set up an interactional dynamic that differed from that in the face-to-face 
interviews, posing additional dilemmas for the previously interviewed participants 
around whether and how they might identify themselves with the findings presented. 
This was not intended as an exercise in directly confirming or refuting findings from the 
interview data. Instead, the purpose was to use the interview findings as a device to 
elicit talk about asthma management that might further indicate the role of moral 
discourses in that talk.   
 
The data displayed a range of varying participant views on medications, from 
reproducing the medical directive to regularly take prophylactic medications to 
challenging the safety of medications. The inclusion of P4 was fruitful in this respect as 
he seemed to play a key role in activating this medical directive which needed to be 
managed by the other participants. In contrast to approaches that advocate member 
checking, a DP perspective provided a means of locating such variation in relation to 
changes in talk about medicine taking alongside the activation of different moral 
discourses between several participants. From a DP perspective, therefore, using a focus 
group in this study could be seen to provide fresh and interesting data that could be 
purposefully compared with data in earlier interviews in which participants were seen to 
manage issues of morality. 
 
The insights from the analysis of the focus group transcript provided key points of 
contrast with the interview data in how moral discourses of medicine taking could be 
seen to be activated. The dynamics of the focus group represented a clear shift away 
from the individualistic focus within interviews where questions were directed at 
individuals who then were required to discuss their asthma management with the 
researcher. Through this new interactional dynamic the role of the researcher was 
arguably reconstructed from someone who was an expert on asthma to someone with a 
much vaguer position and background. However, there was evidence that this 
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reconstruction was not immediate but could be seen to emerge as the discussion 
proceeded. This could be seen by the way participants’ responses to the vignettes 
reproduced a medical discourse of asthma management, while, once the main task of 
reviewing vignettes was addressed, the discussion shifted to more critical positions, and 
at the end of the whole discussion a more explicit statement suggested an important 
shift in positioning had occurred “we thought you were an expert” (page 37, line 9). The 
participants’ framing of the focus group moderator as an expert on medications, their 
realisation that this was not the case, and their expectations of the discussion were 
analysed. This work can be found in Appendix D. The issue for the main research 
questions is how this reconstruction impacted upon the talk and how this talk can be 
viewed as different data to that obtained in the face-to-face interviews. 
 
The analysis revealed that although participants may have initially framed the 
researcher as an expert on asthma, a moral discourse of asthma management could be 
seen to be activated in this interaction where participants had to undertake a different 
task to that required in their own face-to-face interview. Instead of participants having 
to respond to questions about their individual behaviour and attitudes regarding asthma 
management, this task provided participants with a different discursive space in which 
to position their “attitudes.” Instead of participant views being set alongside their own 
medicine taking behaviour, here participants’ views were positioned alongside the 
views of a fictitious person. The collective reproduction of a compliant medical 
discourse to each vignette could be seen as a response to a task which was potentially 
viewed by participants as a test of individual knowledge about asthma and medications. 
This dynamic could therefore be seen to present participants with a different dilemma 
from the interview data about whether to articulate statements about the function, 
pharmacology and efficacy of medications which may then be considered incorrect and 
challenged. This was therefore a different manifestation of a moral discourse of asthma 
management in which blame and accountability was potentially allocated for incorrect 
knowledge. Individual responses to the vignettes, like the talk identified in interviews, 
could therefore be seen as performances which were dependent on having the 
appropriate resources – in this case, knowledge of medications. The sequential 
development of the discussion, in which the moderator did not display access to these 
resources, revealed how his talk could also be viewed as a performance which proved to 
be inadequate to maintain the view that he was an expert on asthma. 
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The majority of the participants had the additional dilemma of identifying with the 
findings presented. Their apparent reluctance to discuss the vignettes could be seen as a 
response to this interactional condition. However, this was not the case with Participant 
4 who had not participated in the face-to-face interviews. Participant 4 demonstrated a 
greater willingness to stick to the main task of reviewing the vignettes, (contrast the 
different participants’ responses to the second vignette between pages 11-20). The 
contrast between his and the other participants’ contributions may have been because he 
was not able share experiences of asthma or medications, thus revealing a different set 
of required resources to medical knowledge. However, his reproduction of the medical 
directive, and moral discourse on medicine taking indicated that the production of this 
discourse within this focus group was not only situated within the context of being a 
person with asthma participating within the broader asthma study. It could also be seen 
as a discourse that circulates different social spaces and manifests differently according 
to different interactional tasks.  
 
The shift in the participants’ talk from being compliant to being more critical of 
medicine could be seen as a result of the ongoing discussion, moving away from 
attending to the vignette task and which may have also been influenced by the 
moderator’s ongoing reluctance to contribute to the discussion. There are likely to be a 
number of reasons for this shift to personal experiences, but even without exhaustively 
exploring these reasons, these data could be seen to provide types of evidence that 
would clearly have been unobtainable within an individual interview. The increased 
noise and overall level of contribution seen in Extract 18 provided an example of the 
group dynamic not identified elsewhere in the discussion. Instead of a few individuals 
taking turns, the discussion of the stigmatizing effects of being labelled with asthma 
elicited a higher frequency of turn-taking from more participants, culminating in several 
participants responding simultaneously to the negative connotations associated with the 
term “I suffer from asthma.” This discursive variation provided a strong indication that 
participants shared a moral incentive to present themselves as not suffering from illness 
across a range of social contexts. This provided further evidence that prophylactic 
medicine taking is situated within lifeworld settings where a moral discourse of 
admitting illness will “go against you.”  
 
These discussions therefore suggested how this talk was structured by a number of 
moral discourses, which were seen to be activated at different points through the 
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sequential development of the discussion. The emergence of concerns about the safety 
of medications, receiving a diagnosis of asthma and accessing treatment revealed how 
discussions and decisions about medicine taking may be manifested differently in 
lifeworld settings to medical conceptualisations of asthma management. This suggests 
that these are important insights provided by taking a discursive approach to understand 
talk about medicine taking, which might enable researchers and clinicians to better 
understand and support people with asthma and other chronic illnesses. These issues 
will be examined in the discussion chapter. 
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Chapter Seven 
Discussion 
 
I mean I feel quite comfortable taking that ((blue inhaler)) (2) and it don’t seem 
to affect me (.) an awful lot (1). It helps (2) in a way (1) with, I mean I take that 
and the wife says to me (.) “you’ve stopped wheezing”. (2) I’ve wheezed all my 
bloody life so (1) I don’t even hear it (.) you know? (1) She can hear it. (.) I 
don’t. 
(261906, Interview 1, page 13, lines 31 to 38) 
 
The study reported in this thesis explored the discursive construction of prophylactic 
medicine taking for people with asthma and particularly the role of morality within this. 
In this chapter, the reasons for doing this are reviewed before examining how the three 
questions set out in Chapter One have been answered using the discursive approach to 
understand talk about medicine taking. The three research questions were: 
 
• How is talk about asthma management and medicine taking constructed with 
people who are not taking prophylactic asthma medications as prescribed? 
• What role do moral discourses play in constructions of medicine taking by 
people with asthma and what does this say about the objectives of asthma 
policies and guidelines? 
• How may discourse-related insights help us understand the limitations and 
achievements of a discursive psychological approach in understanding talk about 
medicine taking? 
 
This chapter will examine this study’s contribution to knowledge of adherence to 
prophylactic medications. It will go on to highlight issues raised by the methodological 
approach underpinning the study’s findings, for communicating and treating patients, as 
well as for conducting future research in this field. These are issues that will not have 
been apparent in adopting more commonly-used approaches to adherence, which have 
focused on the individual as the unit of analysis in explaining medicine taking 
behaviour. Rather than interpreting individual talk about illness management and 
medicine taking as a representation of an internal psychological state, the approach 
adopted in this study has instead led to a view of talk as a “performance” (Goffman, 
1959) on the part of an individual, conditional on their having access to specific 
   
 
 
179
linguistic resources drawn from their social and cultural context.  
 
Review of Background to Research 
 
The present study was informed by a review of clinical policies and guidelines to 
asthma management because the objectives of these documents have influenced 
research on adherence and also informed decisions about appropriate asthma 
management in clinical practice. Key amongst these documents have been the Global 
Initiative for Asthma (GINA), and the British Thoracic Society (BTS), and the 
objectives of these organisations have been to achieve individual patient’s asthma 
control through the use of appropriate medications. From a clinical perspective meeting 
these objectives has often been described as essential for reducing the “burden” of 
asthma on healthcare resources (Barnes et al., 1996), resulting from poor adherence to 
medications. Researchers have therefore attempted to identify the barriers to adherence 
and help clinicians and patients overcome them to meet the objectives that GINA and 
BTS set out.  
GINA and BTS have broadly grouped a range of barriers to adherence around either 
practical considerations for the collection and use of medications or those factors 
influencing beliefs about illness, perceptions and understanding of medications and the 
doctor patient relationship. Factors identified by researchers which are seen as relating 
to individual patient’s personality or cognitive characteristics in effect represent 
components of a model of the individual in their relationship with medications – 
individuals’ beliefs or understandings they may hold about their medication, their fears 
about side-effects and their beliefs about asthma and attitude to ill-health which may 
influence their medicine taking. Current research on “adherence to medication” usually 
sees the individual patient as a subject whose views of medication, asthma and illness 
must be treated as fixed, if those views are to be measured and related to outcomes of 
adherence or non-adherence. It is also necessary that the versions of medication, asthma 
and illness that individuals refer to, the “objects of thought”, carry fixed definitions to 
enable those views to be measured.  
 
From a clinical perspective, the assumption that asthma, medications and illness are 
fixed objects of thought fits logically within a scientific and biomedical paradigm which 
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is institutionally grounded in the causes of illness and generation of medications. As it is 
individuals who are observed, assessed, measured, treated and reviewed in clinical 
settings, this assumption would also offer some logical fit with adopting an 
individualistic approach to how those patients view their condition, associated 
treatments and how they might comply or adhere to preventive therapies. However, 
such a paradigm will view talk about asthma, medication or illness, as a window to a 
decontextualised and coherent internal reality that could then be measured against an 
external reality and medically-defined object. As a result, perceptions that were not 
found to match the clinical, fixed definition of the object “asthma” for example, were 
frequently seen by those adopting that definition as “distorted.”  
 
The Chapter Two review of asthma guidelines highlighted how the notion that patients 
have incorrect beliefs (an implicit assumption within these guidelines) will lead “patient 
education” to realign that perception with reality. However, other evidence which 
adopted a discursive, rather than individualistic, view of talk, suggested that when 
analysing patients’ discussions of their views about health and illness, the “attitudes” 
these patients articulated could be seen to change over the course of an interaction, as 
could their versions of the objects of health and illness that they related to those 
attitudes. Examining this evidence suggested that the views that people express about 
health and illness may be intimately connected to those objects being discussed and the 
nature of the discussion, in turn raising questions about the viability of attempts to 
pinpoint a coherent individual attitude on a particular health issue. Instead, attitudes 
about health and illness could be seen as a discursive manifestation of the interactional 
conditions in which that talk was taking place.   
 
Other cross-disciplinary research as well as evidence from this study, also indicated 
ways in which individuals, in discussing an issue in which they have a stake, may 
engage in a range of social and moral actions through their talk. Here, instead of 
viewing talk about prophylactic medicine taking where, given the right conditions, the 
speaker would accurately articulate their beliefs, it could also be viewed as a form of 
moral action for presenting the speaker in specific ways. The role of morality in talk 
about asthma prophylactic medicine taking therefore seemed worth exploring to enrich 
understandings of what people with asthma are doing when they talk about medicine 
taking and whether in turn understanding of morality in this talk better reflects the 
issues that inform their everyday life decisions about their medicine taking. Such 
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insights might also inform understandings of how people with chronic illness more 
generally talk about and manage their condition. 
 
Depicting the ontological relationship between an individual’s talk, internal attitude and 
behaviour, predominantly used as a basis for predicting adherence, has the effect of 
reducing an individual patient’s experience of illness to a set of isolated statements 
which can then be categorised as specified types of beliefs, perceptions which are then 
used to predict medicine taking behaviour. Identifying the apparently limited capacity of 
individualistic approaches to capture interactional and moral issues in talk about 
medicine taking raised the need to adopt a different methodology which would avoid 
such reductionism. The alternative methodology provided by the discursive 
psychological approach of Potter, Edwards and Wetherell (Edwards & Potter, 1992;  
Potter & Wetherell, 1987), with an assumption of interactional talk as a form of social 
action, appeared to offer a highly promising framework in which to try and understand 
what happens in talk about prophylactic medicine taking and how such talk might 
engage with morality. 
 
In acknowledging the relevance of engagement with moral positions in such talk it 
became increasingly pertinent to explore what notions of morality might structure the 
talk of participants and evidence that people might engage with moral discourses of 
illness management within a range of social situations. Further historical evidence was 
required to assess how asthma and morality may have been regularly linked in talk and 
text about the causes and management of asthma and which might also be connected by 
the participants in this study in a discussion about asthma management. This would 
enable a path to be traced from the notions of accountability for asthma constructed 
within these discourses to notions of accountability constructed within the talk of 
participants. The tools of DP appeared to provide means for tracing such a path. Other 
research using a discursive approach to talk about health and illness suggested the 
concepts of discursive objects and interpretative repertoires might be relevant in making 
these connections between individual utterance and wider systemic discourse. The 
following discussion examines what has been learnt by using DP to understand talk 
about asthma management and prophylactic medicine taking. 
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The Construction of Talk about Asthma Management and Medicine taking 
 
The data analysed from face-to-face interviews and the data-sharing focus group 
demonstrated challenges to simply interpreting talk about medicine taking as accurately 
representing a person’s internal attitude, belief or perception about their illness and how 
they manage it. Rather than merely describing one’s asthma management, participants’ 
talk could, rather, be seen as performing particular interactional tasks. These tasks were 
typically seen to be to legitimise the individual’s decisions about asthma management 
and medicine taking, so indicating speakers attempting to manage individual notions of 
blame and accountability for those actions. This situated participants’ talk as a mutual 
construction between interactors rather than as an articulation of an individual internal 
representation. Conceptually shifting the origins of individual talk about asthma to a 
social space had fundamental implications for how that talk might be analytically 
treated. Such talk could no longer be categorised as reflecting an “attitude” because the 
data demonstrated discursive properties that precluded any such interpretation. These 
properties were that talk about illness management and medicine taking can be viewed 
as rhetorical, sequentially, interactionally constructed and potentially shifting, and both 
historically and institutionally situated. These properties, identified in the analysis of the 
data, reflect and build on the discursive psychological properties of participants’ talk 
examined in Chapter Four, which emphasised speaker’s interactional dilemmas in talk 
which could be linked to wider moral discourses in discussions about health and illness. 
Following the analysis of interview data in Chapter Five the discursive psychological 
properties were expanded to incorporate a more detailed understanding of forms of 
ethnographic context which may condition the production of interactional talk about 
prophylactic medicine taking.  
 
First, participants’ talk could be seen to be rhetorically constructed. Separate statements 
in talk, which from an individualistic perspective may be categorised as discrete 
attitudes, perceptions or beliefs, could be seen to be interrelated to perform particular 
discursive tasks, typically to justify asthma management. These statements could be 
seen to be contextualised within certain culturally-shared explanations or settings and 
thus seen to be rhetorical devices deployed by participants to construct an account, to 
discredit alternatives and to manage tensions between these competing alternatives. 
Examples of such rhetorical devices, seen in the analysis of interview data in Chapter 
Four, included the construction of discursive objects, generalising and normalising 
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devices, stories, external evidence such as newspaper reports, reproducing or ironizing 
the voice of medicine, use of witnesses or appeals to a common consensus. These 
devices were seen to contribute to different types of participant explanations – 
interpretative repertoires, which could also be seen as versions of moral and other 
discourses identifiable in British society. Similar repertoires could be seen to be 
deployed by different participants to achieve different functions. They could serve 
multiple functions and in some cases could be seen to be deployed by participants 
simultaneously, then requiring further strategies for managing any tensions or 
contradictions. This evidence suggested that people with asthma, in discussing their 
views of asthma and medication-use, may not consistently respond to some separate, 
external, real and fixed object. Instead, asthma, medications and illness may also be 
seen as discursive objects, constructed in a variety of ways to perform particular 
interactional tasks. Evidence of the interactional functions of this kind of talk 
contradicts the construction of such talk as sets of different attitudes which would 
appear to bear little relationship to the meaning of such talk for the person articulating 
it. 
 
Second, participants’ talk could be seen to be constructed sequentially within 
interactions. As interactions proceeded particular issues could be seen to be made 
pertinent at different points within the ongoing discussion. Chapter Five provided 
several examples of how interactional dilemmas could be seen to emerge through the 
researcher’s choice of topics and style of questioning and through the explanations 
provided by participants. Similarly, the focus group data showed how the moderator 
presenting the vignettes led to one type of interactional sequence, (most notably marked 
with extended silences), whilst participants introducing stories led to a very different 
type of sequence. Particular types of talk about medicine taking can therefore be seen to 
constructed sequentially within interactions which means that building understanding of 
talk about asthma, medications or illness is as much about attending to what speakers 
did not say, thereby calling into question any categorisation of talk as a coherent attitude 
or belief. 
 
Third, if talk about medicine taking is sequentially situated, shifts should be detectable 
in “attitudes” being expressed by participants towards asthma and medications. Such 
shifts were seen in the focus group data where individual participants’ views of 
medications could be seen to shift from downplaying the dangers of relief and 
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preventive asthma treatments to expressing concerns about the effects of long-term use 
of those treatments. A social cognitive interpretation might be that such apparent shifts 
in attitudes represented unreliable and distorted data about individual attitudes, a result 
of group influence on the expression of individual attitudes in group situations. 
However, such an argument implies that there is another unbiased set of conditions in 
which people’s attitudes might be obtained. This study has emphasised, from the review 
of literature through to the different data analysed in this study, that talk will always be 
informed by and conditioned by interactional requirements. The notion that well-
designed scientific research methods can somehow minimise or bypass these influences 
is to ignore how talk in a social world cannot remove itself from that world but will 
always be situated within the social historical context in which it takes place. 
 
Fourth, the explanations provided by participants could be seen to be historically 
situated. In order to provide a plausible justification of one’s asthma management, 
participants’ explanations needed to make sense within particular cultural explanations 
of health and illness that circulate British society today. Examples of these were 
provided in Chapter Four and these different explanations could be seen to be situated 
within moral discursive frameworks that allocated blame and accountability for the 
speaker’s actions. Two different speakers discussing the same actions could be seen to 
be judged differently because of how each speaker deployed different cultural and moral 
discourses to position their behaviour. This evidence suggested that a particular reported 
medicine taking behaviour is unlikely to be uniformly categorised within interactions as 
either appropriate/inappropriate, correct/incorrect or responsible/irresponsible. Rather, 
the speaker’s action may be judged according to how effectively the speaker positions 
that action within those moral discourses that are likely to allocate blame and 
accountability for that action. The range of explanations provided by speakers are likely 
to “make sense” differently within different social historical and interactional contexts 
and judged according to the plausibility of the explanations provided within that 
context. The delivery of an explanation or “attitude” may therefore be situated by time 
and place but also how that talk is interpreted and evaluated may be historically 
situated. 
  
Finally, talk about medicine taking could be seen as institutionally situated, 
demonstrated by the analysis of deviant cases and interactional conditions. The research 
process was itself situated within a context of specific relevance; the larger NHS asthma 
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study from which these participants were recruited. Using techniques from linguistic 
ethnography, the role of the researcher in linking the larger study with this study, could 
be seen to construct specific interactional conditions influencing the talk of participants. 
Implementing the face-to-face “interview” method could be seen to activate institutional 
roles of “NHS representative”, “researcher” and “participant” and to structure 
participants’ talk. A range of researcher and participant presuppositions about patients’ 
and researcher’s identities, goals and motivations were not explicit within the interview 
setting but appeared to have influenced how participants understood the interaction 
taking place. This was evident in interactional sequences of both the interview and focus 
group data. Researcher attempts to obtain participant views were therefore also 
constrained by these interactional conditions and dependent on how participants framed 
that interaction. Researchers’ institutional roles are often taken for granted in research 
settings, with researchers often taking care to ensure participants are informed about the 
purpose of the research rather than the researcher’s role within that setting. Informing 
participants about research aims is usually undertaken to uphold ethical standards of 
informed consent. However, the analysis of data, reported in Chapter Five and in 
Appendix D, regarding the role of the focus group moderator, indicated that informing 
participants will not only have an ethical consequence but may, equally, inform how 
data will be constructed within particular parameters. These insights demonstrate that 
talk about illness management and medicine taking, conducted within research and 
healthcare settings may regulate the talk within that setting according to particular 
communicative expectations about how interactions “should” proceed in that setting. 
These expectations may not be explicit or predetermined but can be seen to emerge 
through the ongoing discussion. This suggested that interactions about illness 
management and medicine taking do not therefore provide a complete representation of 
one’s attitudes or illness management behaviour that is consistently reproduced in a 
range of contexts. Instead such discussions can be seen as a presentation of illness 
management in a format that the speaker considers most appropriate for the type of 
interaction taking place.  
 
Talk about medicine taking within research settings can therefore not easily be 
categorised as a particular attitude if a speaker’s talk is viewed as a product of 
interactions, being rhetorically, sequentially, historically and institutionally situated. 
This view of talk therefore reflects much of the literature reviewed in Chapter One, 
particularly the analysis of “interactional dilemmas” by Radley and Billig (1996) for 
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people discussing their chronic illness with a “healthy, employed” researcher and 
Horton-Salway’s (1998) analysis of the discursive construction of ME as a struggle for 
authorship of an illness within a contested historical space. Certain types of interaction 
can be seen to give rise to certain types of talk and this suggests that the discursive 
properties of such talk creates difficulties in assigning fixed categorical statements to 
talk about medicine taking. However, this is not to say that this discursive view of talk 
about medicine taking is so idiosyncratic that we are unable to analyse such talk to gain 
understanding of the issues that influence decisions people make about medicine taking. 
The analysis of interview data in Chapter Four revealed how participants’ talk could be 
seen as simultaneously unique and shared and Birdwhistell’s analogy discussed in 
Chapter Two provided a useful way to conceptualise this view, discussing how the 
different “threads” of individual talk could be seen to form part of a larger social 
structure (“the rope”). Participants’ talk could be seen to be connected through the 
different moral discourses activated within interactions and towards which participants 
orientated in constructing their justifications of their medicine taking. This orientation 
was evident in the devices that participants’ deployed, in particular the use of discursive 
objects and interpretative repertoires (discussed in Chapter Four). Discursive objects 
here could be seen as appropriations of “fixed objects” such as asthma, medication and 
illness, whilst repertoires could be seen as versions of broader cultural discourses. The 
activation of moral discourses in participants’ talk emphasised that understanding these 
different discursive frameworks may not only indicate the issues that were pertinent in 
discussions about asthma management and medicine taking. These same discourses may 
also be activated in other social spaces in participant’s lifeworlds. The circulation of 
these different moralities to lifeworld settings, in which blame and accountability for 
medicine taking decisions are distributed, therefore seems critical in informing how 
people make decisions about their condition. 
 
The five properties identified in the analysis of interview and focus group data has 
enabled knowledge about individuals’ talk about illness management and medicine 
taking to move beyond notions of this talk as representing internal cognitive 
representations. A range of interactional issues can be seen to influence the production 
of this type of talk and people can often be seen to orientate to a range of moral 
dilemmas in managing these interactions. Eliciting a person’s views and versions of 
their illness management and medicine taking may therefore not be a simple matter of 
choosing carefully worded questions, or deploying the correct data collection 
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instruments. The findings suggested that talk about medicine taking is constructed 
within a social space by contextual features that may not be directly observable within 
the interaction taking place, potentially involving a multitude of issues and moral 
dilemmas that may be shifting and negotiated as interactions proceed. “Attitudes” may 
therefore be unlikely to be accurately and consistently articulated within this dynamic 
and changing social space but instead something else may be offered which is amenable 
to a discursive analysis. This is talk which can be seen as a manifestation of socially 
circulated moral issues that may influence decisions about medicine taking in daily life. 
Understanding the relationship between social discourse and individual talk is therefore 
likely to assist with getting closer to those social and moral issues that influence 
individual decisions about medicine taking. 
 
The Structuring of Talk about Asthma Management and Medicine taking 
 
The Chapter Two review of literature and the analysis of language documented within a 
range of sources helped theorise how abstract discourses of asthma management might 
structure the talk of participants. This demonstrated how links have been made 
throughout history between asthma and morality; highlighted how links made between 
asthma and morality have changed; and emphasised how discourses of asthma 
management have been constructed and circulated to a range of social spaces, over time 
and are still evident today. The sources examined included journal articles that reviewed 
and cited historical manuscripts; original publications representing dominant theoretical 
conceptualisations of asthma causation and management; published research findings 
reporting clinical and patient’s perspectives on asthma management; and contemporary 
documents outlining strategies and guidelines for the clinical management of asthma. 
The analysis of these data formed the basis of an argument that moral discourses of 
asthma management were likely to be activated by participants in their talk about 
medicine taking. While individuals in the early twentieth century could be seen to have 
to account for having asthma in the first place, more recently this connection between 
accountability and causation has been replaced by a connection between accountability 
in relation to how individuals manage their asthma and the decisions made about 
medications. In contemporary asthma guidelines, being accountable for one’s 
management of asthma symptoms, has been linked with notions of responsibility, 
autonomy, authority and empowerment, orientating around the central requirement of 
preventive control of one’s breathing.  
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Many participants could be seen to justify their non-adherence to prophylactic 
medications, so indicating how an asthma prevention discourse might structure these 
justifications. At the heart of this rhetorical talk were versions of the individual, their 
attitudes, identities and behaviour, which speakers worked to present as trustworthy and 
authoritative and in which their actions could be seen as reasonable and responsible. 
Being accountable for one’s asthma outcomes could therefore also be seen as a 
reproduction of a moral discourse of asthma management which places clinicians and 
patients as the “empowered decision-makers” yet accountable for those decisions.  
 
However, the historically-situated explanations that participants provided (see fourth 
property of talk discussed above) revealed notions of accountability that were 
constructed within other moral discourses of illness management. These discourses 
appeared to circulate a range of social spaces and constructed versions of doctors, 
patients and the doctor-patient partnership in ways which could be attributed to a variety 
of sources, rather than seen as a direct reproduction of asthma management discourse 
evident in asthma guidelines. In addition, notions of doctor’s and patient’s 
responsibility, evident in asthma guidelines can be seen to be emergent from traditional 
sick-role conceptualisations, and the emphasis on doctor-patient partnership within 
guidelines reflect broader contemporary discourses regarding the “concordant” 
partnership and it’s replacement of the traditional “compliant” doctor-patient 
relationships (Royal Pharmaceutical Society, 1997). The talk identified in the interview 
and focus group data cannot therefore be easily traced to any one particular source, nor 
can a range of distinct moral discourses be identified as independent entities with 
bounded sets of terms that speakers might deploy in their talk. Rather, something much 
messier happens in interactions, with speakers’ explanations appearing to appeal to 
shared understandings that may have multiple explanatory premises, can be seen to have 
origins in a variety of places, and yet wholly attributable to none of them.  
 
The indeterminacy of talk was nowhere more evident than in how the concept of 
“control” was deployed by participants. In all the sources examined in this study, 
control appeared as central: control of one’s emotions, (either consciously to avoid 
symptoms or to express as a form of cure); of one’s mind, (either as emotions and 
desires or as beliefs and knowledge); lifestyle and habits (from sexual activity and diet 
to daily decisions about medicine taking). More recently, the relative success of 
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prophylactic medications in preventing asthma symptoms has increasingly encouraged 
discourses linking control to prevention rather than control by responding to symptoms 
through the use of reliever inhalers. As discussed in Chapter Two, prophylactic 
medications have only been in wide circulation since the 1980s. It was evident that 
many of these participants, who, from a medical perspective, could be considered as 
“non-compliant” or “non-adherent”, justified their medicine taking by deploying the 
older discourse of symptom control. This is a discourse associated with the management 
of acute conditions and participants justifying the control of asthma symptoms through 
relief medication could often be seen to associate the use of a symptom control 
discourse with the discursive construction of the object asthma as “not serious”, “not 
debilitating” or “not proper asthma.” Much of the research reviewed in Chapter One 
(Halm et al., 2006; Horne & Weinman, 2002) pinpointed this “perception” of asthma as 
a key reason why many people do not adhere to prophylactic medications or attend their 
surgery and instead rely on alternative strategies. However, the analysis in the study 
reported here demonstrated how it may be advantageous to view these “perceptions,” 
not in isolation, but as connected by people with different versions of their own self, 
such as someone with asthma, with an acute or chronic illness, fit for work and working 
hard, a fraud, someone who cares and is not cared for and not a burden. These versions 
of the self and one’s condition can be seen not merely as “distorted perceptions” but as 
formulations of health problems that may play a crucial role in influencing which 
versions of the self people can construct and which may enable them to participate in 
everyday life. 
 
The management of asthma and illness more generally may therefore extend beyond the 
physical experience and management of physical symptoms to a social experience of 
asthma and illness. This can be seen as a control not only of symptoms, but of one’s 
attitudes, identity(ies) and behaviour within medical and lifeworld contexts. This 
finding clearly resonated with the concept of “identity work” of Adams et al (1997) in 
which people with asthma engage, Cornwell’s finding of participants’ “public accounts” 
(1984) where moral implications of illness were managed, alongside other work 
emphasising how people with chronic illness actively construct themselves to enable 
participation in society (Charmaz, 1990; Frank, 1995). Notions of self-control are 
clearly not isolated to one aspect of health or indeed to health itself, but can be seen to 
be situated within other moral discourses about individual control and discipline, within 
which speakers actively position themselves.  In his narrative analysis and discussion of 
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chronic illness and the pursuit of virtue in everyday life, Gareth Williams makes this 
connection in commenting that in 1980s British society, health, like wealth was neither 
good nor bad in itself. What was good was “the self-disciplined activity, which 
according to Protestantism and Mrs Thatcher, produces them; and in their absence is a 
sure sign of gluttony and sloth” (Williams, 1993, p. 92). Tracing a path between 
individual utterance, (regarding control or any concept implicated in moral 
accountability), and the moral discourses structuring such talk proved difficult because 
concepts such as control could be seen to originate in a variety of locations. In addition, 
the historically-situated individual whose talk can be seen as both regulated and 
productive of wider discourses added further complexity to tracing these origins. 
 
These difficulties in determining the structuring of “attitudes” and versions of events 
indicates that talk about illness management is not necessarily what Fairclough referred 
to as “naturalised” (1995) within a particular discourse convention. As discussed in 
Chapter Three, Fairclough argued that particular institutional settings bring about, or 
“naturalise” particular discourse conventions. This was reflected in the fifth property of 
talk identified in this study which identified talk about medicine taking as institutionally 
situated. However, in contrast to Fairclough, this property highlighted that the 
regulation of talk was not prescriptive but could be seen as a complex arrangement of 
interactors’ communicative expectations of that institutional context which are difficult 
to determine. The discursive complexity within interactions suggests that Goffman’s 
term “loose coupling” (1983, p.11) between utterance and social structure appears to be 
a more helpful conceptualisation with speakers negotiating a number of moral 
discourses in their talk. However, this suggests that the discursive approach taken in this 
study is limited in the ability to locate talk about illness management and medicine 
taking within a coherent moral discursive framework that might be used to critique 
existing policies and inform the generation of future illness management guidelines. 
Instead it suggests that individual constructions of illness management and medicine 
taking needs to be understood for how shared understandings of illness management are 
manifested in talk in novel ways which might indicate specific concerns that speakers 
orientate towards. 
 
However, this study has built on research that has highlighted interactional and moral 
dilemmas in talk about health and illness by identifying how blame and accountability 
might be differently allocated according to the interactional conditions of different 
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encounters. What was said within interactions could be seen not only to be influenced 
by the talk taking place but also by how the research setting and those interacting within 
it were constructed prior to that encounter. Adopting an approach through which to take 
account of the interactional conditions in which illness talk and medicine taking takes 
place may therefore enable understandings of which moral discourses are likely to be 
activated, how these discourses might structure those interactions and to offer means of 
examining them. This in turn may provide firmer understandings of how speaker’s 
constructions of concepts such as control may be evaluated and categorised. This 
therefore re-emphasises how talk about illness management and medicine taking can be 
viewed as a performance in which speakers must deploy appropriate linguistic resources 
in order to be categorised in what they and other participants may see as appropriate 
ways. These “appropriate categorisations” can be seen as discursive objects that have 
emerged from different moral discourses, such as: the responsible manager of one’s 
health; compliant patient; empowered decision-maker; in control; and hard-worker. The 
findings suggested that being categorised in these ways will enable access to particular 
types of outcomes regarding the clinical management of symptoms, or activities within 
lifeworld settings such as work. Understanding how talk about medicine taking operates 
as a performance therefore provides insight into the process by which people living with 
chronic illness might come to be categorised within consultations and lifeworld settings, 
how relevant these categorisations might be for how they manage their condition and 
the consequences of these categorisations for treatment decisions.  
 
Talk as a Performance 
 
The discursive psychological and linguistic ethnographic methodological framework 
used in this study enabled talk to be situated and linked to wider moral discourses of 
behaviour. However, it also demonstrated how talk about medicine taking may be a 
continuously constructed performance within interactions. Participants could be seen to 
shift the orientation of their talk to meet the specific discursive demands that they 
evaluated as relevant at particular moments within interactions. From a medical 
perspective that deploys a discourse of prevention and adherence in understanding 
patients with asthma, it is possible to argue that some explanations of asthma 
management may be interpreted very differently to others, with different consequences 
for those people. The interview data analysed in Chapters Four and Five illustrated a 
range of ways participants’ accounted for the same kinds of medicine taking behaviour, 
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or “non-adherence”. These different versions could be seen to be historically situated 
with varying degrees of blame attributable to individual speakers. This analytical work 
indicated that people, in discussing how they manage their condition, are potentially 
categorised according to the effectiveness of their rhetorical accounts rather than how 
they actually manage their condition in everyday life. Rather than participant’s 
“attitudes” and medicine taking behaviour, it may be their linguistic performance within 
the interaction that is categorised by the researcher, doctor, nurse, according to the 
criteria that are set up within that interaction.  
 
How these criteria are communicated to patients or research participants appeared in 
this study to be critical in the consequences for the interaction that takes place. The 
institutional roles, presuppositions about those roles, normative expectations about the 
type of interaction taking place as well as the ethnographic contextual features are likely 
to have some bearing on how interactors understand, or “frame” those interactions and 
therefore the perceived criteria used in interpreting the talk within it. People with 
chronic illness will engage with the framing that they feel is relevant for that particular 
interaction and how they want to be understood - according to that framing. The 
variations in talk according to particular framings was made evident through the 
analysis of interviews where a few participants did not appear to frame the research 
interview as one where a narrative was expected and one in which the participant’s 
identities had previously been constructed in particular ways – as a “person inadequate 
control and quality of life” and “person non-adherent with medical care.” The apparent 
lack of access, or use of these resources potentially contributed to a very different type 
of interaction as a result, seen in the analysis of extracts in Chapter Five. The lack of 
display and apparent access to particular resources in these extracts indicated that it was 
these participants’ performances that were categorised and not how they actually 
engaged with their condition.  
 
This view of the performative elements of illness narratives builds on work undertaken 
already on how people provide stories within research interviews, (Bury, 2001; 
Riessman, 2003a, pp. 340-343), and clearly linking with the work of Radley and Billig 
and their concept of “interactional dilemmas” (1996) faced by people with chronic 
illness in presenting themselves as healthy and fit for work. Skultans (2000, p. 9) argued 
that “narrative makes actions intelligible to the self and to others by showing the part 
they play within an intentional project.” These “intentional projects” seen throughout 
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much of the interview data in this study have indicated a manifestation of issues that 
may also be performed in dealings with people in lifeworld settings, reflected closely 
with studies that have also demonstrated the performance of illness in everyday life, 
such as the experiences of patients with arthritis (Bury, 1988, p. 92); patients with 
traumatic spinal cord injury (Yoshida, 1993); and narratives produced within clinical 
care, referred to by Mattingly as “healing dramas” (2004, pp. 73-94).  
 
However, the concept of performance developed from this study’s findings has the 
closest connections with Riessman’s (2003b) analysis of performance narratives for 
men with multiple sclerosis. Using a similar analytical approach to this study, Riesmann 
used the theories of Bourdieu and Goffman to examine two contrasting performances of 
masculinity, situating these accounts within a social historical and interactional context 
in which the social structures of gender, class and disability could be seen to structure 
and be reinvented in accounts of the body and social space. Like Riesmann, the findings 
in this study emphasise a dynamic relationship between social structure and individual 
agency in performances about illness management and medicine taking, in particular 
how the same condition or behaviour may be constructed and therefore construed very 
differently depending on how it is historically and institutionally situated.  
 
Yet the research on performance narratives typically bounds that talk within the 
interactional context taking place. Other research within health (Roberts et al., 2005) 
and outside of health (Billings, 2009, September; Blommaert, 2005; Mehan, 1996) has 
shown the importance of accounting for the distribution of linguistic resources and their 
transference across contexts in how talk and therefore “performances” are interpreted 
within different interactional encounters. This study’s findings combines insights 
regarding the performance of talk and the allocation of linguistic resources, within the 
field of medicine taking and talk about illness management. Understanding how talk 
about illness management can be seen as a performance where speakers’ linguistic 
resources are evaluated against specific criteria enables us to interpret the role and 
functions of power and the dominance or absence of particular discourses in talk within 
research and healthcare interactions. Because illness management and medicine taking 
can be viewed as a social and not just physical experience, people, in discussions with 
clinicians or researchers, may orientate to a number of moral discourses in talk about 
medicine taking. However, the crucial point for how people are viewed within health 
care interactions, and how those discussions proceed, is which versions of illness 
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management and medicine taking clinicians are attending to in those interactions and 
what criteria will be used to categorise the performances that people with asthma or 
other chronic illnesses are displaying. Unlike Goffman’s use of the term “performance”, 
(which carried the implicit assumption that interactors had a shared understanding of the 
meaning of the performance which took place), the success of these performances is 
likely to depend on the distribution of resources within interactions, which may not be 
shared between clinician/researcher and patient/participant. The meaning of these 
performances is also likely to be fluid, as cultural meanings of different health 
behaviours and display of symptoms have been shown, in this study (Chapter Two and 
Appendix D) and elsewhere, to be regulated, negotiated and resisted across space and 
through time (Brandt & Rozin, 1997; Herzlich & Pierret, 1987; Sontag, 1991), 
manifesting itself through policy, guidelines, health promotion initiatives and media 
images (Davison, Davey-Smith, & Frankel, 1991), clinical practice (Pollock, 2005), 
interactions about health and produced by individuals in their talk (Pill & Stott, 1982). 
The interpretative repertoires that people construct within discussions about their illness 
management may closely match contemporary, localised discourse that may be key in 
allocating blame and accountability, or perhaps refer to more out-dated, remote 
discourses that are limited in their functional effectiveness within the interaction taking 
place. Inequalities in access to resources within health interactions may therefore result 
in clinicians or researchers inappropriately categorising a person’s engagement with 
their condition on the basis of “information about attitude” they see as having been 
given in their discussions with that person. The “wrong” kind of patient performance, 
i.e. one’s that are considered incorrect from a medical perspective, may lead to clinician 
accusations of the patient being irresponsible, non-adherent, having the wrong beliefs or 
being in denial. Inappropriate categorisations therefore have the potential to lead to 
inappropriate treatments being prescribed, a view which is reflected in research that has 
shown the potential detrimental effects of a medical agenda controlling consultations 
and marginalising patients’ lifeworlds in those discussions (Barry et al., 2000; Mishler, 
1984). 
 
Asthma or other illness prevention discourses are perhaps only available to people 
whose backgrounds have equipped them with the linguistic resources required to enable 
a discussion that will be effective within the institutional framework of medicine. This 
is not the same as saying that education is the key to improvements in adherence. What 
it means is that because of socio-economic and socio-historical circumstances there are 
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inequalities in access to these resources that means that some people will be more 
effective at accounting for their behaviour than others, whilst not necessarily any more 
likely to be “adherent.” This point is echoed by Roberts et al (2004) who have shown 
that people’s abilities to utilise institutional, linguistic and bureaucratic resources within 
consultations is a growing problem in areas of the UK with increasingly diverse 
populations, having consequences for how consultations proceed and potentially 
treatment outcomes.  
 
People with chronic illnesses may become delineated within the discourse of prevention 
according to clinical and researcher’s assessment of their “beliefs.” The effectiveness of 
the articulation of those beliefs within an interaction about symptom prevention may 
determine the particular subject position that clinicians/researchers “assign” to 
patients/participants within that framework. Moreover, people with chronic illnesses 
may not make decisions about how they manage their condition based on subject 
positions within this discourse and are unlikely to make the judgement about how their 
illness management is positioned within it. The tensions that were manifested in 
eliciting participants’ “attitudes” and versions of their medicine taking behaviour within 
the interviews of this study may be seen as transferable to healthcare interactions more 
widely both at an interactional level in relation to access to resources and also at a moral 
discursive level, in relation to the basis on which decisions about illness management 
are made.  
 
Interpretations of Talk and Decisions about Prophylactic-Medicine taking 
 
If we view interactional talk about medicine taking as a continuously-constructed 
performance then it is difficult determine from that talk how people with chronic illness 
make decisions about medicine taking in everyday life. However, the literature review, 
which included an examination of the language within asthma guidelines, the analysis 
of interview and focus group data provided different types of evidence of how 
discursive links have been made between asthma management and morality and that 
these links could be seen to be circulated and manifested within varied social spaces. In 
asthma guidelines, discursive links could be seen in the incompatibility of an ideology 
of patient-centred medicine with policy directives that regulate the options available to 
clinicians and patients. This tension has the potential to radicalise clinical decisions 
which do not conform to the guidelines and so imposing a moral incentive for clinicians 
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to comply with orthodox treatment recommendations. In the interview data, the 
majority of participants could be seen to be preoccupied with providing plausible 
reasons for the decisions they reported. These reasons were rhetorically constructed 
using different culturally-available discursive objects and interpretative repertoires in 
their talk such as the sick individual passively filling up with tablets or versions of the 
hard-worker. These rhetorical constructions may be particularly effective in allowing 
these people to function in important social networks and lifeworld settings that they 
access in everyday life. The focus group data by contrast displayed evidence of some 
participants’ reluctance to identify with a position running counter to an orthodox 
medical directive on medicine taking. Such reluctance demonstrated an awareness of the 
authoritative medical discourse on the correct function and use of medicines, a 
discourse to which participants may feel required to respond and to position themselves 
in morally acceptable ways.  
 
When people talk about illness management and medicine taking they may (as shown in 
Chapters Four and Six) orientate their talk to multiple moral discourses that have some 
connection with that talk. Blame and accountability can be seen to be allocated 
differently according to the performance of that talk within the particular moral 
discourses that are activated within interactions. This suggests that talk about illness 
management will function differently in different interactional contexts and therefore 
may be indicative of the moral discourses in which people make decisions about 
medicine taking on a daily basis. While a medical discourse of asthma management may 
classify a particular attitude or behaviour as “incorrect” or “non-compliant”; within 
alternative lifeworld discourses, these same attitudes and behaviours may be considered 
appropriate and normal, and function to uphold important lifeworld identities. The 
explanations provided by many participants, indicated that taking relief medications lay 
at the heart of these alternative moral frameworks where blame and accountability were 
distributed. “Non-compliance” or “non-adherence” to medications, attendance at a local 
surgery or to any aspect of healthcare could, in many lifeworld contexts, therefore be 
seen as an appropriate response.  
 
Situating individual’s talk within a lifeworld context reconfigures our understanding of 
how decisions are made about illness management and medicine taking. Instead of 
locating the individual as having a package of attitudes and beliefs which can be elicited 
and measured to predict adherence to prophylactic medications, without reflecting on 
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the construction of those attitudes, a more holistic understanding of the individual is 
made available. This is to more fully appreciate the individual’s management of illness 
at a unique intersection of the other influences in their lives. These influences are not 
discrete entities but form a complex arrangement of concerns into which “having 
asthma” or any other illness has to fit if those people’s lives are to be maintained. This 
understanding resonates with other work which has emphasised that illness and its 
management needs to be viewed as a social and not just as a physical experience in 
which people actively construct their identities in order to participate in social life 
(Bury, 2001; Charmaz, 1983; Frank, 1995). This study has emphasised that dimension 
of this experience which relates to the individual body experiencing a physical 
condition within a range of shifting moral discursive contexts. Medicine taking then, 
can be positioned as a social activity that interacts with other social activities which 
situate medicine taking with a range of moral connotations, defining individuals in their 
use of those medicines. It has therefore been argued that to understand decisions about 
medicine taking we need to view this social activity alongside other such social 
activities and alongside how the individual is positioned within moral discourses 
associated with those contexts. This approach situates the unit of analysis outside the 
individual and within their lifeworld context in which decisions are made and 
discursively managed, while considering that individual’s social and moral activities. 
This evidence provides insight into and considers the compatibility of available and 
efficacious treatments with patient’s lifeworlds, before the compatibility of individuals’ 
beliefs with clinical treatments. This may provide more convincing explanations of 
patients’ practices in relation to adherence than can be provided by individual attitudes 
to medical objects. 
 
In this study, differing discursive contexts were identified in which moral discourses of 
medicine taking could be seen to be activated, and also likely to be activated between 
clinicians and patients in consultations about asthma and other chronic illness 
management. The value of educating patients about medications can, in this way, be 
seen as too limited in the ability to influence how people will use those medications.  
This is because here the relevant issue for patients can be seen not as one of whether 
patients understand their condition, what medications do and the need for adherence but, 
rather, as what these may mean as concerns in people’s everyday lives. One application 
of the ideas examined here may therefore be to find ways to help attune clinicians to the 
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moral dimensions of talk being attended to and to respond accordingly in 
communicating with patients. 
 
Some Implications for Communicating with Patients in Clinical Settings 
 
Within the discourse of adherence, people with chronic illnesses may become 
designated as “good patients”, “bad patients”, “responsible”, “irresponsible”, as having 
“accurate understanding” or “incorrect beliefs“, as “compliant“ or “non-compliant”. 
Such adherence discourse-related designations may be based on clinical judgements of 
the effectiveness of their talk within an interaction according to particular criteria of 
disease control and associated recommendations for appropriate illness management. 
Peoples’ performance of that talk may affect how they are assigned within that 
framework, with likely consequences for the treatment decisions reached by clinicians, 
with patients potentially being prescribed medications they may not have wanted.  
 
Viewed in this way, through a discursive psychological and linguistic ethnographic 
approach, the function of treatment guidelines may need to be repositioned as a 
reference point rather than a recommendation for treatment. If notions of the individual 
need to be re-located within a moral discursive context, so, too, do notions of evidence 
and patient and clinical expertise within a clinical setting. Instead of attempting to 
reconcile the inherent contradictions between clinical, evidence-based and patient-
centred practice, the clinical encounter could deploy a broader notion of evidence than a 
medical paradigm that upholds randomised controlled trials as the gold standard to 
inform practice. This evidence would be provided by the patient, but instead of focusing 
only on their talk as a means of assessing the accuracy of patient’s beliefs, this view 
would understand such talk as indications of the dilemmas and issues at stake for 
patients.  
 
The alternative or additive interpretation offered here would have implications for how 
the consultation may proceed. For example, a patient with asthma reporting that they 
only used a brown prophylactic inhaler when they felt that they were getting a cold 
might lead to the consultation proceeding in one of two distinct ways. A discussion that 
conformed to asthma guidelines might follow whereby the nurse or doctor educates the 
patient about how their asthma is a continuous underlying condition that needs daily 
management, and that in order for the brown inhaler to have any effect the patient needs 
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to take it much sooner before any cold symptoms arise. This would be likely to bound 
the discussion within a medical discourse of asthma management and so close off 
opportunities for the patient to express the role of medications in their everyday life. 
However, when repositioning evidence within patients’ everyday lives, the clinician 
might instead ask the patient whether they are concerned about taking a medication 
everyday. This might lead to a discussion of medicine-use in a lifeworld context, in 
which particular moral discourses circulate, which may then facilitate further discussion 
of the compatibility of a prophylaxis within those settings. The need to facilitate 
discussion of patient’s concerns about medications has already been highlighted in 
research that has shown the difficulties patients experience in articulating concerns 
about medications (Stevenson, Barry et al., 2000). Within this view, the clinician’s role 
as expert would therefore be less about advising patients about what they “should” be 
doing but rather as being able to offer a treatment that best meets the patient’s concerns 
and needs. This is not to say that patients become “empowered decision makers”, and 
that clinical consultations may be more “concordant”. There is evidence to suggest that 
some people do not wish or expect to be given a choice in their treatment (Butler, 
Rollnick, Pill, Maggs-Rapport, & Stott, 1998; Makoul, Arntson, & Schofield, 1995). 
Rather, discussions about illness management need to be repositioned so that decisions 
are more fully informed by the issues that are pertinent to patients in everyday life. The 
patient’s expertise does not lie in providing the solution however, but lies in their 
experiences of the issues that affect their participation in activities such as work, school 
or other social activities.  
 
Instead of viewing evidence as an objective object against which to measure patients’ 
attitudes towards treatment or illness, this sort of evidence varies according to the moral 
discursive contexts of patients’ lives. Instead of viewing talk as a separate entity from 
evidence and assessed as either correct or incorrect, such talk might be seen as 
providing the evidence itself and so avoids any inherent contradictions between clinical 
and patient perspectives. The notion of doctor-patient collaboration might therefore also 
be reconfigured. Instead of attempting to persuade patients to adhere through different 
tactics, using what Habermas called “open” or “concealed strategic action” (Scambler & 
Britten, 2001) this approach is about accepting how and whether medications are 
compatible within people’s lives and the function that “non-adherence” might play in 
lifeworld contexts – an approach which Habermas referred to as “communicative 
action”. Reframing both ideas of evidence and talk in this way may help reduce 
   
 
 
200
clinician and patient time and service resources spent “re-educating” patients to little 
effect and only to repeat such discussions at a later date. 
 
Limitations and Achievements of a Discursive Psychological Approach to 
Understand Talk about Medicine Taking 
 
This study has been able to provide novel insights into the production of talk about 
prophylactic medicine taking in moving beyond individualistic approaches undertaken 
to date to explain and predict adherence to prophylactic medications. However, the 
predominantly discursive psychological methodology used in this study does not 
provide an alternative means of obtaining patient perspectives in order to better 
persuade those patients to take prophylactic medications more regularly. Rather, it 
reconfigures our viewpoint of the individual person with a chronic illness and the role 
of medications within that framework. This is one in which the individual is located 
within a range of interacting social spaces. Medications and medicine-use are then 
assessed as to whether it is compatible with those spaces. This study has attempted to 
understand this by shifting the unit of analysis away from individualistic, attitudinal 
concepts to a study of interactional issues within a social space.  
 
The interview and focus group methods deployed to understand the discursive 
construction of participants’ talk created social interactions in which the language of 
medicine taking would be reproduced and produced through the interaction. However, 
these were not “real-life”, or naturally occurring interactions, but, as the analysis in 
Chapter Five brought out clearly, were unusual encounters for discussing asthma 
management, with vague definitions, boundaries, roles and expectations. The 
construction of the research settings and data within this study will therefore have 
produced a particular type of talk and resulting data. Although examining the contextual 
conditions in which participants were recruited and interviewed provided valuable 
insights on the production of this study’s data, the methods used in this study restricted 
the analysis largely to linguistic techniques, precluding a broader understanding of 
participants’ naturally-occurring language as produced within the social spaces in which 
asthma was managed. This potentially limited the kinds of moral discourses that would 
have been activated within interactions which would reveal the moral concerns of 
participants that might influence daily decisions about medicine taking. These 
limitations were initially identified from analysing the interview data and were 
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addressed with the use of the data-sharing focus group. Whilst this focus group can also 
be viewed as an unusual encounter for participants to discuss asthma and medications, 
the researcher set up the group to help facilitate other kinds of moral discourses that 
might be activated in this different interactional dynamic. The groups’ shared concerns 
about being a person labelled with asthma, of long-term medication use and experiences 
of healthcare suggested that using the focus group was successful in activating different 
discourses to the face-to-face interviews. It also demonstrated that further, potentially 
richer insights regarding the link between moral discourses and medicine taking might 
have been identified by observing discussions of asthma in participants’ lifeworld 
settings.   
 
However, the purpose of this study was to explore the value of investigating talk about 
medicine taking using a discursive methodology, an alternative approach to those that 
have viewed this talk as representing individual attitudes. This study has achieved this 
aim by pinpointing key properties in participants’ talk and showing how this talk can be 
seen as both structured and creative of moral discourses. By adopting a discursive 
psychological and linguistic ethnographic methodology we might now better understand 
talk about medicine taking as a performance, subject to differing linguistic resources 
and as a manifestation of moral issues that inform daily decisions about medicine 
taking. Interview and focus group methods provided appropriate means for examining 
this because they provided opportunities to elicit such talk in direct conversations with 
participants. Discursive psychological analytical techniques provided the tools to 
analyse the discursive construction of participants’ talk and using these tools 
highlighted the interactional dilemmas that people may face in discussing how they 
manage their condition. Additionally, interpreting interview data was enhanced by using 
techniques and ideas from linguistic ethnography to allow a more explicit and detailed 
examination of the exercise of power in context.  
 
This study has therefore provided a foundation on which to build a more sophisticated 
methodology to further examine the relationship between talk and illness management. 
Such examination might focus on how performances relating to illness management are 
seen to play out in everyday settings or to understand the positioning of medicine taking 
as an activity alongside other social activities. A methodology to understand these 
issues might combine linguistic and ethnographic approaches and could be implemented 
using a form of participant observation to identify what sorts of interactional dilemmas 
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and moral discourses are activated when people need to manage their conditions within 
lifeworld settings. These insights would provide further evidence of how illness 
management and medicine taking are positioned within people’s everyday lives and 
suggest new ways in which people might be supported to manage their conditions 
within these contexts.  
In deploying a discursive psychological and linguistic ethnographic approach to 
understand talk about medicine taking, the findings of this study also raised other 
potentially important issues which were not possible to pursue within the scope of this 
project. Firstly, the approach taken in this study could have led to a more detailed 
analysis of how different types of talk could be seen to be dominating or be 
marginalised in discussions of asthma management. The discursive variation identified 
in the analysis of focus group data regarding participants’ “views” of medications 
indicated that medical conceptualisations of medicine taking functioned at certain points 
to marginalise competing alternatives regarding the safety of medicines. In contrast, the 
analysis of interview data provided examples of how participants constructed versions 
of themselves whilst at the same time undermining and marginalising less-desirable 
alternatives. It might therefore have been fruitful to explore further how and when 
medical versions of asthma and illness management could be seen to dominate 
participants’ talk and therefore the implications of this for what may be left unsaid in 
discussions about illness management and medicine taking. 
Secondly, the consideration of the circumstances in which participants’ justified their 
medicine taking led to the concepts of “affordance” and “discursive space,” building on 
Radley’s (1993) analysis of agency and “spaces of action” in how people live with and 
talk about chronic illness. Radley discussed how spaces of action are available to people 
with illness between what is expected regarding their behaviour and what can be 
attained. Appendix D includes a comparison of the rhetoric identified within two 
extracts selected from one interview undertaken in this study. This brief analysis 
indicated that it would be fruitful to further explore examples of variations in the 
“affordance” of “discursive space” to understand how individual choice might be 
positioned within different moral discursive frameworks. Justifying illness management 
may be related not only to the activation of different moral discourses within 
interactions (and speaker’s access to those discourses) but also to the discursive space 
that is afforded within ongoing discussions.  
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Finally, the biographies that were provided by participants regarding the origins of their 
asthma, the circumstances that led to a diagnosis and then use of medications could 
have been explored in more depth. These stories could sometimes be seen to 
contextualise the version of asthma that the participant constructed within interactions, 
which was then used in justifying the decisions that they had made about the use of 
prophylactic medications. In a similar fashion to the work undertaken by Horton-
Salway and her analysis of talk about ME, stories about the origins of asthma could 
have been analysed for how and whether participants “struggled for authorship” 
(Horton-Salway, 1998) of their condition. This may have offered insight into how 
blame and accountability may have been pertinent in discussions of the causes of 
asthma, offering points of contrast to discussions regarding the management of asthma.  
 
Summary 
 
The findings from this study have provided an important contribution to the existing 
body of knowledge on medicine taking and particularly knowledge about prophylactic 
medicine taking for people with chronic illnesses. The findings have indicated that 
attempting to identify individual attitudes or beliefs about illness or medication as a 
technique to improve how people take medications is inadequate in identifying the best 
ways to support people with chronic illness. They have also provided insights into why 
attempting to improve peoples’ adherence to medications solely through educational 
techniques is likely to have limited success. In addition to providing a critique of current 
asthma management strategies and research aimed at improving adherence, the findings 
have suggested that a more useful way of understanding how people talk and make 
decisions about medicine taking might be found using discursive and ethnographic 
methodologies. The approach taken in this study has provided insights that indicate a 
range of contextual features influencing individuals’ talk about illness management 
within interactions and understanding what influences individual decisions about 
medicine taking may involve taking account of these features. Key amongst these are 
likely to be a range of culturally-available moral discourses of illness management that 
can be seen to circulate medical and lifeworld contexts. Individuals’ decisions about 
taking medicines may therefore need to be seen in terms of how it is evaluated within 
those contexts and whether it enables those individuals to participate in important social 
activities. Other contextual features influencing talk could be seen to be produced 
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through the researcher’s role and implementation of the study design. The choice of 
methods could have been improved by incorporating observational data of everyday 
interactions about asthma management which would have provided better understanding 
of the interactional issues and moral discourses that might have more direct influence on 
participants’ daily management of asthma. However, the interview and focus group data 
helped illustrate how people’s talk about medicine taking can be viewed as a 
performance. This insight suggested that individuals’ ability to utilise specific linguistic 
resources within interactions may be key in how performances are categorised by other 
members of that interaction, having important implications for how healthcare 
interactions are conducted. The methodology used in this study provides a means of 
understanding how talk about medicine taking is constructed within interactions which 
might then be used to communicate more effectively with patients but also to better 
understand the issues that inform daily decisions about medicine taking.  
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Chapter Eight 
Conclusion 
 
They’ve always got a weapon (1) like weight, smoking, (1) and something else 
(1) it could be em, (1) excuses as to why (2) you’d suffer less if you were (2) 
perfect. (2) Which we ain’t none of us, are we? (1) That’s how I feel and so (.) 
sometimes I’m reluctant to go because of that. (1) That is the truth.  
(121221, interview 2, page 24, lines 46 to 51) 
 
The contribution of the findings reported here is in providing a novel way of 
conceptualising how individuals talk and make decisions about medicine taking, with 
substantial implications for communicating with and supporting these people in 
managing their condition. Whereas health education approaches have assumed that 
individual attitudes can be elicited from patients, measured and then used as a means to 
improve adherence to prophylactic medications, the new conceptualisation offered in 
this study views the individual within a social and moral historical context which is 
multi-dimensional and shifting. Here, talk about illness management is seen as a form of 
social action and a product of a dynamic relationship between social conditions and the 
individuals within interactions, and to be both structured and productive of moral 
discourses of asthma, illness management and medicine taking. Medicine taking can 
also be viewed as situated within different moral contexts and the decisions that people 
make as social acts defined by these contexts. This final chapter will summarise the key 
insights that have led to this conceptualisation, underline its contribution to knowledge, 
and suggest further related research and implications for improving the clinical care of 
patients with asthma and other chronic illnesses. 
 
The novel conceptualisation of how individuals talk about and take medications, which 
emerges from the findings of this study, arose from adopting a fundamentally different 
understanding of talk about asthma from previous research about adherence to 
prophylactic asthma medications. Instead of viewing individuals’ talk about asthma or 
medications as an articulation of an internal representation, talk was viewed as a product 
of interactions within a social historical context. The primary data collected in this study 
was obtained from transcribed face-to-face interview and focus group data which was 
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then analysed using discursive psychological and linguistic ethnographic approaches. 
The language within a range of other data sources was also examined to see how people 
with asthma were constructed in relation to the causes and management of this 
condition. In addition, non-textual forms of data were examined in relation to how the 
researcher, participants and interviews were constructed within this study. This was 
therefore a study of language and its use, and its view of the individual, as situated and 
defined by context, represented a significant departure from previous individualistic 
approaches to adherence which have identified the individual owning and expressing 
coherent and bounded attitudes and beliefs distinct from context.  
 
Shifting the core unit of analysis from the individual to their situated language therefore 
enabled access to a new form of knowledge about asthma medicine taking. Instead of 
producing an epistemology of the individual and their attitudes or beliefs, set against the 
objective categories “asthma”, “medication” and “illness”, the approach developed from 
discursive psychology produced an alternative form of knowledge of the individual as 
constrained by and producing moral contexts of illness management and medicine 
taking. In discussing asthma management, people could be seen, not simply to be 
reporting how they have managed their asthma, or how they view their condition and 
asthma medications, but also to be managing issues of blame and accountability linked 
to their actions and reported attitudes. This was evidenced by the rhetorical devices that 
participants were seen to deploy and the competing versions that they could be seen to 
manage, both from within a medical perspective of asthma management and from 
lifeworld conceptualisations of what it means to be ill and to manage illness 
appropriately. These culturally-available conceptualisations (Willig, 1999) could be 
seen as moral discourses which allocated blame and accountability for the same 
behaviour and attitudes in different ways, potentially raising difficulties for speakers 
when competing discourses were activated simultaneously within talk. Talk about 
asthma, illness and medications could be seen as a manifestation of these competing 
concerns, thereby repositioning the individual from someone possessing sets of attitudes 
to someone at the intersection of different moral discourses which need to be negotiated 
to participate in everyday activities. This study, using asthma as a case example, has 
therefore provided an alternative means by which talk about medicine taking might be 
understood and studied, suggesting the use of methods that enable the researcher to 
engage more closely with the issues that might influence the everyday talk and 
decisions of people with chronic illness and in which moral issues are foregrounded. 
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This study has also built on other discursive psychological approaches that have already 
researched talk about health and illness. First, whilst several scholars associated with 
discursive psychology may recognise the role of institutional discourse in producing 
meaning within interactions, this study has attempted to trace this path from institutional 
discourse to interactional talk, to understand how moral talk of medicine taking might 
have come about. It did so by moving beyond the transcript of interactions to examine 
moral connections within other forms of text that circulate society and which might 
have structured individual talk. This therefore extended the use of discursive 
psychological tools to help bridge the gap between individual utterance and broader 
systemic discourses. By doing so, the author was able not only to provide insights about 
what happens within interactions about asthma management but also to provide a 
critique of asthma management policies that influence those interactions. Incorporating 
an analysis of ethnographic contextual features that might have influenced the 
production of talk about medicine taking enabled conditions of interactions to be 
pinpointed that appeared to play a key role in the production of participants’ talk. These 
conditions were related to how the research interactions were framed by researcher and 
participant and were not identifiable by a linguistic analysis alone. Developing the 
methodology to study ethnographic contextual features went beyond a more typical 
application of discursive psychology focusing only on interactions. This development 
allowed some generalisations to be made about the production of talk about medicine 
taking, both for people with asthma and other chronic illnesses. This provided 
distinctive lessons in how we might study issues about medicine taking in the future and 
also how clinical practice might be improved. The first of these was that talk about 
medicine taking may now be viewed as a performance and the second was that 
individuals’ talk may be viewed as a manifestation of moral issues that may influence 
everyday decisions about illness management and medicine taking.  
 
The first key generalisation enabled in analysing this study’s findings, was that talk 
about prophylactic medicine taking could be viewed as a performance rather than as an 
articulation of one’s views or behaviour. Goffman’s (1959) use of the term 
“performance”, has suggested that talk about medicine taking can be viewed as a public 
display that is organised by a “loose coupling” (Goffman, 1983, p.11) between social 
structure and individual agency. Here, people with asthma have been shown to present 
themselves in ways that may enable their continued participation in everyday activities 
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that are important to them. Such findings are supported by earlier research which has 
evidenced peoples’ need to construct their lives in ways which enable their participation 
in important everyday activities such as work (Charmaz, 1990; Frank, 1995; Yoshida, 
1993). This view of the person with chronic illness implies that their talk about illness 
and treatment cannot be simply treated as an accurate articulation of how that person 
engages with their condition, nor as representing a specific attitude about their condition 
or medication. Instead, such talk can be seen as a continuously-constructed performance 
and it is these performances that may be interpreted, evaluated and categorised within 
interactions rather than an actual attitude or behaviour. This has the potential to lead to 
clinicians and researchers inappropriately categorising how people manage their own 
condition and prescribing treatments which may be inappropriate to how those 
individuals live with their condition in everyday life.  
 
The structure provided within the research activities surrounding this study indicated 
that how performances are categorised is likely to differ according to the criteria used to 
allocate such categories. Within a clinical interaction which uses asthma guidelines to 
structure the care of patients, these criteria could be whether individuals are considered 
“non-adherent” whilst also classifying them as potentially having inadequate asthma 
control and quality of life. In lifeworld settings, individuals’ talk may be categorised in 
very different ways but in both settings the criteria for evaluating talk is unlikely to be 
made immediately explicit within interactions.  
 
However, realising that people may attend to multiple moral discourses in their talk 
adds complexity to our understanding of people’s performances beyond the immediate 
interactional context. This is to extend Goffman’s use of the term “performance”. 
Rather than being bounded by the immediate interactional context, people’s 
performances about illness management can be seen as transferring linguistic resources 
across contexts that are manifested in different interactions. The “meaning” of 
performances therefore may result from how and how far different criteria, set up within 
interactions about illness management and medicine taking, match the available 
resources deployed by individuals with chronic illness. Effective performances may 
therefore be related to individual’s ability to access and deploy the appropriate 
resources. In the case of asthma management this meant participants displaying a range 
of different versions of themselves including: responsible, actively engaged managers of 
their condition; someone equipped with accurate knowledge of asthma and the 
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medications; compliant; in control; someone with a health problem that is not an illness 
(Cornwell, 1984); someone not dependent on medications; a hard worker; a wealthy 
benefactor.  
 
Further to this, the analysis of deviant cases in this study suggested that if people are to 
achieve appropriate treatment outcomes from consultations, or enable their participation 
in lifeworld activities such as work, they not only need to be able to access the linguistic 
resources that enable those objectives to be met but that they must also appreciate which 
resources are most likely to meet the criteria that determines how they will be evaluated. 
Developing Goffman’s concept of performance still further, evaluating talk about illness 
management may therefore be assumed to be subject to whether individuals have access 
to and display the required resources to meet specific interactional criteria. Positioning 
the individual as needing to align with clinical perspectives within consultations which 
review the management of their condition means that many people’s linguistic resources 
regarding illness management, while functionally effective within their everyday lives 
may be considered inadequate when transferred to clinical or research settings.  In the 
case of asthma management positioning oneself as having a health problem that is not 
an illness, responding to symptoms using a range of strategies including the use of a 
reliever inhaler may be functionally effective within a working context but classified as 
“non-adherent” and essentially irresponsible in a clinical consultation. 
 
The second main generalisation from this study’s findings concerned a theoretical 
relationship between talk and everyday decisions about illness management. Talk about 
illness management has been shown here to manifest different moral discourses that 
transfer across social historical contexts as well as being a product of the contextual 
conditions in which those interactions take place. This evidence indicated that some of 
these moral discourses are likely to circulate the lifeworld settings of individuals, such 
as work, school, home or social settings. These moral discourses may therefore play a 
key role in shaping the decisions that people make about how they manage their 
condition. If so, this suggests a need to develop innovative research methods which 
might enable a better understanding of the relationship between these social settings and 
illness management. This takes a view of the individual within a range of semiotic 
spaces where the meanings attached to illness and medicine taking are situated not only 
by linguistic but by non-textual forms of discourse. The discursive psychological and 
linguistic ethnographic methodology developed in this study has provided a foundation 
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from which to develop suitable approaches in which to examine the connection between 
morality and individual decisions about illness management in lifeworld settings.  
 
The novel insights offered here about the nature of talk about illness management and 
medicine taking suggest ways in which healthcare could productively change  how it 
engages with people with chronic illness. To support people in ways which might be 
more beneficial both to them and to clinical practice, we perhaps need to set aside 
criteria that may categorise individuals in inappropriate ways as “adherent” and “non-
adherent”, while ignoring what the patient may or may not be able to contribute to the 
clinical encounter. Rather than creating an interactional dynamic in which it is the 
patient who has to be able to utilise a particular set of skills to be treated appropriately, 
it is perhaps the clinician who should be helped to learn which linguistic resources will 
elicit patient performances that can engage with the moral contexts of patients’ 
everyday lives. 
 
However, clinical consultations are subject to specific institutional and interactional 
conditions, which will facilitate some moral talk whilst marginalising or excluding 
other, potentially important discourses. There is therefore a need to investigate how 
restructuring clinical interactions might be possible to help avoid excluding discourses 
that might be important in the decisions that people make about taking medications. 
 
The findings reported in this study suggest that restructuring clinical consultations 
might include repositioning the discussion about a patient’s condition away from a 
focus on physical symptoms and towards a discussion of their everyday activities. The 
issue then becomes about whether there are any existing treatments that are compatible 
with patients’ everyday activities which might enable them to participate more 
effectively in those activities, rather than discussing specific symptoms and how to 
control them. This shift in the discussion therefore opens the possibility for grounding 
patients’ talk in the everyday moral issues that influence their decisions, and patients’ 
discussion of those treatments offered as indicative of their concerns set within those 
everyday moral discourses. Treatment decisions may therefore include non-adherence 
as a treatment option, recognising that this decision is set within a lifeworld context 
where other important social acts and identities are upheld by this decision. The role of 
the clinician and clinical advice is therefore not to develop more effective techniques to 
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persuade patients to take prophylactic medications but to recognise the limitations in 
prescribing a treatment that is incompatible with individual’s daily lives.  
 
Helping clinicians to engage with the interactional and moral dilemmas faced by people 
with chronic illness in talking about and managing their condition, may well create 
more opportunities for collaboration between doctor and patient and for offering a 
clinical decision-making process in which the voice of the patient can be genuinely 
heard.  
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Appendices 
 
The following appendices (A to D, plus published article and CD) have been included 
for different reasons. Appendix A and Appendix B.1. will help the reader understand 
how the research interviews were conducted and transcribed. Appendix B.2. and B.3. 
provide additional information to help the reader understand the author’s decision-
making in undertaking the analysis. Appendix C provides additional information that 
assists with understanding how participants were recruited but which also informs the 
author’s interpretation of interview data described in Chapter Five. Items included in 
Appendix D demonstrate additional work that was undertaken in this PhD study, which 
although did not form a key part of the thesis text, either influenced the development of 
the study or complemented the main analysis undertaken in Chapters Four to Six. The 
copy of the published article (Murdoch, Poland, & Salter, 2010) has been attached as 
supporting information and the enclosed CD includes all full transcripts of interviews 
that have been cited in the main text, allowing the reader to follow-up these citations. 
The following list is a summary of items included in the appendices. 
 
• Appendix A. Interview Topic Guides and Focus Group Protocol 
o A.1. Interview Guides and Topic Cards for Face-to-Face Interviews 
o A.2. Data-Sharing Focus Group: Protocol 
 
• Appendix B. Analysis of Transcripts for Evidence of Rhetorical Devices and 
 Moral Discourses 
o B.1. Transcription Conventions 
o B.2. Questions to ask when Analysing Transcripts 
o B.3. Transcript Excerpts  
  
• Appendix C. Recruitment of patients into the ELEVATE Study 
o C.1. Extract from final report documenting recruitment procedure                                
and selection criteria 
o C.2. ELEVATE Screening Questionnaires 
o C.3. Medication Adherence Report Scale (MARS) Questionnaire  
o C.4. Patient Information Sheet and Consent Form 
 
• Appendix D. Other work undertaken not included in main text 
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o D.1. Analytical Process to Identify Participant’s Accounting Styles 
o D.2. Ethical issues regarding informed consent with individual 
participants.  
o D.3. Reflections on focus group and role of moderator 
o D.4. Analytical work Undertaken on Rhetoric and Discursive Space 
o D.5. Review of Health and Illness Literature to Assess the Relevance of 
Morality for talk about Health and Illness 
o D.6. An Interpretation of the ELEVATE Recruitment Process and 
Participants Access to Discursive Resources 
 
   
 
 
214
Appendix A 
Interview Topic Guides and Focus Group Protocol 
 
A.1. Interview Guides and Topic Cards for Face-to-Face Interviews 
 
Loose structure/format of first interviews 
 
 
Introductory Explanation 
 
 
MARS Questionnaire 
 
 
 
 
 
Biography of Asthma 
 
 
 
 
 
Treatments 
 
 
 
 
 
Risk and severity 
 
 
 
 
 
 
 
 
Relationships and Asthma 
 
 
 
 
 
Specific Questions (if not covered elsewhere) 
When/how diagnosed. How treated. What 
prescribed. Perspective/experience of 
treatment. Outcomes, development. 
Exacerbations. 
Perspectives, involvement. Discussions. 
Defining situations. 
History of use. Habits and decisions of use. 
Locations. Role in everyday life. 
Circumstances of use. How developed since 
diagnosis. 
Specific Topics and Issues 
How much at risk does the person feel? What 
precautions do they take? 
What level of asthma severity does the person feel 
they have? How does this fluctuate? Does their 
GP/nurse share this view?  
What ideas do they have surrounding this 
understanding of their illness? 
 
How difficult was it to complete? Why? 
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Topic cards 
 
Biography of Asthma Card (1st Interviews): 
 
• When/How diagnosed. How treated. What prescribed. Perspective/Experience of 
treatment. Outcomes, development. Exacerbations. 
• When/How diagnosed with asthma? Why did you go to doctors? What 
happened? How was it decided it was asthma? What explanations were 
provided? How did you feel about diagnosis? 
• What was prescribed? What explanations were provided? What did you think 
about the treatment? Were alternative types offered or just one? Was a review 
visit arranged? 
• How did you get on? What did you think about taking treatments as prescribed? 
What did your relatives think? What changed after diagnosis and prescription? 
Did you attend a review visit? Why? Why not?  
• Has anything significant happened since then? How felt? Dealt with? What 
changed afterwards? 
• (If 2nd interview) What has happened since last interview? 
 
Treatments Card (1st Interviews): 
 
• History of use. Habits and decisions of use. Locations & circumstances of use. 
How developed since diagnosis. Role in everyday life.  
• How do use your treatments? When? Where? How did you arrive at that 
decision? Has it always been like that?  
• How often do you not take your preventer? How do you feel about that?  
• Remember things which have stopped you from renewing prescription? 
• How long do they think treatment takes to have full effect?  
• Where do they expect the treatment to work? 
• Do they see any limitations with inhaled steroids (ICS)? Do they feel that ICS 
reach all parts of their lungs?  
• What goals do they hope to achieve as being part of the study? Perhaps refer to 
their patient-centred targets? 
• Do you carry your treatments with you at all times? Do you notice/think about 
your asthma every day? Have you ever forgotten your inhalers? What happened?  
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• Have there been any situations when you felt you needed your inhaler but did 
not want to use it? 
• Have there been any situations where your asthma has been very noticeable? 
• How do you see the future in terms of asthma and medication use?  
 
Risk and Severity Card (1st Interviews): 
 
• What ideas do they have surrounding this understanding of their illness? Try to 
ground in experience. 
• How much at risk does the person feel? What precautions do they take? 
• What level of asthma severity does the person feel they have?  
• How does this fluctuate? How would they define their condition? Is it something 
they feel is with them everyday? Does it need to be managed everyday?  
• How random are their asthma episodes? How easily can they predict it getting 
worse?  Is that easy to live with? What would be easier? 
• What does this mean for medication use? How bad would it have to be to make 
you take your medication everyday? 
• How does this compare to other people with asthma? Does their GP/nurse share 
this view?  
• LINK                       Habits with inhalers. 
• What causes the person’s asthma to get worse? Examples 
• What happens when you go to see the doctor or nurse about your asthma? 
• Do you discuss everything you would like to? 
• Do you discuss asthma along with other reasons for going, or on its own? 
• Do you think about the long-term and your asthma? 
• Other people with asthma? LINK                   Causes of illness in general. Role 
of medications in the prevention of illness. 
 
Relationships and Asthma Card (1st Interviews): 
 
• Perspectives, involvement. Discussions. Defining situations. 
• Do you discuss your asthma with anyone apart from your GP and nurse? 
• What role do relatives play? 
• Do you know anyone else with asthma? 
• Have there been any situations where your asthma has been very noticeable? 
• Would you like anything to be done differently in the way your asthma is 
treated? 
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• Specific Questions (if not covered elsewhere) 
 
Loose structure/format of second Interviews 
 
The following is the guide that was used when conducting second interviews. In 
contrast to the first interviews, the topics listed here were not asked in any particular 
order. In addition, participants were re-consented (see Appendix D for rationale) 
following the development of the study beyond a specific focus on medications. 
 
• Re-consent participants: Say “I would like to understand not only your views 
about asthma and medication, but more specifically the reasons why you have 
these views”. Explain that understanding this may involve discussing how the 
person views health and illness in general, lifestyle choices and the person’s 
attitudes to life in general. Remind participants about anonymity/confidentiality 
and offer opportunity to withdraw.  
• Remind participants that the interviews are part of a student project and are in 
addition to the main study. Do not have medical training, not here as an advisor.  
• Biography Since Last Interview: 
o Use of preventive medication- what has happened since last interview? 
Why? (What are the relative differences between the 2 medications?) 
• Risk: 
o Can you tell me about unsafe/risky situations in your life since you’ve 
been living here?  
o Can you tell me about a time when your health/asthma has been at risk? 
o Can you tell me what happened? 
o Can you tell me about a time when you felt that you were overcoming 
your breathing difficulties? 
o Can you tell me about a time when your asthma affected you badly? 
o Can you tell me what happened? 
o Tell me about a time you were in fear of your health/asthma? 
• Medications: 
o Can you tell me about a time when you relied on having your asthma 
medication with you? 
o What about now? 
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o Can you tell me about a time when you were unhappy with your 
medication/inhalers/tablets? 
o What about now? 
• Life Goals: 
o What sort of person would you say you are? How would you describe 
yourself? How does health  (then specifically asthma) fit into this? 
o What do like to get out of life? Do you have any specific goals?  
o Can you tell me about a time when you have had problems pursuing 
these goals?  
o What about now? 
o Where does health (then specifically asthma) fit in to this perspective? 
o Are these goals affected by your health? 
o Asthma goals – what are they?  
o When you are looking after your asthma what are your main aims? 
Anything else? 
o Can you tell me about a time when these goals were not met? 
o What about now? 
o Would you say your lifestyle or anything about yourself has changed 
since the last interview? What are the differences between before and 
after entering the study? 
• Health and Illness 
o What are the aspects/characteristics of a healthy person? 
o What are the aspects/characteristics of an ill person? 
o What would you describe as an illness? 
o Can you tell me about a time when you would see yourself as an ill 
person? 
o Can you tell me what happened?  
o What about now? 
• Doctor-patient relationships 
o Can you tell me about a time when you were happy with your doctor or 
nurse. 
o Can you tell me about a time when you were unhappy with your doctor 
or nurse. 
o Why don’t you take your medication? Do you still pick it up? Does the 
GP think you should take it? 
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o Can you tell me what stops you from taking your GPs advice? 
o Do you feel that is your decision to make? 
o Is it important to you to feel you are making the decisions about your 
med taking? 
o Do you see any consequences for your choices? 
o Do you think there is any long-term risk in non-adherence? 
• Future: 
o Have you thought about your health/asthma in the future? 
   
 
 
220
A.2. Data-Sharing Focus Group: Protocol 
 
Location: Centre for Adult and Continuing Education, Norfolk 
Participants: No more than 10 people, at least one person from each accounting style. 
Seating/Materials: Round a table. JM to sit just back from the table to try and emphasise 
the discussion involves them not me. Paper and pen for each participant. Copies of 
vignettes. Table Mics and tape recorder. 
 
Thank everyone for attending. Introduce myself, remind them that everyone here all 
participated in the asthma study and were also interviewed by myself for my student 
project.  
 
What will happen in the focus group 
 
“What we will be doing in today’s group will be to have a good discussion and to get 
your reactions as a group of people who may well have some differing views, to some 
of the findings from the first interviews. The materials I will be showing you are sets of 
opinions that different people may make. They have no names attached and are not 
taken from any one interview.  They have been put together, from my own 
interpretations after I closely examined the different ways that people in interviews 
talked about their asthma.” 
 
i) This is a chance to talk about what you think. 
ii) I’m recording the discussion and I plan to transcribe what you say, but your 
names will not be used in the resulting transcription.  
iii) Later on in the research I will want to quote some of your words because 
sometimes using real people’s words can often be the best way to show what 
issues matter.  But this won’t be done in a way that would allow anyone to be 
identifiable. 
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Ground rules 
 
To help ensure everyone is comfortable with the discussion I would like to ask everyone 
to agree these ground rules: 
i) No one to discuss the details of what is said afterwards, or outside this room 
ii) Respect everyone else’s’ contribution – even if you disagree with it 
iii) No using insulting language to each other 
Is everyone happy to agree these? 
I hope we will have an enjoyable and interesting time.  
Tell the group I will make a few notes. These will be about who is speaking when so 
when I listen to the tape I can understand who I am listening to. Pass round the numbers 
and explain that I will just note down the number and a brief note about what is being 
talked about. 
 
Ice breaker: From (Crossley, 2002) 5-10mins. 
 
Tell participants that before the main group discussion, I’d like them to think of two 
people they know, one ‘healthy’, the other ‘unhealthy’. Divide piece of paper into 2, 
left side write down 3 characteristics of a healthy person, on the right 3 characteristics 
of an unhealthy person. Then feedback what they have written to the person sat next to 
them. When finished ask them to briefly tell the group a couple of things that they 
talked about. 
This is to help prepare participants to discuss the vignettes between themselves rather 
than to and from me as moderator and also primes them for the reflexive task of 
comparing themselves with each vignette. 
 
Anonymous Vignettes (“findings from interviews”) of 4 out of 5 accounting Styles 
 
Each vignette is a representation of ‘attitudes’ that can be seen in the data from Phase 
One interviews and what I consider to make up each accounting style. Whilst I have 
created each sentence within the vignettes, some of the words and phrases are direct 
quotes. Each vignette is spoken in the 1st person to elicit responses from focus group 
participants that position the speaker in relation to the person they consider to be 
represented in the vignette. Relational positioning is a key rhetorical strategy in 
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accounting for one’s own health (Radley & Billig, 1996), and is evident throughout 
Phase One interviews. 
 
Tell the group that I am going to pass round some of the findings from the one to one 
interviews and I’d like them to discuss them as a group. Pass the first vignette round, a 
copy for each participant. Remind them that the person speaking isn’t a real, individual 
person. What they show is how several people I interviewed talked about their asthma.  
 
Read the text aloud and ask them “What do you think of this person’s opinion?” Wait 
15-20secs. If nobody speaks then focus in on part of the vignette (e.g. Medications are 
necessary to control my asthma but I don’t rely on them.) and ask again “What do you 
think about this?” Keep representing if necessary. DO NOT OFFER ANY OF MY 
OWN IDEAS ABOUT THE VIGNETTE. 
 
Text in bold italics was the text (vignette) that was presented to the group. The 
preceding plain text is the description of the accounting style. 
1. Compliance as passive: The participant positioned her(him)self as engaged with 
their asthma, emphasising themselves as responsible and in control. There was a 
frequent use of the self-regulatory repertoire to position her(him)self against 
those who uncritically comply with medication instructions. This was an active 
rejection of compliance as an ideal. 
 
Medications are necessary to control my asthma but I don’t rely on them. I decide for 
myself whether I need to take a particular medication. Some people use medication 
for the sake of it and are dependent on it. I assess how I feel and then take the 
necessary action. 
 
2. Minimisation repertoire using several rhetorical devices to justify medicine 
taking. Participants with this accounting style either claimed that they did not 
have asthma, or that their condition was too mild to warrant adherence to 
prophylactic medication. Their own version of their condition was pivotal in 
justifying non-adherence to prophylactic medications, but did not blame 
healthcare for any mis-diagnosis. 
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I do not have proper asthma. I have very few breathing problems and the brown 
inhaler doesn’t make any difference to the way I feel. I don’t have any concerns 
about taking medication but I often forget to do so.  
 
3. Tension between lifeworld and medicine. Adherence potential threat to 
lifeworld: Participants positioned prophylactic medicine taking as incompatible 
with activities in their everyday life. However, individuals with this style 
appeared to resist challenging the medical directive on adherence. 
 
Asthma is a nuisance, an inconvenience but it doesn’t interfere with my life. I use my 
blue inhaler to stay in control of my asthma and I avoid situations that affect my 
breathing.  I should take the brown inhaler everyday and it is my fault that I haven’t, 
but I don’t want to be hooked on too many medications.  
 
4. Blame of healthcare breaches sick role contract: Participants blamed healthcare 
for not identifying the “real” cause of symptoms or for not communicating with 
them effectively regarding their condition and health generally. Taking 
prophylactic medications was therefore positioned as potentially treating the 
wrong condition.  
 
I don’t think I have asthma. I think doctors and nurses do not understand my 
symptoms and I don’t feel that they listen when I go to see them or talk about the 
causes of asthma properly. I am concerned about the side-effects of medications. The 
experts say that some medications are now unsafe so I don’t want to take a 
medication everyday that I don’t think works very well. 
 
Management of discussion 
 
• Latecomers: Expecting 10 people maximum so will start either when 8 are 
present or after 15mins. 
• Methodological confusion: Potential danger that participants spend too much 
time figuring out what to do and not actually discussing the statements. The 
icebreaker and representing the vignette is the strategy to deal with this. On this 
point it is essential I do not offer my own opinions as this type of intervention 
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undermines the whole point of having the focus group – which was to provide a 
different piece of data that isn’t subject to the same kind of interactional 
conditions as the face to face interviews, where I potentially represented an 
NHS, medical figure to which they were responding to. 
• People dominating or too many people speaking – will need to judge whether 
and when to interrupt. If I do interrupt look around the other participants and ask 
“What do other people think?” Do not target any one particular person. 
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Appendix B 
Transcription Conventions, Analytical Questions and Transcript Excerpts 
B.1. Transcription Conventions 
 
The following conventions were based on the system developed by Gail Jefferson in 
Atkinson and Drew’s “Courtroom Metaphor” (1979).  
  
[   ] Square brackets mark the start and end of overlapping speech.  
Position them in alignment where the overlap occurs. 
 
Underlining Signals vocal emphasis; the extent of underlining within 
individual words locates emphasis, but also indicates how heavy 
it is. 
 
↓        ↑ Vertical arrows precede marked pitch or intonation movement. 
 
CAPITALS mark speech that is obviously louder than surrounding speech 
(often occurs when speakers are hearably competing for the floor, 
raised volume rather than doing contrastive emphasis). 
 
°I know it,° ‘Degree’ signs enclose obviously quieter speech (i.e., hearably 
produced-as quieter, not just someone distant). 
 
(2) Numbers in round brackets measure pauses in seconds. Place on 
new line if not assigned to a speaker. 
  
(.) A micropause, hearable but too short to measure. 
 
solid.= =We had ‘Equals’ signs mark the immediate ‘latching’ of successive talk, 
whether of one or more speakers, with no interval.   
 
hhh Aspiration (out-breaths); the more hh the longer the out-breath. 
  
.hhh Inspiration (in-breaths); as for out-breaths. 
 
y’know? Question marks signal stronger, ‘questioning’ intonation, 
irrespective of grammar. 
 
((text)) Additional comments from the transcriber, e.g. context or 
intonation. 
 
(??) or (text?) Inaudible speech on tape. A guess as to what was said may be 
inserted with a question mark. 
 
heh heh Voiced laughter.   
 
sto(h)p i(h)t Laughter within speech is signalled by h’s in round brackets. 
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she wa::nted Colons show degrees of elongation of the prior sound; the more 
colons, the more elongation. 
 
>he said< ‘Greater than’ and ‘lesser than’ signs enclose speeded-up talk. 
Sometimes used the other way round for slower talk 
 
B.2. Questions to ask when Analysing Transcripts 
 
The following questions were used in applying discursive psychological tools to 
identify evidence of participants justifying their asthma management. 
 
What context was the version of events/asthma etc being set within? What is the 
purpose of what is being said? What version of themselves are they constructing? What 
alternative versions are being discredited? How are they doing this? What/Who do they 
blame for this behaviour? What “facts” are prevalent in the text? How were “facts” 
used? How were metaphors and stories used? What emotive vocabulary was used? 
What references were used to add authority to the account? How were timeframes used? 
What were the participant role patterns, (e.g. self as moral agent, doctor as 
“professional”). How were pronouns used and linked to verbs. What categories were 
constructed by the speaker? How were objects such as asthma, health, illness, 
medications constructed? When was the active or passive voice used, and what choice 
of expressions were there (e.g. good patient, compliant).  
Were similar positions were being constructed in other sections of the interview? Are 
there any important similarities or differences in what and how the text is being built? 
How do sections not explicitly discussing asthma management inform the analysis? 
 
Interpretative repertoires 
 
What kinds of interpretative repertoires did the interviewee deploy during the 
interview? What evidence is there to support that interpretation? 
 
Was only one repertoire used when discussing a particular topic? At what sorts of points 
are different repertoires used? This step also involves looking for whether different 
repertoires create new problems for the speaker? Is there a particular combination of 
repertoires as Wetherell suggested (M. Wetherell, personal communication, February 2, 
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2006) that creates “trouble” for the participant? Are there any tensions between 
repertoires? Do the participants orientate to these tensions? How do they manage these 
difficulties? A note of caution is needed here about contradictions that can be seen in a 
participant’s talk. What may appear as a contradiction may have some supportive causal 
link which made sense in the context of the interview. The issue for any discursive 
tension is whether the sequences of talk are closely linked in the interview. Has the 
person shown some management of this contradiction? If not then the analyst might 
hypothesise about a circumstance when this contradiction might be salient but needs to 
acknowledge if the participant’s orientation is absent. 
 
What evidence is there in the rest of the interview which creates a problem for the 
interpretations developed?  
 
Blame and accountability 
 
What versions of themselves and their behaviour were being constructed through the 
different devices and repertoires within the interaction? Was there evidence that the 
interviewee was managing a potential threat to this interpretation? Was there evidence 
that alternative versions were being discredited by the interviewee? How did the 
interviewee want to be understood?  
 
Moral discourses 
 
How might these different versions be interpreted from different perspectives both in 
medicine and in participant’s lifeworlds? What links were there to the moral discourses 
discussed in Chapter Two around appropriate illness management as seen from the 
asthma guidelines? Was there evidence that older discourses of asthma and emotional 
control were being deployed? Could interviewees be seen to utilising contemporary 
notions of illness prevention or those relating to symptom control as seen in the latter 
half of the 20th century? What other discourses were being activated outside of medicine 
and does the participant’s talk contribute something new to these different discourses? 
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B.3. Transcript Excerpts 
 
The table below summarises the excerpts from interview and focus group data that have 
been included in Appendix B.3.  Each excerpt includes one of the extracts that were 
reported in the analysis chapters. The excerpts enable the author’s choice of extracts to 
be examined and facilitate further insight of how participant’s versions were 
sequentially constructed within the interactions taking place.  
 
 
Excerpt  
Number 
Participant number Pseudonym Excerpt details Extract 
included in 
main text 
1 500367 Dave (D) Interview 2, pages 
3-7, D’s home 
Extract 1, 
Chapter 4 
2 121221 Irene (I) Interview 2, pages 
1-4, I’s home 
Extract 2, 
Chapter 4 
3 660345 Stephen (S) Interview 1, pages 
17-20, S’s home 
Extract 6, 
Chapter 4 
4 670287 
 
Martin (M) Interview 1, pages 
10-13, M’s home 
Extract 9, 
Chapter 4 
5 670289 
 
Dawn (D) Interview 1, pages 
17-20, D’s home 
Extract 10, 
Chapter 5 
6 650405 
 
Janet (J) Interview 1, pages 
7-11, J’s local GP 
surgery 
Extract 12, 
Chapter 5 
7 261284 Frank (F) Interview 1, page 7, 
line 1 to page 8, 
line 29, F’s home 
Extract 14, 
Chapter 6 
8 Focus group Participants 
numbered 1 to 
6 
Page 26-29, adult 
education centre 
Extract 16, 
Chapter 6 
 
 
Table 1: List of Transcript Excerpts included in Appendix B 
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 1 
D: I’ve probably still got one kicking around 2 
somewhere. 3 
 4 
JM: So can you just talk through, since I last saw you 5 
about a year ago what’s happened in terms of your 6 
medication use? What? 7 
 8 
D: Well at, at the moment, what I do now is tablet 9 
twice a day (1), but I’ve got (1) one thing that has 10 
changed (1) the (name) practice had a policy (3), 11 
more financial than any other reason (1) of taking 12 
people off ventolin and putting them on to 13 
becotide. 14 
 15 
JM: Right. 16 
 17 
D: (??) Then they tried something else which was 18 
even cheaper (1) becotide and the other one (2) 19 
didn’t work (1) they just didn’t. Well they, they 20 
didn’t work would be not quite right (1), they 21 
didn’t work as effectively as ventolin does. 22 
Ventolin worked beautifully (1) cleared it there 23 
and then (1) and I (3) had my repeat prescription 24 
dose halved right. (1) They were insistent that I 25 
have the brown inhaler and (.) the blue one (2). Ok, 26 
I was having two or the blue ones at a time (1), no 27 
you can’t do it you’ve got to have one. (??) ok. 28 
Then I got on to this asthma (1) study (1) and (1) 29 
(Name) very kindly changed it back so that I could 30 
have a ventolin as opposed to one of the others (1), 31 
quite a while ago now and that’s been (.) 32 
wonderful (2). It really has. (1) It’s made world of 33 
difference. 34 
 35 
JM: So that’s you, you’ve still got your ventolin? 36 
 37 
D: Yeah. 38 
 39 
JM: Yeah. 40 
 41 
D: (2) I’d get through a ventolin probably (1) about 42 
one (2) a month, five weeks, four – five weeks (2). 43 
Something that (??). 44 
 45 
JM: (2) ok, a, and that’s, how long has that been (.) the 46 
situation? 47 
 48 
D: Oh, years. (1) what that I’ve used ventolin? 49 
 50 
JM: Well you, no, you sort of saying you’ll use it once 51 
every four or five weeks or? 52 
Excerpt 1: 500367, Interview 2, pages 3-7, D’s home 
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 1 
D: No, no, no I don’t use it once every four weeks, I 2 
have a new one every four or five weeks. 3 
 4 
JM: Sorry, right. 5 
 6 
D: I use (2) I’d say quite, you know probably I would 7 
only, you’ll have a day like today when the 8 
weather suddenly changes (.) and I will probably 9 
use it at some point during the proceedings of 10 
today (1) and probably again at night time if it. 11 
 12 
JM: (1) Yeah. 13 
 14 
D: It’s impossible to judge. (.) And you’ll have a day 15 
(1) when the sun shines when you, you just don’t 16 
(.) at all. (3) It’s a different thi, I mean (2). I’ve 17 
heard the argument about air quality and (.) 18 
everything else but I mean (3), this isn’t a city full 19 
of smog I mean it’s (2) I work on the edge of quite 20 
a big city but, 21 
 22 
JM: Yeah. 23 
 24 
D: The air quality isn’t perfect but it’s all we’ve got 25 
(3) down here in the swamp part of ((place name)) 26 
we have to put up with what we can I’m afraid it’s 27 
(2). Yeah I’m sure, I’m sure it certainly, I’ve been 28 
on (1) we’ve got friends that live up in the lake 29 
district (1) and I’ve been up there (1) for (2) a 30 
week and certainly two or three days into that it’s 31 
amazing the difference. I can breathe a lot, lot 32 
easier than down here. 33 
 34 
JM: Down here? 35 
 36 
D: Yeah. 37 
 38 
JM: Even though you live in the country? 39 
 40 
D: Even though I live in the country, yeah, yeah. 41 
Living in the countryside and then they grow a lot 42 
of, my family are farmers so I mean, I’m the worst 43 
person in the world (1), but they grow a lot of oil 44 
seed rape around here, an awful lot of weed. 45 
 46 
JM: Right, right, right. 47 
 48 
D: (2) Yeah. 49 
 50 
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JM: (1) So what, what are the differences do you think, 1 
or the relative difference between (1) eh, tablets 2 
and the brown inhaler? 3 
 4 
D: (3) I think it’s, I think there’s an element of 5 
psychology comes into it. (1) And I think there’s a 6 
degree of psychology comes into everything (1) in 7 
as much as (.) partly because I think those tablets 8 
are doing some good (.) it’s certainly got to help 9 
the job a lot (1) help the fact that they are. 10 
 11 
JM: Yeah. 12 
 13 
D: (2) Em, (1) the brown one I’m absolutely, I’ve 14 
managed to convince myself beyond a reasonable 15 
doubt, it doesn’t work or its effects are (.) 16 
minimum, minimum effectiveness. (2) I know, I, 17 
I’ve had (1) asthma (1) all my life. I’ve you know, 18 
I started with the little pink tablet but through to 19 
the ventolin, then went on to the big white ones 20 
which were foul, before that we had spin halers 21 
and all these thing we used to have to put out 22 
fucking cups in and things and cracking and things. 23 
I’ve been through the full nine yards with this. (1) 24 
As soon as ventolin appeared (1) instantly you 25 
have something which is a cure (1) (??). You went 26 
from having (1) asthma (1) to using it (.) to being 27 
perfectly normal again (1), like that. (1) It was (2) 28 
a big, big difference. (5) The brown, I mean with, 29 
I’ve had two or three or four different doses of the 30 
brown one and I’ve played about with it for (1) a 31 
week, for (.) nine months sort of thing, and I’m 32 
adamant that it’s not made any difference. (3) It 33 
really hasn’t. (1) Yeah and I did forget to take it 34 
and I did forget to, it was just (.) h, how (4) and 35 
the, this thing about using the two in conjunction. 36 
(1) Well, (2) it just, I just never (1) really accepted 37 
it. 38 
 39 
JM: (1) So is it, is it just the eh (3) the drug itself or is it 40 
the device that, that’s in it as well [is there 41 
anything else about] 42 
 43 
D: [Oh no, I don’t think] there’s anything (??). No. 44 
 45 
JM: It’s not like I 46 
 47 
D: (3) I, (2) it’s, it’s, I, I have experimented with it 48 
and, and you know a week playing with it and then 49 
a week without it and then a week with it and I 50 
really can’t tell you that there, that there was a 51 
great deal of difference among any. 52 
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 1 
JM: Right 2 
 3 
D: There really was none (?) (2). I’ve been better with 4 
these tablets in as much as I know for a fact that I 5 
have ordered less ventolin (.) since I’ve been using 6 
those than I was before. 7 
 8 
JM: (1) Do you think you’ve eh, (1) taken (.) the tablet 9 
more regularly? 10 
 11 
D: I’ve taken the tablet, yeah. 12 
 13 
JM: Right. 14 
 15 
D: Oh definitely, definitely (2). 16 
 17 
JM: What would you say about the (2) given what 18 
you’ve said about psychology (2) what you know 19 
about it and the fact that you definitely taken them 20 
(??) more regularly (1) what do you think the 21 
possible differences in treatments? 22 
 23 
D: (3) Well I mean there’s lots, for all I know they 24 
could be the same thing, two different formats, (.) I 25 
don’t know I mean I’m not (3). Going back to what 26 
I said at the beginning (1) I think there’s an 27 
element of psychology in as much as (.) because 28 
I’m (1) pretty adamant I’ve been told that this will 29 
(1) help effectively but, (.) I’ve been taking it, I’ve 30 
been going along with it, I’ve certainly as I said, 31 
used less ventolin at the same time (2). No, no 32 
problem at all. (1) Brown one was very hit and 33 
miss in as much as I would forget to take it didn’t 34 
matter where I put the thing. (2) I had them 35 
scattered, I had one in the car, one in the, beside 36 
my bed, one in my office and I’d still forget to take 37 
it. (1) I don’t know why but I just did.  38 
 39 
JM: (3) That’s interesting. 40 
 41 
D: (2) I think it was, I think it was (1) the fact that (1) 42 
it, it’s so similar to the original (.) the blue one, the 43 
ventolin (.). That (1) you use when you’ve got 44 
asthma, when you’re having an asthma attack or 45 
(??), you use the (??) (1) and it’s (1) that’s a cure, 46 
you pick it up, you reach for it at that point (2) to 47 
(1) go to the action of using exactly the same sort 48 
of (1) when there’s nothing wrong with you, is not 49 
a natural (2), and I think there is an element of that 50 
feeling. 51 
 52 
   
 
 
233 
JM: Yeah, that’s interesting. (3) I was just going to pick 1 
up on a point you made last time I was here, (1) 2 
which was (1) the, the, that there was cure (1) for 3 
your form of asthma ie. Ventolin 4 
 5 
D: Mmmm. 6 
 7 
JM: And eh, (1) preventative medication was then 8 
something which came in recently [or relatively 9 
recently] 10 
 11 
D: [well that, that is] it is relatively recently (1) and 12 
(2) up until (2), it’s only up until those tablets it (.) 13 
had (.) far to go. (3) preventative. I mean I (2), I’ve 14 
got two or three friends that have got the same sort 15 
of asthma as myself (1) and we’re all pretty much 16 
on a par (.) in as much as our beliefs are (2) about 17 
what I just said.  18 
 19 
JM: Right. (3) d, do they, do they use (1) eh, any other 20 
medications? 21 
 22 
D: well they’re still, they’ve not got the tablets. 23 
 24 
JM: No. 25 
 26 
D: they’re not on the study but they are still using (.) 27 
the brown one in a spasmodic sort of way. 28 
 29 
JM: (1) Right. (2) And have you, do you think there are 30 
differences in your (2), your, your ability to sort of 31 
so things? Do you know what I mean, like (3) what 32 
you were doing before? 33 
 34 
D: (5) I certainly think that the (1), the, the things that 35 
usually trigger (1) asthma are (2) not necessarily 36 
always the things you forget (??) (1) If you’d 37 
expect something, if I left here and forgot to take 38 
(2) my ventolin with me (2) I could pretty much 39 
guarantee that I would suffer asthma at some point 40 
during the proceedings (2) before. (1) Now, that is 41 
certainly less likely (6). You know, before you of 42 
thought oh my god I haven’t got and then it’s 43 
inevitable you’re going to have an attack. Now it’s 44 
more case of oh, it well it doesn’t matter I’ve got a 45 
tablet (??). 46 
 47 
JM: Right, (4) do you think you’re an advantage to (2) 48 
your friends (1) like (??)49 
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 1 
 2 
 3 
JM:  Ok, I just wondered if you can tell me, (1) I, I was 4 
here about a year ago wasn’t I? Em, and you had 5 
just entered the study then (.) and you were 6 
prescribed (1) eh, a tablet I think. 7 
 8 
I: That’s right I’ve got to confess I don’t (1) very 9 
much take it now but em, (1) I take so much 10 
medication at the moment, (1) you know and I 11 
didn’t think (.) that that made that amount of 12 
difference to me. (1) I just stopped, you know? 13 
 14 
JM: How long after (1) you were prescribed it? 15 
 16 
I: Oh, about I only stopped about couple, two or 17 
three months ago now. (1) But at the time, (.) I 18 
thought I’d finished the study anyway and I just. 19 
 20 
JM: Mmmmm. 21 
 22 
I: °I got to admit I just found other ways (??) °.  23 
 24 
JM: What ways? 25 
 26 
I: Well, if that’s in your way just throw them there. 27 
I’m eh, (1) just back to my normal medication and 28 
(1) I still have to take that every night. (1) I suffer 29 
cramp a lot, I take a cramp tablet, I take pain 30 
killing tablets at night, (1) and I just think that’s 31 
keep pushing tablets into me (.) I ain’t  really, 32 
really into that much, (1) you know? (2) °So I just 33 
didn’t (.) bother too much°. (1) You see the thing 34 
with the asthma thing is (1), that ain’t my 35 
primarial, (1) I, I have asthma, I have asthma 36 
attacks (1) especially my worst times are (1) as I 37 
told you before, (.) when the windows have to be 38 
closed due to inclement weather outside (1) and 39 
that then I can guarantee I shall have an asthma 40 
attack in the night (.) but, (.) it’s either that or (.) 41 
get blown out your bed almost, you know cos our 42 
windows aren’t designed (2) so that, you know 43 
that’s a stupid window we got up there, (1) and 44 
that blow right through and em, (1) he’s got 45 
tinnitus in the ear and he got ear ache once through 46 
it. (1) So I have to just close it down (1) but 47 
otherwise when I got it open and get (.) (??) 48 
indoors (1), I generally you know don’t, (1)  I 49 
won’t say I suffer as much perhaps some others. 50 
When I do get it it frightens me (1), you know? I’m 51 
always taking my (1) eh, puffer with me 52 
Excerpt 2: 121221, Interview 2, pages 1-4, I’s home 
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 everywhere (1) but just before Christmas (2), I had 1 
a em, (1) I had the flu injection in October (1), now 2 
I don’t know whether that was relevant or not cos I  3 
have the flu injection every year, (.) but this 4 
particular year, (.) last year (1), I had very bad bout 5 
of bronchitis (1) and I was on antibiotics (2) and 6 
(1) that didn’t clear it up and I had to have another 7 
dose of antibiotics. That really went on for about 8 
(3) all of two months that did you know (1). 9 
Concurrent and I just couldn’t breath (.) and course 10 
I mean I had to use the puffer (.) more frequent 11 
than ever (.) for that (1) and that was really nasty. 12 
(1) But as I said I have occasional bouts what, but 13 
mostly if the weather (1) and I can get some air (1). 14 
I do get it (??) as well but not so much you know? 15 
(1) So I don’t, I’ve got so many other things it’s 16 
like, you, you  know so, but I just, that ain’t a 17 
primarial problem. That is when I get it (1) cos I’m 18 
afraid I’m gonna die cos I hate, (1) I think it would 19 
be an awful death. (1) gasping, (1) but (1) the other 20 
things I got are like arthritis is fine and the pain (1) 21 
dominates my life. (2) And the condition I now 22 
told you about that’s eh, (1) I’ve had a major 23 
operation for (1) em, (2) adhesions and for some 24 
reason or other, I don’t know why (1) I just, you 25 
know, don’t really like (1) now, say if I was talking 26 
to you, I’d have to go now but I (??). (1) That’s, 27 
that wrecked my life. (1) Where ever I go (1), 28 
when that come on (1) I have to go (1) and that’s 29 
not pleasant. (1) As a child you know, there can be 30 
holiday’s that, days out (1) I take Imodium for that, 31 
(1) if I do and sometimes that don’t even work. (1) 32 
So what, what with that and (1), and the pain of my 33 
asthma, em , my arthritis (.) you know, that’s all 34 
just (1) combination of things, (1) and my general 35 
(1) eh, (.) feelings on illness itself is em, (1) I think 36 
that’s the price we pay with God, (1) it seem like to 37 
me (1) because em, (2) these things just sort of 38 
seem to happen (1) in an almost way you know? 39 
 40 
JM: mmmm. 41 
 42 
I: (1) And also I think that (1) the arthritis is ruled by 43 
the weather. (1) Now today it’s nice and dry (1) 44 
and I shall be alright today. (1) I can tell you when 45 
it’s wet without even looking (1) cos the pain is 46 
horrendous (1) it’s like having toothache in your 47 
back and all down your neck. 48 
 49 
JM: mmmm. 50 
 51 
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I: And I just em, (2) as I say I’ve got so much going 1 
on (1) in my actual (3), on the whole (1) one 2 
doesn’t, you know unless it happening (2) I don’t  3 
think too much about these things (1) you know, 4 
(1) unless they’re actually occurring do get? 5 
 6 
JM: Yeah. 7 
 8 
I: Do you understand that? 9 
 10 
JM: yeah, so you, when you entered the study and you 11 
were prescribed the tablet. 12 
 13 
I: Mmmm. 14 
 15 
JM: You said you stopped taking it two or three months 16 
ago, were you taking it every day or? 17 
 18 
I: I took it every night. I had it up beside my bed, but 19 
what actually happened I lapsed (1) eh, over 20 
Christmas time (.) I didn’t get one in because I 21 
didn’t order it in time (1) and then I went without 22 
and then I just sort of (1) left it you know? 23 
 24 
JM: (2) You said you didn’t notice any difference? 25 
 26 
I: I haven’t noticed any difference because (1) I still 27 
had the attacks (1) you know, (1) but em, (2) as I 28 
said I’ve also got another one I take for (2) eh, 29 
(??). (2) Arthritis (1) now I don’t like that tablet at 30 
all (1) I, and I don’t even think that works either 31 
(1) [and actually 32 
 33 
JM: What don’t] you like about them? 34 
 35 
I: Pardon? 36 
 37 
JM: What don’t you like about the tablets? 38 
 39 
I: (1) I think you keep filling your body up with all 40 
these tablets and (1) you know (3), I don’t know I 41 
just feel that, is that causing my problem (2), you 42 
see with my problem (1) my stomach problem (1) I 43 
just, I (??) with my stomach. (2) em, (1) I feel 44 
everything I eat (1) I get pain in here I ain’t been to 45 
the doctors with it yet (1). Sort of there like, I don’t 46 
know if I got an ulcer or what (.) and I, I think 47 
tablets (2) you know, (1) I don’t know it might be 48 
me, I ain’t really a (1) big fan of tablets. (1) You 49 
see but I have been taking them for years (1) 50 
coproximol and I’m saying years, no there’re now 51 
telling you (1) that they’re bad. (1) They going to  52 
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 take them off the shelf, don’t know if you saw the 1 
article? 2 
 3 
JM: (1) No, I, I didn’t see it, Em , (2) so (2) you didn’t 4 
notice any difference with the [tablet at all? 5 
 6 
I: Not really no] cos I still had the [asthma 7 
 8 
JM: But you] (1) were happy just to carry on taking 9 
them? 10 
 11 
I: I well, I, I mean I take things but as I said I just 12 
lapsed once (1) because they, I didn’t order them 13 
(1) and you have to order them so many days prior 14 
(1) and that was all over Christmas (1) and I didn’t 15 
feel any different so I just didn’t (.) re-ordering. 16 
 17 
JM: So are you using any eh, (1) are you using [the 18 
brown inhaler?] 19 
 20 
I: [I, I have my] inhaler. 21 
 22 
JM: (1) What, what a blue one? 23 
 24 
I: Blue one all the time. 25 
 26 
I: Is that all you have at the moment? 27 
 28 
I: It is. 29 
 30 
JM: How long have you (??) using that for? (1) Since 31 
Christmas has it just been the blue inhaler, you 32 
stopped taking the tablet? 33 
 34 
I: Oh yeah the blue inhaler if I need it yeah. (1) I take 35 
it when I need (1) see that’s my problem (1) if I 36 
need something (.) I grasp to it like that inhaler you 37 
see, when I’m having an (1) attack (.) that inhaler 38 
is in my hand and (1) inhaling it obviously (1) but, 39 
when I’m (1) going about my life (2) I don’t eh, 40 
tend to (1) think. (1) It’s like mostly on my brain 41 
(2) rightly or wrongly, you know I mean if I was to 42 
suffer with a real episode, obviously (1) I don’t 43 
really think I’m (2)  44 
 45 
JM: Have you [any 46 
 47 
I: There] must be a lot of people, a lot worse than I 48 
am, honest. 49 
 50 
JM: Have you had any attacks since? 51 
 52 
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S: ventolin and then maybe five, ten minutes later 1 
take (1) the, the Becotide, (1) or Beclomethasone 2 
or 3 
 4 
JM: Yeah. 5 
 6 
S: whatever. 7 
 8 
JM: Yeah. 9 
 10 
S: Em, 11 
 12 
JM: (2) but (.) did you, how long did you take the 13 
brown, the brown one for the first time or anytime 14 
you’ve taken it how long did you do it again for 15 
or? 16 
 17 
S: Em, (3) not very long. (1) Not very long at all 18 
really. 19 
 20 
JM: Couple of days or (1) a week? 21 
 22 
S: Yeah, could have been a week or two weeks or  23 
 24 
JM: (1) Right, and did you notice any changes at all in, 25 
in (1) your lifestyle? 26 
 27 
S: Errrr, (1) yes I have (1) noticed some benefit from 28 
using (.) Becotide or (.) Beclomethasone or you 29 
know? 30 
 31 
JM: Yeah. 32 
 33 
S: When I have taken it regularly there’s been (1) 34 
some benefit from using it. 35 
  36 
JM: Wh, what, which is? 37 
 38 
S:         (1) Em, (4) lessening of (.) asthma symptoms (1) 39 
basically. Em, (2) not quite as wheezy (2) but em, 40 
(2) I sort of find that (1) unless my asthma’s really 41 
bad (1) which is usually when I’ve got a cold (1) or 42 
you know, whenever I get the cold I get a chest 43 
infection. (2) And (1) unless it’s at peak times in 44 
the year i.e. summer (1) or when I’ve got a cold (2) 45 
my asthma is (1) or has been ((coughing)), sorry, 46 
up until the last three years (.) fairly (.) mild, if you 47 
know what I mean? Only in extreme times have I 48 
needed to use (1) em, any form of prev, (.) 49 
medicine. I mean there was a time where, in the 50 
winter (1) I didn’t use ventolin in the winter at all. 51 
(1) Em, now I’m using it all the time (2) more so 52 
Excerpt 3: 660345, Interview 1, pages 17-20, S’s home 
239 
 
 in, as I say in summer and if I’ve got a cold. So 1 
what I tended to do (2), when my asthma was (1) 2 
milder in winter (1) and when I was well (1) I 3 
didn’t use any (2) asthma preventative or reliever 4 
(1) and then at times when I was unwell (1) or in 5 
summer, I tended in the last, sort of six or seven 6 
years (2) to go with em, (2) go to the doctor with a 7 
chest infection and then it’s just been a course of 8 
antibiotics which never work (1) cos I’ve had so 9 
much flucloxicillin or (2) amoxicillin I don’t know 10 
what you know? Every time I go to the doctors 11 
with a cold (.) I get a chest infection. Get a chest 12 
infection you get bad asthma (1). If I run out of 13 
ventolin I need more ventolin and it’s usually got 14 
to the stage where (.) the doctor will prescribe me 15 
prednisolone (1) er steroids eh, to boost me up 16 
again. (2) Or at times, seasonal times an 17 
antihistamine (2) and more ventolin, and that’s 18 
how it’s worked. It’s sort of been a pattern of (.) 19 
not having many symptoms and not having any 20 
preventative or reliever (1) or very little reliever 21 
(1) and then (1) when the times come when I’m not 22 
well or seasonally in summer (1) I have (3) still no 23 
preventative medicine. Go and get prescribed it (.) 24 
from the doctor (.) knowing full well that I’m not 25 
going to take it (1). I don’t know why. 26 
 27 
JM:  Did you initiate going to see the doctor for the 28 
preventative medication? 29 
 30 
S: (2) What in, initially or? 31 
 32 
JM: Sort of, em, em (1) well yeah both actually, I 33 
mean, I mean initially I guess they came up with 34 
(2) the idea to prescribe the brown inhaler, is that 35 
right? 36 
 37 
S: Yeah. Yeah. 38 
 39 
JM:      And, and then (1), then after that you, it comes 40 
round to the summer (1). 41 
 42 
S: Yeah. 43 
 44 
JM: What would happen, w, would you, would think 45 
“right I’ll go and get some preventative 46 
medication?” 47 
 48 
S: Yeah. (1) Normally, usually around June time. 49 
 50 
JM: Right. 51 
 52 
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S: Sort of mid June (1) my asthma symptoms (1) get 1 
dramatically worse. (1) Em, (1) due to (.) grass 2 
being cut and 3 
 4 
JM: Yeah. 5 
 6 
S: pollens and (1) dust and everything else. (1) So (1) 7 
at that point (.) I sort of think, oh you know (.) 8 
usually get a summer cold (.) or my chest starts 9 
getting tight and I think “oh (.) I’m getting low on 10 
ventolin” so I go to the doctors and say (1) I’d say 11 
the last sort of three or four years (1) it was more 12 
then to get the antihistamines cos I found they have 13 
actually worked (1) quite a lot. (1) You know 14 
they’ve significantly (1) decreased the (1) asthma 15 
symptoms in summer. (1) Em, and I’ve sort of 16 
used those as a preventer (1) as such (1) and (.) I 17 
do take them because they do make a lot of 18 
difference ((said with mild chuckle)). (1) You 19 
know? Em, (1) I mean I’ve been prescribed with 20 
them again this year (1) for the summer (1) and I 21 
did take them and they did make a difference. And 22 
they usually do (.) make a difference. Em, whereas 23 
the (3) Becotide (1) I just get out of the habit of 24 
taking it. (.) I just (2), I’ve never forced myself (2) 25 
to get in the habit of taking it. (2) 26 
 27 
JM: So when you went along and you went to go and 28 
get ventolin and antihistamines, not specifically to 29 
get Becotide or, or whatever? 30 
 31 
S: No, no. 32 
 33 
JM: The, that would obviously come up and they’d 34 
prescribe it. Would you ever discuss (.) how you 35 
felt about that or? 36 
 37 
S: No, no, I’ve never really (2) said how I feel about 38 
it. I mean, I’ve, I’ve always sort of said (1) thought 39 
that I need some form of preventative medicine (.) 40 
at certain times in my life (3). As I say, at certain 41 
times of the year not needed any (1). Em, (2) but as 42 
I say you know when I (1) in recent times when 43 
I’ve gone to the doctors it’s because of I’ve been 44 
unwell (.) basically or the season, if its (.) summer 45 
and I’m unwell (2) so unless (2), unless I am bad I 46 
wouldn’t go to the doctors. Em, (2) or unless I was 47 
out of ventolin (.) I wouldn’t go to the doctors. (3) 48 
I mean several doctors over (2) a long period of 49 
time tried to get me to go to (1) asthma clinics and 50 
it’s not a case of (.), it’s not been made available, 51 
because it has, you know? (.) Every surgery that 52 
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 I’ve been at has sort of said you know, (1) “we’re 1 
running an asthma clinic (1) every (1) whenever 2 
(2), would you like to attend you know can you 3 
come and attend to it?” (2) Which (2) I never 4 
really have, never sort of, you know? 5 
 6 
JM: Why? Why did you not want to? 7 
 8 
S: Em, (1) I don’t know really. I don’t know (2). I 9 
don’t know. 10 
 11 
JM: (1) Just, I’m just interested in em, (.) you saying 12 
that you wanted to manage your, I mean how, is it 13 
only recently that you really (1) decided that you 14 
really wanted to manage your asthma? 15 
 16 
S: Yeah, I mean [we read] 17 
 18 
JM: [Or has it] (.) been like that you’ve not (1) done 19 
anything about it? 20 
 21 
S: Em, (1) I suppose because it’s been getting worse 22 
(1) over recent years (1) em, (2) whether it’s partly 23 
the toll of me smoking (.) or (2), or what, I don’t 24 
know. Or more stress because of the work 25 
environment that I’m now in. (1) Being self 26 
employed (2) or, or being married I don’t know. 27 
((laughter)) But, you know my, my asthma has got 28 
worse over the last sort of three or four years (1) 29 
and (2) yes I would like to control it better. (3) As I 30 
say you know, with, (2) with (.) and when we first 31 
heard about the eh, (.) this tablet, I don’t know 32 
whether it’s the same tablet we’d heard about em, 33 
(.) read it in a newspaper, saying that there was a 34 
new tablet coming out to (.) try and prevent asthma 35 
(.) or to cure, not cure asthma you know it’s like 36 
this wonder pill for asthmatics (.) that might 37 
(.)have the answer and, my wife read it and 38 
showed it me and I thought “now that’s (1) that’d 39 
be handy” you know what I mean? (1) If it actually 40 
worked. 41 
 42 
JM: Mmmmm 43 
 44 
S: Rather than taking the ventolin all the time or (.) 45 
trying to take the Becotide at various points or (.) 46 
antihistamines or steroids or, or what, you know? 47 
(1) Em, (.) and then as I say, I was contacted 48 
through the study (2) em, if I’d like to take part in 49 
this (2) study, I suppose. 50 
 51 
 52 
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JM: What sort of patterns were for[med] 1 
 2 
M:           [Which the the= 3 
 4 
JM: =For both, wh what happened with ((? Sentence 5 
doesn’t seem to finish)) 6 
 7 
 (.) 8 
 9 
M: Well the first, the first thing I when I was (.) when 10 
I went on the nebuliser I think I was given 10 times 11 
the dose that you would get from the inhaler (1) so 12 
at the onset I realised that (.) I mean within reason 13 
one puff in 4 hours weren’t actually going to do me 14 
much good as way of relief (1) um and they did 15 
say that you know you really (.) are able to give 16 
yourself more than that if the symptoms demand it. 17 
(1) I mean for instance you have two puffs (.) but 18 
in any event you’re getting 10 times the dose on 19 
your nebuliser (1) um so that was a comfort 20 
because obviously that is so so effective with me I 21 
really don’t need to resort to th(h)o(h)se kind of 22 
doses it really is you know one puff perhaps two (.) 23 
um (.) and you feel the symptoms you know (1) 24 
um (.) diminishing (.) in half a minute (.) its s:o 25 
effective (.) and if its so effective you know (1) 26 
one wonders what the you know what the brown 27 
one is is um(.) what use that is the brown one you 28 
know if if I suppose in time you might even get 29 
immune to the(.) to the ventolin, the salbutamol. 30 
 31 
JM: Has the nurse discussed that with you= 32 
 33 
M: =No, no 34 
 35 
JM: So y you did you did you actually take the brown 36 
one at all when you were given it or(.) did you just 37 
use the blue one 38 
 39 
M: I did actually to start with and then ˚didn’t do till it 40 
actually just was there but I didn’t actually [(??)˚] 41 
 42 
JM:               [What] 43 
what stopped you using it do you think? 44 
 45 
M: ↓Probably(.) I don’t really want to be hooked on 46 
these for the rest of my life sort of thing(.) possibly 47 
(.) um at the time I was going through um (.) 48 
problems with um (1) my eyes which I was under a 49 
cornea consultant (.) because um I got very itchy 50 
eyes and it um (.) was diagnosed (??) which um (1) 51 
at that time I you know was taking medication for 52 
Excerpt 4: 670287, Interview 1, pages 10-13, M’s home 
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 that (1) and obviously I need to have um (.) sort of 1 
the eczema controlled with um (.) I’ve got one 2 
cream that is magic on me but is obviously quite a 3 
strong steroid which isn’t that essential um and 4 
again I (.) I was warned not to take that too 5 
regularly (nevertheless?) (.) fantastic does a good 6 
job and a couple of (.) couple of doses of that and 7 
the problem is gone for 10 days to a fortnight. SO I 8 
THINK IT WAS A:::LL THAT I I DON’T 9 
REALLY WANT TO BE HOOKED, DO I NEED 10 
TO BE HOOKED ON ALL THIS STUFF AND IF 11 
THERE IS ANYTHING I CAN DROP OFF 12 
˚obviously I s’pose the beclonase was was one of 13 
them˚.  14 
 15 
JM: And did you go back to (.) the surgery and sort of 16 
discuss (.) the way you managing your asthma= 17 
 18 
M: =No. Um (1) basically (.) I didn’t (1) I didn’t go 19 
back unt:il (.) um (1) ((trying to recollect)) how did 20 
I get involved with the asthma clinic? ((asking self 21 
the question)) I think it was the GP is saying (.) um 22 
was was looking at the number of times I had had 23 
the salbutamol on prescription (.) and saying I 24 
don’t know whether they actually just got the 25 
asthma nurse or or (.) or whether (.) um she 26 
thought it was my an idea that they could be better 27 
managed than I was doing so at the time (.) that I 28 
saw the the asthma nurse and (.) um perhaps saw 29 
her a couple of times before (.) she rang me and 30 
said would you like to (.) y’know join the scheme. 31 
 32 
JM: Right= 33 
 34 
M: =So I have it has been. But I stress it is not a 35 
debili(.)tating (.) problem insofar as my (.) y’know 36 
˚my work is concerned or my you know my life is 37 
concerned. (.) Um (.) I don’t play (.) football I do 38 
(.) occasionally bouts of strenuous work (1) um but 39 
its managed˚ and I’m very fortunate in that (.) you 40 
know I can choose (in the middle?) ((of 41 
something?)) what what I do (.) a- at work rather 42 
than (.) um (.) you know being in a managerial 43 
position I mean I don’t wanna (1) y’know er (2) 44 
brag but you do have a little bit of flex(h)ib(h)ility  45 
um and if there’s you know y’know there’s 46 
somebody else available who will move the grain 47 
lorry up and you know I would do his job while he 48 
did while he did that (.) and if its unavoidable well 49 
I (.) I’ll do you know put a mask on and move the 50 
lorry myself which is its not an issue as far as I’m 51 
concerned (1) you know the guy um (.) you know I 52 
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 can certainly ask somebody else can you just move 1 
down (.) while I take over from you= =Everybody 2 
knows that the reason I’m doing it I’m not 3 
frightened of work but they just (.) I can manage it 4 
in that way (.) um (.) so (.) I suppose you could say 5 
well actually you are changing your lifestyle but 6 
not to that degree. 7 
 8 
 (1) 9 
 10 
JM: Um (.) Um when you entered the study (.) and you 11 
were randomised to the (.) brown inhaler= 12 
 13 
M: =↑Mmhm  14 
 15 
 (1) 16 
 17 
 JM: did the nurse talk about how she would like use it= 18 
 19 
M: =Yes 20 
 21 
JM: ˚What did she say˚ 22 
 23 
M: She said morning and night 24 
 25 
 (.) 26 
 27 
JM: ˚What did you say˚ 28 
 29 
M: I said fine. if its part of the study, of course I’ll do 30 
it 31 
 32 
JM: And and [have] 33 
 34 
M:     [And ] I have been doing it 35 
 36 
JM: ˚And how long’s that been, how long have you 37 
been on it˚ 38 
 39 
 (1) 40 
 41 
M: With the study you should have the de↑tails of 42 
that= 43 
 44 
JM: =I have but its in my car= 45 
 46 
M: =Right [okay]  47 
 48 
JM:  [hh   ] 49 
 50 
M: um its probabl::y (1) err 51 
 52 
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JM: It’s a few weeks is it 1 
 2 
M: I think I’ve got it in my diary but its been going 3 
just before Christmas was it?= 4 
 5 
JM: =How’s it been going 6 
 7 
M: Absolutely fine yeh I haven’t missed a I haven’t 8 
missed a (.) um (.) you know a preventative dose? 9 
(2) ˚I’m quite disappointed  (??)˚. (.) I mean  I I 10 
have been as religiously as I possibly can, (1) if the 11 
study is going to have any value you don’t 12 
particularly want people doing their own thing if 13 
you’ve been told to take it ˚twice a day then you 14 
take it twice a [day˚] 15 
 16 
JM:   [And] you’re happy with that= 17 
 18 
M: =↑Of course, (1) its part of the survey and if it does 19 
(.) I mean if it MAY IF IT ISN’T DOING ME 20 
ANY GOOD WELL (.) AT LEAST ITS DATA 21 
FOR SO(h)MEBOD(h)Y EL(h)SE TO MAKE A 22 
DECISION of whether its doing me any good.= = I 23 
must admit WHEN WHEN my number was called 24 
out (.) I think there is a there is another group 25 
taking um tablets isn’t there (2) ((perhaps non-26 
verbal confirmation from I)) I WOULD HAVE 27 
LIKED TO TRY THAT ˚but it wouldn’t make any 28 
difference˚ (3) I was you know I said I was happy 29 
to do the survey and (1) if it involves standing on 30 
your on one leg and hopping round before you take 31 
it I mean that’s you know that’s what you sign up 32 
to do isn’t it. 33 
 34 
JM: Have you noticed any differences? 35 
 36 
M: Well I haven’t had any symptoms since I must 37 
admit (.) um it isn’t a kind of a (.) polleny type of 38 
season (1) um (2) I haven’t (2) if I’m taking the 39 
Ventolin since I’ve been on the survey if I’ve only 40 
taken the Ventolin twice ˚with the brown inhaler 41 
that’s the up side (1) and that was probably one 42 
evening when I’d got another you know a cold (2) 43 
but um˚ (1) WHETHER OR NOT (2) ITS EARLY 44 
DAYS but I mean as far as I can see yes I mean its 45 
obviously reduced the need to take the (.) to take 46 
the (.) curative. 47 
 48 
JM: As you say its early days but do you (.) do you 49 
think that um (1) the benefits outweigh (.) the ˚you 50 
were sort of saying earlier that you didn’t want to 51 
be hooked on [ ((too many medications??))˚ ] 52 
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D: Yes I wrote about I think I think I did I wrote about 1 
walking up a hill oh yes walking up a hill sleeping 2 
all night and um (.) being able to go round peoples 3 
who’ve got animals (.) which live indoors 4 
 5 
JM: And have things changed with those? 6 
 7 
D: Well I haven’t really walked up steep hi(h)lls s(h)o 8 
I don’t kn(h)ow heh heh but a- as for the sleeping 9 
better a night yes they have changed I haven’t been 10 
waking up coughing (.) and had this irritation in 11 
my throat so much during the night that has got 12 
better (.) but I haven’t been round anybody’s with 13 
animals either since I’ve been taking it so I don’t 14 
know about those two. 15 
 16 
JM: ˚Okay˚. How would you say your um how would 17 
you describe your asthma would you is it does it 18 
stay pretty much constant or does it change a lot 19 
from day to day? 20 
 21 
D: No it stays pretty much constant really (.) yeah no 22 
that doesn’t (.) that doesn’t change (.) only if I get 23 
as I say if I get a bad cold or anything like that it’s 24 
the only time that change or um (.) PERHAPS IF I 25 
GET IF I GET REALLY STRESSED out about 26 
something (.) that’ll that will change (.) y- you 27 
know I’ll find that um the chest will tighten up and 28 
I’ll need to use it if I get really stressed about 29 
something (.) but apart from that that’s sort of just 30 
stays the same really 31 
 32 
JM: ˚Okay˚.  How how much um at risk do you do you 33 
feel do you (.) um (.) do you feel that (.) is is do 34 
you think about asthma everyday is it so[me]thing 35 
 36 
D:           [No] I 37 
don’t think about it no I don’t feel at risk really 38 
with it at all 39 
 40 
 (1)  41 
 42 
JM: Okay ((said as if ‘never mind lets try another 43 
angle’)) um and you what habits do you have with 44 
your blue inhaler, do do you have that with you 45 
everyday or?  46 
 47 
D: Yes I always have one in my bag I always take 48 
have one with me.  I have one laid I I’ve got, I 49 
always have one beside my bed and um I do I do 50 
carry one about with me just in case  51 
 52 
Excerpt 5: 670289, Interview 1, pages 17-20, D’s home 
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JM: Okay 1 
 2 
D: But I never use it (.) well touch wood ˚heh heh 3 
heh˚ 4 
 5 
JM: Do do you always have more than one in (.) one 6 
blue inhaler or do you have do do you make sure 7 
how how if you run out of a blue inhaler um when 8 
would you go and renew a prescription when you 9 
have none left or? 10 
 11 
D: No I I try and keep two so I can leave one beside 12 
the bed and keep one um when one gets when one 13 
is virtually run out um (.) I just >go and get another 14 
one< (.) I just phone up I just because I get them 15 
on repeat prescription anyway (.) so I just 16 
 17 
JM: Do they ever talk to you about when how often do 18 
you go for a review visit 19 
 20 
D: I don’t. Heh heh heh heh no I don’t go for asthma 21 
review visits at all 22 
 23 
JM: Do they invite you to come for a review 24 
 25 
D: NO THEY HAVEN’T NO that’s usually if I go for 26 
something else he would say “oh that’s about time 27 
we did something about your asthma” OR if um if 28 
the prescription if the prescription runs out (.) you 29 
know because you have they only give you sort of 30 
like six months don’t they and then I’ll go and (.) 31 
but um (1) its usually when I’ve been for 32 
something else (2) cos um I have to go to review 33 
for review for my (.) thyroid so he used to he used 34 
to (just?) do both at the same time 35 
 36 
JM: mm 37 
 38 
D: um and er doesn’t really do much just get me to 39 
blow in the tube and I’m no different that I e(h)ver 40 
a(h)m  41 
 42 
JM: And does he ask you any questions about your 43 
asthma? 44 
 45 
D: Yeah he usually asks me you know some (1) if I’ve 46 
if I’ve got worse or you know if that’s troubled me 47 
very much and things like that but (.) not 48 
specifically 49 
 50 
JM: And and (.) the (.) um do you talk to him about 51 
how you use (.) the brown inhaler we talked about 52 
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 that briefly before um (.) and he said that you 1 
should take that (.) to did he say that you should 2 
take that every day or (.) a long period or did he 3 
how did he say you should use it over a long 4 
period of time (.) cos you sort of mentioned did 5 
you mention to him that you stopped using it  6 
 7 
D: Yes yeah (1) ahhh well he sort of (.) hhh 8 
((sounding slightly exasperated with questioning)) 9 
I mean his advice is really that I should use it (.) all 10 
the while and its totally down to me that I don’t 11 
because his advice to me is (.) to use it (.) y’know 12 
most of the time but I mean I feel fine (.) without it 13 
I don’t really know why I need to use it because 14 
without using it (.) I’m alright I don’t get 15 
breathless or get any asthma symptoms 16 
 17 
JM: And do do you actually share that view with him or  18 
 19 
D: Yes he know I stopped using it yes yeah (.) spose 20 
he just you know he just (.) said you know if I you 21 
know its up to you really (??) SO I I MEAN IF I’M 22 
IF I’M do have a bad attack alright I will start 23 
using it (1) for any reason um (.) have a bad attack 24 
but (.) normal run of the day things I don’t (.) I 25 
don’t want to use it (.) hh every day 26 
 27 
JM: I’m just trying to understand why exactly (hhh) 28 
((slightly nervous laughter))  29 
 30 
D: WELL I I DON’T KNOW I THINK ITS JUST AS 31 
I SAY ITS JUST THE THOUGHT OF TAKING 32 
IT EVERYDAY WHEN I DON’T REALLY 33 
FEEL I NEED IT  34 
 35 
JM: ˚Okay that’s fine˚ um okay that that’s (.) that’s 36 
great um I just wonder when you’ve been out in 37 
public you carry do you take your blue inhaler with 38 
you have you ever been out and realised you’ve 39 
not had it  40 
 41 
D: What and panicked? (1) No. Only that one time in 42 
New Ze(h)ala(h)nd 43 
 44 
JM: [heh heh] 45 
 46 
D: [heh heh] wh(h)en I nee(h)ded it and I didn’t have 47 
it with me ehm no no no I don’t normally panic or 48 
think that I haven’t got it and worried about it (.) 49 
no. 50 
 51 
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JM: So what what would you do in that situation just 1 
carry on? 2 
 3 
D: Just carry on once I’ve sat down 10 minutes or so 4 
and got me breath back um you know I’m alright 5 
 6 
JM: Okay (.) um (.) does does carrying using blue 7 
inhaler inhalers in public is that is that a problem 8 
or is that 9 
 10 
D: No it wouldn’t bother me no. 11 
 12 
 (2) 13 
 14 
JM: Um (.) okay do you know anybody else with um 15 
asthma (1) ˚is there˚ anybody you know at all? 16 
 17 
D: Do I know anyone else with asthma? 18 
 19 
JM: Anyone else? any of your friends or family? 20 
 21 
D: Yes a girl over the road has got it she’s got hay 22 
fever and asthma yeah 23 
 24 
JM: Do you often talk about it with her or? 25 
 26 
D: Not really she’s really bad she has to have 27 
injecti(h)ons and ev(h)erything heh heh  28 
 29 
JM: Really 30 
 31 
D: (??) injections 32 
 33 
JM: How do you compare her asthma to yours 34 
 35 
D: Terrible I mean you know I mean mine is nothing 36 
you know mine doesn’t affect me at all compared 37 
to how she is  38 
 39 
JM: So is does she have she’s diagnosed with asthma 40 
and and uh would (.) you would you consider that 41 
your symptoms are very different to hers 42 
 43 
D: Um (2) I don’t really know I mean mine is 44 
nowhere near as severe as hers (2) um different (.) 45 
no I don’t suppose they’re that much different they 46 
are just a lot milder form I mean hers is much more 47 
severe mine is just so mild compared to how she 48 
suffers yeah.49 
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J: Oh a week a couple of weeks I suppose, week 1 
couple of weeks I suppose what you know you can 2 
(??) the difference  3 
 4 
JM: Right 5 
 6 
J: Not saying I was right but you could feel the 7 
difference  8 
 9 
JM: Right okay so when you first took the brown 10 
inhaler you didn’t notice the difference straight 11 
away 12 
 13 
J: Not straight away but a few days to a week I 14 
suppose and then you’d notice the difference  15 
 16 
JM: Okay what what about the blue inhaler 17 
 18 
J: Well more or less the same as th↑at I think (2) 19 
yeah 20 
 21 
 (2) 22 
 23 
JM: So they both take a week or two weeks 24 
 25 
J: Well well about a week I should think 26 
 27 
JM: Right (1) okay. What did the doctor say about how 28 
the two different treatments work did he explain 29 
anything?  30 
 31 
J: Well he just said um to take the brown one 32 
morning and night and then take the blue one 33 
during the day during the day sort of thing when I 34 
have to take it 35 
 36 
JM: And did he say how what they do? 37 
 38 
J: Yeah he said they sort of you know will help you 39 
and he said I could take I think I could take the 40 
brown one once more during the day but if I want I 41 
could take the blue one during you know more 42 
during the day 43 
 44 
JM: Mm and you and you think it made sort of about a 45 
week two weeks  46 
 47 
J: Yeah about a week  48 
 49 
JM: So you can you describe sort of what sort of habits 50 
you got into with your inhalers 51 
 52 
Excerpt 6: 650405, Interview 1, pages 7-11, J’s local GP surgery 
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J: ↑Oh I just used to make sure I got one both with 1 
me when I went out, they were in me bag or 2 
whatever I’d got and use to make I’ve always got 3 
one one of each beside me bed anyhow and always 4 
used to make sure I got one with me when I ↑went 5 
out ((rising intonation said as if this was no big 6 
deal)) 7 
 8 
JM: Right and you you sort of said that um you didn’t 9 
use it everyday  10 
 11 
J: No 12 
 13 
JM: Your inhaler um again I’m not here to sort of say 14 
 15 
J: No 16 
 17 
 JM: why aren’t you using it but why did you decide not 18 
to or why did you decide  19 
 20 
J: Well I think I probably I did forget to take it first 21 
thing in the morning sort of thing I think that was 22 
half of it and you know if you felt alright you sort 23 
of didn’t think to take it it weren’t not very often 24 
 25 
 (3) 26 
 27 
JM: Ok. Um and have you been did you go back to the 28 
doctors after?  29 
 30 
J: I think I probably had to go back to check that 31 
everything you know was alright I’m sure I did.  32 
He wanted to check you know to make sure it was 33 
alright (1) yeah 34 
 35 
JM: And what did he say do you remember 36 
 37 
J: He said that was y’know sort of carry on with your 38 
inhalers and y’know take them how you should 39 
sort of thing 40 
 41 
JM: You say you’ve been doing that for about 30 42 
years?= 43 
 44 
J: =°Yeah° 45 
 46 
JM: (??) um okay and the first time you changed was 47 
when you entered this study 48 
 49 
J: Yeah 50 
 51 
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JM: What made you um decide to take part in the study 1 
was there 2 
 3 
J: Well I I think I don’t know if I had a letter or they 4 
rung me up 5 
 6 
JM: Yeah 7 
 8 
J: And I said providing that worked round me sort of 9 
thing I could do it 10 
 11 
JM: And you were happy to try something different 12 
 13 
J: Yeah 14 
 15 
JM: And um so you’ve been taking the tablet for  16 
 17 
J: A couple of weeks I think (1) I think I’m on the (1) 18 
cos there’s four strips I think in the packets I think 19 
I must be now on the third strip 20 
 21 
JM: Right 22 
 23 
J: something like that 24 
 25 
JM: And how’s that going 26 
 27 
J: Alri↑ght yeah 28 
 29 
JM: You’re sort of 30 
 31 
J: I think I’ve got to go and see her again oh I forget 32 
I’ve got it in my diary 33 
 34 
JM: It’s a few weeks wasn’t it 35 
 36 
J: Yeah. 37 
 38 
 ((searches in bag for diary)) 39 
 40 
JM: That’s alright don’t worry it’s a few weeks isn’t it 41 
 42 
J: Yeah that is the 20th it’s when I’m starting a new 43 
job I think  44 
 45 
JM: yeah 46 
 47 
J: I’d better tell them I might be a bit late well I aint 48 
gonna be long here about half an hour 49 
 50 
JM: Yeah 51 
 52 
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J: I’ve only got to go a little way up there so it aint 1 
far away 2 
 3 
JM: that’s handy 4 
 5 
J: Yeah 6 
 7 
JM: Um but you manage to remember to take it every 8 
[day or] 9 
 10 
J: [Yeah] (1) well I try to heh heh heh 11 
 12 
JM: Yeah. How would you compare the tablets with the 13 
inhalers 14 
 15 
 (3) 16 
 17 
J: Al. Alri↑ght  18 
 19 
JM: Do you think there’s any differences? 20 
 21 
J: Er (2) they don’t seem to have no side effects or 22 
something (2) so long as I remember you know try 23 
to keep remembering to take one you have to to 24 
take one at night don’t you  25 
 26 
JM: Yeah 27 
 28 
J: Yeah 29 
 30 
JM: And how do you think they work do you feel that 31 
they work 32 
 33 
J: Ye↑ah. (2) Yeah 34 
 35 
JM: How have you noticed just how long it takes sort 36 
of thing 37 
 38 
J: Um. .hhhh hhhhhhh um no I took them I take them 39 
alright and they I seemed alright y’know after I 40 
took them and that so 41 
 42 
JM: But, you said you mentioned the brown inhaler 43 
took about a week two weeks 44 
 45 
J: Yeah I think that was when I first had it I suppose 46 
to get use you know  47 
 48 
JM: Get used to it 49 
 50 
J: Yeah get used to them 51 
 52 
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JM: And then the tablet have you noticed any 1 
difference how long do you think that took to work 2 
 3 
J: Oh it must be oh (1) well just under a week I 4 
suppose yeah 5 
 6 
JM: And has anything changed in in your life that you 7 
like do you do more or 8 
 9 
J: No about the same I think, mind you I have had a 10 
lot of hassles just lately so that’s probably not 11 
helped so heh [heh heh] heh  12 
 13 
JM: [Really] 14 
 15 
J: So, going through a bad patch yeah 16 
 17 
JM: Yeah 18 
 19 
J: Work and home so 20 
 21 
JM: Right 22 
 23 
J: That didn’t help 24 
 25 
JM: So that’s not helped your asthma 26 
 27 
J: Well it weren’t it weren’t too good you know it 28 
weren’t too bad I just you could feel it sort of you 29 
know coming on sort of thing 30 
 31 
JM: Do you think there’s um do you think there’s a link 32 
between sort of what happens in your life and your 33 
breathing 34 
 35 
J: Yes sometimes, I wouldn’t say all the time but 36 
sometimes yeah 37 
 38 
JM: In what way do you think 39 
 40 
J: Well you just get tense and that sort of (1) you 41 
know start coughing or something like that and it 42 
sort of bring it on 43 
 44 
JM: Really, a lot of people say that 45 
 46 
J: Um w↑ell (1) I don’t know heh heh heh 47 
 48 
JM: no [(??)] 49 
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F: cos normally you don’t know when you’re going to 1 
be suddenly doing something sort of quite physical 2 
so you do get caught out 3 
 4 
JM: Did you get invited to go back to the surgery to 5 
discuss your asthma attack? 6 
 7 
F: Yes not no only seen the asthma nurse 8 
 9 
JM: Right so not up until that point 10 
 11 
F: No 12 
 13 
JM: Do you ever think about going back to speak to  14 
 15 
F: Well no because I just thought well you know 16 
everybody’s got asthma and it seems such a 17 
common thing and um quite frankly you don’t feel 18 
ill you know that’s the thing you don’t feel ill ill as 19 
such just the fact you can’t breath do you see what 20 
I mean you don’t its not like you’ve got a cold or 21 
you’ve got the flu anything like that you haven’t 22 
you you’re perfectly okay apart from the fact you 23 
can’t you you’re gasping for breath so sometimes 24 
I’ll feel a bit of a fraud for for (??).  In fact I went 25 
in there one time and said doctor I feel alright and 26 
he said out straight away that’s because me ears 27 
were playing me up  28 
 29 
JM: When was that 30 
 31 
F: That was a couple of years ago um cos he’s quite a 32 
nice doctor well I think he is he always eats 33 
sweets, never got a tie on you walk in and he says 34 
hello ((name)), how’s ((wife’s name)) (??) the wife 35 
which is nice but, um no so ah I just use the blue 36 
one (??) about the brown one. 37 
 38 
JM: Just thinking about you don’t feel uh being out of 39 
breath is is or is an illness 40 
 41 
F:  No I I don’t know 42 
 43 
JM: How would you describe your obviously doctors 44 
say you have asthma  45 
 46 
F: Yeh 47 
 48 
JM: How would you how do you feel about  49 
 50 
F: What, having asthma 51 
 52 
Excerpt 7: 261284, Interview 1, page 7, line 1 to page 8, line 29; F’s home 
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JM: Or what do do its just that asthma is defined as an 1 
illness 2 
 3 
F: Yeh, yeh 4 
 5 
JM: But you feel that you don’t really feel ill 6 
 7 
F: No um 8 
 9 
JM: I’m just trying to understand how you sort of see 10 
yourself 11 
 12 
F: Well I suppose perhaps because my grandmother 13 
had asthma and the number of times we used to 14 
have to rush to hospital and take my mum and dad 15 
uh because she was on death’s door and I (??) and 16 
she had a once (??) pump something into her (??) 17 
and I suppose because I saw her like that it didn’t I 18 
didn’t associate it with being an illness as such it 19 
was just the fact that some people have a job to 20 
expel their air or whatever, that’s how I looked at 21 
it.  Um and as I say if this chap on ((company 22 
name)) hadn’t said to me you know you ought to 23 
get it sorted out because you shouldn’t be like that 24 
um I probably would have carried on cos its just 25 
one of those things some people have got that um 26 
some people lose a hand you know its just 27 
something that happens and um you’ve got to live 28 
with it. 29 
 30 
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P3: around me used to smoke all day cos there was no 1 
such thing as no smoking at work 2 
 3 
P6: mm 4 
 5 
P3: In them days 6 
 7 
P6: mm 8 
 9 
P3: It’s different now intit. 10 
 11 
P6: mm 12 
 13 
P3: And I used to find 14 
 15 
P6: mm 16 
 17 
P3: with the smoke around me I used to find that used 18 
to bring it on perhaps that was what it was I don’t 19 
know 20 
 21 
P5: Once it started then its its 22 
 23 
P3: that’s right yeah 24 
 25 
P5: Only the treatment to control it because if you 26 
hadn’t been in that environment to start with you’d 27 
probably never have suffered 28 
 29 
P3: No might not have [done] no.  30 
 31 
          [no    ] 32 
 33 
P3: mmm when I first started work there was no such 34 
thing no smoking not in work places [heh heh] 35 
 36 
P6:      [↑No: No] No 37 
(2) that was so you you er you welcomed the 38 
legislation 39 
 40 
P3: Oh yes I did yeah 41 
 42 
ALL: heh heh heh 43 
 44 
P3: Yes I can’t I can’t handle smoke  45 
 46 
P2: no no  47 
 48 
P3: being round me at all 49 
 50 
P2: no 51 
 52 
Excerpt 8: Data-Sharing Focus Group, pages 26- 29; Adult Education Centre 
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P3: No I can’t no (2) mm 1 
 2 
P6: yeah (2) 3 
 4 
JM: Ok I’ve got one more ((passes round 4th vignette)) 5 
 6 
P5: It’s surprising when you think of the old days 7 
when you used to go to the cinemas and there’d be 8 
somebody in front of you [smoking] (??) 9 
 10 
P3:         [puf(h)fing] aw(h)ay heh 11 
heh yeah 12 
 13 
P5: I suppose with the modern generation course they 14 
don’t get these problems do they really 15 
 16 
P3: n:o 17 
 18 
JM: Ok this one says “I don’t think I have asthma. I 19 
think doctors and nurses do not understand my 20 
symptoms and I don’t feel that they listen when I 21 
go to see them or talk about the causes of asthma 22 
properly. I am concerned about the side-effects of 23 
medications. The experts say that some 24 
medications are now unsafe so I don’t want to take 25 
a medication everyday that I don’t think works 26 
very well.” 27 
  28 
 (11) 29 
 30 
P6: Well I feel sorry for em they  31 
 32 
 (7) 33 
 34 
P1: Well I was lucky when I went to see the nurse she 35 
actually suffered from asthma which was great 36 
because she knew exactly what I was talking about 37 
and what I should do and shouldn’t do and I seem 38 
to remember she said there were no side-effects 39 
from the brown one but the blue one be careful 40 
with the blue one seem to remember her saying 41 
 42 
 (2) 43 
 44 
P6: Oh I didn’t know tha:t 45 
 46 
P5: What is the compound difference then between the 47 
brown and the blue one 48 
 49 
P1: The bro[wn one coats] 50 
 51 
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P6:  [used to be     ]ventolin but it’s sort of 1 
salbutamol int it 2 
 3 
P1: mm the brown one coats the lung don’t it though 4 
and stop irritation and the blue one opens the opens 5 
the bronchial tubes up 6 
 7 
 (2) 8 
 9 
P6: mm but the I don’t know whether I was (2) 10 
completely awake at the time but I thought when 11 
they when they hook you on to a nebul a nebuliser 12 
I don’t know if that has happened to any of you but 13 
you’re getting 10 times the dose of the blue one so 14 
it really is a really is a kick in the system 15 
 16 
P1: mm 17 
 18 
P5: mm 19 
 20 
P6: Um but that I may have got that wrong but you got 21 
the blue one you do have a puff on the blue one but 22 
actually when hooked on to a nebuliser you’re 23 
actually going to get 10 times the dose um the blue 24 
one in theory can’ t be that harmful can it not your 25 
blue puffer if that’s the case 26 
 27 
P1: mm 28 
 29 
P6: particularly if you are only doing it odd occasions 30 
 31 
P1: mm 32 
 33 
P3: mm 34 
 35 
P6: I think we get hung up on these side-effects 36 
sometimes because you got side-effects with 37 
aspirin as well 38 
 39 
P3: that’s right [side effects on anything ] 40 
 41 
P6:        [every day you take the balance] so if I 42 
do this little bit of side-effect 43 
 44 
P6: but if I don’t=  45 
 46 
P3: =˚but˚ yeah that’s right 47 
 48 
P4: which is the worser of the two evils 49 
 50 
P3: [that’s right] 51 
 52 
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P6: [indeed       ]you’re right you’re right you’ve gotta 1 
fill up your car with petrol so you just have to go to 2 
the petrol station you know so you know that’s a 3 
side-effect in effect it’s a balance isn’t it  4 
 5 
P1: mm mm mm 6 
 7 
P6: do I walk or run? 8 
 9 
P1: I have I must admit I have I went to a chemists 10 
because I was suffering terribly from a cold I said 11 
to him I happened to know her she knew I suffered 12 
from asthma and she said “you wanna take 13 
Echinacea” and ever since I’ve taken Echinacea I 14 
don’t take it all the time, I don’t suffer from colds 15 
anymore 16 
 17 
P6: Echi? 18 
 19 
P1: Echinacea natural root I think natural it’s a herb 20 
[its not its not its not a drug] 21 
 22 
P5: [yeah. Echinacea you take it] as the symptoms of a 23 
cold is coming [don’t you]  24 
 25 
P1:   [yeah]  26 
 27 
P5: and er (??) 28 
 29 
P1: but for me it seems to work 30 
 31 
P6: hmm 32 
 33 
P1: But she said drops were the best drops in a glass 34 
and just drink it so for me [(??)] 35 
 36 
P5:          [yeah] I’ve heard quite a 37 
lot of people say Echinacea is very good 38 
 39 
P1: yeah 40 
 41 
P6: ˚How do you spell that?˚ 42 
 43 
ALL: heh heh [heh] 44 
 45 
P3:    [It is a natural] herb it’s not a  46 
 47 
P5: Ech is it 48 
 49 
JM: ((To Ps 2 and 3, could not get eye contact)) What 50 
do other people think about the statement on the “I 51 
am concerned about the side-effects of52 
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Appendix C 
Recruitment of patients into the ELEVATE Study 
 
C.1. Extract from final report documenting recruitment procedure and selection 
criteria (Price et al., in press, pp. 18-22) 
 
2.1 Participants 
 
In the BTS Guidelines on the Management of Asthma63 the therapy of patients from age 
6 up follows the same strategy as for adults except for alterations in dosage ranges to 
adjust for differences in body mass. Since exactly the same strategy is used across the 
age range of older children and adults, the findings of studies will have greater 
generalisability if they enrol patients from that entire range. Due to limitations of 
validity of the Mini Asthma Quality of Life Questionnaire and the Asthma Control 
Questionnaire (ACQ) we were unable to study children below the age of 12 but did 
allow children over this age as well as adults of all ages to be included to maximise 
generalisability of the study findings. 
In the initial design of the study, participant recruitment was to be by primary care 
practice staff as they conducted acute and routine respiratory care visits, identifying 
patients who met the entry criteria, informing them of the study and, if appropriate, 
consenting and enrolling them into the study. Recruitment by this strategy was slower 
than originally anticipated due to changes in clinical practice resulting from delays in 
study funding and changes in national asthma guidelines. The protocol and the process 
of identification of eligible patients were therefore modified as described below to allow 
prospective identification of possible study participants. All patients entering the study 
met the same eligibility criteria and follow up was identical.   
Further recruitment into the study was via a three-stage process. 
 
Recruitment Stage 1 
 
Patients aged 12 to 80 attending 53 participating primary care (or general) practices in 
Norfolk, Suffolk, Essex, Cambridgeshire, Bedfordshire, Hampshire, and Dorset and 
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who had received a prescription of short-acting β2 agonist in the previous 2 years were 
invited by letter to provide data allowing eligibility for the studies to be determined. 
Patients were asked to provide information on their current asthma status and inhaler 
usage. The case notes of patients whose asthma status was consistent with eligibility in 
the study were reviewed by practice and study staff against the following eligibility 
criteria:  
 
Inclusion criteria: 
a. Capable of understanding the study and study procedures (and parent/guardian’s 
capability of understanding the study and study procedures for patients aged under 
16 years). 
b. Patient had a diagnosis of asthma (defined as: i) documented reversibility after 
inhaled short-acting β2 agonist AND/OR ii) PEF variability on PEF diary AND/OR 
iii) physician diagnosed asthma AND/OR iv) physician diagnosis of asthma plus 
history of response to treatment). 
c. Step 2 trial: patient was not currently receiving, and had not received inhaled steroid 
or leukotriene antagonist within the previous 12 weeks 
d. Step 3 trial: 1) patient had received inhaled steroid for at least the last 12 weeks, as 
ascertained from prescribing records and patient self-report, and 2) had not received 
a long-acting β2 agonist or leukotriene antagonist in the previous 12 weeks. 
 
Exclusion criteria: 
e. Patient had participated in a clinical trial involving an investigational or marketed 
drug within 90 days. 
f. Patients had received a substantial change in anti-asthma medication within the 
previous 12 weeks.  
g. Patient was a current, or recent past abuser (within past 3 years), of alcohol or illicit 
drugs. 
h. Patient had any other active, acute or chronic pulmonary disorder or unresolved 
respiratory infection within previous 12 weeks. 
i. Patient had a history of any illness that was considered to be immediately life 
threatening, would pose restriction on participation or successful completion of the 
study, or would be put at risk by any study drugs (e.g., allergy to leukotriene 
antagonist). 
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j. Patient had received systemic, intramuscular or intra-articular corticosteroids within 
the previous 2 weeks (artificial baseline). 
 
Patients who met those entry criteria that could be assessed by a records review in their 
general practice were invited for a screening visit (visit 1; see Figures 1 and 2). All 
patients had at least 24 hours to review the patient information sheet prior to attending 
the visit. Patients attending for at least visit 1 will from here on be referred to as 
participants.  
 
Figure 1. Study Flow Charts: Patients at step 2 received initial controller therapy with 
leukotriene antagonist or inhaled steroid. Patients at step 3 received leukotriene 
antagonist or long-acting β2 agonist as add-on to inhaled steroid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2 trial 
PRN only 
Tailored treatment as indicated by guidelines 
LTRA 
ICS 
Beta agonist 
 
LTRA - maintained if possible 
LTRA - not used 
Randomisation 
Step 3 trial 
 
Tailored treatment as indicated by guidelines 
ICS+ LTRA 
ICS + LABA 
ICS & 
SABA PRN 
LABA – not used 
LTRA - not used 
Week            Week: 
Baseline 
V1                   V2                  V3                 V4                   V5                V6                    V7   
Week            Week: 
-2                   0                    8                   26                  52                   78                  104 
Baseline 
V1                   V2                  V3                 V4                   V5                V6                    V7   
-2                   0                    8                   26                  52                   78                  104 
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Key 
ICS:  Inhaled corticosteroids 
LTRA: Leukotriene receptor antagonist 
LABA: Long acting β2-agonist 
SABA: Short-acting β2-agonist 
 
 
Recruitment Stage 2 
 
At visit 1, participants (and parent or guardian if appropriate) gave written informed 
consent and were allocated a unique study number. Participants were reviewed for the 
following additional entry criteria: 
a. PEF while withholding β2-agonist for at least 4 hours, of >50% predicted. 
b. Females of child bearing potential agreed to use adequate contraception throughout 
the study. 
Participants meeting the above criteria completed a 2-week PEF diary, Asthma Control 
Questionnaire (ACQ), and asthma specific quality of life questionnaire (MiniAQLQ) 
prior to returning for visit 2.  
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Figure 2.  Time lines for both Step 2 and Step 3 trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment Stage 3 
 
At visit 2, participants scoring ≥1 on the ACQ (range 0 to 6, with ≤0.75 being optimal67) 
and/or <6 (out of a maximum best score of 7) on the MiniAQLQ were registered and 
randomised within the step 2 or step 3 study by an automated “dial-up” centre at the 
University of East Anglia. A computer responded to calls from practices by recording 
identification information. It then used input from the practice about the step at which 
the patient was to enter the study to perform a lookup into predefined tables of 
randomisation allocations (see 2.6) and then inform the caller of the allocation for that 
participant.  
 
 BASELINE  TRIAL PERIOD 
Visit  1 2 3 4 5 6 7 
Study timescale in weeks  
Leeway allowed in days  
-2 0  
+/- 7 
8  
+/- 21   
26  
+/- 21  
52  
+/- 21 
78  
+/- 21 
104  
+/- 21 
General practitioner and/or practice asthma nurse procedures 
Assess inclusion/exclusion criteria  X       
Informed consent X       
Record clinical/asthma history & prior 
medications 
 X      
Review clinical data& asthma therapy (per 
clinical need) 
X X X X X X X 
Check patient has/can adequately use PEF 
meter 
X       
Treatment arm randomisation by dial-up 
centre 
 X      
Review action plan for worsening asthma X X X X X X X 
Review any adverse experiences  X X X X X X 
Record PEF (no inhaled β-agonist for 4 
hours if possible) 
X X X X X X X 
Confirm patient resource utilisation   X X X X X X 
Blinded research assistant  /  Study Office 
Collect completed patient symptom diary 
card 
 X X X X X X 
Collect data on patient costs  X X X X X X 
AsthmaQOL & EuroQOL (Quality of Life) 
Questionnaires 
 X X X X X X 
Rhinitis questionnaires   X X X X X X 
Dispense patient diary card for subsequent 
visit 
X X X X X X  
Collect resource use data from practice 
records 
      X 
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C.2. ELEVATE Screening Questionnaires  
 
MINI – Asthma Quality of Life  QUESTIONNAIRE for age 12+ ©     
The ELEVATE Study 
Patient Initials              Study ID Number                Date  
 
Circle the number that best describes how you have been during the past 2 weeks as a result of your ASTHMA 
In general, how much of the time during the last 2 weeks did you: 
 All of 
the 
Time 
Most of 
the 
Time 
A Good 
Bit of the 
Time 
Some of 
the Time 
A Little 
of the 
Time  
Hardly Any 
of the 
Time 
None of 
the 
Time 
1. Feel short of breath as a 
result of your asthma? 1 2 3 4 5 6 7 
 
2. Feel bothered by or have to 
avoid dust in the 
environment? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
3. Feel frustrated as a result of 
your asthma? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
4. Feel bothered by coughing? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
5. Feel afraid of not having 
your asthma medication 
available? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
6. Experience a feeling of 
chest tightness or chest 
heaviness? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
7. Feel bothered by or have to 
avoid cigarette smoke  in the 
environment? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8. Have difficulty getting a 
good night’s sleep as a    
result of your asthma? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
9. Feel concerned about 
having asthma? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
10. Experience a wheeze in 
your chest? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
11. Feel bothered by or have to 
avoid going  
Outside because of weather or 
air pollution? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
   
 
 
267
 
How limited have you been during the last 2 weeks doing these activities as a result of your ASTHMA? 
 Totally 
Limited 
Extremely 
Limited 
Very 
Limited 
Moderate 
Limitation 
Some 
Limitation 
A Little 
Limitation 
Not at 
all 
Limited 
12. Strenuous activities 
(such as hurrying, 
exercising, running up 
stairs, sports) 1 2 3 4 5 6 7 
 
13. Moderate activities 
(such as walking, 
gardening, housework, 
shopping, climbing stairs) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
14. Social activities (such 
as talking, playing with 
pets/children, visiting 
friends/relatives) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
15. Work/school-related 
activities*  (tasks you 
have to do at work/school) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
*If you are not employed or 
self-employed, these 
should be tasks you have 
to do most days. 
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ASTHMA CONTROL QUESTIONNAIRE ©  
ELEVATE STUDY No__ __ __ __ __ __  
PT. INITIALS: ___ ___ ___ DATE: __ __/__ __/__ __ VISIT: ___ 
 
ALL QUESTIONS MUST BE ANSWERED 
Circle the number of the response that best describes how you have been during the past 2 
weeks. 
1. On average, during the past 
week, how often were you 
woken by your asthma during 
the night? 
0 
1 
2 
3 
4 
5 
6 
Never 
Hardly ever 
A few times 
Several times 
Many times 
A great many times 
Unable to sleep because of 
asthma 
2. On average, during the past 
week, how bad were your 
asthma symptoms when you 
woke up in the morning? 
0 
1 
2 
3 
4 
5 
6 
No symptoms 
Very mild symptoms 
Mild symptoms 
Moderate symptoms 
Quite severe symptoms 
Severe symptoms 
Very severe symptoms 
3. In general, during the past 
week, how limited were you in 
your daily activities because 
of your asthma? 
0 
1 
2 
3 
4 
5 
6 
Not limited at all 
Very slightly limited 
Slightly limited 
Moderately limited 
Very limited 
Extremely limited 
Totally limited 
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4. In general, during the 
past week, how much 
shortness of breath did 
you experience because 
of your asthma? 
0 
1 
2 
3 
4 
5 
6 
None 
A very little  
A little 
A moderate amount 
Quite a lot 
A great deal 
A very great deal 
5. In general, during the 
past week, how much of 
the time did you wheeze? 
0 
1 
2 
3 
4 
5 
6 
Not at all 
Hardly any of the time 
A little of the time 
A moderate amount of the time 
A lot of the time 
Most of the time 
All the time 
6. On average, during the 
past week, how many 
puffs/inhalations of 
short-acting 
bronchodilator (eg. 
Ventolin/ Bricanyl) have 
you used each day? 
0 
1 
2 
3 
4 
5 
6 
None 
1 - 2 puffs most days 
3 - 4 puffs most days 
5 - 8 puffs most days 
9 - 12 puffs most days 
13 - 16 puffs most days 
More than 16 puffs most days 
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C.3. Medication Adherence Report Scale (MARS) Questionnaire 
Permission to use provided by Rob Horne 
 
QUESTIONS ABOUT USING YOUR  
PREVENTER INHALER 
 
 
 
 
• Most people find a way of using their medicines 
which suits them 
• We are interested in what method best suits you  
• Here are some ways in which people have said that 
they use their  preventer treatment 
 
 
For each statement , please tick the box that best 
applies to you 
 
 
 
 
 Your own way of using your preventer 
treatment 
Always Often Sometimes Rarely Never 
M1 
I only use it when I need it      
M2 
I only use it when I feel breathless      
M3 
I decide to miss out a dose      
M4 
I try to avoid using it       
M5 
I forget to take it       
M6 
I alter the dose       
M7 
I stop taking it for a while      
M8 
I use it as a reserve, if my other treatment doesn’t 
work 
     
M9 
I use it before doing something which might make 
me breathless 
     
M10 
I take less than instructed      
 
 
 R Horne University of Brighton 1999 
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C.4. Patient Information Sheet and Consent Form 
STEP 2 PATIENT INFORMATION SHEET 
 
Study Title: Clinical and health economic evaluation of leukotriene 
receptor antagonists 
Patient Name:  Information Sheet edition & date: Version 4 4/9/2003 
Doctor(s) Directing 
Research: 
 Doctor(s) Telephone Number:  
Practice Asthma Nurse  Nurse Telephone Number  
 
PLEASE READ THE FOLLOWING INFORMATION CAREFULLY.   
What would I have to do? 
You are being invited to take part in a clinical research study to help answer how effective 
different treatments are in helping people like yourself with asthma.   
People with asthma have inflamed air passages, which cause symptoms such as cough, 
wheeze and shortness of breath.  The inflammation is often treated with inhalers 
containing a medicine called a corticosteroid (‘steroid’ for short).  More recently, 
however, tablets which treat the inflammation in a different way have been introduced 
and this study aims to see which of these treatments is more effective. Both of these 
treatments are currently available and are used in the treatment of asthma in the UK.  This 
study will involve about 700 patients around the UK. 
You currently do not receive regular preventative treatment for your asthma but your 
doctor or asthma nurse now feel that it might be helpful to consider commencing regular 
preventative therapy. 
If you agree to take part in this study you will need to visit your doctor or practice asthma 
nurse for 5 study visits over a 2 year period which will be similar to your normal asthma 
care. You and your doctor or nurse may arrange extra attendances, as you or they feel 
clinically appropriate.  
For 2 weeks before each of the five study visits you will be asked to complete a diary 
regarding your asthma symptoms, the number of times you need and use your blue 
reliever inhaler and your peak flow reading morning and night. 
At each study visit your doctor or nurse will ask you to complete two questionnaires that 
measure the impact of asthma on your quality of life. If you have trouble with eczema, 
dermatitis, rhinitis (nasal blockage, itch or drip) or hay fever you may be asked to 
complete questionnaires regarding how badly these are affecting you. 
If you agree to participate in the study you will complete the diary card mentioned above 
for two weeks to see whether your asthma is giving sufficient problems to justify the 
additional treatment. If it is you will be randomly allocated, (by chance, like with the toss 
of a coin), to one of the two treatment choices mentioned above either the steroid inhaler 
or tablet therapy. Your doctor or nurse cannot alter this allocation. 
If you have been allocated to the tablet treatment your doctor will prescribe one of the two 
different tablets available montelukast (Singulair™) or zafirlukast (Accolate™).  
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If you have been allocated to the steroid inhaler treatment your doctor will prescribe one 
of the range of different preparations available beclomethasone (e.g. Becotide, 
Becloforte, Beclazone and QVAR), fluticasone (Flixotide) or budesonide 
(Pulmicort) are some of the most common.   
You will continue these treatments for a two month trial period. Depending on your 
response to this addition to your treatment, your doctor or asthma nurse may then modify 
your treatment to try and achieve the best possible control of your asthma.  
Your doctor or asthma nurse will issue you with a self-management plan outlining what 
you should do in the event of a worsening of your asthma, development of a cold etc. 
You will still be allowed to take your regular reliever medication should you need it but if 
you do you should make a note of it on your diary card for the periods you are completing 
this. If you require any other asthma medication you should discuss this with your doctor 
or asthma nurse first, if possible, unless it is part of your self-management plan.   
Optional in depth interviews: 
You may also be asked to take part in some more in depth interviews about your 
asthma and your medication over the course of the study. At your preference, these 
interviews may be conducted at intervals of 3 to 6 months, in your residence or at 
your GP practice. They will be between ½ and 1 hour in length. You may agree or 
decline to have these interviews without it influencing your participation in the 
remainder of the study or your care. All interviews will be recorded on audiotape 
but will remain confidential. At no point will your name be associated with 
recordings of the interview and the tapes will be destroyed as soon as the researcher 
has finished examining what you have said. 
Who should not enter the study? 
Your doctor has a full list of the types of patients who can take part in this study for 
example you must be aged over 16 and the results of your lung function tests must meet 
set criteria.  There may also be other reasons why you cannot participate, in particular you 
should not take part if you are or intend to become pregnant during the study duration or 
are currently breast feeding. You can discuss this in more detail with your doctor or 
asthma nurse. 
What will be the benefits and drawbacks? 
It is possible that no therapeutic or other direct health benefits may result during or 
following completion of this study, however, the information obtained about your 
condition during the course of the study may be helpful to your doctor in planning your 
care. In particular, it is uncertain which of the two treatment options may be most helpful 
to you.  However, studies to date suggest that either of the treatment options give some 
benefit to the majority of asthma sufferers, in particular improvement in quality of life, 
reduced asthma symptoms and attacks.  In addition, you may help other patients with 
asthma, as the information we get from this study may be useful scientifically. 
All medicines may cause some side effects. For those allocated to treatment with a tablet 
more common possible side effects that have been noted from some people include 
headache, stomach pain, dizziness, fatigue, diarrhoea, fever, heartburn, toothache, nasal 
congestion, trauma, cough, mild changes in some blood tests and skin reactions 
(rash/swelling). Your doctor can tell you more about these. There may also be side effects 
of the treatment that are not presently known.  It is not known whether the tablets may 
cause problems for a developing baby.  For this reason we will not include patients who 
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may become pregnant over the next two years.  For this reason, if during the study you 
become unintentionally pregnant you must consult your doctor as soon as possible.   
For those allocated to the steroid inhaler possible side effects that have been noted in 
people include hoarseness, thrush in the mouth or throat, fluid retention or rash.  There is 
also the extremely rare possibility of paradoxical bronchospasm (an unexpected wheezing 
attack – please ask your doctor for more information).  
It is unlikely that you will have a serious side effect or injury resulting directly from this 
study particularly as all the treatments used are currently licensed for the treatment of 
asthma.  If you do you should discuss this with your doctor immediately. Because the 
research is sponsored by the NHS there is no provision to offer advance indemnity to 
participants.  A person suffering injury as a result of having taken part in research will 
need to pursue a claim for negligence through litigation or may be offered an ex gratia 
payment.  Each case will be considered on its merits.  
Should any new information become available about any medication included in the study 
during your participation which may alter your decision to enter or continue you will be 
informed by your study doctor. 
If you agree to participate in the study, unless required by law, only government drug 
regulatory authorities and your doctor or asthma nurse will have access to your medical 
notes.  Under direction of your doctor, authorised representatives of the University of 
East Anglia and the Independent Ethics Committee can see the parts of the notes 
relevant to the clinical study.  Such data may also be seen by government drug 
regulatory authorities. This information will be treated in the strictest confidence.  All 
information about you will be anonymised, your name will not be shown on any forms 
sent to the University of East Anglia or on any reports or publications resulting from the 
study.   The only exception is that the University of East Anglia will keep a separate 
record of your name and address to send you the study questionnaires. 
The study has been reviewed and approved by an independent panel which included 
doctors, nurses and non-medical people. 
You should be aware that your study doctor will be paid by the NHS for the additional 
workload involved in his/her participation in this study and may not mean you carry on 
the treatment given to you during the study. 
What happens at the end of the study? 
Your doctor or asthma nurse will decide, with you, on the best future management of 
your asthma - this may involve a change in medication. 
Can I refuse to take part in the study? 
Taking part in this study is entirely voluntary.  If you prefer, you can decide not to take 
part without having to give any reason and your current asthma treatment will continue.  
If you do decide to take part, you can change your mind later and withdraw. Declining to 
take part will not affect your future medical treatment in any way. 
Your doctor may have to withdraw you from the study if it is thought unsafe or 
inappropriate for you to continue or for administrative reasons.  Your doctor may also 
withdraw you from the study if you find it difficult to comply with the requirements of the 
study.  Again, your future medical treatment would not be affected. 
Who should I contact? 
Your doctor and/or asthma nurse should have answered all of your questions.  If you have 
additional questions during the course of this study about the research or your rights as a 
   
 
 
274
research patient, you may address them to the doctor(s) or asthma nurse mentioned on the 
first page of this information sheet.  Please contact one of these doctors in the event of any 
of the following occurring: 
(a) if you suffer an illness 
(b) if you feel different in any way 
(c) if you are admitted to hospital for any reason 
(d) if you are seen at  casualty ( accident /emergency department) for any 
reason  
(e) you feel that your asthma is worsening between visits 
(f)       if you are seen by a doctor who is not your normal one, please let him / her 
know that    
            you are in this study.    
(g)       if you become pregnant during the study. 
Thank you for taking the time to read this leaflet, if you have any questions please 
discuss them further with your Doctor or asthma nurse who will be happy to answer 
them. 
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DECLARATION OF CONSENT 
  ELEVATE - Effectiveness of Leukotriene receptor antagonists in the  
EValuation of AsthmaTherapies and for health Economics 
Investigator’/GP’s:………………………………………….   Asthma Nurse: ………………………………… 
Address…………………………………………………………………………………………………………..  
Telephone No: ……………………... 
(The patient should complete the whole of this sheet himself/herself)                                         Delete as Applicable 
 1. Have you read and received a copy of the Patient Information Sheet dated: 4.9.2003             YES/NO    
 2. Have you had an opportunity to ask questions and discuss this study?                                      YES/NO   
 3. Have you received satisfactory answers to all of your questions?                                              YES/NO    
 4. Have you received enough information about the study?                                                            YES/NO   
 5. Who have you discussed the study with?  Dr/Mr/Ms……………….. 
 6. Do you understand that you are free to withdraw from the study: 
 -      at any time?                                                                                                                                YES/NO  
 -      without having to give a reason?                                                                                             YES/NO  
 -      and without affecting your future medical care?                                                                   YES/NO   
 7. Do you understand you should report possible side effects, changes to medical  
treatment and other health changes.                                                                                                YES/NO   
8. Do you understand and agree to authorised representatives of either the University of  
 East Anglia, Independent Ethics Committee, or government regulatory authorities 
 reviewing your medical records to check clinical information relevant to the study, on 
 the understanding that your confidentiality will be respected and you will not be  
 identified in any report?                                                                                                             YES/NO 
   
9. I understand and agree that information about me arising from my participation  
in this study will be processed by the University of East Anglia.  This information 
may include my initials and date of birth but not my full name or address.  The  
University of East Anglia will:  
-      Analyse my clinical data during and after the trial, to assess the treatments  
involved in the study and to produce reports;                                                                YES/NO 
 -      Such data may be seen by government regulatory authorities.                                      YES/NO 
  
10. Do you agree to take part in this study?                                                                                         YES/NO   
Optional  
11. Do you agree to be interviewed about your asthma and your asthma medications?               YES/NO   
 
 
SUBJECT                                                                                       Study ID number: ___ ___ ___ ___ ___ ___ 
 
 ...........................................................................................   ...............................................................................................  ................................
Name of Subject (Please Print) Signature of Subject 
PARENT OR GUARDIAN (FOR SUBJECTS AGED 16 OR 17 IN ENGLAND AND WALES) 
This is in addition to consent from the subject themselves 
 
 ...........................................................................................   ...............................................................................................  ................................
Name of Parent or Guardian (Please Print) Signature of Parent or Guardian 
CONSENT OBTAINED BY: 
 
 ...........................................................................................   ...............................................................................................  ................................
Name (Please Print) Signature 
IF CONSENT NOT OBTAINED BY A PHYSICIAN, THE PHYSICIAN AVAILABLE TO ANSWER 
PATIENT’S/SUBJECT’S QUESTIONS MUST SIGN BELOW: 
 
 ...........................................................................................   ...............................................................................................  ................................
Name (Please Print) Signature 
 
276 
 
Appendix D 
Other work undertaken not included in main text 
D.1. Analytical Process to Identify Participant’s Accounting Styles 
 
The extracts included in this appendix represent the early analytical attempt to identify 
participant’s accounting styles which were then used to build a sample of participants to 
interview a second time. To identify each person’s style the following procedure was 
followed. First, the recording of interviews were listened to and the author wrote a 
summary of the content of the interview to characterise how the individual justified 
their medicine taking. Second, these characterisations were imported into Nvivo 
software and then coded for rhetorical devices the participant’s appeared to have 
deployed and the effects that this talk appeared to perform. Third, coded devices were 
grouped into categories which were designated an “interpretative repertoire”. Further 
devices were then classified within existing interpretative repertoires or new repertoires 
were created. Definitions of repertoires were refined as necessary. Finally, the 
summaries of interviews were then re-read with devices, effects and interpretative 
repertoires highlighted. This re-reading enabled the author to construct the individual’s 
particular accounting style. Having identified participant’s accounting styles, 
participants were then compared to see whether groups of accounting styles could be 
identified and which would form a basis for a second round of interviews. 
  
Extracts from Characterisations of Interviews 
 
Extract 1 – Characterisation of face-to-face interview with participant no. 650493.  
 
The analytical process for this participant can be traced in this appendix from this 
characterisation to the identification of rhetorical devices (D.2.) to the mapping of this 
650493’s accounting style to other participants (D.3.). 
 
Participant no. 650493: early in tape discusses how uses prophylactic med in relation to 
circumstances. Self-regulatory/monitoring repertoire? 
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Continues this idea with contrast between what he would do if weren’t in trial compared 
with being in it. In trial: will continue to take “for purposes of trial”; if weren’t in trial 
would stop ICS because “I feel perfectly alright”. “Fairly structured” “ongoing 
assessment”. Further supported with descriptions of taking preventive treatment before 
going on holiday. 
 
Salbutamol a “lifesaver”. “As long as I’ve got salbutamol I’m happy”.  “once you 
wheeze…you get anxious” 
 
When asked about the need for long-term management and ideas of risk of severity and 
that he referred to himself as having “had a good innings” he hinted that he felt 
vulnerable, but seemed to hesitate over this and was quite vague, perhaps was 
uncomfortable with my line of questioning. 
 
Expresses (as an ex-GP) “dissatisfaction” (both himself and within medical profession) 
of state intervention into how to treat asthma. Used this to justify that “don’t mind too 
much if I deviate a bit from what I’m told”.  Agreed in the principle of guidelines. 
“Docs are now civil servants. ‘Doctors’ are a sideline”. Interesting contrast with own 
practice as a GP that when I ask “did you tell your pts to take the med 2 times twice a 
day” he replied “Oh yes, you gave them the official line, certainly” and mentioned how 
that was appropriate for some people but not others who have a “more adventurous 
spirit”. Other extreme “downright casual” “cavalier” 
 
Accounting Style: Self-regulatory, supported by criticism of government involvement 
in chronic disease management which suggests that adherence is inappropriate for some 
people, who have a more ‘adventurous spirit’. This categorisation positions those who 
adhere regularly as more passive accepters of medicine. 
 
Extract 2- Characterisation of face-to-face interview with participant no. 670287 
 
Participant no. 670287 – interview at home.  
1st statement: “I’m only really a mild case so it ((completing MARS questionnaire)) was 
quite easy because the asthma don’t actually interfere much with my life anyway”; “I 
take less than instructed, probably that’s the area that I had to admit to” 
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Asked about diagnosis: “I suppose a lot of it is putting a label on, what as a child, 
symptoms we didn’t know what they were”. Lived on a farm, lots of animals, dust, 
mother had an old mattress in the attic, as kids used to go bouncing on it, always came 
back with puffy eyes, wheezing “but we didn’t put a label on it, it was just a thing that 
you did if you did that”. Links hayfever to wheeziness, “obviously”,  “suffered from 
hayfever but didn’t put a label on it”. Says that hayfever/asthma is in the family as 
father had it “allergic to (green wood?) on apple trees”. “Dad had it, we had it and it 
wasn’t an issue because we knew what triggered it off and we avoided it”. 
At school avoided running around by going in goal at football, “but again we weren’t 
putting a label on it, it was accepted, we were brought up with it, wasn’t a problem”. 
 
As if a diagnosis creates a problem. Medicine imposes rules to follow which creates the 
problem hence statements such as “I had to admit” to taking less than instructed. The 
embodied experience is almost irrelevant, rather it is society’s response to the 
experience which creates difficulties. 
 
By constructing his asthma in this way he builds picture of himself as engaged with the 
condition, takes responsible steps to avoid triggers which forms the basis for any 
decisions not to take medicines as instructed. 
 
“obviously grain dust and animals did bring me out in a rash, but quite often 
wheeziness”. Trivialises by using opening term obviously. Then discusses having 
scratch test at GPs which identified cow hairs, cat hairs and house dust as triggers. 
Brings in medical proof to verify his own interpretation.  
 
Daughters have got the same kind of symptoms, “the family trait as it were”. Again 
objectifies the cause. Youngest daughter is “more of a pollen person really”. 
Pathological varieties reinforce the functional power of the medical repertoire. 
 
Then tells story of 10yrs ago when had chesty cough, which tends to go a bit wheezy, 
“one night took a turn for the worse” took some of daughter’s ventolin, only 1 puff  to 
see if get some relief “as didn’t want to overdo it”. Eased it for 15mins. Remembers 
“standing outside in cold night air trying to get air and breathe, actually was getting 
quite worried at that stage”. Next day rang docs and “they actually came out and 
immediately taken to A&E”, got nebuliser and was in hospital for 2 days, “then the 
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label was put on it ‘you’ve got asthma’ and from there on all the medication then kicked 
in, and you know I’ve been in control of it and I’ve never had a repeat of that 
occurrence. The only, recently what was happened with the brown…I was told to take it 
all the while, but I dropped off then missed a dose, in then end, recently just been taking 
it if there was a chesty cold coming, been around people with colds, a quick dose and 
that helped me through it, I’m afraid I dropped it off after that. Just sort of a life history 
of the disease and its impact”. 
 
This ends the opening narrative. Builds self as responsible person (which was supported 
by medical evidence) before the onset of the asthma attack which described in detail 
adds drama to the day of diagnosis. He seems to providing proof of the condition but 
also that he acted responsibly in that situation (rubberstamped by admission to A&E) 
which predicates the subsequent talk on the use of brown inhaler. The style then is a 
combination of medical and responsible repertoires which interplay to form justification 
of non-adherence. His closing statement is interesting as asthma is constructed as an 
independent entity which has impacted upon him, rather than referring to it in the 
possessive sense. 
 
Slight contrast to Cornwell’s legitimacy exonerates the need to justify. Here there is a 
more complex interplay between providing proof to prepare the grounds to justify and 
manage potential accusations of irresponsibility. 
 
Asked about personal significance of having label of asthma. “It doesn’t bother me” In 
the family has always been eczema, hayfever and asthma. I just happened to get all 3. 
“It is a family weakness”. 
 
Reports life changed after diagnosis, so has a before and after story. Before “it wasn’t 
interfering with your life to that extent” “perhaps I was treating too lightly, until that 
attack, then realised going to the hospital in the ambulance, the kidology stops now 
because actually this is pretty serious”. So this changes the interpretation of the earlier 
talk with this before and after story. Now he takes seriously whereas before he didn’t. 
Told as children ‘you would never die of asthma, but of course is serious if not under 
control’. So is using a more compliant repertoire in the after story based on ‘new 
knowledge and experience’. This would seem to provide an explanation to the before 
story which removes personal blame. In Cornwell’s framework the absence of proof 
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locates the breathing problems in the before story as a ‘health problem that is not an 
illness’ which therefore requires that personal blame for the problem be dealt with. He 
achieves this with detailed description of his activities as a child and the triggers, a 
shared awareness in the family of this, but justifies not taking as seriously as he should 
do (and therefore not taking meds) because he lacked the correct information. 
“that was the time the significance of the problem was realised, but before then it was 
inconvenient”. The story is the marker of this change. The use of detail adds drama then 
to mark this as the point where his response to the embodied experience shifted. 
 
Goes on to use self-regulatory repertoire. “It’s about knowing where the problem is, 
then avoiding it, if you can’t avoid it, do something about limiting the effects it can 
have”. 
 
Described salbutamol as “your friend” who is always with him wherever he is. Uses 
brown when gets a cold but doesn’t think it does much. “Obviously is a preventer so 
you can’t tell if it has done any good or not” Thinks he has been using it incorrectly, 
because “you need to use it on a regular basis, not just in an emergency” “and I’ve been 
neglecting that should be using it all the time on a regular basis”. Says he has been 
shown how to use it, and knows how to use it. Thinks explanation of the brown came 
from the GP. Describes in detail what was told about a nebuliser and that you can take a 
lot of salbutamol if need to which was “a comfort” because it is “so so effective with 
me” he only needs one puff. “and if it is so effective one wonders what the brown one, 
what use is that brown one”. Describes how was on other med for his eyes and was 
warned about overusing it so he thought “do I need to be hooked on all this stuff, is 
there anything I could drop off, obviously I suppose the Beconase was one of them” 
((think he means brown inhaler here)). Uses addiction repertoire to justify not taking 
brown, overuse is akin to being an addict, “hooked”. 
 
For him, salbutamol provided the answer. He could control his asthma, acting 
responsibly by complying with the demands of asthma management, whilst avoiding 
becoming “hooked” on drugs. The brown inhaler is constructed as an option which he 
could “drop off”, the blue acting as a better alternative. This possibly has links with 
Cornwell’s private worlds. How the medicalization process is assimilated (in a bottom-
up fashion) into sub-cultures. Whilst salbutamol is assimilated comfortably “is a 
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comfort” the brown inhaler is not easily accommodated, as it falls within  a “drug-
users” discursive framework. 
 
Hasn’t been back to the surgery to discuss, vaguely mentions that a GP may have 
wanted to manage differently but “stress it is not a debilitating problem in as far as my 
work is concerned”. Says because he is in a managerial position he can get others to do 
tasks which might affect his asthma, which they understand.  
 
When asked to use brown inhaler for the study he said “Fine. If it is part of the study” 
Talked about trying to take “religiously”. Discussed not knowing long-term effects of 
taking the preventative are, “doesn’t seem to have any side-effects, effects your voice, 
suppose you get to adapt to that, accept it”. Largely uncritical of specific medicines but 
has particular praise for blue inhaler, “it is so good, you forget the reason you took it”.  
Mentions one of the personal orientated targets for the study was to reduce dependency 
on medication, doesn’t talk much more about this but earlier talk is informative here. 2nd 
target was to be able to do more activity at work, but was at pains to play this down, 
“asthma is a nuisance” “not a serious issue” “not something I worry about at all”. Refers 
back to the asthma attack as the “crisis” that “frightened me, probably did me good, 
made me treat it with respect”. 
 
I ask about whether he thinks practice view his asthma differently to him and he 
discusses the idea of respect. That he is not doing what they told him to do so I’m not 
treating them with respect. “If I gave advice to somebody who then blatantly ignored it, 
I tend not to actually treat them with the same respect or care, than somebody who was 
actually trying to do as they were told”.  
 
Avoids direct criticism of practice by saying they are following “standard procedure”. 
When I ask what he thinks is going on in terms of his and their goals he says that he 
hasn’t analysed that deeply really. Hasn’t engaged with the idea of not following their 
advice. Could explore ideas of work and respect and how linked to health and illness for 
him.   
 
Asked about what would do beyond study “if it proves to be effective, the considered 
opinion of the experts that it is the way it should be controlled rather than the curative, I 
will do as I’m advised, by people who I would trust to advise me correctly rather than 
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any self-opinionated thoughts that I knew better. I’ve got every faith in the medical 
practice. If the study is 6 or 7 years, spend the time with consultants and specialists and 
they advise you and you don’t do it, then it is to your discredit I think.” If proved 
preventive med is responsible for reducing symptoms then “so be it”. 
 
Post-interview comments: 
21/12/04: participants number 670287 – comments made when listening to tape for 
characterisation on 28/7/06 
 
Remember feeling irritated with his attempt to adopt some kind of powerful position in 
the interview. Didn’t want to “brag” about being a manager. Challenged me when I 
asked how long he had been taking the brown inhaler “you should know”. Not sure why 
I feel this happened, maybe because of the potentially accusatory nature of the 
interview, with a potential power imbalance between questioner and responder. I also 
mentioned it was a student project so perhaps that gave him a slight feeling of authority. 
 
Accounting Style: Uses effect of labelling symptoms with “asthma” as the key 
rhetorical tool in managing accountability. Before and after story justifies his actions 
through the use of this labelling device and the traumatic event associated with the 
diagnosis. Reinforced with “self as expert” devices, utilising medical evidence to 
authenticate his own interpretations. Non-adherence constructed as minor deviation 
from position of control. Self-regulatory repertoire used when arguing how in control of 
asthma now. This disappears when discussing reasons for not taking ICS in favour of an 
‘overuse’ and addiction repertoire, but defers to medical expertise and blames self for 
not following their advice, so upholds the medical agenda of compliance as the ideal. 
Asthma constructed as not an issue as seems to represent threat to his lifeworld. 
 
Extracts from Analysis of Interview Summaries for Rhetorical Devices and Effects 
 
The following is a list of devices and effects used to generate identification of the self-
regulatory repertoire. These were preliminary categorisations that were used to build a 
sample for a second round of interviews. Note that the attached comments, the “Internal 
Dbs”, on devices and effects may refer to a larger piece of text than that coded as 
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performing a specific effect. It is useful to include however as it helps place the coded 
text in a broader sequence of the interaction. 
 
The following eight effects were identified as making up a self-regulatory repertoire: 
1. Acceptance of utility of meds 
2. Asthma as 'not an issue' 
3. Compliance is passive 
4. In control 
5. Independent, engaged, not compliant 
6. Medicine taking is an addiction 
7. Self-aware 
8. Undermines solidity of knowledge 
 
The following extracts are sections of different interviews that were coded in NVivo 
with Effect 3, “compliance is passive”, (paragraph numbers refer to NVivo not 
transcript). 
  
Compliance is passive – Extract 1, participant no. 650493  
 
Passage 1 of 8 Section 0, Para 14, 160 chars. 
14: “Oh yes, you gave them the official line, certainly” and mentioned how that was 
appropriate for some people but not others who have a “more adventurous spirit”.[3] 
 
[3]  Internal DB. Device and effect: uses consensus with medical colleagues to 
undermine authority of asthma guidelines dictated to by 'state intervention'. This 
justifies deviating "from what I'm told" but then uses the other extreme to position self 
between two extreme points. "more adventurous" implies adherence has an obedient 
connotation, whereas the other extreme is more reckless "downright casual", "cavalier" 
 
Compliance is passive – Extract 2, participant no. 121350 
 
Passage 2 of 8 Section 0, Para 25, 78 chars. 
25: “pumped into me all the time. Everyday.”  “More likely to get bruised and cut[5]” 
[5]  Internal DB. Device and effect: passive metaphor, body as receptacle. Effect is 
to position those who take inhaled steroids regularly as passive objects which positions 
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herself as an active person. Use of claim of physical outcome gives position scientific 
credibility which adds authority to her position. Clear contradiction in the use of this 
device as it is medical knowledge which is being challenged by adopting this position. 
 
Compliance is passive – Extract 3, participant no. 351823 
 
Passage 4 of 8 Section 0, Para 220, 437 chars. 
220: Used to work on a respiratory ward as a nurse, knew how to use inhalers as has 
given that advice to other people. “done that, on ‘drug rounds’ ((laughter on the term 
drug rounds)) for a long time, I recall very clearly thinking ‘I don’t know how you do 
that’, you know I don’t think I could, I don’t enjoy using at all, it really does make me 
gag… if it’s bad enough you do.. did already have ideas of not liking that mode of 
something”[36]. 
[36]  Internal DB. Device and effect: story of when worked on respiratory ward on 
'drug rounds' provides a relational positioning between herself and the patients on the 
ward. Herself as someone not able to take meds as they "make me gag", whereas she 
about the patients thought "I don't know how you do that". Her use of the term 'drug 
rounds' and associated laughter suggests her discomfort with this term because the 
passive position it places patients in. The story perhaps carries the message that taking 
medication is for the sick. 
  
Compliance is passive – Extract 4, participant no. 121350 
 
Passage 3 of 8 Section 0, Para 39, 75 chars. 
39: Grandparents rather than lots of inhalers “rather than just give up on it”[10]. 
[10]  Internal DB. Device and effect: Grandparents positioned as 'giving up on it' for 
taking lots of meds unquestionably. This relational positioning identifies herself as 
actively engaged with the impact medications have on her body. 
 
The following extracts are sections of different interviews that were coded in NVivo 
with Effect 5, “Independent, engaged, not compliant” 
 
Independent, engaged, not compliant - Extract 1, participant no. 650493 
 
Passage 1 of 4 Section 0, Para 14, 657 chars. 
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14: Expresses (as an ex-GP) “dissatisfaction” (both himself and within medical 
profession) of state intervention into how to treat asthma. Used this to justify that “don’t 
mind too much if I deviate a bit from what I’m told”.  Agreed in the principle of 
guidelines. “Docs are now civil servants. Doctors’ are a sideline”. Interesting contrast 
with own practice as a GP that when I ask “did you tell your pts to take the med 2 times 
twice a day” he replied “Oh yes, you gave them the official line, certainly” and 
mentioned how that was appropriate for some people but not others who have a “more 
adventurous spirit”. Other extreme “downright casual” “cavalier[3]” 
[3]  Internal DB:  Devices and Effects: Uses consensus with medical colleagues to 
undermine authority of asthma guidelines dictated to by “state intervention”. This 
justifies deviating "from what I'm told" but then uses the other extreme to position self 
between two extreme points. "more adventurous" implies adherence has an obedient 
connotation, whereas the other extreme is more reckless "downright casual", "cavalier" 
 
Independent, engaged, not compliant – Extract 2, participant no. 121350 
 
Passage 2 of 4 Section 0, Para 21, 262 chars. 
21: Learnt from Grandparents (who both have asthma) that smoking was bad. “you 
couldn’t find someone more against smoking than me”. They have a lot of inhalers 
because they smoke, “I only have 1”. “I don’t want to be on that much medication, even 
when I’m their age[4]” 
[4]  Internal DB. Devices and effects: Uses story of Grandparents to position self as 
not at the mercy of medications and asthma and is engaged with her health. Having a lot 
of medication seen as a result of smoking. Assertion that "you couldn't find someone 
more against smoking than me" strengthens her position. 
 
Independent, engaged, not compliant – Extract 3, participant no. 121350 
 
Passage 3 of 4 Section 0, Para 25, 78 chars. 
25: “pumped into me all the time. Everyday.”  “More likely to get bruised and cut[5]” 
[5]  Internal DB. Device and effect: passive metaphor, body as receptacle. Effect is 
to position those who take inhaled steroids regularly as passive objects which positions 
herself as an active person. Use of claim of physical outcome gives position scientific 
credibility which adds authority to her position. Clear contradiction in the use of this 
device as it is medical knowledge which is being challenged by adopting this position. 
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Independent, engaged, not compliant – Extract 4, participant no. 121350 
 
Passage 4 of 4 Section 0, Para 39, 75 chars. 
39: Grandparents rather than lots of inhalers “rather than just give up on it”[10]. 
[10]  Internal DB:  Device and effect: Grandparents positioned as 'giving up on it' for 
taking lots of meds unquestionably. This relational positioning identifies herself as 
actively engaged with the impact medications have on her body. 
 
Mapping Accounting Styles 
 
On the following page is an extract from the final step in building a sample of 
participants that could be interviewed a second time. Each person’s accounting style is 
summarised in the first column. The second column indicates the key theme to emerge 
from that style that links them with other participants. The bold 1s mark the style 
documented for that person and tally with their study ID on the top row. The red 1s 
mark where else a person's style might be categorised and so indicate how many people 
might be grouped into a particular style. Participant 650493 can be used as a starting 
point. 
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(Original in colour)
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D.2. Ethical issues regarding informed consent with individual participants. 
 
Used as a starting point: Ramcharan & Cutliffe (2001) “Judging the ethics of qualitative 
research: considering the ‘ethics as process’ model”. 
 
Context of research interviews 
 
Theoretical rationale of study implicitly hypothesises that participants’ are perhaps 
“disengaged” in some way from their illness. There is a structural relationship between 
myself and participant, “researcher from UEA, asthma study taking place at GP surgery 
– patient”.  
 
Ethical/Research issues 
 
1. Fully informed consent of research aims. Patients are currently consented for 
interviews about their views of asthma and medications. Whilst this is a broad 
area I feel there is a need to inform aim of research is about morality/identity 
and risk tensions, (in some form). This would seem desirable both for form of 
interview questions and for the patient’s awareness of research aims. 
2. Objective to explore in-depth aspects of morality-risk-adherence relationship 
versus individual’s right to remain disengaged from their asthma. Danger of 
causing tension between myself and interviewee, their doctor/nurse and/or 
perpetuating how patient identifies with their asthma through the research 
relationship. 
3. Informing of aims. Need to strike balance between informed consent and 
producing contrived data. It is important not to be too focused as other important 
insights will be missed and my own preconceived ideas will be in danger of 
becoming self-fulfilling prophecies in the data. 
 
Proposal 
 
• Application for ethical approval of new information sheet and consent form is 
not necessarily the most ethical approach. To introduce the research aims at 
outset of interview is likely to frighten participants and undermine the data. 
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• Secure verbally agreed informed consent with individual participants. Explain 
how the aims of the interviews have developed since I have become a 
postgraduate. Explain that it would also be useful to understand some of the 
social and personal issues which influence how people live with their asthma, 
and how asthma care might be provided differently. I would like to understand 
not only patient’s views about their asthma and medication, but more 
specifically the reasons why the person has these views. Explain that 
understanding this may involve discussing how the patient views health and 
illness in general, lifestyle choices and the person’s attitudes to life in general. 
Make explicit my independence from Elevate in these interviews and the 
participant’s GP surgery. Re-emphasise anonymity and confidentiality.  
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D.3. Reflections on focus group and role of moderator 
 
It is clear from the audiotape of the focus group discussion that participants framed me 
as an expert on asthma until the end of the focus group discussion where it became a lot 
clearer:  
 
P5: I thought that um I was expecting you to inform us of all the er 
 
P2: yeah 
 
P5: all the things we should and shouldn’t be doing 
 
P2: yeah 
 
JM: what gave you that impression 
 
Several: heh heh heh 
 
P1: we thought you were an expert 
 
JM: what do you think now? 
 
P1: Not sure heh heh heh 
 
(Data sharing focus group, page 36, line 48 to page 37, line 13).  
 
This is despite stating both in the face to face interviews and at the beginning of the 
focus group that I have not been medically trained. There was it seemed a common 
perception that I was in a position to communicate to them the value of medications, 
their side-effects, how they compare to other medications and also objective definitions 
of asthma. This is not surprising given the initial context in which I met them for face to 
face interviews (a health researcher working on the main asthma RCT in which they are 
participating).  
 
This shared perception was enhanced further in conversations prior to commencing the 
focus group. I was asked what sorts of patients were being studied in the asthma study. I 
do not have a note of the exact wording of this question but I evaluated this question in 
the following way before responding: this person is perhaps wondering if there is 
anything special about their invitation to the focus group today other than that I had 
interviewed them? Perhaps they are concerned that I/the main study considers their 
asthma to be more severe than they do? 
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I therefore responded by explaining the particular medications that they would need to 
be taking to be recruited and then unfortunately got too technical and explained that 
there are 5 asthma steps and they were being recruited at step 2. I did this to try and 
answer what I considered to be his concern without stating that his asthma was mild. It 
was then stated by either himself or somebody else present that they were at the milder 
end of the asthma spectrum. 
 
I also provided them with a brief summary of the findings of the main study in response 
to a question I cannot specifically remember. These discussions only served to reinforce 
the idea that despite my protestations I was an expert on asthma and I can provide them 
with answers to specific clinical questions about asthma. 
 
The questions are: How does this impression impact upon the data that I have collected? 
The whole point of the focus group was to provide data based on a different set of 
contextual conditions. This was achieved in terms of the time and location (beyond the 
end of the RCT and not in participants homes but neither an NHS or university venue); 
in terms of the interactional dynamics, (other people with asthma talking to each other 
around a table) and the type of activity (reviewing findings from the 1st set of interviews 
as opposed to direct questions about their own experience). Within those constraints 
participants were free to talk or not talk as they pleased rather than having to respond to 
particular questions about their own asthma. 
 
Ethical Issues: Were participants under a false impression of the purpose of the focus 
group? It seems from the data that some or all participants thought that I was 
specifically interested in medications (and perhaps the pharmacology of medications) 
and did not grasp my primary interest in “attitudes” and “beliefs” until my disclosure 
that I had a background in psychology (page 37-39). The interviews that they had 
consented for were always presented as their views of asthma and medications, that is 
what was discussed and that is indeed what I am looking at. The purpose of the focus 
group was to provide some feedback on these opinions. This was clearly stated in 
inviting them to take part, both in the initial phone call and the confirmation letter. The 
materials presented were opinions about asthma and opinions about medications. What 
was not fully understood was my own position on these issues, but this whole research 
is highlighting these interactional issues that are prevalent in any research/clinical 
interaction and this is no different. As soon as I mentioned psychology it seemed that 
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they were more able to pigeon hole my agenda. An important point is that people in 
general are just not used to discussing their health and illness with anyone who is not a 
nurse or doctor and so it is difficult to move out of this expectation. It does not seem 
that their expectations of the task were not met, but rather their expectations of who I 
am and what information I might provide them were not met. Does this constitute a lack 
of consent? What may have been upsetting for people is that they became aware of how 
they might have talked differently “had they known”. But I can categorise myself in a 
number of ways and the one I have tried to use has been “student” which did not seem 
to make any difference. It is only when the asthma expert is stripped away that there is a 
space to fill. Secondly, after saying my background is in psychology are they now fully 
informed? What else do they not know about me? As we manage the distinction 
between the observer and the observed we make decisions about what information to 
provide, so as to not “bias” if you are a positivist, or to impose our own position on the 
data we decide where to draw the line, they can never know all about the researcher. 
 
The emergence of their awareness that I was not an expert on asthma and my awareness 
of this came about through the process of the focus group, (my role as listener and not 
“filling the spaces” in conversation and their apparent discomfort with this, my inability 
to provide answers to their clinical questions) it did not come about through me 
repeatedly informing them that I was not an expert. In the face to face interviews the 
impression of an “asthma expert” was perhaps constructed, whereas here it was being 
deconstructed. This is perhaps evidence supporting that indeed we did have a different 
set of contextual conditions to the face to face interviews. What is interesting is how 
they managed this “new” information. 
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D.4. Analytical work Undertaken on Rhetoric and Discursive Space 
 
Reflections on transcript 670287 and Extract Nine, Chapter Four 
 
Participant 670287 (interview one, page 11, lines 35 to page 12, line 7) 
M:  =So I have it has been. But I stress it is not a debili(.)tating (.) problem 
 insofar as my (.) y’know ˚my work is concerned or my you know my life 
 is concerned. (.) Um (.) I don’t play (.) football I do (.) occasionally 
 bouts of strenuous work (1) um but its managed˚ and I’m very fortunate 
 in that (.) you know I can choose (in the middle?) ((of something?)) what 
 what I do (.) a- at work rather than (.) um (.) you know being in a 
 managerial position I mean I don’t wanna (1) y’know er (2) brag but you 
 do have a little bit of flex(h)ib(h)ility  um and if there’s you know 
 y’know there’s somebody else available who will move the grain lorry 
 up and you know I would do his job while he did while he did that (.) 
 and if its unavoidable well I (.) I’ll do you know put a mask on and move 
 the lorry myself which is its not an issue as far as I’m concerned (1) you 
 know the guy um (.) you know I can certainly ask somebody else can 
 you just move down (.) while I take over from you= =Everybody knows 
 that the reason I’m doing it I’m not frightened of work but they just (.) I 
 can manage it in that way (.) um (.) so (.) I suppose you could say well 
 actually you are changing your lifestyle but not to that degree. 
 
 
Pollock (1993, p. 55) cites Freidson when she argues that patients with chronic illness in 
contrast to acute conditions are afforded “permanent legitimation” – on condition they 
make effort to “improve themselves” and are socially acceptable by minimizing the 
demands on others. These standards of acceptability, or ideologies of appropriate 
behaviour constrain or facilitate the number of positions afforded to people with 
illnesses. For example Pollock identifies a range of literature including her own where 
participants stress the importance of “attitude of mind” and “mind over matter” which 
are directly related to ideas about personal responsibility for, and control over, health 
and illness. She discusses how people diagnosed with multiple sclerosis are helped and 
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encouraged to adopt an “attitude of mind”, whereby a positive attitude is attributed to 
those people susceptible and experiencing positive health outcomes whilst a negative 
attitude attributed to those susceptible to and experiencing poor health outcomes.  
 
In his account of how metaphor links domains of experience Radley (1993) discusses 
how spaces of action are available to people with illness between what is expected 
regarding their behaviour and what can be attained, between public morality and private 
fate, and how this space for agency regarding one’s behaviour is manifested in the 
discursive positions taken up by people when discussing their health. 
The quality and size of this discursive space is what I am referring to as “affordance”. 
From a medical perspective, by minimising the impact of asthma this person in the 
above extract affords themselves the space to take up a wider range of positions than if 
their asthma was having a large impact on their life. However, what is being shown here 
is that whilst appropriate asthma management is being oriented to by the speaker within 
the demands of this specific interaction he is also managing the moral expectations of 
the different social networks in which he participates. The dilemmas that this creates do 
not merely orientate around being seen to be in control of one’s asthma but refer to 
much smaller “affordances” in the discursive positions of conscientious worker, a good 
manager and someone who has a health problem that is not an illness. The example of 
swapping duties at work as an acknowledged practice amongst his workforce 
demonstrates the boundaries of the behavioural space that the morality of the workplace 
affords him. 
 
What this extract shows is that these different concerns are not discrete properties but 
are interwoven and at times managed simultaneously.  Seen within all of these concerns, 
the medical agenda of adherence is only likely to play a small part. This creates 
dilemmas surrounding the need to appear both in control to a health researcher, 
(consider Horton-Salway’s (1998) concept of “double jeopardy” – where there is a catch 
22 situation for the speaker). In adherence this might be between being categorised as 
irresponsible because the person has not taken preventive medication as prescribed and 
being categorised as irresponsible for over-use of medication, to be passive and 
dependent. Might be evident where someone is trying to straddle the moral frameworks 
of medicine and the lay world. See Horton-Salway (1998, p.179), who also cites Radley 
and Billig (1996). 
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 This participant can be seen to manage differing perspectives on illness management 
and adherence according to the different interactional and ideological contexts, shifting 
position when the issue at stake shifts from his understanding, awareness and 
responsibility over his illness (pages 1-10 of full transcript for 670287, page 5 is a good 
example) to whether it has changed his lifestyle (again pages 1-12, but his biography in 
pages1-3 and page 11 are good examples) to the appropriate behaviour for a research 
participant (page 13). In this last context, adherence is constructed more as 
“compliance” because he has “signed up”, and he would “hop around on one leg” if he 
was told to do so. There is no tension here with whether taking the prophylactic 
medication interferes with his life because it is judged within a context independent 
from whether he needs that medication in his everyday life and his position is therefore 
inoculated against the morality of those contexts. The clinical decision taken by a nurse, 
(supported by evidence regarding quality of life and level of asthma control obtained via 
study questionnaires) that he might benefit from taking regular preventive medication, 
(that represented an essential component in screening asthma patients for their 
eligibility to take part in the randomised controlled trial) is not seen to play a part at all 
here. The reason for this appears to be related to how he understands the main asthma 
study which seems to be as a new drug trial. His role within this study therefore is to act 
as a “tester” for these new treatments. This appears to construct a relationship whereby 
he is the willing, but arbitrary volunteer, and the medication is the object of analysis. He 
does not demonstrate an awareness that his participation in the study is (supposed to be) 
based on clinical reasons alone and that aside from the study this clinical decision 
would be that he needs to take the preventive medication everyday anyway. This 
hypothesis is supported on page 20, lines 36 to page 21, line 5) when asked about what 
he will do after the study he responds by referring to the specific efficacy of preventive 
medications as opposed to the “curative” and at other points where he refers to the study 
as a “survey” (page 13, lines 19, 40) and “scheme” (page 11, line 31). 
 
670287, Interview 1, page 20, lines 30-50 
 
JM: outside outside of that do you think what will happen at the end of the 
study will you stop taking it or  
 (1) 
M: If its proved to be effective (.) and it is the considered opinion of the 
experts (1) that it is (.) um the way it should be controlled rather than the 
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curative (.) I will do as I’m advised (.) by people who (.) um (.) you 
know who (.) who I would trust to advise me correctly (.) rather than any 
(.) um (1) opinionated self opinionated thought thoughts that I thought I 
knew better. (3) I mean these I mean I have got every faith in in in you 
know in the medical practice I mean if if (1) ((rustling papers)) the study 
is 6 or 7 years and then spend the time and then you know with 
consultants and specialists (.) and they advise you to do something and 
you don’t do it then I think basically its um (.) it’s to your discredit I 
think (.) 
 
What is of interest to the analysis here is the relationship between inequalities in 
possession of linguistic resources, affordances in discursive space, morality and 
therefore rhetoric. In this above example the adoption of a compliant position to the 
aims and objectives of medicine is a position on his future behaviour taken up well 
within what is expected from a medical perspective; he is respecting the authority of 
medicine, accepting of its science and willing to follow its commands. This compliant 
position can only be seen in a good light from a medical point of view. There is nothing 
to justify because the person is positioning his future, and as yet unaccountable 
behaviour, within the boundaries of medical expectation for someone with asthma. 
However, rather than simply stating his intention to take the medication if that is the 
advice, the speaker chooses to go further by providing a strong defence of medicine and 
discrediting a non-compliant position. With the absence of a competing set of moralities 
to which the speaker must orientate to he is afforded the space to take up as compliant 
as position as he wishes. Here we can see this with the way that he constructs a vivid 
contrast between the opinion of the experts, consultants and specialists which is 
“considered” and the “self-opinionated” thoughts of himself. Here this statement 
encapsulates the tension between the authority of science and the lifeworld but it is here 
where the lifeworld is subjugated as irrelevant, to be discredited.  
 
In contrast to earlier sections of the interview (e.g. page 10), this person does not 
demonstrate the compliant position as having any conflict with other lifeworld 
moralities because the severity of his asthma is not at stake here. Through a 
combination of my own questioning and the person’s understanding of the aims of the 
study his future behaviour is isolated from his own current clinical need to take 
prophylactic medication. He avoids having to enter into another rhetorical account of 
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how he manages his asthma and whether he should be taking regular preventive 
medication. It is the interactional elements of this particular sequence and his apparent 
lack of access to the linguistic resources of the study that explains the style of rhetoric 
that is deployed here and which contrasts so markedly with earlier discussions.  
 
What is being proposed here is that, in addition to differing levels of discursive 
affordances according to differing social networks which is related to the amount and 
type of rhetorical work that takes place in a piece of discourse, rhetorical practice is 
regulated by the possession or absence of particular sets of linguistic resources, in this 
case what the randomised controlled trial is about, what it means, what is being tested. 
Here the participant is demonstrating that he does not possess an accurate understanding 
of the study and without the linguistic resources that go with that understanding his 
account and position on future plans after completion in the trial is inadequate when 
seen from the perspective of the researcher who does possess these resources and is 
deploying them to frame the question about future plans. What is not clear is whether 
the participant himself realises he does not have access to these resources, despite the 
“information” being provided.  
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D.5. Review of Health and Illness Literature to Assess the Relevance of Morality 
for talk about Health and Illness 
 
To understand the relevance of morality in the management of chronic illnesses today 
we need to examine why and how morality and health have been historically connected. 
In Britain the biblical link between sin and illness was activated by the Christian church 
in the 15th century (Thomas, 1997, pp. 15-34). Thomas cites the Elizabethan Puritan 
Perkins who said “Sicknesse comes ordinarily and usually of sinne” (Perkins 1608-
1631, 1:497) to argue that when the godly man became ill they had to search themselves 
for what they had done wrong to bring such an affliction upon themselves or saw their 
illness as a test from God. This connection between purity and health on the one hand 
and immorality and illness is identified by Thomas across a range of health-related 
behaviours from the 15th to the 19th centuries - eating and drinking, cleanliness, 
smoking, sex and exercise. The reason for abstinence or moderation in these activities 
was commonly related not to any physical consequence but because of the moral 
connotations of that behaviour and Thomas cites Sir George Cheyne in 1725 to point 
this out,  
 
The infinitely wise Author of Nature has so contrived things, that the most 
remarkable rules of preserving life and health are moral duties commanded to 
us, so true it is, that godliness has the promises of this life, as well as that to 
come” (Thomas, 1997, p. 24).  
 
These connections between morality and health are by no means uniform. Cleanliness 
has been seen as “comely and honest” (Thomas, p. 27), as “ever deemed to proceed 
from a due reverence to God” whilst medieval Catholicism regarded extreme neglect of 
physical cleanliness as a sign of sanctity.  
 
In the 19th century the growing acceptance and application of science as a paradigm to 
explain a range of phenomena meant that the connection between the individual, 
society, health and morality was re-conceptualised. The identification of the germ as 
agent of disease had massive implications not only for medicine’s understanding of 
health and illness but also the role of the clinical practitioner. Illness was no longer 
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idiosyncratic and random but could be classified with a discrete pathology. People were 
now diagnosed with specific conditions with an organic origin which meant that 
previous connections between illness and immorality were undermined. This was 
problematic from the point of view of controlling the health and morals of society by 
targeting individual behaviour (Rosenberg, 1997, p. 43). However, it was now possible 
to attribute disease to different groups of people with an empirical basis which had 
economic and political implications. Science provided the type of evidence that meant 
diseases such as tuberculosis came to be seen as “social scourges” rather than associated 
with romantic fragility and sensibility (Herzlich & Pierret, 1987). The social status of 
medicine as an institution, its practice of standardising care and the social and 
professional status of the medical practitioner were heightened as a result. 
 
Herzlich and Pierret argue that this shift from individual to collective classifications of 
disease causation meant that specific illness identities began to be used to control and 
attribute moral states to groups in society such as the working-class. It is here that the 
concept of the “sick person” and Parson’s “sick role” (1951) can be seen to emerge, an 
illness identity which partly came about from the collective needs to have a healthy 
workforce, which then led to collective constructions such as “the sick”. By linking 
illness to the capacity to work, illness became a social phenomenon and with it the idea 
that people had an identity that orientated around being healthy or unwell which they 
had to manage when dealing with other people. Identity, beliefs and accounts of 
behaviour then are social categories in this view which are intimately connected to 
material outcomes of employment. The need to have the right identity and beliefs to 
participate in work was therefore a crucial issue. 
 
Frank (1995) in his book “The Wounded Storyteller” suggests that the triumph of 
Modern Medicine was that people, who were previously dying, were now able to re-
enter society, to be identified with “the healthy” but to be in a state of constant recovery. 
Frank calls this the “remission society” which include people who have had almost any 
cancer, on cardiac recovery programs, diabetics, people with allergies and 
environmental sensitivities requiring some form of dietary and other self-monitoring, 
those with prostheses and mechanical body regulators, the chronically ill, the disabled, 
those recovering from abuses and addictions, and for all these people, the families that 
share the worries and daily triumph of staying well. Frank demonstrates by listening to 
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the stories of people falling into one of these categories how society was not equipped 
for dealing with these new identities. If you were not wholly healthy or could be 
ascribed some aspects of illness you were therefore sick and possibly excluded from 
participating in various areas of social life. However, instead of people simply accepting 
the categories of sick or healthy, people in remission started to develop their own ideas 
about whether they were healthy or not that went beyond a medical description and 
diagnosis of physical symptoms. Importantly, these ideas about themselves, their own 
versions of self therefore quite commonly did not match the medical version.  
 
The need for people living with chronic illnesses to adopt new ways of living, versions 
of themselves and beliefs meant that the relationship between morality and health was 
constituted in new ways. Identities, beliefs and actions relating to the different ways in 
which people engaged with their conditions needed to be explained and justified to 
healthcare professionals, family members, work colleagues etc. So instead of 
individuals needing to present themselves as virtuous and without sin in their 
explanation of the onset of disease, here morality and health were being linked to its 
management over a long period of time. This led to new sets of narratives being 
employed in which to talk about health and illness, and arguably the very concept that 
patients have “health and illness narratives” (Frank, 1995, pp.3-26) can be seen to 
emerge out of these conditions.  
 
This focus on lifestyle, beliefs and individual actions inevitably placed individual 
responsibility at the heart of this moral framework. We can see how the notion of the 
individual as accountable has been upheld and reflected by broader cultural patterns in 
British society in the last 30 years. In his narrative analysis and discussion of chronic 
illness and the pursuit of virtue in everyday life, Gareth Williams argued that in British 
society in the 1980s, health, like wealth was neither good nor bad in itself. What was 
good was “the self-disciplined activity, which according to Protestantism and Mrs 
Thatcher, produces them; and in their absence is a sure sign of gluttony and sloth” 
(1993, p.92). 
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Connections between health, illness and morality in the 21st Century 
 
There is plenty of background evidence that the link between morality and health is still 
important today which sets the scene for a study of morality in how people with chronic 
illness talk about medicine taking. We can see the same relationship between individual 
action, beliefs and morality being constructed in health promotion initiatives in ways 
which have developed from the individualistic ideology Williams identifies in the 
1980s. The strategy to prevent risky lifestyles can be seen through efforts aimed at 
specific behaviours deemed under the voluntary control of individual citizens. For 
example media messages such as “Smoking When Pregnant Harms Your Baby” 
(http://news.bbc.co.uk/1/hi/health/2617585.stm, Wednesday, 1 January, 2003) and 
campaigns to improve healthy eating using powerful images: 
http://www.food.gov.uk/news/newsarchive/2009/feb/satfatcamp.  
 
Davison, Davey-Smith & Frankel (1991) discussed how the attempt to reduce risky 
lifestyles in the UK has been implemented using a two pronged approach. Driven by 
academics, private and public bodies in liaison with different forms of media, this has 
been done firstly through advertising and health promotion campaigns, and secondly by 
attempting to create a moral climate whereby “healthy choices are easy choices”. This 
moral climate ballooned more recently with the perpetuation of lifestyle programmes 
that present “problem cases” who undergo a “makeover” to become healthier and 
therefore “better” people - http://www.channel4.com/programmes/you-are-what-you-
eat/4od. Davison argued that this promotion of individual ideologies of illness 
prevention orientate around self-control triumphing over self-indulgence and, in British 
health promotion these ideological and political debates are presented as a relatively 
unproblematic relationship between knowledge (awareness of information) and the 
decision to do healthy things (or do unhealthy things). The individual as the “reflexive 
consumer” is therefore armed with this knowledge and has the “free will” to adopt 
healthy lifestyles or not, as seen in powerful messages such as “NHS Choices. Your 
Health. Your Choices” (http://www.nhs.uk/Pages/homepage.aspx). Therefore, an 
ideology of the individual as decision-maker diverts attention from the social causes of 
illness (Crawford, 1984) and arguably creates a “discourse of responsibility” (Wellard, 
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1998) which needs to be managed when communicating to other people about one’s 
health.  
 
The relationship between individual control of one’s health outcomes and choice can be 
seen not only in terms of responsibility over one’s own health but also in terms of our 
responsibility to the collective needs of society. In the 1980s Williams identifies the 
ambiguity that people in Britain often report towards the provision of social welfare, 
supporting it in principle, yet finding the idea of themselves and their families being 
“dependent” as abhorrent. At the start of the 21st Century our collective responsibility is 
often seen more towards increasingly scarce and limited resources within society. With 
the NHS now 60 years old it is frequently portrayed as an institution buckling under the 
strain of increasing demands, higher expectations and limited resources “Ageing 
population 'will strain NHS resources”, (Society Guardian, Friday December 9 2005), 
“Middle-age mums 'put huge strain on NHS” (The Independent, Sunday, 13 August 
2006) “Superbugs drain NHS resources” (Daily Telegraph 25 January 2007). Within 
this discursive framework of collective and individual responsibility, users of the NHS 
have a moral obligation to the collective needs of society as well as to themselves to 
avoid putting unnecessary further pressure on clinical resources. From this perspective, 
the tension between individual choice on the one hand and blame and accountability on 
the other has arguably never been more acute. 
 
In this discussion of morality it is clear that while in the 21st century there is a much 
greater discussion of the physical consequences of behaviours like gluttony, alcoholism, 
smoking, sexual promiscuity and cleanliness, the connection with morality is still 
extremely pertinent. Rosenberg (1997, p. 44) argues that the 3 basic elements of 
“personal”- “choice”- “lifestyle” present in today’s health promotion discourse have 
their origins in the far older view of disease causation linking habitual sin with disease 
and which are linked logically, rhetorically and emotionally. As was the case in the 
‘pre-germ-theory’ era, morality is now linked to health by quantification of cigarettes 
smoked, sexual partners had, alcoholic units drunk, portions of fruit and vegetables 
eaten. The consequences of our actions are not judged merely in terms of the physical 
outcomes however but also by our moral worth. This suggests that the earlier 
connections between morality and health are not merely consigned to history but can be 
seen to underpin some of the ways in which the same behaviours are viewed today and 
communicated across society. In other words, while there are many different ways in 
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which the link between morality and health has been formulated through history, there 
are clear patterns in the development of the language of morality and health which are 
communicated over time and which continue to be employed to control of the health of 
society.  
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D.6. An Interpretation of the ELEVATE Recruitment Process and Participants 
Access to Discursive Resources 
 
One way in which to assess the influence this recruitment process has on the research 
interview itself is to specify the roles that are operating in this process. Erving Goffman 
provides a useful analytical framework which although was designed to apply to 
interactional talk can be used here to emphasise the relative control over resources that 
the different participants have and the impact this might have on the movement of 
dialogue within the interaction of the research interview. Goffman (1974, 1981) in his 
analysis of talk discusses how, when an individual speaks there is a structuring of roles 
of the relative participants involved. He sets out the differing production formats that an 
individual may engage in when speaking and hence the differing roles that emerge as a 
result.  
These are:  
Animator: the “emitter” (the physical source/ soundbox in use), who can also inflect the 
message with personal style and intonational attitude markers (1974:518).  
Author: the person who selects the words and meanings  
Principal: the person who in a particular capacity/role takes/holds responsibility for the 
message  
Figure: the protagonist represented in a scene described. As a figure, the speaker has 
enormous flexibility in the projection of his/her identity, allowing her/him to talk in a 
“self-dissociated, fanciful way” (1981:146-152) 
 
Although Goffman never set out any comparable roles for the listener, Scollon (1998, p. 
257) used Goffman’s framework to develop the following: 
 
Receptor: the mechanical receiving of the communication (a person can repeat a 
message but have no idea of its meaning) (Comparable production role: animator)  
Interpreter: derives a meaning from the communication (Comparable production role: 
author)  
Judge: takes responsibility for interpretation of the meaning (Comparable production 
role: principal)  
Figure: e.g. you listen differently if you are a character in a tale (Goffman 1981, p. 
152). 
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Using Goffman’s framework a straightforward interpretation of the patient’s role in the  
recruitment process could be that they act simultaneously as author, animator, principal 
and figure, with a large amount of control over the meaning to be taken. However, there 
are a series of tools used here to apply notions of truth and objectivity regarding  asthma 
control and quality of life to the person’s experience of asthma. The questionnaires, 
peak flow diaries and reversibility test construct a set of linear measurements on which 
the person’s responses have to fit. For example, question 1 of the Asthma Control 
questionnaire asks “On average, during the past week, how often were you woken by 
your asthma during the night?” with the available responses being “Never”, “Hardly 
ever”, “A few times”, “Several times”, “Many times”, “A great many times”, “Unable 
to sleep because of asthma”. The use of bold emphasises that the person should only 
focus on being woken up and nothing else which is reinforced by the options available 
to them. The experience of asthma at night and its significance is reduced to a frequency 
of occurrence rather than anything else. This places considerable restrictions on the 
sorts of things that can be said and the types of interpretation that are possible. Rather 
than the person being seen as author here it is science that provides a limited range of 
words and meanings that the person can use and it is the objectivity of science that 
authorises evidence, fact and meaning. This authorisation of evidence means that while 
there is some space for the person to provide their own evaluation of their breathing 
difficulties, the capacity for the person to be “animator”, to contribute anything unique 
to their responses is extremely limited.  
 
Despite the restriction on responses available, the person with asthma nevertheless 
holds both the roles of “figure” and “principal”. They are both the person represented 
within the questionnaires and breathing tests and also hold responsibility for the 
message being conveyed. However, where Goffman refers to the enormous flexibility 
within interactional talk that the figure has in how their identity is projected, there is no 
such flexibility here. The identity of the person is determined by a cut-off point on an 
average of scores, a cut-off point that the person does not have access to. This creates a 
paradox in that the individual plays a passive role in their identity construction of 
“person with inadequate asthma control and quality of life” but yet is considered 
responsible for that identity because of the responses that they have provided. 
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The role of the nurse at study visits 1 and 2 is to act as both “interpreter” and “judge” 
based on the clinical evidence available. However, what is being shown here is the 
tension between the autonomy of clinical opinion and the weight of an evidence base 
that assesses inadequate asthma control and quality of life based on broad generalities. 
The tools of objective measurement may be both an aid and a constraint to clinical 
judgement depending on the value afforded to that evidence by clinical guidelines, a 
criticism which has been made by some advocates of patient-centred medicine and 
which was discussed in chapter two. The clinician therefore may be judge but may also 
be seen as facilitator or agent to scientific fact.  
 
Similarly, my role as Research Associate working on the clinical trial in which 
participants have been recruited is to act as interpreter and judge to the evidence of 
prescription refills and the self-reporting of adherence by the people I wanted to 
interview. I thereby set up my own criteria by which to judge the person and assign the 
identity of “non-adherent”. This assessment was based on accordance to medical 
assumptions which I am critiquing in my research but nevertheless this again is a 
categorisation that the individual had little access to when being considered for 
interview. The use of the Medication Adherence Report Scale as a precursor to the 
interview and as a prompt for discussion serves to set out the parameters for the 
interaction within the interview that places the person within the framework of 
medication adherence that I have set up. 
The outcome of this process of recruitment from the participants’ point of view is that 
their identity is constructed in ways which they have little control or awareness. They 
are “person with asthma”, “person with inadequate asthma control and quality of life”, 
“person who has been non-adherent with their medication”. The one identity that the 
participant has provided consent for and therefore does have access to is “research 
participant”. There is a clear separation here between possible utilitarian connotations of 
helping society through participation in research and the clinical constructions that have 
been constructed from an academic perspective. What is of relevance to the analysis of 
interview data is how the framing of research participant influences what interviewees 
say and how this interacts with my own frames orientating around adherence.  
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Glossary of Acronyms and Abbreviations 
 
A&E Accidents and Emergencies 
ACQ Asthma Control Questionnaire 
AIDS Acquired immune deficiency syndrome 
BTS British Thoracic Society 
CA Conversation Analysis 
CDA Critical Discourse Analysis 
CFS Chronic Fatigue Syndrome 
DP Discursive Psychology 
ELEVATE Acronym referring to large randomised controlled trial 
comparing the cost-effectiveness of two prophylactic 
medications for asthma 
GINA Global Initiative for Asthma  
GP General Practitioner 
HIV Human immunodeficiency virus 
ICS Inhaled corticosteroids 
LABA Long acting β2-agonist 
LE Linguistic Ethnography 
LTRA Leukotriene Receptor Antagonist 
MARS Medication Adherence Report Scale 
ME Myalgic Encephalomyelitis, otherwise known as 
chronic fatigue syndrome 
MiniAQLQ Mini Asthma Quality of Life Questionnaire 
NHS National Health Service 
RCT Randomised Controlled Trial 
SABA Short acting β2-agonist  
SCM Social Cognition Model 
SIGN Scottish Intercollegiate Guidelines Network 
SMP Self-Management Plan 
TWOD Truth Will Out Device 
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